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ABSTRACT 
ROBERT ALLEN OVERMAN: Prediction and Utility of a Clinical Fracture Risk Score in 
Administrative Claims 
(Under the direction of Stacie B. Dusetzina) 
The clinical manifestation of osteoporosis is osteoporotic fracture, which has been 
estimated to cost $25.3 billion by 2025 within the US healthcare system. Osteoporotic fracture 
risk has been measured using various risk scores with the most prevalent being FRAX® from the 
World Health Organization.  FRAX® scores are used clinically to guide treatment, but these 
scores and key inputs (such as bone mineral density and body mass index) cannot be measured in 
administrative claims. The objectives of this dissertation are 1) to create a claims-based fracture 
risk score to determine if administrative claims data can be used to predict FRAX® (interval 
validation); to evaluate how the risk score performs in a different population (external validity); 
and 3) to determine the best way to utilize the fracture risk score in a research study. 
For this project, we linked registry data including clinical fracture risk factors from a 
multispecialty academic hospital with Medicare administrative claims for individuals receiving a 
dual energy x-ray absorptiometry scan (DXA) between 2009 and 2013. FRAX® has 4 different 
scores for 10-year fracture risk of hip and major osteoporotic fracture (MOF) with and without 
bone mineral density. We created the Calculated Fracture Risk Index (CFRI) to estimate these 4 
scores. We found that we were able to predict a continuous FRAX® score with an adjusted R2 
that accounted for between 21 to 43% of variation in the estimates. We found these estimates to 
be internally valid. 
  
iv 
Subsequently we used the linked dataset and a 20% random selection of fee-for-service 
Medicare beneficiaries to evaluate the external validity of our CFRI scores. We found no 
significant differences in CFRI and FRAX® ability to predict 1 year fractures. Additionally, we 
found CFRI and FRAX® to be similarly calibrated. 
Lastly, we found that we were not able to sufficiently reduce confounding in a non-
experimental comparative effectiveness study of alendronate users versus non-users to that of a 
randomized clinical trial using CFRI as a regression component or a restriction device. Although 
estimates including CFRI reduced confounding, residual confounding remained and estimates 
differed from those in the Fracture Intervention Trial (FIT); the gold standard in for our 
comparisons. 
Overall CFRI appears to be internally and externally valid and a useful tool in reducing 
confounding compared to its non-use in osteoporosis research, though not to the level of an RCT. 
It also appears to be a reasonable proxy score for FRAX® when only administrative claims data 
are available. Therefore, CFRI when calculated in administrative claims should be useful for 
both researchers and policy makers to determine who is at risk for osteoporotic fracture. 
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 INTRODUCTION 
1.1 Overview 
Osteoporotic fractures are the clinical manifestation of osteoporosis and hip fractures and 
increase mortality, morbidity, future fracture risk, and health care costs while decreasing quality 
of life (1-4). The direct healthcare cost of osteoporotic fractures was estimated at $18.7 billion 
US dollars in 2010 and expected to rise to $25.3 billion by 2025 (5-7). Osteoporotic fracture risk 
increases with age and Medicare beneficiaries account for 80% of fracture-related costs (8). 
Osteoporosis is defined as a bone mineral density (BMD) t-score of ≤-2.5 standard deviations 
below the mean value for young healthy Caucasian women, measured using dual energy x-ray 
absorptiometry (DXA). However BMD alone does not predict all fracture; in fact, the majority of 
fractures occur in persons without osteoporosis (9-12). In 2010, 10.3 million US men and women 
≥50 years of age were estimated to have osteoporosis, with a total of 43.1 million persons having 
low bone mass (5, 13, 14).  
Decisions for treatment and prevention of osteoporosis and osteoporotic fracture utilize 
the osteoporotic BMD, prior fracture, and may use fracture risk tools to estimate future risk. 
FRAX® from the World Health Organization is a risk tool recommended by US guidelines, and 
is the most commonly used fracture risk tool (15). FRAX® estimates a patient’s 10-year fracture 
risk and, if guidelines are used to make treatment decisions, is likely related to the therapy 
decision and may serve as a marker of future fracture risk. Research which fails to account for 
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fracture risk and its relation to treatment decisions may produce results that are counterintuitive 
and overestimate the effectiveness of specific anti-osteoporosis therapies (16, 17). In clinical 
practice FRAX® is a diagnostic risk tool and a potential confounder in research of comparative 
effectiveness or patterns of anti-osteoporosis medication use.  
Although the variables used to calculate FRAX® should be available from a clinical 
interaction or from a medical records review, research using secondary data may not contain the 
variables necessary to calculate FRAX® or a recorded FRAX® score is generally not possible 
(18). For example, payers may be interested in evaluating the quality of care delivered to 
individuals they insure and basing reimbursement payments on that quality (19).  Payers readily 
have access to administrative claims, which contain the reimbursed services a patient has 
received, but rarely contain any clinical variables. We are aware of only one claims-based 
algorithm for predicting fracture risk, however this score results in its own estimate of fracture 
risk, rather than producing an estimate of FRAX®, which is the fracture risk score clinicians use 
to make treatment decisions (20). Although useful in a research context, this administrative 
claims-based algorithm cannot be used directly for information at the clinical decision point, or 
as a measurement of guideline concordant care.  
Rationale for the Calculated Fracture Risk Index (CFRI) 
We propose to create a calculated fracture risk index (CFRI) to predict FRAX® using 
only administrative claims variables to provide payers and researchers with a proxy of the 
fracture risk score a clinician would have used to make a treatment decision. Although CFRI 
may not be the optimal tool to fully reduce epidemiologic confounding, whether it could be used 
as a proxy for FRAX for evaluations of care quality or to improve confounding control as a 
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disease risk in comparative effectiveness studies is unknown (21). Additionally, CFRI could be 
computed using existing data and made available to providers. 
In non-experimental studies of treatment, it is challenging to validly contrast medication 
initiators to non-users due to baseline differences between the two groups, specifically due to 
confounding by indication (22-24). Approaches to making comparisons between these groups 
have included comparison groups of non-users (i.e., not using the medication of interest) or of 
groups using a different class of medication from the class of interest  Although non-users 
comparisons are generally not done, for our study we desire to compare effect estimates using 
CFRI to those which compared alendronate users to placebo users from the Fracture Intervention 
Trial (FIT) (25-27). The FIT trial represents the best estimate of the effectiveness of alendronate 
to non-users, because the placebo users are assumed to have similar medical histories and 
medication use as the alendronate users and change in fracture risk is attributed to the use of 
alendronate based on the theory of randomization. We will investigate ways that CFRI can 
balance baseline characteristics between alendronate users and a population of non-users by 
reducing confounding by indication in comparison to the FIT results. 
The most promising technique where CFRI may be used is restriction, which can 
minimize confounding by creating more homogenous sub-populations (23). Which may be more 
likely to require treatment and medical care. This restricted population should be at a similar risk 
for fracture, with CFRI performing similarly across the entire population. FRAX® and by proxy 
CFRI are designed as tools to assist in making treatment decisions, therefore restricting the 
population to users and non-users with similar fracture risk based on the FIT trial will help to 
clarify the utility of these diagnostic risk tools to reduce confounding by indication for users 
versus non-users. Additionally, after restriction we will evaluate different 
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pharmacoepidemiologic methods for estimating osteoporosis treatment effects, including inverse 
probability of treatment weighting compared to unadjusted and multivariable-adjusted estimates. 
This analysis will evaluate the potential use of CFRI by payers to evaluate the utility of the 
current AOM treatment quality measures based on treatment guidelines. 
1.2 Specific Aims 
To address the influence of FRAX® on the treatment decision and subsequent fracture 
outcomes we will determine if it is possible to identify surrogates for FRAX® in administrative 
claims data. We are interested in the information a clinician had at the face-to-face interaction 
where a decision on initiation of treatment was made, which is most applicable to evaluation of 
the quality of care. This information (CFRI) will use claims-based encounters to approximate the 
risk score at the face-to-face interaction for female patients. The analysis is restricted to female 
patients only due to long-term risks of fracture differing between men and women as well as 
possible differences in the ability for FRAX® to identify long-term fractures by sex. The long-
term goal of this work is to develop a proxy score for FRAX® which could be used to identify 
the quality of prescribing for individuals at risk for fracture and to reduce confounding in 
comparative effectiveness studies of AOMs. The objectives of this study are to develop and 
validate a claims-based algorithm for identifying FRAX® and to identify the best strategy for 
incorporating this measure into comparative effectiveness studies for optimal confounding 
control. To accomplish these goals, three specific aims have been crafted: 
Aim 1: Develop and internally validate a claims-based fracture risk index (CFRI) to 
estimate FRAX® risk scores at clinical interaction (office visit) using clinical registry data 
linked to Medicare claims data.   
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Hypothesis 1: In the final model, there will be no significant difference in predicted 
(CFRI) to observed (FRAX®) scores based on aR2. 
This aim will utilize clinical DXA registry data from the Cleveland Clinic Foundation 
that has been linked to Medicare Fee for Service (FFS) administrative claims. FRAX® scores are 
recorded during a DXA examination and include 10-year risks of major osteoporotic and hip 
fracture with and without BMD.  
We will create CFRI by estimating FRAX® utilizing both content knowledge of 
variables associated with osteoporosis and fracture based on the 2004 US Surgeon General’s 
report as well as identification of non-content variables associated with FRAX® using a high-
dimensional variable selection method during the 365-days prior to DXA in only females (5, 17, 
28). We will use an elastic net model to predict the independent variable (known FRAX®) using 
the factors associated with osteoporosis/ FRAX® as dependent variables (29-31). Validity of the 
estimates will be evaluated using calibration plots, R2, and mean-squared prediction error. This 
process will be repeated for all 4 types of FRAX® score; major osteoporotic fracture with and 
without BMD and hip fracture with and without BMD, with the internally validated model 
coefficients comprising the 4 CFRI algorithms.  
Aim 2: Externally validate CFRI in a 20% random sample of Medicare beneficiaries 
by comparing the performance of CFRI and FRAX® to predict future fractures.  
Hypothesis 2: There will be no significant difference between FRAX® and CFRI to 
predict future fractures as a continuous variable (calibration) between the linked and random 
sample.  
Hypothesis 3: CFRI will identify fractures at a similar rate based on c-statistics in the 
random sample as FRAX® in the linked sample (discrimination). 
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This aim will utilize only females from the linked sample as well as a 20% random 
sample of Medicare fee-for-service beneficiaries. We will externally validate the CFRI algorithm 
using major osteoporotic fracture or hip fracture endpoints at 1-year, using hip fracture for hip 
risk scores, and major osteoporotic fracture for those scores. In the random sample a single 
randomly selected office visit with at least 365-days continuous enrollment prior to the visit will 
be used to calculate CFRI.  
The data will be split into three groups, 1) linked sample FRAX®, 2) linked sample 
CFRI, 3) random sample CFRI. Calibration will be assessed using the Brier score and goodness-
of-fit testing by use of the Hosmer-Lemeshow test. Discrimination will be measured using 
receiver operating curves (ROC) and area under the curve for the 3 populations. We will also 
examine the equivalency of calibration and discrimination between the populations (32).  
Aim 3: Evaluate the utility of CFRI and restriction in a comparative effectiveness 
research study of alendronate users to non-users.  
Hypothesis 4: Comparative effectiveness estimates will most closely approximate 
Fracture Intervention Trial results after restricting by trial inclusion criteria and incorporating 
CFRI, then estimates generated without CFRI. 
Using the 20% sample of Medicare beneficiaries, we will compare estimates of fracture 
risk reduction in this sample for patients newly prescribed alendronate (users) versus patients 
with a new prescriptions for any drug other than medications prescribed to reduce fractures, 
including alendronate (non-users) to estimates generated from the randomized controlled 
Fracture Intervention Trial (FIT) which compared alendronate 10mg daily to placebo with up to 
4 years follow-up (25-27). Three other approaches to define non-users, users of specific 
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medication classes, and anchoring on the receipt of a DXA. As a first step, we will restrict the 
candidate population to only those with CFRI values similar to patients in the FIT trial.  
The goal of this aim is to present a likely way that payers would use CFRI to evaluate 
quality measures and reduce confounding in comparative effectiveness studies of AOMs. We 
will compare the effect estimates from our CFRI restricted population to those of the FIT trial to 
illustrate a user versus non-user application which may be applicable to payer quality 
measurement. To illustrate this we will present unadjusted, and multivariable adjusted estimates 
for the study population. The study population will be restricted to high-risk patients similar to 
FIT patients, and finally by all FIT inclusion/exclusion criteria with estimates created at each 
restriction. Lastly, we will fit a propensity score to model the receipt of alendronate using the 
content knowledge variables from Aim 1 (28, 33). This propensity score will be converted into a 
stabilized inverse probability of treatment weights, and weighted effect estimates will be 
produced. All analysis will utilize cox proportional hazards model and compare female new 
users of alendronate to new users of a non-AOM, with only the requirement of 365-days 
continuous enrollment in Medicare Parts A, B, and D prior to an office visit to calculate CFRI 
(22).  
1.3 Importance of Proposed Research Plan 
Benefits of Claims-based Algorithms for Defining Fracture Risk 
The use of claims data to calculate FRAX® is important to payers and researchers for a 
number of reasons. FRAX® is the most widely recognized fracture risk score in current clinical 
practice and is a component of several US osteoporosis management guidelines. There are no 
methods to estimate FRAX® in administrative claims data wherein payers typically evaluate 
quality measures. Manual abstraction of FRAX® from medical records by payers would be 
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costly and time consuming as FRAX® scores and bone mineral density measurements are 
generally only available in unstructured data. The claims-based fracture risk index (CFRI) on the 
other hand is based solely in administrative claims and will allow payers to tie medical care to 
quality measures using data which they already collect. Additionally, CFRI can be used by 
payers to identify high-risk patients using readily available data without additional costs.  
For researchers, collection of FRAX® from unstructured clinical data including the 
identification and collection of all patient-level FRAX® risk factors would be unfeasible on a 
population level. Calculating FRAX® using CFRI in administrative claims would provide the 
opportunity to account for FRAX® and treatment decisions related to FRAX® using available 
data. A clinician’s decision based on National Osteoporosis Foundation (NOF) guidelines to 
initiate an anti-osteoporosis medication accounts for FRAX® risk, however without CFRI it 
cannot be measured or controlled for by researchers using administrative claims. Because 
FRAX® is a significant part of the US clinical osteoporosis guidelines with treatment decisions 
based on FRAX® risk, calculating FRAX® in administrative claims data available to payers and 
researchers will provide previously unavailable opportunities for the evaluation of care quality 
and effectiveness of therapies. 
Payment Implications of Claims-based Fracture Risk Guidelines 
Centers for Medicare and Medicaid Services (CMS) and commercial payers have 
increasingly moved towards reimbursement for medical care based on care quality. Quality 
measures generally are based on national guidelines and expert opinion. However, in 
osteoporosis, quality is assessed through diagnoses of osteoporosis, fracture, or AOM use. The 
rationale behind basing osteoporosis quality measures on these factors is related to the ability to 
capture these values in administrative claims (where most payers will evaluate care quality). As a 
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result, osteoporosis quality measures have only focused on specific groups at risk for fracture 
(AOM users, fracture patients, and patients with osteoporosis), rather than the general population 
as intended by the NOF guidelines. Payers reimbursing medical expenses, including CMS now 
linking reimbursement for hospital stays to quality may prompt both commercial payers and 
CMS to use quality measures based on NOF guidelines to increase clinician prescribing based on 
the guidelines, reduce preventable osteoporotic fractures, and not reduce their amount 
reimbursed for care administered (34).  
CFRI may also be used to identify patients at high-risk for fractures and allow for 
intervention prior to a fracture, rather than after the patient has already had a fracture, been 
diagnosed with osteoporosis, or is prescribed an anti-osteoporosis medication. Up to thirty 
percent of patients with osteoporosis do not have a corresponding diagnostic code, and the 
majority of fractures occur in those without osteoporosis (35). Targeting patients based on 
fracture risk rather than prevalent fractures will allow payers to target primary prevention 
interventions rather than treatment of osteoporotic fractures, potentially reducing future costs.  
Comparative Effectiveness Implications of Research 
CFRI will be important in comparative effectiveness research (CER) as it may be used to 
create and evaluate “empirical equipoise” in osteoporosis research. Equipoise occurs in clinical 
practice when treatment options are considered interchangeable (no clear winner); for example, 
when a clinician chooses a therapy based on preference rather than on the merits of the specific 
therapy (21). For empirical equipoise to be valid, researchers need to be confident that a clinician 
views two patients at equal risk for fracture and make treatment decision based on preference.  
In osteoporosis, fracture risk may be argued as the best proxy for empirical equipoise. 
Based on NOF guidelines, if two patients have equal fracture risks, it is a clinician’s choice as to 
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which medication to start rather than the guidelines. Ergo the clinician’s preference should drive 
the choice of therapy for patients with similar fracture risks. In this way, propensity scores can be 
used to restrict or balance CFRI between the treated and the untreated and should serve as a 
proxy to control confounding by patient characteristics and create empirical equipoise. The 
results of these analyses should provide a basis to explain the difference in treatment decisions 
and effectiveness for the treatment of osteoporosis and osteoporotic fracture. Specifically, CFRI 
based restriction will be important for payers to determine optimal treatment groups, policy 
makers to evaluate the appropriateness of osteoporosis guidelines, and researchers to evaluate 
empirical equipoise in osteoporosis research.  
CFRI would be an essential tool for payers and those interested in the quality of care as 
well as a proxy for empirical equipoise. Although FRAX® itself is an imperfect estimate of a 
patient’s future fracture risk, it is the most commonly used fracture risk tool in the US, has 
physician buy-in, and is currently used in national guidelines. Therefore, understanding patients’ 
fracture risks retrospectively during clinical encounters will allow payers, policymakers, and 
researchers to assess appropriate care and identify ways to improve patient outcomes.  
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 BACKGROUND 
2.1 Introduction 
To help guide the reader through this project, an explanation of how each aim fits into the 
standard of care is warranted. Although standard of care is primarily a legal term, most 
authorities agree that a particular specialties standard of care is based on guidelines or consensus 
statements (36). In the US, the most common osteoporosis guidelines are those of the National 
Osteoporosis Foundation, and their Clinician’s Guide. The 2014 Clinician’s Guide describes the 
continuum of care as assessing fracture risk, diagnosing osteoporosis, administering treatment 
when appropriate, and measuring the effectiveness of treatment (Figure 2.1) (37).  
Figure 2.1 Osteoporosis Standard of Care 
 
Revised from the Cosman et al, 2014 (37) 
In brief FRAX®, DXA, and general health characteristics are first assessed by the 
clinician to assist in making a diagnosis. Once the patient has been assessed for osteoporosis by 
DXA bone density criteria, the clinician can then utilize the information gathered to determine if 
the patient meets the requirements for an osteoporosis diagnosis, or warrants treatment outside of 
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the osteoporosis diagnosis. For those patients who warrant treatment the next step is for 
treatment to be administered, and after a period of time for the effectiveness of therapy to be 
reevaluated. If a decision to treat is not made then the patients should be reassessed in the future 
to determine if a diagnosis or treatment are warranted. 
The aims for this project are based on this standard of care model and follow along the 
continuum of care. We present where each of the Aims fall along the model in Figure 2.2. For 
this project, we are estimating FRAX® utilizing administrative claims data to create CFRI and 
evaluating its internal validity in Aim 1 which represents assessing fracture risk. Then in Aim 2 
we are externally validating CFRI in a random population of Medicare beneficiaries and 
evaluating its ability to predict 1-year fracture rate, which requires both assessing fracture risk, 
and determining if the given fracture risk warrants treatment. Finally, in Aim 3 we are assessing 
the utility of CFRI to reduce confounding in the comparison of alendronate users to non-users, 
which spans both the administration of treatment and the evaluation of treatment effectiveness.  
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Figure 2.2 Aims role in Standard of Care 
 
To understand why fracture risk and fractures in general are important, we felt it was first 
important to understand what type of fractures we were discussing. Therefore, we begin our 
background by discussing how fractures have been deemed to be osteoporotic, the relationship to 
osteoporosis, and the epidemiology of these fracture sites. Knowing the sites wherein 
osteoporotic fractures occur helps us to explore the costs, both economic and societal including 
morbidity and mortality of osteoporotic fracture, primarily in the US. Although these are the 
costs of fracture, there are ways to identify patients at risk prior to the fracture occurring, to this 
end we discuss the current fracture risk assessment tools, particularly focusing on FRAX®. To 
provide a context for building the claims-based fracture risk index (CFRI) we describe the data 
that FRAX® was built upon, including the patient characteristics and proprietary algorithm. 
With the discussion of FRAX® we also investigate its applicability to the US, including its use 
in the National Osteoporosis Foundation (NOF) guidelines and other risk tools that are currently 
being used in the US. Because AOM have been found to reduce fracture risk, and 
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recommendations are made for their use by the NOF guidelines we then describe the currently 
available Food and Drug Administration (FDA) approved therapies. We finish our background 
by discussing Andersen’s model for Healthcare Utilization which provides a context for 
characteristics used to predict the use of AOMs in Aim 3. 
2.2 Osteoporotic Fracture 
To better understand how osteoporotic fracture effects the population it is imperative to 
first understand what an osteoporotic fracture is. In this section, we discuss the different 
definitions of osteoporotic fracture including the definition currently favored by the FRAX® 
algorithm. The relationship between osteoporosis, bone mineral density, and fracture. The 
epidemiology of the fracture sites thought to be osteoporotic, and finally how these fracture sites 
have been identified in administrative claims-based analyses. 
2.2.1 Definition 
Although fracture is the clinical manifestation of osteoporosis, there is no universally 
agreed upon definition of osteoporotic fracture. The actual cause of a fracture is multi-factorial 
including heredity, fall mechanics, and bone density among other characteristics (Figure 2.3) 
(37-39). One common way to define osteoporotic or fragility fractures are those which occur in 
the presence of low bone mass with either no or a low-energy impact (40, 41). Low-energy 
impact fractures also commonly referred to as “fragility fractures” and are fractures which likely 
would have not occurred in healthy persons, particularly those that result from falls at a standing 
height or less (41, 42). When a person falls from a standing height the force exerted on the femur 
has been estimated to be at least 10 times the impact needed to fracture the femur (43). Only 
10% of all falls result in serious injury and 5% in fracture (44). Cohort studies have found low 
bone mineral density, fall history, concomitant diagnoses, and how the patient falls are 
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associated with if a fall will cause a fracture (44-47). Studies of the addition of a hip protector for 
patients who have a fall history has not consistently shown fracture reduction, suggesting that 
only reducing the force on the femur at a fall is not sufficient to prevent fracture (48, 49).  
Fragility fractures were found to be responsible for the majority of hip and humeral fractures as 
well as 75% of vertebral fractures in a Swedish cohort (50). Though data from the Study of 
Osteoporotic Fracture (SOF) has suggested that only classifying fractures based on the amount of 
trauma needed to cause the fracture will lead to an under estimation of osteoporotic fractures 
(51).  
Figure 2.3 Pathogenesis of osteoporosis-related fractures 
 
From Cosman et al (37), adapted from Cooper and Melton (39), from Riggs (38) 
SOF analyses also have demonstrated that all fractures, excluding those of the face, but 
including fractures caused by trauma are associated with low bone density measured at either the 
radius, hip or spine (51-53). For example, a one standard deviation decrease in BMD was 
associated with between 1.39 and 2.01 increase in the risk for hip fracture based on duration of 
follow-up and measurement site (51, 52). This increased risk also transfers to high-impact 
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fractures with patients having low bone mass at a greater risk of fracture after high-energy 
impact compared to those with normal bone mass (54, 55).  
With the difficulties of quantifying the amount of trauma needed to cause the fracture, 
another definition based on fractures which are associated with low bone mass and increase after 
age 50 has been proposed (56, 57). Using this definition vertebral, rib, pelvic, humeral, forearm, 
hip, tibia and fibula in women, as well as fractures of the clavicle, scapula, and sternum are 
considered osteoporotic fractures (51, 53, 56, 58). In this definition, the only fracture sites which 
were not considered to be osteoporotic were skull and face, tibia and fibula in men, feet and toes, 
ankle, and patella fractures, though ankle fractures specifically have been found to be associated 
with low peak bone mass. One criticism of this definition is that it underestimates the burden of 
osteoporotic fracture for person under the age of 50 as the definition itself requires that fractures 
are at an increased rate after this period (40). Still another definition has been based on sites 
where reduced bone density has been associated with the fracture and consider fractures of the 
vertebrae (spine), proximal femur (hip), and distal forearm (wrist) as quintessential osteoporotic 
fractures (59). 
Attempting to quantify osteoporotic fractures by bone mass or amount of trauma has not 
led to a concrete definition. However, to estimate the economic impact and societal burden of 
osteoporosis and osteoporotic fracture a common definition was sought. The first published 
report used discharges from the 1985 National Hospital Discharge Survey, National Nursing 
Home Survey, and National Ambulatory Medical Care Survey to determine what proportion of 
healthcare utilization with osteoporosis listed as a diagnosis were directly attributable to low 
bone mass (60). This report was the first to directly tie dollar amounts to osteoporosis and 
osteoporotic fracture using attribution rates for the contribution of osteoporosis to each medical 
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cost. Pathologic and non-pathologic fracture of vertebrae, pelvis, femoral neck, and humerus 
were the fracture sites most attributable to osteoporosis (70% attribution for patients aged ≥60) 
(60).  
In 1995, the National Osteoporosis Foundation (NOF) convened an expert panel to assess 
the cost effectiveness of osteoporosis interventions. The expert panel viewed hip, spine, and 
forearm fractures as more than 50% attributable to osteoporosis, although the attribution did 
differ somewhat based on age and gender (42). The most attributable fractures were hip fractures 
(0.95 attribution probability) for all women aged 85 years or older. This panel for the first time 
addressed the differences in attribution of osteoporosis for men and non-white women. However, 
the only sites which were assessed were broadly defined as hip, spine, forearm, and other 
fractures which lack specificity for site specific probabilities and cost. The panel gave attribution 
weights which were designed to be utilized in cost analyses as the proportion of fracture costs 
which could be directly linked to osteoporosis and fracture in 1995 and are based solely on 
expert opinion. 
With increasing use of administrative claims to evaluate osteoporosis, a 2011 meta-
analysis and expert panel review provide likelihood estimates for fracture sites to be associated 
with osteoporosis. This working group for the first-time integrated ICD-9 codes for fractures into 
osteoporosis attribution to better estimate the burden and costs of osteoporosis and osteoporotic 
fracture. Femoral neck, pathologic vertebral fractures, lumbar, thoracic, closed distal forearm and 
radius/ulna (NOS), and pelvis were sites which had a median of rating of 9 (most likely because 
of osteoporosis) from the expert panel (61). Conversely open fractures of the proximal humerus 
and closed fractures of the skull and facial bones were viewed as least likely to be associated 
with osteoporosis (61).  
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In osteoporosis RCTs the difference in bone mineral density at the femoral neck or 
lumbar spine commonly are used as surrogate end points for treatment efficacy rather than 
differences in fracture rate. This is due to a very large population being needed to demonstrate a 
significant reduction in fracture rate between the treatment groups. Also, it has been suggested 
that it may be unethical to treat patients with established osteoporosis with placebo rather than 
active drug because we know that active drug can reduce fractures (62). In randomized clinical 
trials, all non-traumatic fractures other than those of the skull, fingers, and toes generally are 
used in endpoint definitions. In recent trials of osteoporotic medications, fractures at the femoral 
neck and vertebral spine commonly are specified as endpoints with other fractures combined into 
an omnibus category (63, 64). Trials of osteoporosis medications generally have separately 
analyzed hip and vertebral fractures with all fractures other than those of the skull, fingers, and 
toes also being assessed for treatment efficacy.  
For epidemiologic studies the most commonly studied fracture definition is that of 
clinical spine, forearm, hip or shoulder which is defined by the WHO FRAX® tool as major 
osteoporotic fractures. This definition and specific sites are further discussed in section 2.5. In 
this proposal, we will utilize two osteoporotic fracture definitions. For aims 1 and 2 we will only 
use fracture sites included in FRAX® major osteoporotic fracture (spine, forearm, hip, or 
proximal humerus [shoulder]) with codes presented in Table 3.3 (65). While for aim 3 we will 
utilize a broader definition including all sites included in the MOF definition as well as pelvis 
tibia/fibula, clavicle, thoracic, and lumbar spine, because these were the sites from the Fracture 
Intervention Trial which corresponded to clinical fracture.  
Osteoporotic fracture is the clinical manifestation of osteoporosis (low bone mass) or 
bone fragility. The first attempts to classify osteoporosis based on fracture risk found that the 
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90th percentile of 90% of all hip and vertebral fractures were approximately 2 standard deviations 
(SD) below the normal bone density distribution for both young men and women (66). This -2 
SD threshold was found to hold for measurements at the hip, proximal femur, and distal radius in 
both men and women (66). When reporting on this topic Riggs et al were the first to provide 
support to the idea that if a patient decreased past a specific bone mineral density threshold then 
they were more likely to sustain a fracture.  
In 1994 a specific threshold, that of -2.5 SD below the average value for a young healthy 
woman was proposed by the WHO for epidemiologic identification of osteoporosis using bone 
mineral density calculated by dual energy x-ray absorptiometry (DXA) (9, 67, 68). The reference 
value for defining osteoporosis among “young healthy women” were further clarified to the 
National Health and Nutrition Examination Survey (NHANES) III BMD values for 20-29-year-
old Caucasian women (69, 70). Specifically, a femoral neck t-score is calculated as 
(BMD – 0.858 [reference mean])
0.120 [reference SD]
 with all other bone mineral density sites based on the same 
population. The 1994 WHO definition also gives definitions for osteopenia (T-score -1.01 to -
2.49), normal (T-score >-1.0), and severe osteoporosis (T-score ≤-2.5 and prevalent hip or 
vertebral fracture) (Table 2.1) (9). The WHO definition was clarified in 2008 to encourage use of 
the NHANES III reference values and measurement of BMD at the femoral neck for the 
diagnosis of osteoporosis (70).  
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Table 2.1: Osteoporosis Classifications 
Bone Density T-Score Diagnostic Category 
Greater than or equal to -1.0 Normal 
Less than -1.0 and greater than -2.50 Osteopenia 
Less than or equal to -2.50 Osteoporosis 
Less than or equal to -2.50 with one or more fragility 
fractures 
Severe Osteoporosis 
From WHO Technical Report, 1994 (9) 
A position statement was presented in 2012 that argued that some of the under treatment 
and diagnosis of osteoporosis in the US may be due to a very limited definition of osteoporosis, 
which may need to be revised (71). To address insufficiencies of the current osteoporosis 
definition the Bone Health Alliance Working Group formalized a new definition in a 2014 
position statement (72). The working group argues that patients who have experienced a low-
trauma hip fracture and for those who have osteopenia by BMD who sustain a low-trauma 
vertebral, proximal humerus, pelvis, or, in some cases, distal forearm fracture, sites which are 
known to confer an increased future fracture risk, patients with a t-score ≤-2.5, as well as patients 
at an increased fracture risk based on fracture prediction tools should all be classified as having 
osteoporosis (72). This definition would include more persons in the US who previously had not 
been classified as osteoporotic and was intended to identify all persons at an increased fracture 
risk. At the present time, the new definition including fracture risk has not been formally 
accepted by payers as adequate for treatment reimbursement. If this new definition were to be 
adopted a formal process for assessing fracture risk based on data available to payers would need 
to be created and automated. 
At the present time, BMD is important but not required in calculating fracture risk. Since 
2006 the percentage of patients receiving DXA scans in the United States has diminished 
possibly due to a reduction in reimbursement in the outpatient setting (73-79) or a reduction in 
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serial scanning for patients where repeat scans are not warranted (76). However, King et al have 
suggested regardless of why fewer scans are being performed their decrease will lead to more 
osteoporotic fractures which will increase the cost of osteoporosis for the United States (74). 
Adding to the confusion is lack of consensus on when to start screening for osteoporosis, how 
often to screen, and whom to screen (80). 
2.2.2 Epidemiology of Fracture 
2.2.2.1 Hip Fracture 
Hip fractures are fractures at the proximal femur either through the femoral cervix or 
through the trochanteric region (40). These fractures although only accounting for 20% of all 
osteoporotic fracture are the most readily captured and studied type of osteoporotic fracture as 
they typically require medical intervention (40, 81). It has been estimated that only 1% of all 
femoral fractures do not require medical intervention, possibly due to patients already lacking 
mobility and the risk of surgery outweighing the possible benefits of surgical fixation (82). 
Depending on location and severity of the fracture differing surgical interventions can be 
undertaken.  
Incident hip fractures are associated with an increased risk of death within 1-year, with 
between an 8.4% and 36% of the risk of death attributed to hip fractures (83). Additionally, 
~20% of patients require care at a long-term facility and only 40% regain the level of 
independence they had prior to the fracture. As such, hip fractures are responsible for much of 
the excess morbidity and healthcare cost associated with osteoporotic fracture. This has led to 
their use as a surrogate for the overall cost of osteoporosis and related care.  
In the Rochester cohort increased between 1928 and 1982 before a decrease between 
1983 and 1992, and a further decrease from 1992 to 2004 (84-86). Additionally, proximal femur 
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fractures decreased between 1989-1991 and 2009-2011 (87, 88). Results from the Framingham 
cohort suggest that when a person was born has as much to do with fracture rate as their age with 
more recent births having an increased fracture risk (89). Showing that hip fracture rates may 
differ based on US region. With only regional cohorts to base US hip fracture rates on, the 
National Hospital Discharge Survey for the years between 1970 and 1983 was used to make a 
nationally representative estimate. Between 1970 and 1983 hip fractures increased by 9.3% (90). 
A subsequent analysis of the National Hospital Discharge Survey (1965-1993) indicated a linear 
increase in hip fractures for men regardless of age group with a less sharp increase for women 
during the study period (91). This suggests that regional estimates alone may be insufficient to 
estimate hip fracture rates for the US. 
The first estimate of hip fractures utilizing administrative data in the US utilized a 20% 
Medicare sample between 1985 and 2005 to estimate hip fracture in the United States. Using age 
adjusted rates hip fractures increased 9.0% in women between 1986 and 1995 before decreasing 
by 24.5% by 2005 (92). Men saw an increase of 16.4% between 1986 and 1995 before a decline 
of 19.2% by 2005 (92). These findings were echoed by an analysis of 1998 to 2007 rates of 
intracapsular hip fracture in a 5% sample of the Medicare population (93). In a non-Medicare 
commercially insured female population between 2000 and 2005 hip fractures increased (94). 
Which may suggest a continued increase in hip fracture for persons less than Medicare age (<65) 
with a decrease in hip fractures for older adults.  
US and non-US hip fracture incidence rates were compared using the Rochester cohort 
between 1928 and 1982 and all other available estimates finding men to have similar fracture 
trajectories (84). While in women the US rates appear to stabilize in the 1950s, European and 
Oceanic estimates continued to rise (84). This was updated in 2011 finding that hip fractures 
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increased until the 1980s where they began to decline in the US, Canada, and Norway (95). In 
most other estimates hip fractures increased until the 1990s wherein they too began to stabilize 
or decline other than those from Japan. The study suggests that the secular trends are due to one 
of three rationales, 1) a change in the frequency of risk factors for fracture which act relatively 
late in the life course; 2) a change in the frequency of risk factors influencing bone strength and 
propensity to trauma in early life which feed through as altered fracture rates in successive birth 
cohorts; and 3) alterations in the demographic structure of the populations studied within age and 
sex strata (95).  
2.2.2.2 Vertebral Fracture 
Changes in the size and shape of the L1-L4 lumbar are typically considered vertebral 
deformities or fractures. It has been reported that less than 1/3 of all vertebral deformities noticed 
by radiologists necessitated medical attention with less than 1/10 necessitating hospital 
admission (96).  Many patients complain of lower back pain or kyphosis (curvature of the spine) 
which prompts the discovery of vertebral fractures. Once a vertebral deformity is found it has 
been estimated that women have a four times higher risk of having an additional vertebral 
deformity without intervention (97, 98). Additionally, vertebral fractures were found to be 
associated with a 1.5 to 11.1 incidence rate increase in the Rochester cohort depending on site of 
future fracture (98). Though a study from European Vertebral Osteoporosis Study (EVOS) 
indicated that vertebral fractures were associated with an increase in hip but not forearm 
fractures (99). Vertebral deformities are typically augmented through balloon kyphoplasty or 
vertebroplasty which provide stability for the spine after the fracture. A recent randomized 
controlled trial has indicated that patients receiving either of these two treatments have similar 
long-term outcomes (100).  
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There are multiple definitions for vertebral fracture which make comparison across 
epidemiologic studies difficult. Some favor the idea of “you know one when you see one”, based 
on x-ray which is commonly referred to as expert opinion, however there have been recent 
attempts to create a more objective definition, these fractures are generally referred to as 
“clinical vertebral fractures” (101, 102). Clinical vertebral fractures generally are also based on if 
the patient sought medical attention care for their fracture. Morphometric vertebral fractures are 
diagnosed by vertebral measurements at the anterior, middle, or posterior heights of each 
vertebral column exceeded a pre-specified measurement (57, 101, 103). However, this technique 
has been found to underestimate the number of symptomatic and overall vertebral fractures 
(104). A second technique is based on a semi quantitative method proposed by Genant which 
summarizes the changes in shape as graded reductions in overall height and area (105). A further 
revision to a quantitative assessment has also been proposed (106). However, because all of the 
definitions differ at least slightly, they commonly disagree on the incidence and prevalence of 
vertebral fracture in the population (101, 107, 108). 
In an EVOS study Leidig-Bruckner et al found that depending on age, sex, and definition 
of vertebral deformity prevalence ranged from 2% to 17% (estimated from figure) in men to 3% 
to 27% (estimated from figure) in women (109).  The incidence of vertebral fracture has also 
been shown to increase after age 50. Based on data from the cohort in Rochester, Minnesota the 
incidence of vertebral fracture has increased from 659 per 100,000 persons to 968 per 100,000 
persons in both sexes combined comparing 1989-1991 to 2009-2011 (88). The incidence of 
vertebral fracture increased by 280 for women (812 to 1092) and 338 (460 to 798) for men when 
comparing age adjusted rates from 1989-1991 to 2009-2011 (88). 
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In a study of patients (including men) admitted to an internal medicine service in Italy, 
47.5% of all patients had at least one vertebral deformity. Of most interest was 79.7% of these 
vertebral fractures were found in persons without a previous diagnosis of osteoporosis. Although 
the rate of vertebral deformities is relatively high, with 32% (atraumatic vertebral fracture) or 
25% (vertebral compression fracture) of women expected to have a measurable vertebral 
deformity in their lifetime (depending on definition), severe vertebral deformities representing 
~10% of all vertebral deformities are responsible for substantial increases in back pain and 
disability (110-113). They also represent the majority of deformities which are symptomatic and 
require medical intervention (96, 114). Therefore, estimates based on report rather than 
measurement of vertebrae likely underestimate the prevalence of vertebral fracture.  
2.2.2.3 Other Fractures 
The most common fracture site after hip and vertebral are fractures of the wrist, typically 
classified as fractures of the ulna or radius. In an analysis of a commercially insured population 
between 2000 and 2005 Islam et al found the age adjusted incidence of wrist fractures to increase 
from 10.2 to 16.4 per 10,000 persons (94). Within this cohort, they also found an increase in rib 
and pelvis fractures between 2000 and 2005 (94). Based on the Rochester cohort, distal forearm 
fractures had increased by ~0.5% per year from 1945 to 1994 (115). While distal forearm 
fractures were reported to have decreased from 646 to 475 per 100,000 person years between 
1989-1991 and 2009-2011 (88). Rib and pelvis fractures have also been noted to have decreased 
during this time period (88). However, the epidemiology of other fracture sites has not been well 
documented within the United States. 
In a longitudinal study of the Geelong Osteoporosis Study 55.2% of the study population 
(females and males) had a fracture at some point in their lives. The study included all fracture 
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sites and did not discriminate based on age at fracture. First fractures more commonly occurred 
at young ages in men (<30 years of age), while females first fractures occurred mainly after age 
50, possibly in a perimenopausal period (116). 
2.2.3 Validated fracture sites 
Hip fractures, as the mostly costly of osteoporotic fractures, have been the site most 
widely validated by medical record review (117). In the US only Ray et al have evaluated the 
validity of hip fracture codes in Medicare claims to have a sensitivity of 97% and a specificity of 
98% comparing Medicare claims to hospital records (118). To our knowledge, the only other 
validation of hip fracture codes within the US was conducted comparing self-report of the Iowa 
Women’s Health Study to Medicare claims with a sensitivity of 65% and specificity of 35% 
(119).  
The group from Manitoba although not directly validating the codes for hip or other sites 
of fracture compared fracture prevalence based on a national cohort and those which they could 
validate within their own cohort. They found that in general ICD-9 codes generally 
underestimated the prevalence of hip fracture in females without a statistical significant 
difference in men (120). In the US only Curtis et al have validated the diagnostic codes for 
vertebral fracture finding a sensitivity of 56% (95% CI 43, 68%) and specificity of 69% (95% CI 
58, 80%) comparing diagnoses and procedural codes to medical records (121). 
2.2.4 Administrative claims-based definitions 
Epidemiologic studies of fracture using administrative data typically include fractures of 
the hip, spine and humerus defined using International Classification of Disease, Ninth Edition 
(ICD-9) diagnoses of fracture and /or Common Procedure Terminology (CPT) or Healthcare 
Common Procedure Classification System (HCPCS) codes for repair of the fracture (Table 2.2). 
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Definitions may or may not take into account the duration of time between diagnoses and 
procedures, or how to differentiate between same site or multiple site fractures occurring around 
the same time.  Most studies have defined osteoporotic fracture as hip and spine/vertebral 
fractures only, which underestimates osteoporotic fracture and has been shown to result in low 
power to detect a difference between AOMs (17). Because of this, including all fractures which 
can be logically attributed to osteoporosis (other than face, skull, fingers and toes) should 
increase the power to detect differences in effect size. However, in an analysis of GIO patients, 
the inclusion of all fracture sites increased the number of fractures, but reversed the directionality 
of the effect, suggesting that fracture locations outside of hip, vertebral, pelvis, humerus, or wrist 
may be poorly defined and may cause misclassification (17). When a fracture definition only 
including the hip, vertebral, pelvis, humerus, and wrist sites the expected directionality resumed, 
with most of these sites having administrative definitions which have been validated with 
medical records.  
Many of these studies also use diagnosis codes for pathologic fractures (ICD-9 733.10-
733.19) which are defined as fracture caused by disease other than those which are attributable to 
osteoporosis. In a review of pathologic fractures in Medicare claims, Curtis et al found that 
~25% of patients with a pathologic vertebral fracture and ~66% of patients with a pathologic hip 
fracture had evidence of a possible cancer diagnosis associated with the fracture (122). However, 
the authors concluded that excluding pathologic fractures would result in a substantial 
underestimation of osteoporotic fracture (122).  
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Table 2.2 Administrative Claims Osteoporotic Fracture Definitions 
First Author, Year Sites Used 
Halpern, 2011 (123) Hip, vertebral, humerus, wrist, radius-ulna, femur, patella, tibia-
fibula, ankle, pelvis, clavicle; Associated CPTs 
Kim, 2010 (124) Hip Pelvis, humerus, wrist; Accompanying CPTs 
Liu, 2013 (125) Hip, Radius, Humerus and Vertebral; Accompanying CPT codes 
Lix, 2012 (120) Hip (820-821.xx); Wrist (813.xx); Humerus (812.xx); Clinical 
Vertebral (805.xx) and accompanying CPTs 
Looker, 2013 (126) Hip, humerus, radius, spine  
Martin, 2011 (127) Hip, pelvis, femur, lower forearm, radius/ulna, humerus, vertebral, 
and other; Accompanying CPTs 
Overman, 2015 (17) Hip, pelvis, humerus, wrist, or spine; Accompanying CPTs 
Patrick, 2011 (128) Hip, distal forearm, spine, proximal forearm, humerus, non-hip 
femur, pelvis, clavicle/scapula, sternum, tibia/fibula; 
Accompanying CPT codes 
Solomon, 2014 (129) Hip Fracture (820.0x, 820.2x, 820.8, 733.14, 733.95) and 
accompanying CPTs 
Taylor, 2011 (130) Hip, pelvis, leg (other than hip), ankle, distal forearm, radius/ulna, 
humerus-closed, humerus, clavicle-closed, clavicle-other, spine, 
wrist 
 
2.3 Burden of Osteoporosis and Osteoporotic Fracture 
2.3.1 Prevalence 
In the US estimates of osteoporosis prevalence have primarily been based on the National 
Health and Nutrition Examination Survey (NHANES) a cross sectional study of the non-
institutionalized population of the United States (131). Based on femoral neck BMD from 
NHANES III (1988-1994), the NOF estimated that ~10 Million US adults aged 50 or older had 
osteoporosis with ~33 Million more US adults having osteopenia (14). This figure has been 
updated based on NHANES 2005-2010 to 10.3% (10.2 Million) of US adults aged 50 or older 
had osteoporosis and 43.9% (43.4 Million) US adults with low bone mass (osteopenia) (13). 
Estimates for European countries are similar to those of the US (40).  
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A 2014 analysis by Wade et al estimated the prevalence of osteoporosis in the US using total 
hip and lumbar spine BMD finding osteoporosis in 14% of females and 2% of US males 50 and 
older based on total hip BMD (8,237,129 persons) and 4% of males and 16% of females based 
on total hip and lumbar spine BMD (10,277,771) (132). Both of these figures are based on 
estimates combining weighted populations from NHANES III (1988-1994) and NHANES 2005-
2008 and standardizing the population to 2010 US Census population (132). Prevalence 
estimates based on this methodology were significantly greater for European countries when 
lumbar spine was also used to estimate osteoporosis prevalence. The estimates by Wade et al for 
European countries however are lower than estimates by Hernlund et al basing osteoporosis 
prevalence for the European Union on population data extrapolated from NHANES III (133). 
One estimate of osteoporosis prevalence has been made based on administrative claims data 
for the United States. Using the Medicare Fee-For-Service population from 1999-2005, and a 
definition both using a diagnosis, and an associated procedural code 29.7% (95% CI 29.6, 
29.8%) of the population ≥65 were presumed to have osteoporosis. Specifically, 42.5% (95% CI 
42.4, 42.6%) of women and 10.1% (95% CI 10.0, 10.2%) men in this age range were presumed 
to have osteoporosis (134). Age and sex specific estimates were similar in this analysis to those 
of Looker et al using the NHANES data (134, 135). However studies have found up to 30% of 
patients with osteoporosis on DXA did not have a corresponding diagnosis code within 1-year of 
DXA (35, 117, 136, 137).  
Estimates of osteoporotic fracture within the US suggest that one out of every two Caucasian 
women and one in every five men in the US will experience an osteoporotic fracture at some 
point in their life (14).  
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2.3.2 Morbidity 
Osteoporotic fracture particularly hip fractures are associated with a significant disability 
post-fracture. Between 20-60% of patients with hip fractures are reported to have needed long-
term post-fracture care, including nursing home admission (14, 82). Additionally, in patients who 
survive to one year after fracture, between 40 and 49% of patients had returned to their pre-
fracture state (14, 82).  
A 2014 meta-analysis of studies providing health utility values (HUV), with a value of 0 
being death and 1 being perfect health, for osteoporosis and osteoporotic fracture found a 
decrease of 0.19 for hip fractures and 0.17 for vertebral fractures at one year compared to pre-
fracture value of 0.76 (138). Which indicates nearly 20% of a patient’s health (quality of life) 
compared to perfect health is lost due to a hip or vertebral fracture. Immediately after the fracture 
the HUV values were 0.31 for hip fracture and 0.44 for vertebral fracture indicating that patients 
gain back a significant proportion of their expected health as time from fracture increases, but 
that a significant impairment is caused by fracture (138). A 2009 meta-analyses estimated the 
health of a patient after 1-year for vertebral fractures to be 0.30 and 0.24 for hip fractures (139). 
As meta-analyses are published it is important to note that osteoporosis and osteoporotic fracture 
are found to have a greater effect on health than previously thought (140). Overall osteoporosis 
and osteoporotic fracture cause a significant decline in patients’ health in both the near and long-
term, warranting early identification and intervention. 
2.3.3 Mortality 
Osteoporosis, regardless of osteoporotic fracture, is associated with an increased risk for 
mortality (4, 141, 142). This increased risk is typically due to associated complications (such as 
pneumonia due to lack of mobility) of the hip fracture, rather than the hip fracture itself. A 2010 
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meta-analysis reported a 5 to 8-fold increase in mortality risk in the 3 months after hip fracture 
(143). In the first year post-hip fracture mortality risk has been reported as high as ten times and 
as low as two times that of the general population (4, 144-146). The risk of death is greatest in 
the period immediately following the fracture, but continues to be elevated for the rest of a 
patient’s life compared to the general populace (142, 143, 147). In an early analysis of the 
Rochester Cohort, 41% of patients with a hip fracture were deceased within one year after 
fracture (82). In women 60-69 an estimated 3,993 additional deaths per year could be attributed 
to osteoporotic fracture in the US, while an additional 9,303 deaths in men 60-69 based on data 
from a 1999 Australian study (4). Another study has estimated that 24% of all deaths after hip 
fracture are causally related to the fracture itself (148). 
Following a vertebral fracture there also is an increased risk for death (4, 141, 142, 146, 
147, 149-152). In one study women who had at least one morphometric vertebral fracture had a 
mortality rate 23% greater than that of women of a similar age (149). Clinical fractures however 
have a greater mortality risk with a hazard ratio of 4.4 reported in one study (151). Additionally, 
a prevalent vertebral fracture continues to be associated with an increased risk of fracture up to 
22 years after the initial presentation of the fracture (152, 153).  
Reports have indicated that there is no increase in mortality risk after wrist fracture (4, 
142, 146, 150, 154, 155). However, in a 2002 study with 7 years of follow-up patients with a 
distal forearm fracture were found to be at increased risk for death, though this was most 
pronounced in patients with significant comorbidities (156). The increased risk was strengthened 
by a 2013 analysis of the Rochester cohort indicated that the risk of mortality is increased with 
fractures at the distal forearm at up to 22 years post-fracture, although this association was not 
previously documented in the same cohort with a shorter follow-up (146, 147). Numerous 
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studies have indicated an increased mortality risk following proximal humeral fracture (142, 147, 
154, 155, 157-159).  
The 2013 Rochester cohort study also indicated that mortality was increased at all 
skeletal sites other than hands/fingers, upper arm other than proximal humerus, and feet/toes 
(147). These results are similar to the fracture sites which were determined to be associated with 
osteoporosis by expert review (61). This may suggest that bone loss, and particularly 
osteoporosis is associated with an increased risk for fracture and death, therefore early 
identification of those at risk for fracture could reduce preventable deaths. 
2.3.4 Economic 
Osteoporotic fractures were estimated to cost the US healthcare system $13.8 billion 
dollars in 1995, $15.7 billion dollars in 2005 and are estimated to increase to $25.3 billion by 
2025 due to the aging population (7, 160). Hip fractures were responsible for nearly 65% of all 
osteoporotic fracture costs (160). Because the majority of fractures occur in older populations, in 
the US, Medicare is expected to be responsible for up to 80% of the fracture related costs (8).  
Although AOMs are available for the treatment and prevention of osteoporosis, AOM 
treatment after hip and vertebral fracture has been reported to be as low as 15% in multi-national 
cohorts (161, 162). While the probability of treatment in a Medicare cohort was estimated at 
28.5% in the year after hip fracture (129). An analysis of younger commercially insured patients 
indicated that only 9% of all osteoporotic fracture patients received an AOM within 1-year of the 
fracture (163). Additionally, non-adherence to AOM therapy is estimated to increase direct costs 
by 76% per month to the health system (164). As well as an increased risk of fracture for those 
who are non-adherent, which causes increased hospitalizations and associated costs (164, 165). 
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In patients currently receiving anti-osteoporosis medications the 6 months after a fracture were 
estimated to cost an additional $10,000 compared to the period prior to the fracture (166). 
2.4 FRAX® WHO Fracture Risk Assessment Tool 
2.4.1 Background 
In 1995, the National Osteoporosis Foundation (NOF) established a development 
committee to explore factors associated with and guidelines for treating osteoporosis (42). This 
committee examined and promoted the concept that fracture risk, rather than BMD alone, be 
used for establishing diagnostic and treatment thresholds. However, for this to occur a model of 
fracture risk would need to be created. The decision was made that intervention thresholds would 
be based on absolute probability of fracture (i.e. risk over a specific time period compared to the 
general population), derived from age, sex, life expectancy, and risk factors for fracture 
including bone mineral density (167-170).  
To further investigate the relationship between clinical risk factors and fracture, the 
World Health Organization, with support from key osteoporosis-related organizations, 
established a group based at the WHO Collaborating Centre at Sheffield led by John A Kanis 
MD, FRCP, to evaluate and determine the relationship between clinical risk factors and fracture 
worldwide with and without the use of BMD (171). The risk tool which was created from this 
working group is property of the WHO rather than individual authors. This approach and goals 
were presented and endorsed by the IOF and NOF in year 2011(167).  
Although osteoporosis is diagnosed based solely on a patient’s BMD the ability to predict 
fracture based solely on BMD is no better than predicting heart disease based solely on LDL (9). 
This is due to a patient’s risk for fracture also including other aspects including patient health, 
concomitant diagnoses, medications, likelihood to fall, and force of the fall among others. 
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Therefore, evaluations of risk should utilize information above and beyond BMD alone (170, 
172). However, for a factor to make sense to be included in risk calculations it must present 
better accuracy for fracture risk above that found by BMD alone. Age is one example as it has 
been shown that an elderly patient with the same BMD is more likely to have a fracture than a 
young person (173).  
The University of Sheffield group undertook a multitude of meta-analyses to quantify the 
risk of fracture associated with clinical risk factors and determine if the relationship between 
these factors were attenuated by age, sex or BMD. These meta-analyses assessed the relationship 
between BMI, BMD, alcohol intake, family history of fracture, smoking, glucocorticoid use, low 
milk intake, rheumatoid arthritis, and fracture risk (174-182). All of these factors other than milk 
intake were found to be associated with fracture risk irrespective of age, sex, and BMD (182).  
Although absolute risk of fracture for the remainder of a patient’s lifetime is generally 
greater than the 10-year risk, the WHO and IOF agreed that, for clinical practice, the risk of 
fracture was best expressed as the risk in the next 10-years. Using clinical practice as a model, 
10-year probabilities of fracture were used as they would be easily understood in practice, AOMs 
had unknown efficacy past 5 years and the impact of risk factors may differ at longer time 
intervals (167). Specifically, studies have shown that the effect of BMD and associated risk 
factors on the long-term risk are varied due to differential changes in BMD over time as well as 
changes in lifestyle risk factors (183). For some AOMs, they have been shown to be no longer 
effective after cessation of use, this allows a 10-year risk to accommodate for treatment for 5 
years with the risk returning to baseline in the next 5 years. Therefore FRAX® was designed to 
be based on 10-year risks rather than a different time period (167). Although FRAX® expresses 
10-year risks, guidance on 1-year risks is espoused on their website “In young healthy 
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individuals (with a low mortality) the one year probability is approximately 10% of the 10-year 
probability. Thus, an individual with a 10-year fracture probability of 40% would have 
approximately a 1-year probability of 4%. Higher percentage figures are more readily understood 
by patients and clinicians.” This suggests that for patients who do not have a full 10-years of 
follow-up, fracture risk can be degraded by the amount of follow-up time they possess (65). 
Although this statement has been made for “young healthy individuals” this is the only advice 
given by FRAX® to reduce 10-year risks to a smaller fraction. It is likely that there will be lower 
fracture risk in the first years followed by a higher risk as the patient ages for many in a 
Medicare population, however without documentation we will use this method to calculate 
shorter risk periods. 
2.4.2 Development of FRAX® Algorithm 
The gradient of risk associated with different levels of BMD as well as the strength of 
association (beta-coefficients) from the meta-analyses were then evaluated in 9 primary 
prospective cohorts to create the FRAX® algorithm and externally validated in an additional 11 
cohorts (18). The 9 sites were the Rotterdam Study, the European Vertebral Osteoporosis Study 
(later the European Prospective Osteoporosis Study (EVOS/EPOS), the Canadian Multicentre 
Osteoporosis Study (CaMos), Rochester, Sheffield, the Dubbo Osteoporosis Epidemiology Study 
(DOES), a cohort from Hiroshima and two cohorts from Gothenburg (184-198). The algorithms 
were then externally validated in an additional 7 international prospective cohorts including the 
Epidémiologie de l’osteoporose (EPIDOS) study in France, the Study of Osteoporotic Fractures 
(SOF) in the United States, two cohorts from the Geelong study in Australia, the Osteoporosis 
Ultrasound Study (OPUS) drawn from five European countries, the Prospective Epidemiological 
Risk Factors Study (PERF) from Denmark, the York cohort in the United Kingdom, the Health 
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Improvement Network (THIN) research database from the United Kingdom, the Swiss 
Evaluation of Measurement of Osteoporotic Fracture Risk (SEMOF) study in Switzerland, the 
Women’s Health Initiative (WHI) from the United States and the Miyama cohort from Japan 
(199-210). Of note, the US based cohorts were all female while the international cohorts 
included males and females. This may indicate that FRAX® is not well calibrated for US males. 
The association between risk factors from the meta-analyses (presented as Table 2.3) and 
fracture risk were evaluated using Poisson regression. Four models (hip fracture and major 
osteoporotic fracture with and without BMD) evaluated the risk of fracture while accounting for 
the likelihood of death by the end of the 10-year period (144). This procedure rather than 
affixing death to every patient at the same age has been found to better represent the likelihood 
of fracture (144). Covariates used in the building of the models included age, time since start of 
follow-up, sex, continuous BMI, and with and without BMD (based on sex- and cohort-specific 
Z-scores). Significant interactions which had been identified during the meta-analyses based on 
the risk factor, age, sex, BMD, and time since cohort entry were entered into the model. If the 
interactions were subsequently not found to be significant they were removed from the model in 
a step-wise manner. The interactions that were used in the final model include age * sex, BMD * 
age, BMD*BMD, family history * age, prior fracture * age, BMI*BMI, and age*age (18, 171). 
Beta coefficients from these model variables are what are subsequently used to create the 10-year 
risks for major osteoporotic and hip fracture. The algorithm demonstrated an ability to better 
discriminate fracture risk using multiple risk factors than BMD alone (18).  
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Table 2.3: Risk Factors Included in the Fracture Risk Assessment Model (FRAX) 
Clinical Risk Factors Included in the FRAX Tool 
Current age Rheumatoid Arthritis 
Gender Secondary causes of osteoporosis: Type1 
(insulin dependent) diabetes, osteogenesis 
imperfecta in adults, untreated long-standing 
hyperthyroidism, hypogonadism or premature 
menopause (<40 years), chronic malnutrition 
or malabsorption and chronic liver disease 
A prior osteoporotic fracture (including 
clinical and asymptomatic vertebral 
fractures) 
Parental history of hip fracture 
Femoral neck BMD Current smoking 
Low body mass index (BMI, kg/m2) Alcohol intake (3 or more drinks/d) 
Oral glucocorticoids ≥5 mg/d of prednisone for >3 months (ever) 
From: WHO Technical Report (171) 
There are two fracture risk outputs from the FRAX algorithm, one for 10-year risk of hip 
fracture and a second for 10-year risk of major osteoporotic fracture. However, if a patient’s 
femoral neck BMD is available, outputs (10-year risks) will be created that both use BMD and 
BMI alone, therefore creating 4 rather than 2 outputs. We provide the specific fracture sites used 
for calculation of the 10-year risks including the medical locations of these fractures in Table 
2.4. 
Table 2.4 FRAX® 10-year risk sites 
FRAX® Output (10-year risk)* Fracture sites (Medical Definition) 
Hip fracture Hip (Proximal Femur) 
Major osteoporotic fracture Hip (Proximal Femur), Spine (Clinical vertebral fractures 
[L1-T4]), shoulder (proximal humerus), or wrist (distal 
radius) 
*: Can be calculated using femoral neck BMD (when available) or Body Mass Index (BMI) alone. 
Producing two outputs one with BMD and one without when BMD is available. 
 
FRAX® outputs the 10-year risk of hip fractures separately as this is the fracture site 
associated with the greatest disutility, mortality, and healthcare costs, as well as prompting the 
use of the femoral neck BMD value in the algorithm as it is a strong predictor of hip fracture. 
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FRAX defines major osteoporotic fractures as fracture of the hip, spine, shoulder (proximal 
humerus), or wrist (65). It has been suggested that these fractures were classified as osteoporotic 
due to their increased association with age and disutility and were first used as osteoporotic 
fractures by Kanis et al in 2000 (211). Earlier publications had regarded other fracture sites 
including wrist, ankle, etc however these likely were used because epidemiologic data was 
available.  
The calculation of FRAX® is based on weighted beta coefficients for each of the risk 
factors and risk factor interactions, however the model is based on 9 cohorts which may not 
actually be representative of fracture risk in a general population. To accommodate for this the 
WHO group has recalibrated the beta-coefficients from the model to the epidemiology of 
specific countries to create 10-year risk estimates for the general populace, with the first 
calibration being to the UK (212). FRAX is currently calibrated for 57 countries across Europe, 
North America, Asia, and Australia (65) and is available on the web 
(http://www.shef.ac.uk/FRAX/), however a batch program is also available. Research has found 
that expressing osteoporotic fracture risk as absolute rather than relative risk is better understood 
and accepted by both specialists and non-specialists (213). Based on clinical research and 
anecdotal evidence FRAX® is widely used in clinical practice. 
Although FRAX® currently is the most widely used and validated osteoporotic fracture 
risk score it is not overly indicative of actual fracture risk. The c-statistics in the validation 
cohorts ranged from 0.78 (Hip fracture with BMD) to as low as 0.60 (Major osteoporotic without 
BMD) (18). Therefore, using FRAX® scores alone will not eliminate confounding by fracture 
risk, but offers the best estimate of the fracture risk a clinician could have accounted for when 
making a treatment decision. The FRAX® authors state that FRAX® is a “…technology 
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platform on which to build as new validated risk factors become available” and “…provides an 
aid to enhance patient assessment by integration of clinical risk factors and/or in combination 
with BMD” but that FRAX® itself is not a perfect measure of fracture risk (214). Although 
FRAX® itself may imperfectly predict fracture, its use in clinical practice make its results more 
applicable to practice than a perfect epidemiologic fracture score. 
 
2.4.3 US-FRAX 
The current FRAX® interface for the US-FRAX calculator is presented as Figure 2.4. 
The first iteration of the FRAX-US algorithm was calibrated to the Rochester cohort which 
consisted of hip and major osteoporotic fracture incidences from the inhabitants of Olmstead 
County, Minnesota between 1989 and 1991 and national mortality rates (87, 215). If the 
Olmstead County hip fracture rate was standardized to the 2000 US non-white population, 
similar incidence rates would be produced for both its (3.86 per 1,000) and an analysis of the 
2001 National Inpatient Sample (NIS) (3.91 per 1,000) (7). However, the estimates of hip 
fracture incidence were greater in the NIS analysis due to a secular aging of the population, the 
hip fracture rates were updated to the NIS rates and revised to hip fracture based on a specific 
age rather than in 5-year groups to include updated mortality and incidence rates (215). 
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Figure 2.4 US-FRAX® web interface 
 
From WHO FRAX® Website (http://www.shef.ac.uk/FRAX/) (65) 
The comparison of major osteoporotic fractures from the NIS analysis to the Rochester 
cohort indicated a large discrepancy between rates. It was determined that this difference was 
primarily due to a high rate of vertebral fractures in the Rochester cohort that was not also shown 
in the NIS analysis. This was further supported by looking at data from the SOF cohort which 
gave similar vertebral fracture rates to those of the NIS. To account for this US-FRAX now uses 
a calculated ratio of vertebral fractures to hip fractures that was first established in Malmo, 
Sweden population (211, 212).  The other fracture sites (shoulder and forearm) use updated 
epidemiologic estimates from the NIS analysis. Finally, mortality estimates were updated to 
2004 figures from 2001 figures.  
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The last issue that was addressed in the updated US-FRAX version 3.0 algorithm was the 
overlap between each of the fracture sites, which if not accounted for would increase the rate of 
incident fracture. Based on the experience from the Malmo population and comparison of data to 
the SOF cohort, incident fracture was discounted by 10% for those under 65, 15% in 65-74 year 
olds, and 20% for person’s ≥75 years of age (215). 
The WHO group utilized these updated data points to complete the US-FRAX revision. 
In a publication which compared the calculated rates based on FRAX® 2.0 and 3.0, there was a 
significant reduction in the overall risk of major osteoporotic fracture and hip fracture based on 
the revised estimates (216). These revisions most affected the fracture probabilities for young 
men and women, with little change in estimates for older persons (216). No further US-FRAX 
revisions were made through the end of 2014. FRAX® estimates in the US are currently 
available for Caucasians, Blacks, Asians, and Hispanics (categories published by the WHO). 
These estimates were created by taking the ratio of fractures in these age groups compared to 
Caucasians based on epidemiologic data (59, 217).  
2.4.4 Other Risk Scores 
The goal of risk scores has primarily been to identify risk factors which are predictive of 
osteoporosis or fracture. However, the majority of these risk tools has only been internally 
validated and includes a significant number of variables that providers may or may not be able to 
access.  
Other than FRAX® two risk scores, Garvan and QFracture have been validated in at least 
one independent cohort. Garvan is a risk score based on the Dubbo Osteoporosis Epidemiology 
study and includes data on 1,358 women and 858 men aged ≥60 years from Australia (218, 219). 
It outputs a 5 and 10-year risk of an osteoporotic fracture (hip, clinical vertebral, wrist, 
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metacarpal, humerus, scapula, clavicle, distal femur, proximal tibia, patella, pelvis and sternum). 
It includes fewer risk factors than FRAX®, though includes a fall history and requires either 
femoral neck BMD or weight. Garvan has been externally validated using the CaMos, GLOW, a 
calcium supplement trial, and a cohort of 600 Australian women (220-224). C-statistics for these 
cohorts ranged from 0.60 to 0.85 depending on cohort and type of fracture assessed (220). 
Qfracture is a risk score developed based on data from the primary practice setting in the 
United Kingdom. They utilized data from 357 general practices in England and Wales for the 
creation of the risk score, and utilized an additional 178 practices to assess internal validation of 
the model (225, 226). The model outputs 1 to 10-year risk of hip fracture and includes 
significantly more risk factors for assessment than the other two risk scores. QFracture as well as 
Garvan includes a history of falls, which are highly correlated with hip fracture, but have been 
shown to not improve the FRAX® calculator’s prediction of future fracture. There were two 
attempts to externally validate the prediction tool, one using 2.2 million adults from the THIN 
database in the UK and the other using 246 postmenopausal women with low-trauma fractures 
and 338 non-fracture controls. The AUC varied between 0.63 and 0.82 based on gender and 
cohort for these validation studies (227, 228). 
2.4.5 National Osteoporosis Foundation (NOF) 
In the United States, multiple clinical societies have produced guidelines for the 
treatment and prevention of osteoporosis. North American Menopause Society, USPTF, AACE, 
NOF, ACR for GIO, Guidelines for treatment and prevention of osteoporosis from the American 
Academy of Family Physicians were released in 1999 with treatment and prevention based on if 
a patient is likely to sustain an osteoporotic fracture because of low bone mineral density or an 
increased risk of falling, both based on clinician’s opinions (229). However, the most commonly 
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utilized guideline is that of the National Osteoporosis Foundation, entitled the “Clinician’s 
Guide”. 
Table 2.5 US Osteoporosis Guidelines 
Organization PMW Men AOM Treatment Decision 
American Academy of 
Family Physicians, 1999 
(229) 
X   Is the patient likely to sustain an osteoporotic fracture because of 
low bone mineral density or an increased risk of falling? 
US Preventive Services 
Task Force, 2011 (230) 
X   No advice on use of AOM 
American Association of 
Clinical Endocrinologists, 
2003 (231) 
X   1.) Women with postmenopausal osteoporosis, either by BMD or 
low-trauma fracture and low BMD 
2.) Women with borderline-low BMD (t-score <-1.5) if risk 
factors are present 
3.) Women in whom nonpharmacologic preventive measures are 
ineffective 
North American 
Menopause Society, 2010 
(232) 
X   1.) Women who have had an osteoporotic vertebral or hip 
fracture 
2.) Women who have osteoporosis (t-score ≤-2.5) at femoral 
neck, total hip, or lumbar spine 
3.) Women with osteopenia (t-score -1.0 to -2.5) and a 10-year 
FRAX® risk of MOF ≥20% or hip ≥3% 
ACR, 2010 (233) X X Specifically, for patients being treated with glucocorticoids 
National Osteoporosis 
Foundation, 2014 (37) 
X X 1.) Women who have had an osteoporotic vertebral or hip 
fracture 
2.) Women who have osteoporosis (t-score ≤-2.5) at femoral 
neck, total hip, or lumbar spine 
3.) Women with osteopenia (t-score -1.0 to -2.5) and a 10-year 
FRAX® risk of MOF ≥20% or hip ≥3% 
PMW: Postmenopausal women 
 
Prior to 2008 the NOF began producing a yearly clinicians guide in 1999 basing their 
recommendations on a cost-effectiveness analysis of relevant diagnostic, evaluation, and 
treatment of osteoporosis from 1998 (234, 235). The 1999 guide specifically recommends 
treatment for women with BMD T-scores below -2.0 by central DXA with no risk factors, BMD 
T-scores below -1.5 by central DXA with one or more risk factors, or a prior vertebral or hip 
fracture. A 2003 update did not make any changes to treatment recommendations from the 1999 
guide, though it anticipated changes once additional information was known about fracture risk 
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(236). The most significant change in the 2003 guide is the updated information on HRTs based 
on the WHI, which no longer recommend them as first line therapy for osteoporosis (236).  
The Clinician’s guide was revised in 2008 with substantial changes to evaluation of 
osteoporosis and treatment recommendations based on the updated US-FRAX algorithm (217, 
237, 238). The 2008 guide was developed by the NOF in collaboration with the American 
Association of Clinical Endocrinologists, ACR, American Osteopathic Association, ASBMR, 
ISCD, and International Society for Physical Medicine and Rehabilitation. The guide was 
accompanied by an economic analysis which to determine FRAX® values wherein treatment 
was cost-effective (217, 238). For the first time the guide includes diagnostic and treatment 
recommendations for both postmenopausal women and men age ≥50. 
The new CEA calculated the cost effectiveness of AOM therapy based on 10-year risk of 
hip fracture based on US-FRAX 2.0 (217). The model used for the CEA was similar to the model 
used by the NOGG group to determine the intervention thresholds for Europe. A yearly cost of 
$600 was used for treatment with sensitivity analyses also assessing the cost effectiveness at 
$300 and $900 (with $300 being the estimated yearly cost once bisphosphonates were available 
as generics). The CEA estimated the effect of a first fracture without an increase in future 
fracture risk based on similar analyses done for the UK and Swedish population (239, 240). The 
CEA found that based on the expected decrease to $300 for generic bisphosphonates, for all age 
groups and races a treatment threshold of 3% for females and 3.5% for males (217). 
The 2008 guide used the results of the CEA as well as clinical judgment to amend their 
previous treatment recommendations and to expand the groups who recommendations were 
made to include men age 50 and older. AOM treatment was recommended for 3 groups, 1) those 
with hip or vertebral (clinical or morphometric) fractures; 2) those with osteoporosis at the 
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femoral neck, total hip, or lumbar spine; and 3) those with osteopenia who’s FRAX® 10-year 
risk of major osteoporotic fracture is ≥20% or hip fracture is ≥3%. The 3% hip fracture figure is 
representative of the results of the CEA for women and represents a woman 65 years of age with 
no risk factors which was determined to be cost effective (241). Based on nomograms (risk 
graphs) without fracture this patient has a 10-year risk of MOF of 14% but 26% with a fracture, 
which may represent how the 20% threshold was established (238). The new recommendations 
although based on different methodologies and included men ≥50 years of age, did not 
substantially increase the proportion of the population to be treated or screened (238). This was 
due to the FRAX® algorithm having similar risk factors to the 1999 guide, and two of the groups 
(prevalent fractures and current osteoporosis) are basically universally recommended treatment 
by clinical guidelines (238). 
In 2010, the guide was updated to provide additional guidance on biochemical markers 
and update indications for medications, including the use of dinosaur (242). In 2013, the guide 
was updated 3 separate times for updated information on calcium, and vitamin D use, current 
knowledge about AOMs, additional guidance on the appropriate use of vertebral fracture assessment 
and the use of biochemical markers of bone turnover (11). 
2.4.5.1 Current NOF Guidelines (2014) 
The clinician’s guide was further updated in 2014 with additional information on 
calcium, vitamin D, AOM use including duration, use of vertebral fracture imaging, use of 
biochemical markers of bone turnover, and further evaluation of secondary causes of 
osteoporosis (8). The 2014 guide has been endorsed by the American Academy of Pain Medicine 
(AAPM), American Association of Clinical Endocrinologists (AACE), American Orthopaedic 
Association (AOA), American Osteopathic Association (AOA), American Society for Bone and 
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Mineral Research (ASBMR), and International Society for Clinical Densitometry (ISCD). Also 
for the first time the guide was published as a peer reviewed article in 2014 by Osteoporosis 
International (37).  
2.4.5.1.1 Treatment Recommendations 
To graphically illustrate the steps that a clinician must take to make a treatment decision 
we are presenting the Cleveland Clinic Foundation Carepath diagram as Figure 2.5. The guide 
includes information on all therapies currently FDA approved for treatment of osteoporosis in 
the US, including bisphosphonates (alendronate, ibandronate, risedronate, and zoledronic acid), 
calcitonin, estrogen agonist/antagonist (raloxifene), estrogens and/or hormone therapy, tissue-
selective estrogen complex (conjugated estrogens/bazedoxifene), parathyroid hormone 1–34 
(teriparatide), and receptor activator of nuclear factor kappa-B (RANK) ligand inhibitor 
(denosumab). However, the guide does not promote the use of any particular therapy leaving that 
decision up to the patient and the provider. 
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Figure 2.5 Carepath diagram1 
 
                                                 
1 Used with permission from Chad Deal, MD from the Cleveland Clinic Foundation 
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2.4.5.1.2 Applicability 
There have been research efforts to determine how applicable the NOF guidelines are to 
the general US population and particularly the proportion of the population who would be 
recommended treatment. Two treatment estimates were made based on US cohort studies. 
Donaldson et al utilizing the SOF dataset found that based on the 2008 thresholds 72% of US 
Caucasian women ≥65 years of age would be recommended treatment, while 93% of women ≥75 
would be recommended treatment, however these estimates were made prior to the US-FRAX 
update in 2008 (243). Berry et al utilized the Framingham Osteoporosis Study finding 
recommended treatment for 41.1% of all women based on the 2008 guidelines and 47.8% based 
on the 2003 guidelines. Additionally, 17.0% of all men were recommended treatment based on 
the 2008 guidelines (244). In comparison, when using estimates from a nationally-representative 
sample (NHANES from 2005-2008) for person of all races ≥50 years of age 30.8% for women 
and 19.3% for men were estimated to be eligible for treatment (245). For non-Hispanic whites 
aged ≥65 the proportion to be treated increased to 51.7% for women and 31.8% for men (245). 
This analysis also gave proportions of the population with t-scores between -1.0 and -2.5 for 
whom treatment is based on FRAX, finding 24.6% of women and 28.2% of men aged ≥50 would 
be recommended for treatment (245). An update using data through 2010 suggests that ~16 
million persons in the US would qualify for osteoporosis treatment based on the current NOF 
guidelines (246).  
Because there is no population based way to identify patients at risk for osteoporosis and 
treatment largely relies on events (diagnosis of osteoporosis or fracture) a sizeable portion of the 
population eligible for treatment remain untreated. As many as 25% of all women and 28% of 
men aged ≥65 are estimated to be eligible for but not receiving therapy (245). This highlights the 
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need for a population based fracture risk tool that identifies patients who would benefit from 
treatment prior to diagnosis of osteoporosis or occurrence of fractures.  
2.5 Treatment 
2.5.1 Pharmacologic Therapy 
In 1979, the FDA published the first guidance document on therapies for osteoporosis. 
The effectiveness threshold in the 1979 guidance document stipulated that if a therapy could 
demonstrate an improvement in normal bone mass then fracture trials would not be required. 
However, more current guidance requires documented fracture reduction for approval of 
therapies (247). We present the therapies which are approved with their current dosing and their 
efficacy and list 4 therapies which have not been approved by the FDA in Table 2.6. Aim 3 of 
this dissertation is most interested in the comparison of alendronate to placebo, however we felt 
that a full review of Food and Drug Administration (FDA) approved AOMs was appropriate for 
this project. 
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Table 2.6 Anti-Osteoporosis Medications 
Drug Trade Name(s) Label Indications Dosing Efficacy 
Bisphosphonates 
Alendronate Fosamax, Fosamax 
Plus D, Binosto  
Indicated for treatment and 
prevention of osteoporosis 
in postmenopausal women; 
increasing bone mass in 
men with osteoporosis; 
treatment of 
glucocorticoid(GC)-induced 
osteoporosis in men and 
women with low bone mass  
One 10mg tablet, once 
daily, or 70mg (as tablet, 
effervescent tablet, or oral 
solution) once weekly; 
70mg (as tablet, 
effervescent tablet, or oral 
solution) once weekly or 
one 10mg tablet daily; One 
35mg tablet weekly or one 
5mg tablet daily; One 5mg 
table daily 
In meta-analyses compared to placebo 
alendronate has been shown to decrease the 
incidence of vertebral fractures, as well as 
non-vertebral fractures (248-253). It has 
also been shown to decrease hip fractures, 
particularly in patients with osteoporosis or 
prior vertebral fractures (248-250, 254). 
Alendronate also has demonstrated the 
ability to reduce the loss of BMD compared 
to placebo (249, 255). 
Ibandronate Boniva Indicated for the treatment 
and prevention of 
osteoporosis in 
postmenopausal women 
One 150mg tablet once 
monthly or one 2.5mg tablet 
once daily or 3mg injectable 
every 3 months 
In meta-analyses compared to placebo oral 
ibandronate has been shown to reduce the 
incidence of vertebral fractures (252). 
However meta-analyses have not been able 
to clarify if ibandronate reduces non-
vertebral fractures (247, 256, 257). In 
RCTs both the oral and IV forms of 
ibandronate have been shown to increase 
BMD compared to placebo (258, 259).  
 
Risedronate Actonel, Actonel with 
calcium, Atelvia 
Indicated for the treatment 
and prevention of 
osteoporosis in 
postmenopausal women and 
glucocorticoid-induced 
osteoporosis; Treatment to 
increase bone mass in men 
with osteoporosis 
Treatment of 
postmenopausal women: 5 
mg daily; 35 mg, weekly; 
75 mg taken on two 
consecutive days each 
month; or 150 mg once 
monthly; Actonel with 
calcium is packaged as the 
once weekly 35mg with 
1,250 mg calcium carbonate 
tablets to be taken daily; 
Atelvia is taken once 
weekly after breakfast 
In meta-analyses compared to placebo 
risedronate has been shown to decrease the 
incidence of vertebral fractures, as well as 
non-vertebral fractures (248, 251, 260-
263). It has also been shown to decrease 
hip fractures, particularly in patients with 
osteoporosis (248, 260). Risedronate also 
has demonstrated the ability to reduce the 
loss of BMD compared to placebo (261, 
264-266). 
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Drug Trade Name(s) Label Indications Dosing Efficacy 
Zoledronic Acid Reclast Indicated for treatment and 
prevention of osteoporosis 
in postmenopausal women 
and glucocorticoid-induced 
osteoporosis; Treatment to 
increase bone mass in men 
with osteoporosis 
Treatment of 
postmenopausal women: 
5mg infusion annually; 
prevention in 
postmenopausal women: 5 
mg infusion biennially   
Currently there are no meta-analyses of 
zoledronic acids efficacy. RCTs of ZA 
compared to placebo at a 5mg dose have 
shown decreases in all clinical fractures, 
vertebral fractures, and non-vertebral 
fractures based on the Health Outcomes 
and Reduced Incidence with Zoledronic 
Acid Once Yearly (HORIZON) Pivotal 
Fracture Trials (64, 267). Also, there is 
some evidence to suggest that ZA also is 
associated with a decrease in hip fractures 
(64). Zoledronic acid also has demonstrated 
the ability to reduce the loss of BMD 
compared to placebo (64, 268). Recent 
research has also suggested that a single 
dose of zoledronic acid may be as effective 
in reducing fractures as a consecutive series 
of three yearly infusions (269). 
Peptide Hormones 
Teriparatide Forteo Indicated for treatment of 
osteoporosis in 
postmenopausal women at 
high risk for fracture 
20 mcg subcutaneously 
once daily, maximum of 
two years use 
In meta-analyses compared to placebo 
teriparatide at a 20µg/d has been shown to 
decrease the incidence of vertebral 
fractures, as well as non-vertebral fractures 
(248, 270). There are no meta-analyses 
which have shown a decrease in hip 
fractures, however RCTs have indicated a 
statistically significant reduction. 
Teriparatide also has demonstrated the 
ability to reduce the loss of BMD compared 
to placebo (270-273).   
 
Biologics        
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Drug Trade Name(s) Label Indications Dosing Efficacy 
Denosumab ProliaTM Indicated for treatment of 
postmenopausal women 
with osteoporosis at high 
risk for fracture, defined as 
a history of osteoporotic 
fracture, or multiple risk 
factors for fracture; or 
patients who have failed or 
are intolerant to other 
available osteoporosis 
therapy. 
60 mg injected 
subcutaneously every six 
months 
Denosumab has been shown to decrease the 
likelihood of vertebral, non-vertebral, and 
hip fractures in women treated for post-
menopausal osteoporosis at 36 months (63). 
However, there was not a statistically 
significant reduction at any of these sites in 
another RCT at two years (274). 
Additionally, denosumab has been shown 
to reduce bone loss compared to placebo 
(63, 274). Denosumab has been reported to 
have a treatment efficacy of ~6 months, 
which requires re-administration of therapy 
for continued effectiveness (275, 276). 
Though recent reports suggest that the 
effective period may be >6 months (276). 
Selective Estrogen Receptor Modulators  
Raloxifene Evista Indicated for treatment and 
prevention of osteoporosis 
in postmenopausal women 
60 mg tablet once daily Subsequent trials and results from meta-
analyses after FDA approval have shown a 
decrease in vertebral fractures with 
raloxifene compared to placebo (248, 277-
279). AHRQ CERs have deemed the 
evidence for the reduction of vertebral 
fractures to be strong but have concluded 
that there is no evidence of a reduction in 
non-vertebral fractures (247, 280-282). 
Recent clinical guidelines have 
recommended raloxifene as a second line 
therapy due to other therapies 
demonstrating better fracture reduction. 
Based on not being a first line therapy, 
raloxifene will not be used as a primary 
AOM in this study. 
Steroid Hormones 
Conjugated equine 
estrogen 
Premarin Indicated for prevention of 
postmenopausal 
osteoporosis 
0.3mg tablet daily Meta-analyses comparing estrogen and 
placebo represent good evidence of a 
decreased rate of vertebral, non-vertebral, 
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Drug Trade Name(s) Label Indications Dosing Efficacy 
Conjugated estrogen 
(CEE)/Medroxyproge
sterone (MPA) 
Prempro Indicated for prevention of 
postmenopausal 
osteoporosis 
0.3 mg CEE/1.5 mg MPA 
daily;0.45 CEE/1.5 mg 
MPA; 0.625 mg CE/2.5 mg 
MPA; 0.625 CEE/5 mg 
MPA 
and hip fractures for women on estrogen 
(283-286). The results from three pooled 
meta-analyses have shown a decrease in 
overall fracture risk, no significant 
difference, and were unable to assess the 
difference based on sample size (248, 283, 
287).  
 
Estradiol(E)/norgesti
mate(NE) 
Prefest Indicated for prevention of 
postmenopausal 
osteoporosis 
1.0 mg E daily for 3 
consecutive days; 1.0 mg E/ 
0.09 mg NE daily for next 3 
consecutive days 
17β 
Estradiol/norethindro
ne acetate 
Activella, femhrt Indicated for prevention of 
postmenopausal 
osteoporosis 
Activella: 1.0mg E.0.5mg 
NE or 0.5 mg E/0.1 mg NE 
daily Femhrt: 1/0.5 mg or 
0.5/0.25 mg daily  
17β 
Estradiol/levonorgest
rel 
ClimaraPro Indicated for prevention of 
postmenopausal 
osteoporosis 
0.045mg estradiol/ 0.015 
mg levonorgestrel delivered 
daily 
Estradiol oral Estrace Oral Indicated for prevention of 
postmenopausal 
osteoporosis 
0.5, 1, or 2mg daily 
Estradiol transdermal Vivelle, Climara, 
menostar 
Indicated for prevention of 
postmenopausal 
osteoporosis 
Variable 
Calcitonin 
Salmon Calcitonin Miacalcin Treatment of 
postmenopausal 
osteoporosis, 
hypercalcemia, Paget's 
disease 
Nasal - 200IU, Injectable - 
Variable 
RCTs showed reduced bone turnover and 
increased BMD when compared to placebo 
in post-menopausal women prompting its 
FDA approval in 1995 (288-291). The 2007 
ARHQ CER of treatments to prevent 
fracture indicated that based on meta-
analyses calcitonin was effective in 
reducting vertebral fractures, created no 
change in the likelihood of non-vertebral 
fractures, and was not evaluated for its 
effect on hip fractures (281, 282). However 
calcitonin was not included in the 2013 
AHRQ CER based on subject matter 
expert’s requests because calcitonin is 
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Drug Trade Name(s) Label Indications Dosing Efficacy 
thought to no longer represent appropriate 
treatment for osteoporosis (247).  
Not FDA Approved 
Sodium Flouride, Etidronate, Pamidronate, Stromium Ralonate 
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2.5.1.1 Alendronate v Placebo (PCB) Randomized Controlled Trials (RCT) 
Bisphosphonates are classified as antiresorptive medications due to their affinity to slow 
bone breakdown. This is done by inhibiting reabsorption by osteoclasts before effecting bone 
formation (8). This causes more bone to be created than is broken down, increasing bone density. 
Although after a period of time formation may normalize there is an increase in bone density, 
improved bone mineralization, and reduced fracture risk.  
Alendronate was the first bisphosphonate to receive FDA approval in 1995 and has been 
available in a generic formulation since 2008 (292). Based on its first in class designation and its 
availability as a generic it is the most utilized anti-osteoporosis medication. Although 
alendronate was originally approved at a 10mg QD indication the most common formulation 
currently being used is a 70-mg dosage once weekly, and is the only formulation still available 
from Merck (the alendronate patent holder) with a half-life of ~10 years (292).  
Early bisphosphonate trials demonstrated a reduction in fractures, however to detect this 
difference a significant sample size was required (20,000 patients for 5 years). Further, following 
alendronate’s approval, it was thought to be unethical to withhold active therapy from the control 
arm of future studies. This resulted in use of surrogate endpoints of change in BMD and bone 
turnover markers rather than actual fracture reduction for subsequent studies (51, 62). Recently 
superiority and non-inferiority trials have been undertaken to compare a new drug or formulation 
to previously-approved products (63).  
In Aim 3 we are comparing alendronate users to non-users. We chose this comparison 
based on a bevy of published work on Alendronate and a large portion of this work comparing 
alendronate to placebo. After the initial bisphosphonate trials, ethical concerns have reduced the 
number of placebo controlled trials in osteoporosis with alendronate representing the largest 
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number. Aim 3 will directly compare estimate of fracture reduction in alendronate users to non-
users using CFRI as a variable in regression models to the effect estimates from the published 
RCTs. We provide a summary of the placebo controlled RCTs with alendronate compared to 
placebo including all inclusion and exclusion criteria as well as a meta-analysis summary of the 
relative risks of fracture based on the placebo controlled trials in this section. Although these 
results primarily use patients who are adherent to their therapy they provide a benchmark for 
comparison to non-users. Based on a 2008 Cochrane review by Wells et al we identified 11 trials 
which either had published fracture rates or were available in the meta-analysis and an additional 
3 trials based ARHQ Comparative Effectiveness Reviews in 2012 and 2014 by Crandall et al 
(247, 280, 293). We provide a brief synopsis and exclusion criteria for these 14 studies in Table 
2.7.  
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Table 2.7 Alendronate v Placebo Randomized Control Trials with Fracture as an Outcome 
RCT (Author, Year) ALN Dose^ Population Inclusion/Exclusion Criteria Outcomes 
Ascott Evans, 2003(294) 10 mg ALN (95), PCB 
(49) 
≥3 yr PMW, <80 yo, 
used HRT >1yr and d/c 
HRT <3mo before 
enrollment 
Inclusion: LST -3.5 to -1.5; Exclusion: 
other metabolic bone disease or 
osteoporotic fracture, recently received 
BP or GC 
Bone Turnover, BMD 
Black, 1996(25) 
Fracture Intervention 
Trial (FIT) with vertebral 
fracture 
5-10mg ALN (1022), 
PCB (1005) 
≥2 yr PMW age 55-81, 
prevalent vertebral 
fracture 
Inclusion: FN BMD <0.68 g/cm2; 
Exclusion: peptic-ulcer disease (a single 
hospital admission for 
uppergastrointestinal bleeding or two or 
more documented ulcers within the 
preceding 5 years), dyspepsia requiring 
daily treatment, abnormal renal function 
(serum creatinine >144 μmol/L), major 
medical problems that would be likely 
to preclude participation for 3 years, 
severe malabsorption syndrome, 
uncontrolled hypertension (blood 
pressure >210 mm Hg systolic or >105 
mm Hg diastolic), myocardial infarction 
during the previous 6 months, unstable 
angina, or evidence of disturbed thyroid 
or parathyroid function. Use of 
oestrogen or SCT within the preceding 
6 months or BP or sodium fluoride (>1 
mg daily for 2 weeks or longer) at any 
time 
Bone Turnover, BMD, clinical 
vertebral, hip, or wrist fracture 
with ~3yr FU 
HR for any clinical fracture: 
0.72 (0.58, 0.90) 
Bone, 1997(295) 1 mg ALN (81), 2.5mg 
(85), 5mg (85), PCB 
(90)  
Women 60-85 Inclusion: LST <-2.0; Exclusion: 1 or 
more lumbar crush fractures, recent 
major gastrointestinal disease, such as 
peptic ulcer, esophageal disorder, or 
malabsorption, or had recently used a 
drug to inhibit gastric acid secretion for 
more than 2 weeks. In addition, patients 
receiving chronic nonsteroidal 
antiinflammatory therapy or agents 
known to affect bone metabolism (such 
as etidronate, estrogen, glucocorticoids, 
fluoride, or calcitonin) were excluded. 
Bone Turnover, BMD 
Fractures:  
9/93 16/91 
0.55 (0.26,1.18) 
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RCT (Author, Year) ALN Dose^ Population Inclusion/Exclusion Criteria Outcomes 
Subjects receiving thyroid hormone 
replacement were required to have been 
on a stable dosage for at least 6 months 
before entry into the study and 
euthyroid by ultrasensitive TSH assay. 
Clinically significant vitamin D 
deficiency was similarly excluded or 
corrected. 
Chesnut, 1995(296) 5, 10, 40mg ALN 
(157), PCB (31) 
≥5 yr PMW 42-75 Inclusion: LS BMD <0.68 g/cm2; 
Exclusion: any disease or drug therapy 
potentially affecting bone metabolism. 
Prevalent hip or spine fractures due to 
osteoporosis  
Bone Turnover and BMD, 2-yr 
fractures 
Cummings, 1998(26) 
FIT without vertebral 
fracture 
5-10 mg ALN (2214), 
PCB (2218) 
≥2 yr PMW 55-80 
without vertebral 
fracture 
Inclusion: LS BMD <0.68 g/cm2; 
Exclusion: peptic-ulcer disease (a single 
hospital admission for 
uppergastrointestinal bleeding or two or 
more documented ulcers within the 
preceding 5 years), dyspepsia requiring 
daily treatment, abnormal renal function 
(serum creatinine >144 μmol/L), major 
medical problems that would be likely 
to preclude participation for 3 years, 
severe malabsorption syndrome, 
uncontrolled hypertension (blood 
pressure >210 mm Hg systolic or >105 
mm Hg diastolic), myocardial infarction 
during the previous 6 months, unstable 
angina, or evidence of disturbed thyroid 
or parathyroid function. Use of 
oestrogen or SCT within the preceding 
6 months or BP or sodium fluoride (>1 
mg daily for 2 weeks or longer) at any 
time 
Bone turnover, BMD, clinical 
vertebral, hip, or wrist with ~4 
yr FU 
HR for any clinical fracture: 
0.86 (0.73, 1.01) 
Dursun, 2001(297) 10mg ALN and 
calcium 1000mg (51), 
1000mg calcium (50) 
PMW no age range 
given 
Inclusion: LS BMD <-2.0 SD at either 
LS or FN; Exclusion: Documented 
history of drug or alcohol abuse, any 
bone metabolism disorder, active 
gastrointestinal or liver disease, renal 
Vertebral fractures at 1-year 
HR 0.84 (0.43, 1.63) 
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RCT (Author, Year) ALN Dose^ Population Inclusion/Exclusion Criteria Outcomes 
failure, renal calculi, treatment with 
specific therapy for osteoporosis, 
treatment with systemic corticosteroid 
therapy, malignancy, disorder of 
calcium metabolism, and lumbar 
vertebrae abnormalities preventing 
evaluation of BMD. 
Greenspan, 1998(298) ALN 5mg (60), PCB 
(60) 
Women 65+ Inclusion: None;  Exclusion: history of 
any illness affecting bone and mineral 
metabolism, currently taking 
medication known to affect bone 
metabolism, or had been treated for 
osteoporosis with BP, HRT, or 
calcitonin within 1-year of study entry 
Non-vertebral at 3-yr 
3/60 ALN, 1/60 PCB 
3.00 (0.32, 28.03) 
Hip at 3-yr 
0/60; 1/60 
Wrist 
3/60; 0/60 
18.93 (0.99, 361.25) 
Greenspan, 2002(299) ALN 10mg (163), PCB 
(164) 
Women 65+ Inclusion: Currently residing in a long-
term facility, LS or TH T-score <-2.0; 
Exclusion: disorders of bone 
mineralization, 25-
hydroxycholecalciferol level less than 
25 moll/L, untreated hyperthyroidism, 
recent major upper gastrointestinal 
mucosal erosive disease, or use of bone-
active agents 
Hip fractures at 2yr 
2/163; 4/164 
0.50 (0.0069, 2.71) 
Hosking, 1998 (300) ALN 5mg (498), PCB 
(501) 
≥ 6mo PMW 45-59 Inclusion: Only 10% of women at each 
center could have LS BMD <0.8 g/cm2; 
Exclusion: abnormal renal function 
(serum creatinine, >1.5 mg per deciliter, 
a history of cancer, peptic ulcer or 
esophageal disease requiring 
prescription medication within the 
previous five years, previous treatment 
with a bisphosphonate or fluoride, 
regular therapy with a phosphate 
binding antacid, estrogen-replacement 
therapy within the previous three 
months, and therapy with any other 
drug that affects the skeleton 
Bone Turnover and BMD  
All fractures 
22/498 ALN v 14/501 PCB 
1.58 (0.82, 3.05) 
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RCT (Author, Year) ALN Dose^ Population Inclusion/Exclusion Criteria Outcomes 
Liberman, 1995 (255) ALN (526), PCB (355); 
3 groups of ALN (5, 
10, 20mg not well 
defined as how many in 
each) 
≥5 yr PMW 45-80 Inclusion: LST <-2.5; Exclusion: other 
causes of osteoporosis (e.g., treatment 
with glucocorticoids) or other disorders 
of bone and mineral metabolism (e.g., 
vitamin D deficiency, Paget’s disease, 
or hyperparathyroidism); active peptic 
ulcer disease, abnormal renal function 
(serum creatinine level, >1.5 mg per 
deciliter, or abnormal hepatic function; 
abnormalities of the lumbar spine 
precluding the assessment of bone 
mineral density at a minimum of three 
lumbar vertebrae or a history of hip 
fracture; or any prior treatment with 
bisphosphonates or treatment within the 
preceding 12 months with estrogen, 
progestin, calcitonin, fluoride, or an 
anabolic steroid. 
Vertebral fractures 0.52 (0.28, 
0.95) 
Orwoll, 2000(301) ALN 10mg (146), PCB 
(95) 
Men 31-87 yo Inclusion: (FNT <-2.0 and LST <-1.0) 
OR (FNT <-1.0 and prior osteoporotic 
fracture or vertebral deformity); 
Exclusion: secondary causes of 
osteoporosis other than low serum free 
testosterone concentrations were 
ineligible, including those who were 
taking medications or who had medical 
conditions associated with bone loss, as 
were those with other bone diseases, 
vitamin D deficiency, renal disease 
(indicated by a serum creatinine 
concentration of more than 1.6 mg per 
deciliter), severe cardiac disease, a 
history of cancer other than basal-cell 
carcinoma of the skin, a recent history 
(within the previous year) of peptic 
ulcer or esophageal disease, or 
esophageal abnormalities that delayed 
esophageal emptying. We also excluded 
men who were unable to follow the 
Bone Turnover, BMD, and 
fractures 
Using semi quantitative 
methods, we found that 
vertebral fractures occurred in 
8.1 percent of men in the 
placebo group and 3.1 percent 
of men in the alendronate 
group (P=0.12). However, 
quantitative methods revealed 
that the incidence of vertebral 
fractures was 7.1 percent in the 
placebo group and 0.8 percent 
in the alendronate group 
(P=0.02). Four men had painful 
vertebral fractures: three (3.2 
percent) in the placebo group 
and 1 (0.7 percent) in the 
alendronate group (P=0.3). 
Nonvertebral fractures 
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RCT (Author, Year) ALN Dose^ Population Inclusion/Exclusion Criteria Outcomes 
instructions for taking the study drug 
and those with a history of treatment for 
osteoporosis 
occurred in five men (5.3 
percent) in the placebo group 
and six men (4.1 percent) in the 
alendronate group (P=0.8).  
Pols, 1999(302) ALN 10mg (950), PCB 
(958) 
≥3 yr PMW and <85 yo Inclusion: LST <-2.0, otherwise in good 
health and between 20% below and 
50% above ideal weight; Exclusion: 
women with metabolic bone disease 
other than postmenopausal 
osteoporosis; disturbed parathyroid or 
thyroid function; major gastrointestinal 
disease (for example, peptic ulcer or 
malabsorption) within the year before 
enrollment or use of a drug to inhibit 
gastric acid secretion for >2 weeks 
within 3 months of study entry; 
myocardial infarction within the year 
prior to enrollment; uncontrolled 
hypertension or untreated angina; 
significantly impaired renal function 
(serum creatinine >150 mmol/l); or 
evidence of significant end organ 
disease. Also excluded were women 
who had received a bisphosphonate or 
fluoride (>8 mg/day) during the 
previous 6 months; estrogen (except 
vaginal 43 times/week), ipriflavone or 
calcitonin during the previous 4 months; 
or any anabolic steroid, glucocorticoid 
or progestin for >2 weeks within the 
previous 6 months. Participants could 
not be receiving any medications that 
might alter bone or mineral metabolism, 
including vitamin A in excess of 10.000 
U/day, vitamin D in excess of 1000 
U/day, anticonvulsants or phosphate-
binding antacids. Finally, at least three 
vertebrae from L1 to L4 had to be 
BMD, Bone Turnover, 
fractures at 1 yr FU 
HR: 0.53 (0.30, 0.90) for non-
vertebral fracture 
(ankle/lower leg, foot, hand, 
hip/femur, rib, shoulder, 
wrist/arm, other), most 
difference for wrist/arm 
~1.60% v 0.6% 
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RCT (Author, Year) ALN Dose^ Population Inclusion/Exclusion Criteria Outcomes 
evaluable by DXA to determine BMD 
in this region.  
Quandt, 2005(27) 
FIT Trial 
5-10 mg ALN (2214), 
PCB (2218) 
Same as FIT, ie FIT 
subgroup analysis 
Inclusion: T-score -1.6 to -2.49; 
Exclusion: Same as FIT 
3-yr clinical vertebral 0.40 
(0.19, 0.76),  
Sato, 2006(303) 5mg ALN (144), PCB 
(144) both receiving 
1,000 IU of 
ergocalciferol 
Women ≥65 Inclusion: Parkinson Disease; 
Exclusion: Patients with impairment of 
renal, hepatic, cardiac, or thyroid 
function or those who had known 
causes of osteoporosis, such as primary 
hyperparathyroidism or renal 
osteodystrophy, were excluded from 
this study. Patients were excluded if 
they had been treated with 
corticosteroids, estrogens, calcitonin, 
bisphosphonate, calcium, or vitamins D 
and K for 3 months or more during the 
12 months preceding the study; and 
those who had been administered these 
agents for even a brief period during the 
preceding 2 months were also excluded. 
PD patients at stage 5 in Hoehn and 
Yahr stage16 were excluded, because 
their total disability virtually predicted 
minimum chance of a fracture. Patients 
with a previous history of non-vertebral 
fractures were also excluded.  
Hip fracture 0.29 (0.10, 0.85) 
@ 2yrs 
#: or any associated health problems that could affect their participation in the study or interfere with interpretation of the data; BP: Bisphosphonate; PMW: 
Postmenopausal Woman; ^: Dose per day unless otherwise specified; FN: Femoral Neck; TH: Total Hip; LS: Lumbar Spine; FNT: Femoral Neck T-score; 
THT: Total Hip T-score; LST: Lumbar Spine T-score; PCB: Placebo; ALN; Alendronate 
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Generally trial inclusion criteria were based on postmenopausal status and specific 
lumbar spine or femoral neck BMD. Three of the trials highlighted were from the same parent 
trial (Fracture Intervention Trial [FIT]). Although there were additional trials of alendronate and 
placebo, the 14 trials reported here were the only to capture fracture outcomes.  
Estimates of the risk ratio for vertebral and non-vertebral fractures are reproduced from 
Wells et al in Table 2.6. At 4 years Wells reports a weighted RR for ALN 10mg of 0.56 (95% CI 
0.39, 0.80) for vertebral fractures and 0.89 (95% CI 0.76, 1.04) for non-vertebral fractures (293).  
The individual studies RR varies from 0.55 to 0.84 for vertebral fractures and 0.52 to 3.00 for 
non-vertebral fractures (293). Overall this demonstrates that alendronate is associated with a 
decreased risk for future fracture. The meta-analysis of dosages and time is particularly helpful 
to compare against any results of claims-based analysis, as risk changes over time. However 
these estimates may not be reachable due to patients likely being more adherent to their 
alendronate than patients in the real world. 
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Figure 2.6 Weighted Relative Risks 
 
From: Wells et al, 2012 (293) 
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2.5.1.2 Fracture Intervention Trial 
Of particular focus in the alendronate placebo RCTs are 3 reports of the same trial, the 
Fracture Intervention Trial (FIT) (25-27). The three reports were authored by Black in 1996, 
Cummings in 1998, and Quandt in 2005 and represent the largest participant numbers for any of 
the placebo-controlled alendronate fracture trials (25-27). FIT had a primary aim of testing “if 
alendronate reduces the risk of fracture in postmenopausal women with low bone mineral 
density” (304). The trial began recruiting in May 1992 and finished recruitment in May 1993 
with follow-up continuing for up to 4 years through May 1997. Women aged 55 to 80 were 
recruited to two different arms, those with prevalent vertebral fractures (n=2023) and those 
without (n=4434) called the clinical fracture arm, with various inclusion criteria specified in 
Figure 2.8 (304). The primary endpoint for the vertebral fracture trial was new vertebral 
deformities while the primary endpoint for the clinical fractures arm were new clinical fractures. 
Clinical fractures were defined as any non-pathologic, non-traumatic fractures other than skull 
and facial fractures (26). Both trials also collected new occurrences of the other type of fracture 
as well as change in BMD, change in height, and bone turnover markers (304).  
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Figure 2.7 Inclusion and Exclusion Criteria for the Fracture Intervention Trial (FIT) 
 
  
Inclusion Criteria: 
1. Female, 55-80 years old 
2. BMD at the femoral neck <= 0.68 g/cm2 (Hologic 
QDR 2000) 
3. Understands procedures of study 
 
Exclusion Criteria: 
1. Unable to give informed consent 
2. Participating in another trial 
3. Intends to move within 4 years 
4. Alcohol Abuse 
5. Major illnesses, including severe malabsorption, 
severe hypertension, myocardial infarction (within 6 
months), unstable angina, serum creatinine > 1.6 
mg/dl 
6. Erosive gastrointestinal disease within 5 years. 
Dyspepsia requiring daily treatment 
7. History of cancer (except: resected superficial skin 
cancer and treated malignancies, except breast, 
without recurrence in 10 years) 
8. Metabolic bone disease (e.g. hyper- or 
hypoparathyroidism, Paget’s disease, osteomalacia) 
9. Treatment affecting bone turnover: 
a. Estrogen, anabolic steroids, calcitonin, or 
progestins, within 6 months 
b. A change in thyroid hormone dosage within 
the last 6 weeks 
c. >2 weeks fluoride treatment (>1 mg/day) at 
any time 
d. Glucocorticoid within 6 months 
e. Bisphosphonate for more than 2 weeks 
10. Unexplained weight loss > 10% of ideal body 
weight within last 12 months 
11. Unsuitable anatomy on spinal radiographs 
12. BMD at the femoral neck >3 SD below age-specific 
mean 
13. Noncompliance with pre-randomization study 
procedures 
14. Not ambulatory 
15. History of bilateral hip replacements 
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The original intention of the FIT trial was to assess women with low bone mass, or a t-
score of <-2.0. However the femoral neck BMD of ≤0.68 g/cm2 was found to correspond to a t-
score of -1.6 based on NHANES III (26, 69). Treatment in both arms was initially initiated at 
5mg per day but increased to 10mg based on other trial results at the second annual visit. The 
vertebral fracture arm was adequately powered to detect a 40% decrease in cumulative incidence 
of new vertebral fractures but underpowered to detect a change in clinical fractures and the 
clinical fracture arm was adequately powered to detect a 25% reduction in clinical fractures 
(304). 
The vertebral fracture data was published in 1996 and categorized fractures into clinical 
vertebral, clinical fractures (composite of clinical vertebral, hip, wrist), hip, and wrist fractures 
with 4 years of follow-up. At 4 years there was a significant reduction in clinical vertebral 
fractures RR 0.45 (95% CI 0.27, 0.72). Also they found a significant reduction in any clinical 
fracture (RR 0.72, 95% CI [0.58, 0.90]) which included clinical vertebral fracture, hip fractures 
(RR 0.49, 95% CI [0.23, 0.99]), and wrist fractures (RR 0.52, 95% CI [0.31, 0.87]). However 
summing all non-vertebral fractures did not produce a significant reduction (RR 0.80, 95% CI 
[0.63, 1.01]) based largely on the non-significant reduction for all non-vertebral, hip, or wrist 
fractures (RR 0.99, 95% CI [0.75, 1.31]).  
The clinical fracture arm study categorized their results up into clinical fractures, 
vertebral, hip, and wrist fractures as well as separating their results based on baseline t-score. 
With 4 years of follow-up the clinical fracture arm of the study found a non-significant relative 
risk of 0.86 (95% CI 0.73, 1.01) for clinical fractures in all study participants, but a significant 
RR of 0.64 (95% 0.50, 0.82) in women who had osteoporosis (t-score <-2.5) at baseline. There 
was no significant reduction in RR for hip fractures overall 0.79 (95% CI 0.43, 1.44), but again a 
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reduction in osteoporotic women 0.44 (95% CI 0.18, 0.97). Wrist fractures also varied based on 
baseline t-score (overall RR 1.19, 95% CI [0.87, 1.64]; osteoporosis RR 0.88, 95% CI [0.55, 
1.40]) with neither reaching statistical significance. Vertebral fractures were reduced by 
alendronate use RR 0.56 (95% CI 0.39, 0.80) overall and RR 0.50 (95% CI 0.31, 0.82) in those 
with osteoporosis. 
The third report was based solely on those women who had non-osteoporotic t-scores (t-
score between -2.5 and -1.6). This reanalysis contained 484/456 (ALN/PCB) from the vertebral 
fracture arm and 1394/1403 from the clinical fracture arm. Combined there were 3737 women 
with non-osteoporotic t-scores, 1878 received alendronate and 1859 who received placebo. They 
report that regardless of baseline vertebral fracture, ALN is associated with a RR 0.40 (95% CI 
0.19, 0.76) with 3.0 to 4.5 years of follow-up. This study only assessed vertebral fractures. 
Overall these three studies found that alendronate was efficacious at reducing future 
fractures in comparison to placebo and were the basis of the FDA approval in 1995. Additionally 
a 70 mg once weekly dose was approved by the FDA in 2001 and it has been found to be as 
efficacious as the 10-mg dose once daily (305).  
2.5.2 AOM Safety 
Although commonly used in real-world practice and generally considered to be a safe and 
effective treatment, several significant safety concerns have been raised related to the use of 
AOMs. These include atypical femoral fractures, osteonecrosis of the jaw (ONJ), cardiovascular 
complications, and risk of cancer. Case reports of atypical femoral fractures began appearing in 
the late 2000s, these fractures occur in the subtrochanteric or diaphyseal femur rather than the 
femoral neck. An initial analysis of three AOM RCTs suggested that the incidence of atypical 
fractures was rare, even in women using AOMs for up to 10 years (306). A 2010 task force from 
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the American Society for Bone and Mineral Research (ASBMR) concluded that the incidence of 
atypical fractures appears to be rare, though it may be associated with long-term bisphosphonate 
use (307). This report was updated in 2014 and further suggested that these fractures be given a 
different procedural code as an increased awareness may help to further clarify an association 
between bisphosphonates and atypical femoral fractures (308). 
Osteonecrosis of the jaw (ONJ) is defined by the 2007 ASBMR task force as “as the 
presence of exposed bone in the maxillofacial region that did not heal within 8 weeks after 
identification by a health care provider” (309). Estimates of the prevalence of ONJ in 
osteoporosis have been <1 in 100,000 person years in the US (309-311), with an increase in ONJ 
with intravenous bisphosphonates, treatment for >5 years, and among patients with concomitant 
malignancies (309). Recent analyses have suggested that treatment for malignancy may be a 
greater contributor to ONJ than osteoporosis (312).  
As osteoporosis is a disease which primarily affects older adults, determination of an 
association between the use of AOM and cancer has been an important area of study. Oral 
bisphosphonates have been shown to increase esophageal irritation if they become lodged during 
swallowing prompting the recommendation of a prone position for the 30 minutes after 
ingestion. This esophageal irritation has given rise to the question regarding potential increased 
risk of esophageal cancer. To date there are conflicting results as to the association between 
bisphosphonates and cancer (313-316). In cases of breast cancer and bone metastases due to 
cancer, bisphosphonates have been investigated as possible treatment options and - in the case of 
zoledronic acid - are currently approved (317).   
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2.5.3 Comparative Effectiveness and Epidemiology of AOM use 
RCTs have been performed comparing therapies which have been approved for 
osteoporosis. We will only discuss those trials, meta-analyses, and systematic reviews which 
compare two therapies which are considered AOMs in this analysis. Additionally we only 
discuss studies which compare two different agents rather than comparison of different 
formulations of the same agent. A comprehensive review of all trials comparing all therapies has 
been compiled by MacLean et al and Crandall et al (247, 282). In RCTs alendronate was found 
to not have a significant difference in clinical fractures at 2 years, or composite fractures at 1 
year (318-321). No difference was found in non-vertebral fracture at 14 or 36 months or hip 
fracture at 36 months (322, 323).  
Observational studies have found no significant difference in the risk of non-vertebral 
fracture between alendronate, risedronate, and raloxifene (324). In British Columbia an increased 
risk for hip fracture in women who used risedronate compared to alendronate was found (325). 
Alendronate users had lower non-vertebral and hip fracture rates after hip or vertebral fracture in 
Taiwan (326). In a managed care cohort a reduction in non-vertebral fractures for risedronate 
users compared to alendronate or calcitonin was found, but no difference in non-vertebral 
fracture risk between alendronate and calcitonin users (327). In women aged ≥65 a reduction in 
incident fracture rates for risedronate compared to alendronate users was found (328). In 
adherent commercially insured women aged ≥65 who were weekly users of risedronate were at a 
greater risk of hip fracture than alendronate users, but no greater risk for clinical vertebral or 
non-vertebral fractures compared to weekly alendronate users (329). Alendronate has been found 
to be more effective at reducing fractures (vertebral and non-vertebral) compared to ibandronate 
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users, while risedronate was no more effective (330). In summary alendronate is an effective 
therapy for reduction of fractures even when compared to other AOMs. 
Although osteoporosis must be defined by BMD, clinical guidelines and US quality 
measures encourage AOM treatment after fragility fracture (hip or vertebral) (331-333). 
Research has found that women are more likely to be treated than men, however less than 35% 
of patients typically receive an AOM within 6 months of fracture (125, 129, 163, 334). Although 
AOM treatment after fracture shows a decrease in future fracture a large portion of the 
population who are known to be at risk for future fracture are not utilizing AOMs (267). 
Estimates of AOM utilization by the population at risk for osteoporosis is difficult owing 
to the under diagnosis of osteoporosis. After diagnosis of osteoporosis less than 50% of patients 
have been reported as receiving an AOM (334, 335). In patients known to be at risk for 
glucocorticoid-induced osteoporosis, less than 40% of patients are reported as treated with 
AOMs (16, 336-341). It appears that in cases where patients and clinicians are aware that a 
patient is it at risk for fracture, therapy is somewhat utilized. However AOMs cannot be effective 
in reducing fractures if they are not used by patients. At an adherence (Medication Possession 
Ratio [MPR]) of ≥ 80% fewer fractures occur (342, 343). Also 50% compliance is thought to be 
necessary for fracture reduction (344). However meta-analyses and systematic reviews have 
found one-year MPRs for daily oral bisphosphonates to be ~50% with even lower compliance at 
24 months and ~60% in weekly bisphosphonates (345, 346). Patients who are at least 70% 
compliant with AOM therapy have been found to incur 9% less osteoporosis related costs and 
7% less overall costs within 2 years (347). There are multiple rationales for low compliance to 
AOMs including patient side effects and questions regarding the efficacy of treatments (348, 
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349). However it is difficult to completely define who is at risk for fracture and should be treated 
or how effective treatment will be if medication isn’t properly used. 
2.5.4 Universal Supplement Recommendations 
In all patients an adequate dietary intake of calcium and Vitamin D are recommended. In 
early life calcium plays a major role in increasing peak bone mass which plays a role in the 
development of osteoporosis. Vitamin D is involved in calcium absorption, bone health, muscle 
performance, balance, and the risk of falls Although supplements are an important part of 
treating osteoporosis and osteoporotic therapy, their use alone is not sufficient to reduce future 
fractures. However in an attempt to increase Vitamin D intake some AOMs have begun 
including it in the capsule, ie Fosamax plus D, though it may cause osteomalacia in patients who 
are Vitamin D deficient (350). 
2.6 Quality Measures and Evaluation of Guidelines 
With diminishing resources for healthcare, payers and providers are increasingly looking 
for ways to measure quality patient care and improve outcomes. Quality measures (QM), which 
are derived from evidence-based medicine and expert opinion, are used to evaluate the care that 
patients receive. Commonly these quality measures are then used to incentivize reimbursement 
based on specific care measures in a process known as pay-for-performance (P4P). Although 
P4P has not convincingly been shown to improve outcomes many payers, including Medicare, 
have begun tying reimbursement to both processes and outcomes of care (351-353).  
To our knowledge there are no P4P measures currently in use by Medicare for 
osteoporosis however establishment of reliable quality measures is necessary to tie 
reimbursement to quality. In osteoporosis, QMs are currently in place through the Joint 
Commission on Accreditation of Healthcare Organization (JCAHO), National Quality Forum 
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(NQF), and the National Committee for Quality Assurance. Current QMs for osteoporosis are 
listed in Table 2.8. The presented QMs measure process of care or treat-to-target measures likely 
due to the relative ease of assessment based on physician ordering or prescribing of therapy 
rather than the effect of the therapy on clinical outcomes (354).  
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Table 2.8 Quality Measures by Steward 
Measure Title Description Number Steward 
Osteoporosis Management 
in Women Who Had a 
Fracture†§ 
The percentage of women 67 years of age and older who 
suffered a fracture and who had either a bone mineral 
density (BMD) test or prescription for a drug to treat or 
prevent osteoporosis in the six months after the date of 
fracture. 
NQF #0053 NCQA 
Osteoporosis testing in 
older women†§ 
Percentage of female patients aged 65 and older who 
reported receiving a bone density test (BMD) to check for 
osteoporosis 
NQF #0037 NCQA 
Osteoporosis: 
Communication with the 
Physician Managing On-
going Care Post Fracture 
of Hip, Spine or Distal 
Radius for Men and 
Women Aged 50 Years and 
Older§ 
The percentage of patients aged 50 years and older treated 
for a hip, spine or distal radial fracture with 
documentation of communication with the physician 
managing the patient’s ongoing care that a fracture 
occurred and that the patient was or should be tested or 
treated for osteoporosis. 
NQF #0045 NCQA 
Osteoporosis: Management 
Following Fracture of Hip, 
Spine or Distal Radius for 
Men and Women Aged 50 
Years and Older§ 
Percentage of patients aged 50 years or older with 
fracture of the hip, spine or distal radius that had a central 
DXA measurement ordered or performed or 
pharmacologic therapy prescribed 
NQF #0048 NCQA 
Osteoporosis: 
Pharmacologic Therapy 
for Men and Women Aged 
50 Years and Older§ 
Percentage of patients aged 50 years and older with a 
diagnosis of osteoporosis who were prescribed 
pharmacologic therapy within 12 months 
NQF #0049 NCQA 
Osteoporosis: Screening or 
Therapy for Women Aged 
65 Years and Older§ 
Percentage of female patients aged 65 years and older 
who had a central dual-energy X-ray absorptiometry 
(DXA) measurement ordered or performed at least once 
since age 60 or pharmacologic therapy prescribed within 
12 months. 
NQF #0046 NCQA 
Steroid Use - Osteoporosis 
Screening§ 
The percentage of patients aged 18 years and older who 
have been on chronic steroids for at least 180 days and 
had a bone density evaluation or were taking osteoporosis 
treatment 
NQF #0614 ActiveHealth 
Management 
Osteopenia and Chronic 
Steroid Use - Treatment to 
Prevent Osteoporosis 
The percentage of women aged 55 years and older, or 
men, aged 50 years and older, who are taking chronic 
steroids (>/=3 months), and are taking drugs to prevent 
osteoporosis 
NQF #0633 ActiveHealth 
Management 
Osteoporosis - Use of 
Pharmacological 
Treatment 
The percentage of women, aged 55 and older, or men, 
aged 50 and older, with a diagnosis of osteoporosis who 
are taking osteoporosis therapy. 
NQF #0634 ActiveHealth 
Management 
Risk assessment/treatment 
after fracture- Inpatient 
The percentage of all patients who had had a CBC, 
kidney and liver function tests, serum calcium, and 25 
(OH)vitamin D level prior to discharge with a diagnosis 
of osteoporosis or fragility fracture of the hip, spine or 
other fracture 
7 JCAHO 
Risk assessment/treatment 
after fracture-Emergency 
Department 
The percentage of all patients who had had a CBC, 
kidney and liver function tests, serum calcium, and 25 
(OH)vitamin D level prior to discharge with a diagnosis 
of osteoporosis or fragility fracture of the hip, spine or 
other fracture 
7a JCAHO 
NCQA: National Committee for Quality Assurance, NQF: National Quality Forum, JCAHO: Joint Commission on 
Accreditation of Hospital Organizations; HEDIS: Healthcare Effectiveness Data and Information Set; †: Use in 
HEDIS 2014; §: NQF Endorsed 
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At the present time there are no QMs which measure the receipt of an AOM based on 
NOF guidelines, as there is no agreed-upon proxy for measuring FRAX® in most data sources 
(35, 136, 137). This leaves potentially a large proportion of the population at risk for 
osteoporotic fracture not having the quality of their care measured or administered in a 
systematic way.  
In osteoporosis, the prevention of fracture is the primary measurable QM outcome as 
there is no target level for BMD wherein fractures will not occur (355-357). The creation of 
treatment guidelines and the measurement of quality care in osteoporosis is an ongoing process, 
and although numerous measures have been proposed, only process measures are currently in use 
(331, 358, 359). Of note, three NQF measures lost their approval due to an inability to accurately 
assess the effectiveness of the QM because of a lack of pharmacy, bone density, and fracture risk 
information. 
The use of process measures also generally prevents researchers from determining if the 
receipt of a quality measure improves the patient’s clinical outcome as evidenced by the 
conflicting results of two studies of AOM use in glucocorticoid-induced osteoporosis (16, 17). 
Although clinicians would generally agree that the use of an AOM should reduce the risk of 
fracture, if other factors including baseline fracture risk are not properly accounted for, spurious 
conclusions can be reached. 
Current QMs based on receipt of an osteoporosis medication for patients with 
osteoporosis or prevalent fractures and/or the receipt of a DXA for women over age 65 both have 
shown less than optimal receipt of care. In patients with new fractures between 9.4% and 40.2% 
of patients treated for hip or vertebral fracture also received an AOM with the inclusion criteria 
for these populations varying widely (125, 129, 163, 334). Additionally only 41.6% of patients 
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with a diagnosis of osteoporosis received an osteoporosis medication within 90 days of their 
initial diagnosis (334). In a study of 25 million Medicare patients (5% Medicare sample), less 
than 30% of women aged 65 and older received a DXA between 1999 and 2005 (78). Other 
researchers have reported that less than 20% of Medicare patients received an AOM after 
diagnosis of osteoporosis (336, 360) and AOM use has been found to be even less among 
patients at risk for secondary osteoporosis (340, 361). A study by Antonelli et al found that fewer 
than 20% of patients with incident hip or vertebral fracture were screened for osteoporosis or 
provided with an AOM (362). Although these studies were not intended to measure the real-
world effect of QM, they demonstrated that preventative care measures are not being utilized in 
actual practice for osteoporosis. 
Attempting to evaluate QM based on real world practice is likely to be highly confounded 
by variables not available in most current datasets available to payers – specifically BMD and 
FRAX® 10-year risks for major osteoporotic or hip fracture. BMD is important to measure as 
this is currently the only accepted way to diagnosis osteoporosis and up to 30% of patients with 
osteoporosis by BMD do not have a corresponding diagnosis recorded (9, 35, 70, 137). FRAX® 
10-year risk of fracture on the other hand is based on clinical characteristics that are generally 
unavailable in administrative claims which can be calculated with or without patients’ BMD and 
provide a diagnostic threshold for treatment (65, 363).  
2.7 Framework for variable selection 
The purpose of this project is to estimate a fracture risk score based on characteristics 
which can be obtained through administrative claims. Primarily we are concerned with factors 
and patient characteristics which are associated with a patient’s future fracture risk, including 
bone strength (decrease due to disease as well as possible increase due to the use of calcitonin, 
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HRT, or raloxifene), propensity to fall, as well as factors included in the FRAX® model (5, 8, 
18, 46, 280). The patient characteristics listed in this section have been chosen based on their 
known relationships to bone strength, osteoporosis, falls, or propensity to fracture (364-370). 
Additionally we have included health system variables which have been shown to be associated 
with osteoporosis and osteoporotic fracture (including DXA utilization) (20, 80, 369, 371). 
Because CFRI is an estimation of FRAX®, the variables used in FRAX® which can be captured 
in administrative claims, age, gender, prior osteoporotic fracture, rheumatoid arthritis, secondary 
causes of osteoporosis, and current use of oral glucocorticoids will also be utilized (17).  
2.7.1 Andersen’s Behavioral Model of Health Services Use  
Within the project Aim 3 is used to demonstrate how CFRI could be used in actual 
practice. The intention is to create groups which are best representative of both users and non-
users of alendronate and determine if the use of CFRI improves effect estimates. Although not 
intended for this purpose, Andersen’s Behavioral Model of Health Services Use may be 
applicable to categorize the characteristics used in this analysis.  Briefly Andersen posits that 
there are predisposing, enabling, and need factors which predict a patient’s use of health services 
(372, 373). We previously have discussed the content variables which we expect to be associated 
with osteoporosis and possibly associated with the receipt of an AOM. We have taken the 
content variables in addition to health system variables and divided them into predisposing, 
enabling, and need factors based on Andersen’s Model (Figure 2.8) (364-369).  
The three facets of the model are predisposing, enabling, and need characteristics which 
explain why a person does or does not utilize healthcare. In Andersen’s model predisposing 
variables are both biological imperatives, ie age, gender; social factors including education and 
race; as well as health beliefs, in our context the patient’s ideas about osteoporosis and treatment. 
78 
 
Enabling characteristics generally can be split into financing and organizational factors. The 
financial factors can include those a patient’s ability to pay for health care as well as the overall 
cost of healthcare, while the organizational factors include if a patient has a regular source of 
healthcare and what type care that is. Organizational factors also can include things like 
transportation or parking costs and the amount of time it takes for a patient to be seen. Lastly are 
need characteristics which have been split into perceived and evaluated need for healthcare. In 
the model perceived need are how the patient themselves views their health, ie do they think of 
themselves as sick, while evaluated need is moreso objective measures of the patients health 
(364-369, 372). When a researcher fills in each of the categories they are better able to 
understand the barriers which patients may face to receiving care, as well as possible 
intervention points to improve the patients care. Although much of this project is focused on 
predicting an actual clinical event, rather than use of medical services around the event, a better 
understanding of why a patient may or may not have sought help for the condition allows our 
research team to contextualize factors which are associated with either event.
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Figure 2.8 Modified Andersen's Behavioral Model of Health Services Use 
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2.7.1.1 Study Variable Framework 
Based on Andersen’s model, predisposing characteristics fall into three groups. First are 
those characteristics which represent biological imperatives which will cause the patient to need 
the health service (372). Second are those characteristics which are associated with a patients’ 
social structure, including their status within the community, and coping responses (372). Third 
are patients’ health beliefs which are their attitudes, values, and knowledge the patient has about 
their health condition and the treatment of the health condition which influence if a patient uses 
the healthcare resource (372).  
For this study race, gender, and age can be considered as biological imperatives; age, 
race, gender, education, parental history of hip fracture, and social structure are variables which 
could be considered as social structure; as well as a patients belief about osteoporosis and 
osteoporosis medications could be considered beliefs all of which can be labeled as predisposing 
variables (5, 8, 13, 69, 366, 374, 375). We would also include calendar year, urban/rural, 
geographic region, median income which were variables found to be associated with 
osteoporotic fracture in previous studies of Medicare data, as predisposing variables (20, 130). 
During creation of CFRI we found little to no variation in geographic region, urban/rural, or 
median income due to all patients being treated in Northeast Ohio. Additionally we removed 
calendar year from the algorithm as not all years ended up being significant covariates and if the 
algorithm was to be used with any other time period than it was created in the calendar year 
variable would not be informative or useful. Important but unmeasured variables include: 
education, social structure, or patient’s beliefs about osteoporosis or osteoporosis medications. 
As BMI and parental hip fracture are part of the FRAX® calculator we will not directly be using 
these variables in this analysis. All factors expressed as predisposing variables have been 
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empirically shown to be associated with the development of osteoporosis, osteoporotic fracture, 
or the use of an anti-osteoporosis medication. 
The model describes enabling resources as being in one of two main groupings, either 
personal/family or community. Andersen states that “Both community and personal enabling 
resources must be present for use to take place. First health personnel and facilities must be 
available where people live and work [community]. Then people must have the means and 
know-how to get to those services and make use of them [personal/family]” (372). For this 
analysis the personal/family predisposing variables are thought to be Medicare eligibility, 
Medicare low-income subsidy, direct cost of medication and medical services for the patient, and 
availability or ability for transportation, though based on the exposure of an office visit for Aim 
3, these variables were not measured in the analysis. The community enabling variables are 
thought to include availability of DXA, distance and availability of osteoporosis specialists 
(Rheumatology, Endocrinology), as well as the inclusion and availability of specific AOMs 
within the patients insurance coverage (formulary), however for this analysis they were not 
measured (364-369). 
Within the model, Andersen states that there are also need factors which are the 
immediate reason for health care utilization to take place, both realized and perceived (372). First 
are the diagnosis of osteoporosis or the actualization of a fracture. For our study many of the 
evaluative need factors are conditions (diseases) associated with osteoporosis, low bone mass, or 
falling based on prior research and meta-analyses including: fracture, parental history of fracture, 
healthcare encounter, DXA, Medicare factors (listed previously), factors associated with falling 
(comorbid conditions, medication use listed in Table 2.10), diagnosis of primary osteoporosis, 
diagnosis of secondary osteoporosis (clinical factors listed in Table 2.9): Lifestyle factors, 
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genetic factors, hematologic disorders, hypogonadal states, endocrine disorders, gastrointestinal 
disorders, rheumatologic and autoimmune diseases, medications, and miscellaneous conditions 
(5, 8, 17, 124, 130, 148, 175-180, 376, 377). The specific diseases which fall within these groups 
are listed in Table 2.9, the different diseases and disease groups have varying specific 
mechanisms for low bone mass and increased fracture risk with basic mechanism groupings 
provided in Table 2.10, including changes in bone resorption and formation, low peak bone 
mass, decreased sex hormones, malabsorption including Vitamin D and Calcium, use or excess 
production of glucocorticoids, excess parathyroid hormone, inflammation, decreased mobility, 
physical exercise, and balance, as well as an increase in falls and lower bone mass due to 
conditions which effect muscle strength and overall bone loss (5, 378-380).  
Many of the conditions listed as content variables in Table 2.10, particularly the 
gastrointestinal, rheumatologic, and immunologic diseases necessitate the use of specific 
medications including glucocorticoids and proton pump inhibitors which have been shown to be 
associated with decreases in bone mass and increased risk for fracture (5, 37, 176, 381-384). The 
nine groups listed in Table 2.10 are decreased BMD, malabsorption, glucocorticoid use or 
production, falling, decreased sex hormones, low peak bone mass, changes in parathyroid 
hormone (PTH), immobilization, and inflammation. In many cases the conditions within a given 
group increase fracture risk by more than one of these categories. Broadly a decreased BMD 
either at or after peak means the patient has less bone to lose to before they are at risk for fracture 
due to a low BMD, the groups which have been checked in the table either reduce a patient’s 
bone mass at a later point or are known to not allow a patient to achieve the highest possible 
bone mass prior to adulthood (385). Malabsorption is an issue in osteoporosis due to nutrients 
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including calcium not being absorbed in the gut preventing the body from having the necessary 
building blocks for bone formation (386-388). 
Glucocorticoid use has been shown to be ~1.2% in the US, with glucocorticoids 
continuing to be a drug which is commonly prescribed for conditions that fall under endocrine 
disorders, rheumatic conditions, as well as in central nervous system disorders (particularly 
multiple sclerosis) (361, 389-391). Glucocorticoids both in the medication form as well as the 
body’s own production effect bone remodeling and when used at high doses or prolonged 
periods of time put patients at an increased risk for osteoporosis (glucocorticoid-induced 
osteoporosis) as well as fracture (392). Decreased estrogen has been found to be associated with 
osteoporosis, as such hypogonadal states including premature ovarian failure, alter a patients 
estrogen levels and effect their bone (393-396). 
Parathyroid hormone is an essential part of bone resorption by changing the absorption 
and expression of calcium in the bone (397, 398). Studies have shown that patients who are at a 
higher BMI are associated with stronger bones, under the hypothesis that their bones are being 
made to work more due to the increased weight, this is the same rationale as to why 
immobilization causes weak bone (399). If you are not putting weight onto and utilizing your 
bones they will become brittle and at a higher risk for fracture (400, 401). The last broad 
category was inflammation which has been shown to be associated with changes in bone 
turnover which can cause weakening of the bone (402, 403). 
The specific conditions and medications which have been shown with at least moderate 
evidence to be associated with falls are checked in Table 2.10 and described in more detail in 
Table 2.11, and are arthritis, stroke, Alzheimer’s, Parkinson’s, Dementia, incontinence, postural 
hypotension, sedatives, antidepressants, cardiovascular drugs, and polypharmacy (370, 404). 
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Lastly are height, weight, BMI, peak bone mass which are biological determinants which 
predispose a patient to weak bones. Height, weight, and BMI are all interconnected and it has 
been found that persons with a higher BMI or greater weight have better BMD and are less likely 
to fracture. The thinking is that the extra weight stimulates the bone, thereby making it stronger 
(399). Peak bone mass effects the long-term fracture risk because if a patient had a low peak 
bone mass, then they do not have much to lose before they become osteoporotic thereby putting 
themselves at a greater risk for fracture (385). Peak bone mass although interesting and 
potentially important cannot be measured at the point of our study and therefore will be an 
unmeasured variable. 
In general a face to face healthcare encounter is necessary for a patient to be diagnosed 
with osteoporosis, have their fracture risk evaluated, or receive a DXA, or have FRAX® 
calculated. Because the NOF guidelines use FRAX® to guide treatment decisions, the presence 
of osteoporosis or specific FRAX® score is a need variable to initiate treatment, but has little 
association with the independent development of osteoporosis (37).  
Although not all of these risk factors can accurately be measured in administrative 
claims, when possible, measurement will be based on previously published algorithms. We 
previously measured the majority of the need variables in a study of glucocorticoid-induced 
osteoporosis (17). The variables used in this study grouped by type of disease, medication, or 
demographic characteristic are presented as Table 2.9. Variables both based on content 
knowledge and high-dimensional methods will be utilized in Aim 3 to control for confounding 
and include factors related to both the exposure and outcome (405-407). Failure to adjust for 
these confounders cause biased treatment estimates (407). Although the factors specified will be 
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used to create CFRI they also will be introduced into the model when CFRI is utilized as a 
disease risk score.  
We are estimating a clinical fracture risk score (FRAX®) with our tool CFRI in this 
study. The intended purpose of CFRI is to inform researchers and policy makers of the 
information that a clinician had at the time of treatment decision. The clinical model which we 
have proposed allows our projects to address critical points in the decision-making process for 
treatment and evaluation of treatment for osteoporosis.  
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Table 2.9 Variables associated with Osteoporosis or Osteoporotic Fracture 
Lifestyle Factors Hypogonadal states Medication Classes 
Alcohol Abuse Androgen insensitivity Cyclosporine A and tacrolimus 
Falling Anorexia nervosa and bulimia Proton pump inhibitors 
Vitamin D insufficiency Hyperprolactinemia Anticoagulants 
Excess Vitamin A Premature ovarian failure Selective serotonin reuptake 
inhibitors 
Genetic factors Athletic amenorrhea Anticonvulsants 
Cystic fibrosis Turner and Klinefelters's 
syndromes 
Glucocorticoids 
Homocystinuria Panhypopituitarism Aromatase inhibitors 
Osteogenesis imperfect Endocrine disorders GnRH (Gonadotropin releasing 
hormone) antagonists and agonists 
Ehlers-Danos Adrendal insufficiency Thiazolidinediones 
Hypophosphatasia Diabetes mellitus (Type 1) Barbiturates 
Gaucher's disease Cushing's syndrome Lithium 
Idiopathic hypercalciuria Hyperparathyroidism Methotrexate 
Porphyria Central Adiposity Calcitonin 
Glycogen storage diseases Thyrotoxicosis Hormone Replacement Therapy 
Marfan syndrome Gastrointestinal disorders Raloxifene 
Riley-Day syndrome Celiac disease Miscellaneous conditions and 
diseases 
Hemochromatosis Gastric bypass AIDS/HIV 
Menkes steely hair syndrome Inflammatory Bowel Disease Congestive Heart Failure 
Hematologic disorders Malabsorption Muscular dystrophy 
Hemophilia Pancreatic disease Depression 
Thalassemia Primary biliary cirrhosis Amyloidosis 
Sickle cell disease Rheumatologic and autoimmune 
diseases 
End stage renal disease 
Systemic mastocytosis Ankylosing spondylitis Sarcoidosis 
Multiple Myeloma Lupus Chronic metabolic acidosis 
Leukemia’s and Lymphomas Rheumatoid arthritis Hypercalciuria 
Central nervous system disorders Medicare Factors Asthma/Chronic obstructive lung 
disease 
Epilepsy Gender Idiopathic scoliosis 
Parkinson's disease Race Kyphosis 
Stroke Age by 5 year increments Immobilization 
Multiple sclerosis Calendar Year Emphysema 
Spinal cord injury Urban/rural  
 
Geographic region  
 Median Income  
 
  
From: US Surgeon General, 2004 (5), Taylor et al 2011 (130) 
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Table 2.10 Mechanism of Action for Conditions and Medications Associated with Osteoporosis and Osteoporotic Fracture 
Factor group associated with 
osteoporosis and osteoporotic 
fracture 
Decreased 
BMD (5, 
37, 176, 
381-384) 
Malabsorption 
(386-388) 
Glucocorticoid 
Use or 
production 
(361, 389-391) 
Falling 
(370, 
404) 
Decreased 
Sex 
Hormones 
(393-396) 
Low Peak 
Bone 
Mass 
(392) 
PTH 
(397, 
398) 
Immobilization 
(400, 401) 
Inflammation 
(402, 403) 
Lifestyle Factors X X 
 
X 
     
Genetic Factors X 
        
Hematologic Factors 
         
Hypogonadal States 
    
X X 
   
Endocrine Disorders 
  
X 
   
X 
  
Gastrointestinal Disorders 
 
X X 
      
Rheumatologic and 
autoimmune diseases 
  
X 
  
X 
  
X 
Medications  X X X 
  
X 
  
X 
Miscellaneous Conditions X X 
   
X X 
 
X 
Central Nervous System 
Disorders 
X X X X 
   
X 
 
PTH: Parathyroid Hormone 
 
Table 2.11 Conditions and Medications associated with Falling  
Arthritis Stroke 
Alzheimer’s Parkinson’s 
Dementia Incontinence 
Postural Hypotension Sedatives 
Antidepressants Cardiovascular Drugs 
Polypharmacy  
From citations (370, 404)
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2.8 Summary 
Osteoporosis and osteoporotic-fracture are common and result in significant morbidity 
and mortality. Evidence suggests that a large proportion of patients who may benefit from 
therapy are not treated due largely to an inability to accurately and easily identify patients who 
may be eligible for treatment. Identifying patients who will go on to have a fracture isn’t precise 
and the risk tools currently available generally rely on a patient’s bone mineral density which 
isn’t readily accessible to providers or payers. By developing a claims-based algorithm for 
accurately measuring FRAX we hope to provide a tool for identifying patients who might benefit 
from treatment and that could be used to improve the rigor of comparative effectiveness research 
studies comparing treatments for osteoporosis.  
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 METHODS 
3.1 Data Sources 
For this project two different data sources will be used, a clinical registry which has been 
linked to Medicare Claims referred to as the “linked sample” and a 20% random sample of 
Medicare administrative claims for fee-for-service beneficiaries. We describe how the linked 
sample is created, the inclusion and exclusion criteria of the linked sample, and the data which 
was linked in this section. Additionally we describe the data contained in the 20% random 
sample of Medicare beneficiaries.  
3.1.1 Cleveland Clinic (CCF) 
The Cleveland Clinic DXA Registry (CCF DXA) began prospectively collecting patient 
information in 2009 in an attempt to better measure the quality of their osteoporosis care (408). 
Patients administered DXAs at one of 9 sites within the CCF health system were consented to 
include their information in the registry. The information gathered includes all variables needed 
to calculate FRAX, current and past use of AOM, and basic demographic characteristics. Data is 
entered into the registry by DXA technologists or directly imported from the medical record. 
FRAX® is retrospectively calculated for all patients in the first quarter of the following year 
using either the batch utility tool or the current web version (65).  
Through the end of 2014, 45,000 patients have had their data entered into the registry. 
Periodic quality checks of measures which are entered by hand such as height, weight, and BMD 
are conducted with changes made as needed. CCF DXA patients have successfully been linked 
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to their electronic medical record (EMR) (99.1% of cases) based on medical record number. This 
linkage allows analysis and collection of all discrete data elements contained within the patients 
EMR including all visit diagnoses, clinic notes, labs, procedure reports, and prescribed 
medications. Due to its registry status and linkage to the patients EMR the CCF, DXA is 
approved by the CCF Institutional Review Board (IRB). 
3.1.2 University of Alabama at Birmingham (UAB) 
Utilizing a collection of multiple stakeholders the University of Alabama at Birmingham 
(UAB) under the direction of Jeffrey Curtis, MD, MPH, MS have gathered Medicare fee-for-
service claims for patients at increased risk for fracture. This includes a 5% sample of all 
Medicare beneficiaries from 2006 to 2013, as well as 100% of women with a diagnosis of 
osteoporosis, claim for a fracture, or claim for an osteoporosis therapy between 2010 and 2013. 
The UAB FFS data includes the beneficiary annual summary file, Medicare claims file, and 
prescription drug claims file for the specified time periods. These files include demographic 
information including region of residence and date of death, inpatient and outpatient encounter 
based diagnosis and procedures, as well as all filled medications under Medicare Part B. Files 
can be linked based on a de-identified beneficiary id variable. Medicare FFS files have been used 
extensively in pharmacoepidemiologic research (20, 75).   
3.1.3 CCF/Medicare Linkage (Linked Sample) 
CCF patients aged 55 years or older with Medicare Part A/B as the primary payer for the 
service on the date of their CCF DXA were identified. Specifics of the matched population are 
presented as Figure 3.1. Patients available for linkage from the Medicare data were enrolled in 
Medicare Part A/B at the time of their DXA. This method identified a candidate 11,538 CCF 
patients matched to Medicare enrollment data. Variables used for linking between the CCF 
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registry and the Medicare claims were birth date, sex, and date of DXA. Before attempting to 
link the CCF patients, the CMS data was restricted to only DXAs (CPT 76499, 76977, 77080, 
77081, 77082, 77083, 78399, 76075, 76076, 76078, 77078, 77079, 8898) with the service 
occurring within a zip code served by CCF centers. This restriction – called blocking - is 
intended to increase matching efficiency between the CCF registry and Medicare claims.  
Figure 3.1 CCF/Medicare Linkage Flow Diagram 
 
Based on exact matches to birth date, date of DXA, and gender 6,995 patients (60.6%) 
were matched between the CCF and UAB data. In cases where patients were not uniquely 
matched (n=55), service dates were compared to uniquely identify the patient from multiple 
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claims. In 5 cases no corresponding dates could be identified leaving a final cohort of 6,990 
matched patients.  
For those patients whose data were successfully linked, we identified, height, weight, 
BMD, FRAX® 10-year risks of major osteoporotic and hip fracture with and without BMD 
(when available), as well as responses to all FRAX® variables. A comparison of patient 
characteristics across each phase of data linkage - the full DXA registry (pre-linkage), 
individuals in the DXA registry with Medicare as the payer on record, and the linked population 
are presented as table 3.1. Although a small number of men are included in the linked sample we 
exclude them for our analyses based the small n and we do not know if FRAX® is able to predict 
fracture as well in men and women which could skew our predictions. 
Table 3.1 Linked Population Characteristics 
  Whole Registry With Medicare Linked 
N 38028 11,538 6990 
Male 5411 (14.2) 1653 (14.3) 101 (1.4) 
Female 32,617 (85.8) 9885 (85.7) 6,889 (98.6) 
Mean Age 67.2 (8.4) 72.3 (7.4) 73.3 (7.1) 
2009 2872 (7.6) 1094 (9.5) 468 (6.7) 
2010 8247 (21.7) 2724 (23.6) 1378 (19.7) 
2011 10716 (28.2) 3567 (30.9) 2211 (31.6) 
2012 8654 (22.8) 2431 (21.1) 1766 (25.3) 
2013 7539 (19.8) 1722 (14.9) 1167 (16.7) 
 
3.1.4 Medicare 20% Random Sample (Random Sample) 
We utilized a 20% random sample of all Medicare FFS beneficiaries between 2007 and 
2013 for evaluating the performance of CFRI in administrative data. The data is housed at the 
UNC Cecil B. Sheps Center for Health Services Research. The 20% random sample includes the 
beneficiary annual summary file, Medicare claims file, and prescription drug claims file for a 
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20% random sample of Medicare FFS beneficiaries. As in the linked sample, we exclude men 
from the claims for consistency between the linked and random sample. 
3.2 Aim 1 
Aim 1: Develop and evaluate a claims-based algorithm (CFRI) to estimate FRAX® 
risk scores using clinical registry data linked to Medicare claims data. 
Hypothesis 1: In the final model there will be no significant difference in predicted 
(CFRI) to observed (FRAX®) scores based on R2. 
Aim 1 will utilize the registry-claims linked dataset to create a linear model estimating 
the known values of FRAX® 10-year risk for 1) major osteoporotic fracture without BMD, 2) 
hip fracture without BMD, 3) major osteoporotic fracture with BMD, and 4) hip fracture with 
BMD. These four scores will be listed as continuous numeric variables as calculated using the 
FRAX® website and linked to the patient’s claims data.  
For aim 1, we required all women in the linked dataset to have at least 365-days 
continuous enrollment in Medicare Part A, B, and D prior to the date of DXA in the linked 
dataset (Figure 3.2). Although Part D enrollment could not be explicitly determined within the 
linked data, we required a fill of at least one medication in the 365-day look back period. The 
length of the look-back period allows us to collect the variables which are based both on content 
knowledge and selected using a high-dimensional method to estimate CFRI. Additionally 
patients were required to be anti-osteoporosis medication (bisphosphonates, Raloxifene, 
calcitonin, Denosumab, and Teriparatide) naïve as well as not have an ICD-9 diagnosis code 
associated with a major osteoporosis fracture during the look-back period. If a patient has more 
than one DXA, we will randomly select one of the dates for the parameter estimates. The 
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primary outcome for this aim is the known FRAX® score; we describe how we will chose the 
covariates, and the correct combination of the covariates will yield CFRI. 
Figure 3.2 Aim 1 Study Schematic 
 
MPABD: Medicare Part A, B and D enrollment 
Aim 1 is a classic prediction model of an observed continuous variable. To describe the 
methods of how we are predicting FRAX® we have broken this aim into 3 specific steps (listed 
below).  
STEP 1: Select covariates 
STEP 2: Determine model type and outcome  
STEP 3: Determine optimal model parameters for penalization values, stability, and 
coefficients using 10-fold cross validation 
Further we will discuss how we will accomplish each of these steps in the following 
sections. This will include what information will be passed forward from each step, the 
diagnostics of each step, and the expected result of each step.  
For this aim, we separated the cohort into a test and a training dataset. The training data 
set comprised 70% of the population and all models were created in this dataset. Once the 
models were fit, it was used to predict CFRI in the test dataset. Because some patients did not 
have a femoral neck BMD recorded at the time of their DXA the study population was subset by 
365-days Continuous MPABD 
enrollment 
Known DXA date with 
FRAX® from CCF 
Assess Covariates 
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BMD presence or absence. The same population was used for both models in each group 
(with/without BMD) and all patients are eligible for inclusion in the test and training sample 
regardless of their status in the other cohort.  
3.2.1 Step 1: Select covariates 
The model covariates are being chosen in one of two ways, 1) through content knowledge 
based on the Andersen’s conceptual framework of factors known to be associated with 
osteoporosis, and 2) through a high-dimensional variable selection approach (described in detail 
below) to identify utilization and unknown healthcare characteristics associated with FRAX®. 
All model covariates will be based solely on diagnosis, procedure, medication, and utilization 
codes primarily found in administrative claims. Covariates based on content knowledge are those 
which were likely associated with osteoporosis or fracture in the 2004 Surgeon General’s Report 
and identified in prior work (5, 17), (Table 2.9). For those conditions which are identifiable in 
administrative claims data utilizing The International Classification of Diseases, Ninth Revision 
(ICD-9), Current Procedural Terminology (CPT), or Healthcare Common Procedure Coding 
System (HCPCS) codes we present coding algorithms in Table 3.2. All factors in table 2.9 will 
be recorded as 0=absent, 1=present based on the 365-days prior to FRAX®. Based on the 2004 
Surgeon General’s report we have deemed the following characteristics as associated with 
osteoporosis, but it is unknown if many of these factors would also be associated with treatment. 
As CFRI is designed to estimate fracture risk, we are only concerned with factors which affect 
patients’ bones, rather than those associated with AOM use. Lastly, we captured the use of 
hormone replacement therapy because this is a medication which improves patients bone mass, 
so although it doesn’t demonstrate a decrease or increase in fracture risk, it does alter it. 
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Table 3.2 Content Variables Associated with Osteoporosis (Coding Algorithms) 
Variable ICD-9 Code unless specified 
Osteoporosis 733.0x 
Dual Energy X-ray absorptiometry (DXA) scan CPT Codes: 76075, 76076, 77079, 76499, 77080, 77081, 
77082, 77083 
Lifestyle Factors 
 
Alcohol Abuse 303.xx, 305.0x 
Falling E880-E888.xx 
Vitamin D insufficiency 268.xx 
Excess Vitamin A 278.2 
Genetic factors 
 
Cystic fibrosis 277.0x 
Homocystinuria 270.4 
Osteogenesis imperfecta 756.51 
Ehlers-Danos 756.83 
Hypophosphatasia 275.3 
Gaucher's disease 272.7 
Idiopathic hypercalciuria 275.4 
Porphyria 277.1 
Glycogen storage diseases 271.0 
Marfan syndrome 759.82 
Riley-Day syndrome 742.8 
Hemochromatosis 275.03 
Menkes steely hair syndrome 759.89 
Hypogonadal states 
 
Androgen insensitivity 259.5x 
Anorexia nervosa and bulimia 307.1, 783.0, 307.51 
Hyperprolactinemia 253.1 
Premature ovarian failure 256.31 
Athletic amenorrhea 626.0 
Turner and Klinefelters's syndromes 758.6, 758.7 
Panhypopituitarism 253.7 
Endocrine disorders 
 
Adrendal insufficiency 255.4 
Diabetes mellitus (Type 1 & 2) 250.xx 
Cushing's syndrome 255.0 
Hyperparathyroidism 252.0x 
Central Adiposity 278.xx 
Thyrotoxicosis 242.xx 
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Variable ICD-9 Code unless specified 
Gastrointestinal disorders 
 
Celiac disease 579.0 
Gastric bypass CPT Codes: 43644, 43645, 43770, 43771, 43772, 43773, 
43774, 43842, 43843, 43845, 43846, 43847, 43848, 
43886, 43887, 43888 
Inflammatory Bowel Disease 555-556.xx 
Malabsorption 579.xx 
Pancreatic disease 751.7, 577.xx 
Primary biliary cirrhosis 571.6 
Hematologic disorders 
 
Hemophilia 286.xx 
Thalassemia 282.4x 
Sickle cell disease 282.6x 
Systemic mastocytosis 757.33, 202.6 
Rheumatologic and autoimmune diseases 
 
Ankylosing spondylitis 720.xx 
Lupus 710.0 
Rheumatoid arthritis 714.xx 
Central nervous system disorders 
 
Epilepsy 345.xx 
Parkinson's disease 332.xx 
Stroke 430-438.xx 
Multiple sclerosis 340.xx 
Spinal cord injury 806.xx, 952.xx 
Alzheimer’s* 290.xx, 294.xx, 330-331.xx 
Miscellaneous conditions and diseases 
 
AIDS/HIV 042-044.xx 
Congestive Heart Failure 428.xx, 398.91, 402.01, 402.11, 402.91, 404.01, 404.11, 
404.91 
Muscular dystrophy 359.0-359.1x 
Depression 311.xx, 295-298.xx 
Amyloidosis 277.3x 
End stage renal disease 585.6 
Sarcoidosis 135.xx 
Chronic metabolic acidosis 276.2 
Hypercalciuria 245.40 
Asthma/Chronic obstructive lung disease 496.xx, 491-493.xx, 514.xx, 511.9, 518.0, 793.1, 786.09, 
491.21 
Idiopathic scoliosis 737.xx 
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Variable ICD-9 Code unless specified 
Cataracts* 366.1-366.9, 366.02, 366.03, 366.04, 366.09, 366.20, 
379.31, V43.1 
Glaucoma* 365.xx 
Kyphosis* 737.1x, 737.41, 737.3x 
Medications Classes† 
 
Cyclosporine A and tacrolimus 
 
Proton pump inhibitors 
 
Anticoagulants 
 
Selective serotonin reuptake inhibitors 
 
Anticonvulsants 
 
Glucocorticoids 
 
Aromatase inhibitors 
 
GnRH (Gonadotropin releasing hormone) 
antagonists and agonists 
 
Thiazolidinediones 
 
Barbiturates 
 
Lithium 
 
Methotrexate 
 
Hormone Replacement Therapy# 
 
ICD-9: International Classification of Disease Version 9; CPT: Common Procedure Terminology; †Medication 
Classes were based on National Drug Code (NDC) codes within each drug class; *: Conditions associated with 
falling; #: These are therapies which can be used to treat osteoporosis, however are less effective than 
bisphosphonates. We have included them because they effect (lessen) the patient’s risk of osteoporosis. 
From Overman et al (17) 
Additionally variables for age2, age3, and age*osteoporosis were fit to the data based on 
their interactions.  
The second variable identification method utilized a high-dimensional variable selection 
method of aggregating all procedures, diagnoses and drug classes within the baseline period. We 
used an adapted method for the variable selection as the Harvard HD-PS uses a JavaScript applet 
which requires connection to the Harvard server to give titles to the diagnoses, procedures, and 
medications (personal communication with Brookhart, MA). The Medicare DUA required that 
the data be housed on a server which did not have internet access, which made the connection by 
the applet impossible. Therefore we used coding which defined each of these groups without the 
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need to connect to the applet based on adapted code from M. Alan Brookhart, PhD. It is 
unknown how the method we used differs from the HD-PS approach, although all diagnoses and 
procedure codes were grouped based on Healthcare Cost and Utilization Project Clinical 
Classiﬁcation Software and the medication classes were based on classes from the First Data 
Bank. All diagnosis or procedure codes, or medication classes present in >1% of the study 
population were included as candidate variables for the models. The HD models used both the 
>1% variables and the content variable previously discussed. 
3.2.2 Step 2: Determine model type and outcome 
The principle interest of this aim is creating a score which is a proxy of FRAX® and can 
effectively be used to identify patients at high risk for fracture or to control for confounding in 
comparative effectiveness studies. The outcome of interest is the FRAX® score available in the 
CCF registry. We have chosen to estimate a continuous FRAX® score (henceforth called CFRI) 
using linear regression models. Four different estimates will be derived for this project; 1) Major 
osteoporotic fracture (MOF) 10-year risk without BMD, 2) MOF 10-year risk of fracture with 
BMD, 3) Hip fracture 10-year risk without BMD, and 4) Hip fracture 10-year risk with BMD. 
The processes described henceforth will be reapplied for each of the 4 specified outcomes.  
In this analysis we evaluated multiple ways that the predictive model could be 
constructed. After evaluating the distribution of FRAX® scores, we log transformed the outcome 
variable. All analysis was done with both an untransformed and log-transformed FRAX® score. 
Analysis were split into three different groups, basic, least absolute shrinkage and selection 
operator (LASSO), and elastic net. The basic models were constructed to determine how well 
standard multivariate and automated regression procedures would do predicting the outcome. 
Additionally the basic models could be used to demonstrate the improvement in prediction using 
100 
 
the more sophisticated models. Both the LASSO and elastic net models are penalized models 
which would be assumed to outperform the basic models. The elastic net model is a slight 
variation on the LASSO model which generally produces more accurate estimates, however the 
LASSO will occasionally outperform elastic net. Because we did not know if this would be one 
of the cases where LASSO would outperform the elastic net we chose to do both analyses. The 
optimal model from each group was then directly compared using density plots as well as all 
error terms. The best available model (highest aR2) was also evaluated using a categorical 
outcome of treatment or no treatment based on the NOF guidelines (hip ≥ or < 3% and MOF ≥ or 
< 20%). Finally the elastic net models for each outcome were fit using the HD approach to 
determine if the inclusion of additional prevalent variables improved model prediction.  
The basic linear models were, 1) a null model where there were no covariates, 2) linear 
model with all available covariates, and 3) linear model using backwards stepwise regression 
based on improvement in AIC. The LASSO model was fit by specifying alpha=1 in the glmnet 
model. The elastic net models did not specify an alpha thereby allowing the model to determine 
the optimal alpha value based on the data.  
Ordinary least squares (OLS) is the most common method used in linear regression, as it 
creates estimates which minimize the sum of squared residuals. One of the most common 
measures of how well the model fits the data is the sum of squared error (SSE), which is a 
measure of the total vertical distance between the regression line and the predicted points. The 
mean squared error (MSE) is an estimate of how well the model fits to the data by expressing the 
average of the squared error which is the difference between the expected and estimated values 
which is calculated as SSE divided by 1 minus the degrees of freedom, but is composed of 
squared random error, squared model bias, and the model variance (409). This can further be 
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reduced to the root mean squared error or RMSE which is the square root of the MSE. All three 
of these error statistics are useful in determining how well the model predicts future data based 
on observed values. For many situations OLS is sufficient as it will fit the best line to the data 
available without bias, however in the setting of highly correlated variables, other models may be 
able to reduce the MSE and produced better predictions by altering the bias in the model.  
Penalized Models 
Since MSE is composed of random error, bias and variance, and random error cannot be 
changed, steps to reduce MSE must alter the bias and variance in the model. Models which alter 
the amount of allowable bias to reduce the overall error are commonly referred to as penalized 
models, in that they reduce the coefficient values to meet a pre-specified change in MSE. The 
basic delineation of penalized models is those that allow coefficients to be set equal to 0 and 
those that do not. Due to the correlated nature of variables within the proposed model, 
coefficients can become overly inflated and controlling or regularizing these values can reduce 
the out-of-sample MSE. We will be using an elastic net model which takes the advantages of the 
two other penalized models (ridge regression and LASSO) to reduce the MSE of the estimates.  
Recent methodologic developments have permitted the use of both penalized methods to 
reduce the MSE for the model and provide more harmonious estimates under the umbrella of 
elastic net models (29-31, 409-411). This model shrinks the model coefficients towards 0, but 
does not eliminate coefficients unless their exclusion would correspond to a pre-specified change 
in the MSE. Using both of these methods at the same time allows the model to both determine 
which model inputs are most influential and combine these two penalized methods into one in 
the elastic net model. In this model, coefficients are regularized by reducing their values towards 
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0 and using feature selection to reduce the number of highly correlated estimates in the model 
(409). 
For this study we will utilize the glmnet package for R statistical software (30, 31). This 
specific package was designed to reduce the computational time of computing the entire 
regularization pathway for the lasso model and allowing for the use of ridge regression penalties. 
The authors of the glmnet package have rewritten the naïve elastic net model to account for the 
packages ability to utilize not only linear, but logistic, and time to event models (30).  
 To perform various model diagnostic tests and to optimize the penalization and stability 
selection process for the final model we will also utilize the c060 package which has reduced 
computational time compared to glmnet alone and allows for bootstrapping model parameters 
(412). The glmnet package allows for 4 different penalization shrinkage settings, λ minimum of 
mean absolute error (MAE) and mean squared error (MSE) as well as shrinkage at one standard 
error from the λ minimum (1se). Because we did not assume that any of these parameters were 
superior to another we fit all 4 outcomes with all shrinkage parameters in both untransformed 
and log transformed models. For posterity all models were fit using both elastic net and LASSO, 
and all model results are presented. Additionally the λ value is variable, therefore we 
bootstrapped the output λ 100 times for a more stable result. In this situation λ is the penalization 
value. 
3.2.3 Step 3: Evaluate Model Parameters 
Each model was evaluated using five different measures. We present the number of 
variables which stayed in the model as well as the root mean squared error (RMSE), mean 
absolute error (MAE), R2, adjusted R2 (aR2), and calibration slope. Each of these measures were 
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calculated in the test sample based on the predicted CFRI using the parameters of the training 
sample. The optimal model was chosen based on the highest aR2. 
Root mean squared error is the squared variance of the difference between the observed 
and predicted values. It is calculated by squaring the difference between the observed and 
predicted values for each observation, taking the mean of all of these values, and then taking the 
square root. The mean absolute error is calculated by taking the absolute difference between 
observed and predicted values and taking the mean of the sample. The MAE is useful for 
evaluating how far from the truth predictions are regardless of being high or low. The next 
measure is R2 which can be calculated as 1- the residual sum of squares divided by the total sum 
of squares. The R2 informs the percentage of variance in the outcome which can be explained by 
the predictors. The R2 is generally used as the outcome of how well a model fits the outcome, 
however the R2 increases as covariates are added. Because we are evaluating the optimal model 
to predict FRAX® and our basic models include >80 predictors, accounting for the number of 
variables in the model is necessary. Therefore, we will use the adjusted R2 as our measure of the 
best model, which takes into account the number of variables the model retains in producing a 
statistic for the variance explained. The aR2 is calculated as ((1-R2)*(1- sample N))/(1-sample N-
number of variables). Lastly, we present the calibration slope which is coefficient of a basic 
linear model of the outcome = prediction. In the setting of calibration, a perfectly calibrated 
model would have an intercept of 0 and a slope of 1 (413). The best model from each of the 4 
outcomes will be plotted as observed compared to predicted values with the regression line 
superimposed to better evaluate how well the model predicts the outcome. Lastly, we will 
present the optimal model coefficients for each of the three types of models.  
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The HD variables along with the content variables will be evaluated using all four types 
of elastic net model. These models will produce similar outcomes to the basic models, and when 
superior to the basic models will be presented in full. If they are inferior to the basic models then 
the variables which were retained will be discussed. Additionally if the HD variable based 
models do not produce greater aR2 no variables from the HD selection will be included in future 
models.  
To determine if the models are informative based on treatment cut points from the NOF 
guidelines a planned sensitivity analysis will be undertaken. The linear outcome of CFRI will be 
transformed to a binary outcome based on if it is above or below the NOF threshold, as will the 
FRAX® scores. We will use receiver operating curves (ROC) and the area under the curve 
(AUC) to evaluate how well CFRI predicted above or below the threshold based on the gold 
standard (FRAX®). The cut points of 20% 10-year risk of major osteoporotic fracture and/or 3% 
10-year risk of hip fracture will be analyzed separately for both with and without BMD CFRI.  
For Aim 1 we are using variables based on content knowledge, however we are using 
automated regression procedures which supersede inclusion of variables based on known 
associations. For the variables which are not included in the final models one can view these are 
not influential, whereas variables with larger coefficients can be viewed as more significant or 
influential. We will not be presenting p-values for the coefficients in the final models as the 
difference from null is a better determinant of their influence in the model. Although it would be 
interesting to evaluate how variables are included and excluded in the models as they iterate, this 
information will not change the final models and would only be valuable for future hypothesis 
generation. Therefore we will only be presenting the coefficients for the best models from the 
basic, LASSO, and elastic net groups to evaluate which variables were retained. We are aware 
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that these are essentially black-box methods, however they offer the opportunity to create the 
best models to predict FRAX®. 
3.3 Aim 2 
Aim 2: Externally validate CFRI in a 20% random sample of Medicare beneficiaries 
by comparing the performance of CFRI and FRAX® to predict future fractures.  
Hypothesis 2: There will be no significant difference between FRAX® and CFRI to 
predict future fractures as a continuous variable (calibration) between the linked and random 
sample.  
Hypothesis 3: CFRI will identify fractures at a similar rate based on c-statistics in the 
random sample as FRAX® in the linked sample (discrimination). 
This aim will utilize the registry-claims linked data as well as the 20% random sample of 
Medicare beneficiaries. Calibration in Aim 1 was centered on how well CFRI predicted FRAX®. 
In the second aim we will evaluate how well FRAX® and CFRI predict actual fractures. If CFRI 
has a similar calibration and discriminatory ability in the random sample as the linked then an 
argument can be made that it is accurately predicting FRAX® in a situation where FRAX® is 
unknown. This is based on the external validity of the model and assumptions used to create 
CFRI.  
For this Aim, fracture risk will be assessed among three distinct subgroups: 1) individuals 
with FRAX® risk scores in the linked population, 2) individuals with CFRI scores in the linked 
population (whose FRAX® scores are known), and 3) individuals with CFRI scores calculated in 
the 20% random population (whose FRAX® scores are unknown). In the linked dataset the 
population consists of all patients who have at least 365-days continuous enrollment prior to a 
DXA. In the 20% random sample the only inclusion criteria is that a patient has an office visit 
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after 365-days continuous enrollment. A secondary analysis will replace the office visit 
requirement with that of a DXA. The study schematic for Aim 2 is presented as Figure 3.3. Aim 
2 is broken into two separate steps 1) evaluate the calibration and 2) evaluate the discrimination 
of CFRI.  
Data will be collected from both samples based on Figure 3.3. In the linked sample the 
“FRAX®/CFRI Calculation” will be the date of DXA. In the random population “FRAX®/CFRI 
Calculation” will represent any office visit after the patient has been continuously enrolled in 
Medicare Part A, B, and D for 365-days. For the random population we will have multiple 
records for patients. However we will randomly select an available office visit of all candidate 
visits for the main analysis. In both the linked and random population, covariates used to 
calculate CFRI will be collected in the 365-day look back period prior to “FRAX®/CFRI 
Calculation”. Once the “FRAX®/CFRI Calculation” or index date has been determined patients 
will be followed until occurrence of fracture, 365-days from FRAX®, loss of continuous 
enrollment, death, or the end of the study period (December 31, 2012). A sensitivity analysis will 
be undertaken using only DXA visits (CPT codes 70675 or 77080) from the random population. 
This will help to determine if CFRI is more valid in a similar population to that which it was 
created (patients with DXA). 
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Figure 3.3 Aim 2 Study Schematic 
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In Aim 2 we will be capturing actual fractures which fit the FRAX® model. As 
previously discussed there are two types of fracture estimated by FRAX® - hip fracture and 
major osteoporotic fracture. We present the algorithms that will be used to capture each of the 
fracture sites in Table 3.3. The occurrence of either a hip or major osteoporotic fracture are the 
main outcomes of Aim 2. The primary predictors are the risk scores (CFRI and/or FRAX®). 
Although the death rate may be high in those patients who have hip fractures, we will not use 
death as a competing risk for this analysis.  
Table 3.3 FRAX® Major Osteoporotic Fracture Site Codes 
Fracture Site ICD-9 and CPT Definition 
Hip* Hip fracture diagnosis (ICD-9 code: 820.xx,733.14) during hospitalization AND procedure 
code during hospitalization (ICD-9: 78.55, 79.05, 79.15, 79.25, 79.35, 79.65; CPT-4: 27230-
27248) 
Humerus Humerus fracture diagnosis (ICD-9: 812.xx, 733.11) AND procedure within 30-days of 
fracture date (ICD-9: 78.52, 79.01, 79.11, 79.21, 79.31, 79.61; CPT-4: 23600, 23605, 23610, 
23615, 23620, 23625, 23630, 23665, 23670, 23680, 24500, 24505, 24506, 24510, 24515, 
24530, 24531, 24535, 24536, 24538, 24540, 24542, 24545, 24560, 24565, 24570, 24575, 
24581, 24583, 24585-8, 24516) 
Wrist Radius/ulna fracture diagnosis (ICD-9: 813.xx, 733.12) AND procedure within 30-days of 
fracture date (ICD-9: 78.53, 79.02, 79.12, 79.22, 79.32, 79.62; CPT-4: 24620, 24625, 24635, 
24650, 24655, 24660, 24665-6, 24670, 24680, 24685, 25500, 25505, 25510, 25515, 25530, 
25535, 25540, 25545, 25560, 25565, 25570, 25575, 25600, 25605, 25610-1, 25615, 25620, 
25650) 
Vertebral (ICD-9: 805.8, 805.9, 806.8, 806.9, 733.13) 
*Hip Fractures are part of major osteoporotic fracture but are also a separate category 
 
3.3.1 Calibration  
In a binary setting, calibration is the rate of agreement between the predicted and 
observed outcomes for how well CFRI predicts future fractures. A model can be thought of as 
well calibrated if the mean prediction is equal to the number of outcomes (414). Based on 
observed 1-year fractures we will assess the calibration of the FRAX® and CFRI estimates in the 
linked data and compare these estimates to the 20% random sample. Calibration in this context is 
the ability to predict the risk level compared to observed outcomes (415). Calibration is primarily 
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evaluated in a binary outcome setting using the brier score and the Hosmer-Lemeshow goodness 
of fit test (415).  
In many cases, we do not expect participants to have at least 1-year, let alone 10-years, 
follow-up after their FRAX® or office visit, due to the possibility of the first useable visit 
occurring in the last year of the data. To address this in the main comparison we will utilize the 
first office visit (CPT 99201-99205, 99211-99215) in any given year as the index date of CFRI 
calculation. For a woman to be eligible for inclusion in this aim the only requirement is at least 
365-days continuous fee-for-service Medicare Parts A, B, &D enrollment prior to index. To 
better mimic aim 1, patients with prior AOM use or fracture will be excluded, even though prior 
AOM use has not been shown to significantly influence FRAX® scores (416). We will also 
conduct a sensitivity analysis only including patients who have a DXA, which will be then 
utilized as the index date.  
CFRI will be calculated utilizing the available covariates in the 365-days prior to index 
and will be followed for a maximum of 365-days after index. The primary outcomes will be 
fracture (defined by type of CFRI evaluated) and patients will be censored at death, loss of 
continuous enrollment, or the end of the study period. CFRI and FRAX® will be degraded by the 
maximum length of follow-up (10 years) regardless of event type ie, ((365/36500)*Risk score). 
This is based on recommendations that the FRAX® 1-year risk is essentially 1/10 of a 10-year 
risk (65). We will also conduct a sensitivity analysis varying the proportion of risk from 8% to 
12% to evaluate if this may be a truer representation of a 1-year risk. 
FRAX® major osteoporotic fracture risk is based on fractures of the hip, spine 
(vertebral), shoulder (humerus), or wrist, while hip fracture risk is limited to only hip (65). 
Therefore we will only use fractures at these sites to evaluate the calibration of CFRI to FRAX®. 
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We will use both the applicable CPT codes based on fractures from the Rochester cohort which 
were used to specify the FRAX® model as well as accepted claims-based algorithms using both 
ICD-9 and CPT codes (17, 61, 124).  
Goodness of fit of the model will be assessed using the Hosmer-Lemeshow test which 
splits the study population in k samples, with k typically = 10. The observed number of events is 
calculated as the sum of the events in the sample, and the expected number is the sum of the 
predicted probabilities for the sample. These two values then are assessed using a chi-square test 
with k-1 degrees of freedom (df) in new datasets, but k-2 df in the dataset used to create the 
predictive model as 1 df is lost defining the groups. A p-value of ≤0.05 has typically been used to 
denote an acceptable goodness of fit for the model using the Hosmer-Lemeshow test. We can 
visually inspect a Hosmer-Lemeshow test using a calibration plot with an identity line with slope 
= 1. The calibration plot will break the study population into the same sample populations and 
plot the mean observed and mean predicted values for each of the groups.  
Calibration and its predictive ability will be assessed using the brier score. This score is a 
measure of the accuracy of predicted probabilities. The brier score ranges from 0 (the best score) 
to 1 (the worst score). 
Because we will be using all of the available information for the main analysis, we will 
be conducting a planned sensitivity analysis using only those patients in the random population 
who have DXAs. We will evaluate how the different parameters (FRAX with BMD compared to 
without BMD) behave within the random population. We hypothesize that CFRI without BMD 
will better predict fracture in general, but CFRI with BMD will better predict fracture for patients 
with a DXA. This will be evaluated using the same measures as in the full population. 
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3.3.2 Discrimination 
We will be comparing the 3 risk-scores in the two populations (FRAX® in linked, CFRI 
in linked, CFRI in random) to evaluate discrimination (or ability to predict) actual fractures. 
Discrimination of a model seeks to correctly differentiate between those with and without the 
outcome. Simply, determining whether people with higher CFRI/FRAX® scores have fractures 
more often. Typically receiver operating characteristic curves (ROC) are used to visually inspect 
the discrimination of a model. ROC curves plot the true positive rate (sensitivity) with 1-false 
positive rate (specificity). These curves serve as a graphical representation of the discrimination 
of the model, however they themselves cannot give evidence as to the how well the model 
discriminates. 
Commonly the measure used in tandem with ROC is the area-under-the-curve (AUC). 
This value is equal to the probability that a randomly chosen positive case will be ranked above a 
randomly chosen negative case. The AUC in the setting of binary outcomes (0/1) is 
mathematically equivalent to the concordance statistic or c-statistic (417).  The c statistic is a 
rank-order statistic for evaluation of predictions against true outcomes. Because the c-statistic is 
meant to rank-order observations rather than evaluate model fit, it has been shown to be a poor 
judge of a badly fitting model (418). We will model the optimal c-statistic of FRAX® in the 
linked population by setting the half of the population with the highest CFRI score to a fracture 
outcome, and the other half to a non-fracture outcome regardless of their true outcome. This will 
provide a baseline for the c-statistic to be compared against. 
We will create ROC curves for all 3 populations (FRAX in linked, CFRI in linked, and 
CFRI in random) and will directly compare the curves using a direct comparison of ROC curves 
as proposed by DeLong in 1988 (32). DeLong proposed a non-parametric method to compare 
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ROC curves when their predictions cross even if they have the same AUC. In this manner the 
test can give a permutation test statistic for the amount of variation between the two ROC curves 
as well as a non-parametric area estimate which is reported as the Mann-Whitney statistic (419). 
Both the permutation test and the area estimate are under the null hypothesis that there is no 
difference between the two ROC curves, and will be evaluated with a p≤0.05 indicating 
statistical significance. The discrimination analysis will be conducted using the R-statistical 
software package pROC (420).  
The rationale behind comparing the ROC curves directly rather than visual inspection is 
that two populations can have the same c-statistic but different ability to predict over the whole 
population. Assessing the ROC curve will provide additional information as to how well CFRI 
fits the random population in proportion to FRAX®. If the ROC curves are not statistically 
significantly different in the three populations, we can conclude that CFRI is externally valid. 
Plots will be made of outcomes at 1, 2, and 3 years’ post-index to determine if the main analysis 
cut point of 1 year is too conservative.  
3.4 Aim 3 
Aim 3: Evaluate the utility of CFRI and restriction in a comparative effectiveness 
research study of alendronate users to non-users.  
Hypothesis 4: Comparative effectiveness estimates will most closely approximate 
Fracture Intervention Trial results after restricting by trial inclusion criteria and incorporating 
CFRI, then estimates generated without CFRI. 
The goal of Aim 3 is to demonstrate the utility of restricting a study or patient population 
by CFRI values. For quality evaluations by payers, the use of CFRI in this manner would assist 
payers in identifying those patients at highest risk for fracture and those most likely to benefit 
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from pharmaceutical intervention. To evaluate CFRI-based restriction to identify a suitable 
candidate population we will compare effect estimates of the full population, restriction based on 
CFRI, and finally all inclusion/exclusion criteria specified in the FIT study.  
The analysis utilizes 1) a null hazard model, 2) a hazard model with only MOF CFRI 
both with and without BMD, 3) a multivariable-adjusted hazard model with all content variables, 
and two propensity score based models 4) a stabilized inverse probability of treatment weighted 
(SIPTW) and 5) standardized mortality rate (SMRW) hazard model. We will measure the effect 
of alendronate use compared to non-use in the 20% Medicare Random sample, and compare 
these results to those from the FIT studies. Even if CFRI is not able to sufficiently discriminate 
continuous values of FRAX® the evaluation of restriction based on CFRI may provide a context 
wherein it may be useful to payers. 
3.4.1 Study Design 
Aim 3 is a retrospective cohort study using the 20% random sample. We will utilize a 
similar structure to that of Aim 2 with all office visits eligible for inclusion after 365-days of 
continuous enrollment in Medicare Part A, B, and D for females. We will be identifying patients 
with new alendronate use as the “alendronate users” and the new use of any drug, in any class 
other than AOMs as the “non-users”. The decision to use the new-use of any drug rather than of 
a specific class is based on the idea that the decision to initiate alendronate follows a clinician’s 
determination that a patient has sufficient fracture risk to warrant treatment, in the same way that 
the new use of a drug would be initiated because the clinician determined that the patient’s 
ailment warranted treatment. In this situation a full patient evaluation may have prompted 
alendronate initiation. One of the major drawbacks to the use of “any new user” as the non-user 
group is that depending on the drug, the patients who initiate them may be very different from 
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new users of alendronate, making the non-user group heterogeneous. If the use of “any new 
drug” is found to be too broad a category, we will employ one of the following approaches as an 
alternative approach for this analysis. Alternative approach #1: Schneeweiss et al articulated an 
approach for selecting non-users by taking all persons not initiating the drug of interest 
(alendronate) and taking a random date as their index (23). This theory of taking a random index 
date was the impetus of the any new use categorization as any new use would give a better 
random indexing point to choose from, and would satisfy the need for a similar experience 
within the healthcare system. However, these patients likely will be different from new 
alendronate users because they aren’t starting a medication. Alternative #2 would include all new 
users aside from those initiating medications in the classes which have been listed in Table 3.2 
which are known to affect fracture risk.  
There are two other approaches which were suggested by Schneeweiss et al, the first is to 
compare the new users of a different drug class to Alendronate users (23). For this approach to 
work the different drug class should not be associated with changes in the outcome under study. 
Statin, diabetes, and hypertension medication classes will be evaluated for use as the comparison 
group for this analysis. Drugs within the class will be defined based on Anatomical Therapeutic 
Chemical (ATC) Classification System codes. Some of the drawbacks to this approach are these 
patients were prescribed the new drug class for a different reason than osteoporosis which may 
create a heterogeneous population (421).  
The third approach will be to take office visits and the 30-days after as the window for 
initiation of alendronate. If alendronate is not initiated during this 30-day window then the 
patient will be considered a non-user for the analysis. This approach eliminates the reliance on 
filling a medication other than Alendronate, but the office visit may have been a routine 
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examination where no disease was readily evaluated (23, 422). Also by not requiring the fill of a 
medication in the 30-days post office visit these patients may not be comparable to the 
Alendronate users. However this will allow the patients to at least have had a similar encounter 
within the healthcare system, wherein a medication could have been prescribed. A variation on 
the office visit approach will be to only use patients who receive DXAs (CPT codes 70675 or 
77080) as the index event. 
After evaluation within the 20% random sample the use of a random selection of office 
visits per patient yielded >1.5M patients, making modeling of outcomes computationally 
infeasible. When the same procedures were attempted in the 1% random sample of claims, no 
events were observed in the population after CFRI restriction. Because of this, our third approach 
was modified to include only patients with DXA visits, with patients who used an alendronate 
within 30-days as the alendronate users.  
Knowing the strengths and limitations of each of the three methods, we will utilize the 
“any new drug use” approach as the primary analysis, and the comparison medication classes or 
inclusion based on office visits/DXAs as secondary analyses. We will utilize a new user design 
with a 365-days washout period for this aim (22). For a patient to be eligible for this study they 
must have had continuous enrollment for at least 365-days prior to an office visit and fill a new 
medication within 30-days of that visit. The new user design differentiates between incident and 
prevalent users of a medication as there are systematic differences between these two types of 
use in evaluating short-term outcomes (423). Prevalent users typically have exceeded the period 
of adverse event and continue to tolerate the therapy, therefore including them with incident 
users may cause adverse events to appear less frequently and make the medication appear less 
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hazardous. Incident users on the other hand can be assumed to have a similar risk of the event of 
interest (421). 
Patients with use of any bisphosphonate (alendronate, ibandronate, risedronate, or 
zoledronic acid), teriparatide, or denosumab during the washout period will be excluded from the 
analysis. We are choosing to exclude patients with any use of these therapies during the washout 
period due to their known effect on bone strength and fracture risk. The use of any formulation 
of alendronate (10mg QD, 70mg QWk, 10mg Effervescent) will be identified using national drug 
codes (NDC). Patients using other AOMs will be identified and excluded using NDC codes as 
well. In the comparison class analysis, patients who use one of the comparison medication during 
the washout period will also be excluded. 
3.4.1.1 Inclusion/Exclusion Criteria 
To begin this aim we will identify all office visits based on CPT codes (CPT codes 
99201-99205 or 99211-99215) and collect continuous enrollment information prior to the first 
office visit which had at least 365-days continuous enrollment and where patients are aged ≥65 
(Figure 3.4). Patients will also be required to have the fill of at least 1 medication in the 365-day 
washout period to ensure that they were using their Part D coverage. A sensitivity analysis will 
be performed using the date of a DXA as the index date rather than an office visit to determine if 
this is a more accurate use of CFRI. 
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Figure 3.4 Aim 3 Schematic Part 1 
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We will utilize the office visit that is chronologically prior to and closest to the new fill of 
a drug as the index date with 30-days being the maximum time period allowable between office 
visit and medication fill (Figure 3.5). The medication fill itself however will be the index date, as 
the office visit in the 30-days prior is an exposure event. For the main analysis patients who fill 
alendronate will herein be referred to as users and those who fill another drug will be herein 
referred to as non-users. Any patient who experiences a fracture between their office visit and 
index will be excluded. In the second approach, statins, hypertensives, and diabetes drugs will be 
used as the comparison group, all procedures will be the same, substituting any new drug with 
new statin/hypertensive/diabetes. For the third approach there will be no requirement of a fill of 
any medication in the treatment period for inclusion in the non-users and the users will have had 
an office visit less than 30-days prior to the alendronate fill and the non-users will be identified 
following a visit where a DXA is performed. 
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Figure 3.5 Aim 3 Schematic Part 2 
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Follow-up will begin on day +1 from the medication fill, as the inclusion criteria includes 
the office visit in the 30-days prior, which then allows follow-up to immediately begin. Patients 
will be followed until the occurrence of a fracture, death, loss of continuous enrollment, end of 
study period, or use of a non-alendronate AOM. Censoring for use of an AOM after the 
treatment period is based on a change in fracture risk at the time of treatment initiation (17). 
Lastly, we will investigate censoring at specific cut-points (i.e., 1 and 4 years) to make our 
results more directly comparable to those of the FIT trial. After evaluation with data 1 year 
follow-up was used as well as all available time. The schematic including these specifications is 
presented as Figure 3.6.  
Although figure 3.5 is representative of how we will select patients for inclusion in the 
population for Aim 3, we will be introducing further restrictions for the majority of the analysis. 
The schematic including the restrictions are presented as Figure 3.6 and further details regarding 
the specific restrictions are presented in Section 3.4.2.3.
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Figure 3.6 Aim 3 Restriction Study Schematic 
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3.4.1.2 Outcomes 
The FIT Trial grouped fractures into six different fracture outcomes based on study type, 
1) clinical vertebral fracture, 2) radiographic vertebral fracture, 3) clinical fracture (humerus, 
vertebrae, pelvis, wrist, ribs, legs, hand, feet, toes, and clavicle), 4) nonvertebral fractures, 5) hip 
fracture, 6) wrist fracture, and in women without pre-existing vertebral fractures 7) nonvertebral 
osteoporotic fractures (clavicle, humerus, wrist, pelvis, hip, and leg) (25, 26, 304).  
Because alendronate has been shown to significantly reduce vertebral fractures compared 
to placebo, a vertebral only definition would be optimal, however there is a low prevalence of 
these fractures in administrative claims, likely under powering any estimates. Although the 
clinical fracture definition would seem to be the best for our study, the codes used to identify the 
fracture types are largely non-specific and when used this omnibus definition provided a 
significantly different estimate to all others in our glucocorticoid-induced osteoporosis study 
(17). Therefore, we will use the “nonvertebral osteoporotic fracture” and vertebral fracture 
outcomes as the main outcomes for Aim 3. Because the vertebral fracture outcome alone is 
unlikely to have enough events, we will create a third outcome which combines the two 
definitions. Coding algorithms used to define the three fracture outcomes for this study are in 
Table 3.4.  
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Table 3.4 Aim 3 Fracture Definitions 
Fracture  Definition  Vert Non-Vert 
Hip Hip fracture diagnosis (ICD-9 code: 820.xx,733.14) during 
hospitalization AND procedure code during hospitalization (ICD-
9: 78.55, 79.05, 79.15, 79.25, 79.35, 79.65; CPT-4: 27230-27248) 
 X 
Wrist Radius/ulna fracture diagnosis (ICD-9: 813.xx, 733.12) AND 
procedure within 30-days of fracture date (ICD-9: 78.53, 79.02, 
79.12, 79.22, 79.32, 79.62; CPT-4: 24620, 24625, 24635, 24650, 
24655, 24660, 24665-6, 24670, 24680, 24685, 25500, 25505, 
25510, 25515, 25530, 25535, 25540, 25545, 25560, 25565, 
25570, 25575, 25600, 25605, 25610-1, 25615, 25620, 25650) 
 X 
Humerus Humerus fracture diagnosis (ICD-9: 812.xx, 733.11) AND 
procedure within 30-days of fracture date (ICD-9: 78.52, 79.01, 
79.11, 79.21, 79.31, 79.61; CPT-4: 23600, 23605, 23610, 23615, 
23620, 23625, 23630, 23665, 23670, 23680, 24500, 24505, 
24506, 24510, 24515, 24530, 24531, 24535, 24536, 24538, 
24540, 24542, 24545, 24560, 24565, 24570, 24575, 24581, 
24583, 24585-8, 24516)  
 X 
Pelvis Pelvis fracture diagnosis (ICD-9: 808.xx)  X 
Tibia/Fibula (ICD-9: 823.xx, 733.16)  X 
Femur (ICD-9: 821.xx, 733.15)  X 
Clavicle (ICD-9: 810.xx)  X 
Radius/Ulna (ICD-9: 813.xx, 733.12)  X 
Vertebral  (ICD-9: 805.8, 805.9, 806.8, 806.9, 733.13) X X 
Thoracic spine  (ICD-9: 805.2, 805.3, 806.20 - 806.39) X X 
Lumbar spine  (ICD-9: 805.4, 805.5, 806.4, 806.5) X X 
Vert: Vertebral Fractures Only; Non-Vert: All specified fractures other than vertebral; All Specified fracture sites 
will be used in the combined outcome 
 
3.4.2 Analysis Plan 
3.4.2.1 Power Calculation 
To calculate if our study would have sufficient power to detect a significant difference 
between alendronate users and non-users we calculated the minimum sample sizes needed for 
specific hazard ratios. These were performed using Proc Power TWOSAMPLESURVIVAL at 
0.8 power with a two-tailed alpha of 0.05, one year accrual time, and one year follow-up time 
with the specified baseline hazards. Baseline hazards were calculated based on 1-year fracture 
rates in placebo users from Wells et al (250). The smallest sample size needed is 15,854 which 
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would represent 7,927 each of alendronate users and non-users, as such our study should be 
sufficiently powered. The specifics of the power calculation are presented as Table 3.5. 
Table 3.5 Power Calculation Table 
Outcome Baseline 
Hazard (250) 
Hazard Ratio 
 0.6 0.7 0.8 0.9 0.95 
Vertebral Fracture 0.1 182 356 876 3808 15854 
Hip Fracture 0.002979 172 338 834 3636 15154 
Wrist Fracture 0.014896 174 340 838 3654 15230 
Nonvertebral 
Fracture 
0.036743 176 344 848 3690 15378 
  
3.4.2.2 No Restrictions 
For this analysis we will identify all patients who meet the new use of either alendronate 
or another drug classification. We will use all patients in this analysis and will use a naïve hazard 
model. This first analysis is designed to demonstrate what the study population and results would 
look like without any modifications or restrictions. 
3.4.2.3 Restriction 
Restriction is a technique whereby an estimate cannot be confounded by a factor after 
stratification or restriction. The rationale behind this is any confounding which would have been 
present for the different levels of the restricted variable will be eliminated by only analyzing that 
specific level of the variable (406). In pharmacoepidemiology studies Schneeweiss et al 
demonstrated that restricting a study population based on inclusion/exclusion criteria used in the 
RCT can create effect estimates of a similar value and magnitude as those from the RCT (23). 
Although the FIT trial used inclusion/exclusion criteria based on BMD we will restrict 
the study population using CFRI values based on FRAX® which correspond to the minimum 
allowable BMD. Inclusion in FIT was based on a femoral neck t-score of ≤-1.6. Therefore we 
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input the average weight (75.39kg) and height (164.1 cm) of an American woman with an age of 
65 and no risk factors into the FRAX® calculator which correspond to a 10-year risk of 9.1% for 
a major osteoporotic fracture and 1.0% for a hip fracture. To mimic FIT we will restrict inclusion 
in the study population to patients with an office visit corresponding to a CFRI major 
osteoporotic fracture score of ≥9.1% or CFI hip fracture score ≥1%.  
Further we will restrict the study population by the other inclusion/exclusion criteria 
specified by the FIT trial. In Table 3.6 we describe each of the FIT inclusion/exclusion criteria 
and how we will evaluate the criterion in the Medicare data. We will describe where the patients 
based on FIT restrictions are lost, and differences for samples with and without BMD CFRI 
scores (424). This restricted population will be used as the main analytic cohort for Aim 3. 
Although FIT included women aged 55-65 whom we cannot include due to the 365-day washout 
period and Medicare only including patients ≥65 years of age, we would speculate that our 
estimate should be similar or further from the null to those of FIT. 
In creating the FIT restricted population we encountered some problems which made it 
impossible to use it as the main analysis population. First, only African-American’s were not 
excluded in the with BMD analysis based on the age coefficient in the CFRI score. Second, in 
the without BMD population analysis not all patients with osteoporosis were excluded, which 
was a primary exclusion in FIT. Finally, the n’s for the with BMD analysis particularly were 
underpowered, with few events causing the confidence intervals to be very wide. 
Table 3.6 FIT Claims-based Restrictions 
FIT Criterion Claims-based Identification Method 
Inclusion  
Female, 55-80 years old Based on age at initiation 
BMD at the femoral neck <= 0.68 g/cm2 (Hologic QDR 
2000) 
Corresponds to a t-score of -1.6 and MOF of 9.1 and 
hip fracture of 1.0 
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Understands procedures of study Not possible to identify 
Exclusion*  
Unable to give informed consent Not possible to identify 
Participating in another trial Not possible to identify 
Intends to move within 4 years Not possible to identify 
Alcohol Abuse Not possible to identify 
Major illnesses, including severe malabsorption, severe 
hypertension, myocardial infarction (within 6 months), 
unstable angina, serum creatinine > 1.6 mg/dl 
2 options, any hospitalization within 6 months prior 
to alendronate, or just these conditions, serum creat 
will be assessed with ESRD code. 
Erosive gastrointestinal disease within 5 years. Dyspepsia 
requiring daily treatment 
530-539.xx or 531-539.xx?, GERD is 530.81, so 
possibly exclude for H2 or PPI use 
History of cancer (except: resected superficial skin cancer 
and treated malignancies, except breast, without 
recurrence in 10 years) 
140-208.81 except 173.xx 
Metabolic bone disease (e.g. hyper- or 
hypoparathyroidism, Paget's disease, osteomalacia) 
Parathyroid (hypo and hyper) 252.xx, Paget's disease 
731.0, Osteomalacia 268.2 
Treatment affecting bone turnover: 
 
 
Estrogen, anabolic steroids, calcitonin, or progestins, 
within 6 months 
NDC 
 
A change in thyroid hormone dosage within the last 6 
weeks 
NDC 
 
>2 weeks fluoride treatment (>1 mg/day) at any time Not possible to identify 
 
Glucocorticoid within 6 months NDC 
 
Bisphosphonate for more than 2 weeks NDC 
Unexplained weight loss > 10% of ideal body weight 
within last 12 months 
Not possible to identify 
Unsuitable anatomy on spinal radiographs Not possible to identify 
BMD at the femoral neck >3 SD below age-specific mean Corresponds to a BMD value of 0.324 g/cm2 or t-
score of -4.45. FRAX values of 35 MOF and 21 Hip 
Noncompliance with pre-randomization study procedures Not possible to identify 
Not ambulatory Not possible to identify  
History of bilateral hip replacements Applicable CPT are (27090, 27091, 27125, 27130, 
27132, 27134, 27236, 27137, 27138) 
*:Additionally Vertebral fracture was a requirement for one arm of the FIT trial, and an exclusion for the clinical 
fracture population. We exclude all of these patients based on our overall inclusion exclusion criteria 
3.4.2.4 Descriptive Statistics 
All patient characteristics will be presented and compared between alendronate users and 
non-users for each analysis. Categorical characteristics will be assessed using Chi-square tests, 
while continuous characteristics will be assessed using student t-tests or ANOVA depending on 
the number of comparison groups. Any covariate which does not appear in either group 
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(alendronate users and referent) will be excluded from the final adjusted model due to it not 
presenting any influence on the final estimates. 
We will describe characteristics of patients excluded in the treatment period due to 
fracture within the 30-days after their visit, as this is a relevant patient group. However they will 
not be included in the main analysis due to the event of interest occurring before the end of the 
treatment exposure window. Similarly, we will describe characteristics of patients who fill a non-
alendronate AOM at index, but exclude them from the analysis due to the likelihood of fracture 
reduction by use of another AOM. 
3.4.2.5 Cox Proportional Hazards Model 
All analyses in Aim 3 will produce hazard ratios of alendronate users compared to non-
users using cox proportional hazards models. A multivariable cox proportional hazard model 
takes the form 𝜆(t|𝑥) =  λ0(t)exp{𝑥𝛽
′}. Where λ0 is the baseline hazard for a non-user and 𝑥𝛽
′ 
is the vector of specified covariates including treatment effect. The naïve model would be written 
as 𝜆(t|𝑥) =  λ0(t)exp(𝛽1𝑥1) where 𝛽1𝑥1 is the incremental change in the hazard ratio for 
alendronate users compared to non-users. We will report hazard ratios and associated 95% 
confidence intervals (95% CI) for all analyses.  
Cox proportional hazards models (PH) employ marginal likelihood estimates to produce 
a baseline hazard function based on covariate vector 𝛽′ rather than requiring one to be specified. 
The model produces estimates which treat 𝛽′ the same at t0 as at any other time and give the 
difference in hazard for the active versus referent group. As with most models, Cox proportional 
hazards assumes that all observations are independent of another observation.  
We will utilize a Cox model based on both a naïve model and a multivariable model. In 
the naïve model the outcome of interest will be the time to outcome or censoring and the only 
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predictor will be a dichotomous variable of alendronate use (alendronate user = 1, non-user = 0). 
The multivariable model will include the dichotomous alendronate use variable as well as all of 
the content variables specified in Table 2.7 and Table 3.1. Because we are basing our selection of 
factors on content knowledge, we will not be independently assessing model fit, but will present 
statistics such as AIC which give an estimate of model fit.  
3.4.2.6 Multivariable Regression 
After the initial restriction to a high-risk population based on CFRI we will utilize all 
content variables from Andersen’s model in a multivariable regression. This will allow our 
estimates to be statistically adjusted for all measured covariates. All effect estimates which have 
been analyzed with multivariable regression will be referred to as “adjusted estimates” in the 
results. 
In a planned sensitivity analysis we will utilize the continuous CFRI score as a disease 
risk score in the multivariable regression. Disease risk scores are summary scores which are 
meant to include all relevant factors of disease to predict the likelihood or rate of disease in the 
cohort as a function of the measured covariates (425). For interpretable results we will mean 
center the CFRI before including it in the multivariable regression models.  
3.4.2.7 Propensity Score 
In the presence of confounding by indication or unmeasured confounding, multivariable 
adjustment has been shown to not sufficiently reduce confounding (33). Propensity scores (PS) 
are a summary score of the measured covariates on the likelihood of receipt of a medication or 
medical procedure. Because persons who do and do not receive a particular treatment are 
generally dissimilar, the PS is a single score which can be used to balance the distribution of 
covariates between the two groups (426).   
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To control confounding by the specified characteristics, we will estimate a propensity 
score for alendronate use, using logistic regression models including all measured covariates 
from Table 2.7 (33, 427). Because we will restrict the study population based on CFRI values, 
we will not use CFRI as a covariate in the propensity score for the main analysis, but will for a 
sensitivity analysis. The predicted value or PS resulting from the logistic regression equation is 
the probability of alendronate use based on all the measured covariates. Although PS can be used 
in a variety of ways including matching, use in a regression term and weighting, we will only 
focus on weighting in this analysis.  
Propensity score weighting can take a variety of approaches based on the desired 
treatment effect. For this project we are interested in estimating the average treatment effect, 
which will produce the difference in fracture rates for those treated with Alendronate compared 
to those who did not receive alendronate. We chose to estimate the overall average treatment 
effect rather than the average treatment effect in the treated for generalizability of our findings 
(428, 429). We utilize Stabilized Inverse Probability of treatment weights (SIPTW) which when 
used produce a pseudo-population where outcomes will not be associated with measured 
covariates provided the model is correctly specified. Stabilized IPTW use the marginal 
probability of treatment to help reduce weights variance which can improve precision of 
treatment estimates, but will not reduce bias (430-432). To calculate IPTW weights one 
calculates the marginal probability of treatment (PS) for the entire cohort and transforms the 
individual weights based on exposure prevalence in the cohort (33).  
Although stabilizing the weights will reduce extreme weights, to some extent these 
extreme weights can still have a large effect on treatment estimates (433). To investigate their 
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effect we will plan to undertake sensitivity analysis investigating trimming at specified intervals, 
quartiles, and based on caliper distance (434, 435).  
We will present propensity score distributions for each of the study populations 
(restricted only with CFRI and restricted with all FIT criterion). We will present IPTW weighted 
estimates compared to unweighted estimates from the study population. The estimates which 
utilize IPTW weighting will be presented as “Weighted Estimates” in the results. 
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 AIM 1 RESULTS 
Aim 1: Develop and evaluate a claims-based algorithm (CFRI) to estimate FRAX® 
risk scores using clinical registry data linked to Medicare claims data. 
Hypothesis 1: In the final model there will be no significant difference in predicted 
(CFRI) to observed (FRAX®) scores based on aR2. 
4.1 Cohort Selection 
The Aim 1 population is comprised of women aged ≥65 from the CCF DXA registry with 
DXA scans between 2009 and 2013 who were able to be matched to their Medicare claims. For 
all of aim 1 patients had to have at least 365-days continuous enrollment prior to their FRAX® 
score as recoded in the registry, as well as fill at least one medication during the 365-days prior.  
Details of participant inclusion and exclusion are presented as Figure 4.1. Overall there were 
7,885 DXAs scans linked to Medicare claims. There were 925 patients who had >1 DXA 
matched to their Medicare data, comprising 1869 distinct scans. Using a random selection 
method only one scan per patient was chosen yielding 6,881 patients eligible for inclusion in the 
study population. We excluded 654 patients who did not have 365-days continuous enrollment in 
Medicare Parts A, B and 2,176 patients who did not have a medication fill in Part D in the 365-
days prior to DXA. This resulted in 4,051 women eligible for analysis. 
The cohort is further separated based on if the patient did or did not have a score with 
bone mineral density (BMD). FRAX® can be calculated based on a patient’s femoral neck 
BMD, or when this is not available, based on their body mass index (BMI). All 4,051 patients 
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had a score without BMD, however only 3,950 had a score with BMD. Further these cohorts 
were split 70/30 into training and test samples. The without BMD cohort is comprised of 2,835 
patients in the training sample, 1,216 in the test sample while the “with BMD” cohort is 
comprised of 1,958 in the training sample and 840 in the test sample. 
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Figure 4.1 Aim 1 Patient Flowchart 
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4.2 Prediction  
4.2.1 With BMD Cohort 
The characteristics of patients with calculated FRAX scores with BMD are presented in 
Table 4.1. When comparing the training and test samples, the mean ages were similar 74.0 in the 
training and 74.2 in the test with similar distributions of DXAs across the study years (2009-
2013). As each of these patients had a DXA it was interesting to note overall 51.8% of the 
population had a diagnosis of osteoporosis in the year preceding the DXA. Because the vast 
majority of these patients had been treated by a rheumatologist it was surprising that only 7.7% 
had a diagnosis of rheumatoid arthritis, but 96.5% had a diagnosis for kyphosis (back curvature), 
and 43.4% were diagnosed with osteoarthritis. Using the same coding algorithm, we found 
18.1% of the with-BMD population to have kyphosis in an analysis of patients with 
glucocorticoid-induced osteoporosis, while a review of the published studies prior to 2009 
speculated a prevalence of between 20 and 40% (436). As the 20 to 40% estimate was made for 
the general public it is possible that more of these patients had kyphosis as a diagnosis either as a 
consequence or attributable to their use of DXA. Only 3.8% of the population were reported as 
having a vertebral fracture in the preceding year, while 4.1% had a non-vertebral fracture (hip, 
humerus, wrist), and 12.3% fractured at a different site, with 7.1% having been reported as 
falling in the year preceding. Approximately 28.4% of the sample had a diagnosis corresponding 
to Vitamin D insufficiency, possibly related to geographic location (Northeast Ohio, where 
sunshine is not abundant). Other common comorbidities include prior stroke (14.2%), depression 
(16.8%), and COPD/Asthma (21.5%) and diabetes (20.2%), consistent with national trends based 
on Centers for Disease Control and Prevention statistics (http://www.cdc.gov/datastatistics/). 
Medications that were filled in the preceding year were most commonly glucocorticoids (22.5%), 
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proton pump inhibitors (28.8%) and SSRIs (17.6%). This is a higher proportion of glucocorticoid 
use than the general population, however that may have been the reason that they received the 
DXA in the first place. Characteristics were similar between the test and training sets except 
Parkinson’s disease, stroke, anti-coagulant use, and the use of barbiturates.  
Table 4.1 Basic Demographics of with BMD population 
Attribute Test Train Total 
N 
 
840 1958 2798 
Mean Age 74.0 74.2 74.2 
Year of DXA 
  2009 45 (5.4) 116 (5.9) 161 (5.8) 
  2010 159 (18.9) 296 (15.1) 455 (16.3) 
  2011 227 (27.0) 567 (29.0) 794 (28.4) 
  2012 193 (23.0) 493 (25.2) 686 (24.5) 
  2013 216 (25.7) 486 (24.8) 702 (25.1) 
In 365-days prior to index 
Osteoporosis, N (%)  363 (43.2) 857 (43.8) 1220 (43.6) 
Lifestyle Factors, N (%) 
  Alcohol Abuse <11 <11 <11 
  Falling 40 (4.8) 103 (5.3) 143 (5.1) 
  Vitamin D insufficiency 242 (28.8) 550 (28.1) 792 (28.3) 
Genetic factors, N (%)  
  Homocystinuria <11 <11 <11 
  Hypophosphatasia <11 12 (0.6) 14 (0.5) 
  Gaucher's disease <11 <11 <11 
  Porphyria <11 <11 <11 
  Hemochromatosis <11 <11 <11 
Hypogonadal states, N (%)  
  Anorexia nervosa and bulimia <11 18 (0.9) 23 (0.8) 
  Hyperprolactinemia <11 <11 <11 
  Premature ovarian failure <11 <11 <11 
  Athletic amenorrhea <11 <11 <11 
Endocrine disorders, N (%)  
 
  Diabetes mellitus (Type 1 & 2) 184 (21.9) 387 (19.8) 571 (20.4) 
  Cushing's syndrome <11 <11 <11 
  Hyperparathyroidism 37 (4.4) 93 (4.7) 130 (4.6) 
  Central Adiposity 64 (7.6) 133 (6.8) 197 (7.0) 
  Thyrotoxicosis 13 (1.5) 33 (1.7) 46 (1.6) 
Gastrointestinal disorders, N (%)  
136 
 
  Celiac disease <11 16 (0.8) 20 (0.7) 
  Gastric bypass <11 <11 <11 
  Inflammatory Bowel Disease 15 (1.8) 36 (1.8) 51 (1.8) 
  Malabsorption <11 35 (1.8) 44 (1.6) 
  Pancreatic disease <11 28 (1.4) 38 (1.4) 
  Primary biliary cirrhosis <11 <11 13 (0.5) 
  Crohn’s Disease 37 (4.4) 96 (4.9) 133 (4.8) 
Hematologic disorders, N (%)  
   
  Hemophilia 19 (2.3) 31 (1.6) 50 (1.8) 
  Thalassemia <11 <11 <11 
  Systemic mastocytosis <11 <11 <11 
Rheumatologic and autoimmune diseases, N (%)  
  
  Ankylosing spondylitis <11 32 (1.6) 40 (1.4) 
  Lupus <11 24 (1.2) 34 (1.2) 
  Rheumatoid arthritis 61 (7.3) 129 (6.6) 190 (6.8) 
  Gout 19 (2.3) 60 (3.1) 79 (2.8) 
  Polymyalgia Rheumatica 28 (3.3) 51 (2.6) 79 (2.8) 
Central nervous system disorders, N (%)  
 
  Epilepsy <11 32 (1.6) 42 (1.5) 
  Parkinson's disease <11 11 (0.6) 21 (0.8) 
  Stroke 67 (8.0) 201 (10.3) 268 (9.6) 
  Multiple sclerosis <11 16 (0.8) 23 (0.8) 
  Spinal cord injury <11 <11 <11 
  Alzheimer’s 41 (4.9) 106 (5.4) 147 (5.3) 
Miscellaneous conditions and diseases, N (%)  
  
  Congestive Heart Failure 59 (7.0) 139 (7.1) 198 (7.1) 
  Liver Disease 34 (4.0) 97 (5.0) 131 (4.7) 
  Depression 136 (16.2) 308 (15.7) 444 (15.9) 
  Amyloidosis <11 <11 <11 
  End stage renal disease <11 17 (0.9) 21 (0.8) 
  Sarcoidosis <11 <11 17 (0.6) 
  Chronic metabolic acidosis <11 20 (1.0) 26 (0.9) 
  Asthma/Chronic obstructive lung disease 169 (20.1) 424 (21.7) 593 (21.2) 
  Idiopathic scoliosis 28 (3.3) 90 (4.6) 118 (4.2) 
  Cataracts 383 (45.6) 943 (48.2) 1326 (47.4) 
  Glaucoma 103 (12.3) 312 (15.9) 415 (14.8) 
  Kyphosis 796 (94.8) 1878 (95.9) 2674 (95.6) 
  Obesity 64 (7.6) 133 (6.8) 197 (7.0) 
  Disorders of the eye* 515 (61.3) 1278 (65.3) 1793 (64.1) 
  Osteoarthritis 331 (39.4) 859 (43.9) 1190 (42.5) 
  Renaulds 34 (4.0) 73 (3.7) 107 (3.8) 
Medications, N (%)  
  Cyclosporine A and tacrolimus <11 13 (0.7) 15 (0.5) 
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  Proton pump inhibitors 236 (28.1) 575 (29.4) 811 (29.0) 
  Anticoagulants 77 (9.2) 167 (8.5) 244 (8.7) 
  Selective serotonin reuptake inhibitors 139 (16.5) 330 (16.9) 469 (16.8) 
  Anticonvulsants 112 (13.3) 260 (13.3) 372 (13.3) 
  Aromatase inhibitors 25 (3.0) 61 (3.1) 86 (3.1) 
  Thiazolidinediones <11 25 (1.3) 31 (1.1) 
  Barbiturates <11 <11 <11 
  Lithium <11 <11 <11 
  Methotrexate 34 (4.0) 51 (2.6) 85 (3.0) 
  Glucocorticoids 184 (21.9) 428 (21.9) 612 (21.9) 
  Hormone Replacement Therapy 98 (11.7) 234 (12.0) 332 (11.9) 
Fractures  
  
  Non-MOF Sites 45 (5.4) 109 (5.6) 154 (5.5) 
Race  
   
  White 714 (85.0) 1694 (86.5) 2408 (86.1) 
  African-American 105 (12.5) 221 (11.3) 326 (11.7) 
  Hispanic <11 <11 12 (0.4) 
  Asian 11 (1.3) 11 (0.6) 22 (0.8) 
  Other <11 17 (0.9) 21 (0.8) 
All Cells with a total of 0 were suppressed; *: Includes Cataracts and Glaucoma. <11: CMS does not allow 
cells with less than 11 patients to be presented 
 
4.2.1.1 Continuous Prediction of Hip with BMD Fracture Risk 
Models were built for the prediction of the Hip with BMD FRAX® score. In both the 
training and test samples the distribution of the hip score was skewed due to extreme values. The 
mean score in the training sample is 3.12 (SD 4.80) median 2.70 (IQR 1.30, 5.40) while it is 3.10 
(SD 4.46) median 2.60 (IQR 1.20, 5.10) in the test sample. A kernel density plot is presented as 
Figure 4.2 to demonstrate the wide spread of FRAX® values spanning from 0.1 to 60.43, which 
reflects the wide variation of possible FRAX® scores. As the figure demonstrates the majority of 
the scores are less than 10 and primarily grouped closer to 1. Based on a 3% threshold which is 
the National Osteoporosis Foundation (NOF) treatment threshold, 51.2% would have been 
recommended AOM treatment based on their hip FRAX® risk alone (>3%). Indicating a 
relatively balanced population for those who should and should not be treated based on 
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guidelines alone. Because some of these values were very extreme a hand check of the 5 most 
extreme values was done in the CCF data, and based on the patient’s responses and femoral neck 
BMD these were the correct scores. To address the skewed nature of the data, a natural log of the 
outcome was taken and evaluated as well as the untransformed value to determine the best 
model. To describe the models we present the type of model, the number of covariates, the mean 
squared error, the mean absolute error, R2, adjusted R2, and the slope of the regression line.  
Figure 4.2 Density Plot of FRAX(R) Hip with BMD 
 
4.2.1.1.1 Basic Linear Regression Models for Hip with BMD 
Basic linear regression models were used to predict the FRAX® hip with BMD score. All 
FRAX® scores were modeled on both untransformed and log transformed scales. A null model 
was calculated taking the mean of the FRAX® scores – the individual FRAX® scores to 
determine which models were more informative than a random guess. Multivariable regression 
utilizing all available covariates including interactions for age*age, age3, and age*osteoporosis 
were fit. Additionally backward stepwise regression was used to model both the untransformed 
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and log normal (LN) transformed outcome. The stepwise models were used to determine the 
most influential variables, and create a more parsimonious model. The best model was 
determined by the largest adjusted R2 (aR2), which can be interpreted as the amount of variation 
that can be accounted for by the model, accounting for the number of covariates in the model. 
Model results including error terms are presented as Table 4.2. Additionally if the only variable 
in the model is continuous age, the aR2 was 0.12 and log transformed it was 0.03, which shows 
that although age was important, it alone could not be used to predict FRAX®. 
Table 4.2 Hip Linear Model Error Terms 
Analysis # var RMSE MAE R2 aR2 Slope 
Null Model - 5.81 3.52 - - - 
Linear Model 80 5.00 2.77 0.17 0.09 0.75 
LN Linear Model 80 4.88 2.33 0.21 0.12 1.17 
Backwards Stepwise 20 4.97 2.76 0.18 0.16 0.77 
LN Backwards Stepwise 26 4.85 2.32 0.22 0.19 1.22 
# var: Number of variables used in the model 
RMSE: Root Mean Squared Error 
MAE: Mean Absolute Error 
aR2: Adjusted R2 
 
The root mean square error (RMSE) of the best guess model is 5.81 and mean absolute 
error (MAE) is 3.52. Any decrease from these values represents an improved model. Based on 
the criterion of the best aR2, the log-transformed backwards stepwise model is chosen as the 
optimal basic linear model for Hip with BMD with an aR2 of 0.19. Although the linear log-
transformed model had a higher R2 its use of all 80 covariates lowers its aR2 below the 
backwards stepwise model. A slope of 1.21 for the LN backwards stepwise model indicates 
extreme predictions, as a slope of 1 is perfect calibration. 
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4.2.1.1.2 LASSO Models for Hip with BMD 
The LASSO model is created using the r package glmnet and a specified alpha value of 1 
(31). Within linear glmnet model’s shrinkage terms can be specified as MAE (mean absolute 
error) or MSE (mean squared error), and the LASSO penalty can be chosen as either the 
minimum penalty (λ minimum) or one standard error from the λ minimum (1se). To determine 
the best model all four variations were used with both untransformed and LN hip with BMD 
scores and 10-fold cross validation. For the 1se models, 100 bootstrap samples of the 1se value 
were taken with the mean of these estimates used as the value due to each cross-validation in 
glmnet creating different cross-validation cut points (30).  
Table 4.3 LASSO Hip with BMD Model Results 
Analysis # var RMSE MAE R2 aR2 Slope 
LASSO MSE 1se 3 5.04 3.06 0.16 0.15 2.58 
LASSO MSE λ minimum  15 4.85 2.68 0.22 0.20 0.96 
LASSO MAE 1se 4 4.85 2.79 0.22 0.212883 1.43 
LASSO MAE λ minimum  11 4.84 2.68 0.22 0.211979 1.02 
LN LASSO MSE 1se 7 4.99 2.34 0.17 0.17 1.50 
LN LASSO MSE minimum λ  75 4.87 2.32 0.21 0.13 1.15 
LN LASSO mae 1se 7 4.99 2.34 0.17 0.17 1.49 
LN LASSO mae λ min 27 4.90 2.32 0.20 0.17 1.17 
   
Compared to the best guess model, all of the LASSO models, both untransformed and LN 
transformed represent a decrease in RMSE and MAE. The number of variables chosen in the 
optimal model range from 3 to 75. However based on aR2 the best fitting model is MAE 1se with 
an aR2 of 0.212. The smallest RMSE was found in the untransformed MAE λ minimum model 
which represented a decrease of 1.2, while the smallest MAE was found in the LN MAE λ 
minimum model which represented a decrease of 1.3. The untransformed model with the greatest 
aR2 was MAE 1se with 0.212, while the LN MAE λ minimum had an aR2 of 0.175. The 
untransformed model has fewer variables (4 versus 27) compared to the log-transformed model, 
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as well as a smaller RMSE and calibration slope closer to 0. Therefore the best LASSO model is 
the untransformed MAE 1se. 
4.2.1.1.3 Elastic Net Models for Hip with BMD 
The elastic net model is created using the glmnet R package without a specified alpha 
value but otherwise the same commands as the LASSO model, with the program allowed to 
determine the optimal alpha value between 0 (ridge regression penalty) and 1 (LASSO 
regression penalty). The methods to determine the optimal elastic net (Enet) model were 
identical to those of the LASSO model. Model error results are presented as Table 4.4. 
Table 4.4 Elastic Net Hip with BMD Model Results 
Analysis # var RMSE MAE R2 aR2 Slope 
Enet MSE 1se 3 5.05 3.07 0.15 0.15 2.65 
Enet MSE λ minimum 15 4.85 2.68 0.22 0.20 0.96 
Enet MAE 1se 4 4.85 2.78 0.22 0.213636 1.41 
Enet MAE λ minimum 11 4.84 2.68 0.22 0.211918 1.02 
LN Enet MSE 1se 7 4.99 2.34 0.17 0.17 1.50 
LN Enet MSE Lambda min 73 4.87 2.32 0.21 0.14 1.14 
LN Enet MAE 1se 7 4.98 2.34 0.18 0.17 1.48 
LN Enet MAE Lambda min 27 4.90 2.32 0.20 0.17 1.17 
 
The elastic net models all represent a decrease in RMSE and MAE from the best guess 
model. The MAE 1se model represents the greatest predictive ability based on an aR2 of 0.213, 
which exceeds the LASSO model of the same type. The slope of this model is 1.4 which 
indicates that it may have some extremely high predictions. No log-transformed model exceeded 
an aR2 of 0.20. 
4.2.1.1.4 Comparison of the best linear hip with BMD models 
Three optimal basic linear, LASSO, and elastic net models have been chosen and 
constructed. In the basic linear models the backwards stepwise, the LASSO model was the MAE 
1se, and the elastic net was MAE 1se as well. The model results are presented as Table 4.5. 
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Using our criterion of the highest aR2 the LASSO model would be chosen over the basic linear 
and elastic net models. Of note both the LASSO and elastic net models would produce more 
extreme estimates (slope >1), while the backwards stepwise model would have produced more 
conservative estimates. The density plots for all three models are presented as Figure 4.3. The 
LASSO and Elastic Net estimates look very similar, both with bimodal distributions. The elastic 
net model appears to have the largest spread of all of the predicted models as evidence by a green 
line persisting to the end of the figure, whereas the red and blue lines stop, which indicates that 
their highest predictions were <10. 
Table 4.5 Best Linear hip with BMD models 
Analysis # 
va
r 
RMSE MAE R2 aR2 Slope 
LN Backwards Stepwise  26 4.85 2.32 0.22 0.19 1.22 
LASSO MAE 1se 4 4.85 2.79 0.22 0.212883 1.43 
Enet MAE 1se 4 4.85 2.78 0.22 0.213636 1.41 
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Figure 4.3 Density Plot of Best 3 Hip with BMD models 
 
 The model coefficients for the three best models are presented as Table 4.6. Only 
variables which appeared in one model are included in the table. All three models include an 
intercept as well as a linear age term and age*osteoporosis. Cushing’s syndrome was the variable 
which was most predictive of the FRAX® score based on this analysis, other than the intercept 
and linear age. Cushing’s syndrome produces excess cortisol which has a similar effect on bone 
as glucocorticoid use, which would explain greater FRAX® scores based on lower BMD (233). 
The only other variable chosen by the elastic net model was African-American race which when 
present lowered a patient’s risk. 
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Table 4.6 Model coefficients for best linear hip with BMD 
Attribute Backwards Stepwise LASSO Elastic Net 
Intercept  153.4667957 -7.781649239 -7.78430299 
Linear Age  -6.852048321 0.15458841 0.154623293 
Age*Age  0.098895373 - - 
Age*Age*Age  -0.000455398 - - 
Age*Osteoporosis  0.041867044 0.03202327 0.032028816 
In 365-days prior to index  
  
Endocrine disorders  
  
  Diabetes mellitus (Type 1 & 2) -0.445006777 - - 
  Cushing's syndrome 46.29397364 21.47675009 21.48856957 
  Hyperparathyroidism 1.54388651 - - 
Gastrointestinal disorders  
  
  Inflammatory Bowel Disease 1.701265774 - - 
Rheumatologic and autoimmune diseases  
 
  Rheumatoid arthritis 1.302509408 - - 
Central nervous system disorders  
  
  Spinal cord injury 5.562983558 - - 
Miscellaneous conditions and diseases  
  
  Liver Disease -0.912907042 - - 
  Chronic metabolic acidosis 1.976389464 - - 
  Idiopathic scoliosis 1.128290996 - - 
  Renaulds 1.149202584 - - 
Medications  
  
  Anticonvulsants -0.489347769 - - 
  Glucocorticoids 0.701835939 - - 
  Hormone Replacement 
Therapy 
0.548990432 - - 
Race  
  
  African-American -3.256347127 -1.36527375 -1.366183288 
  Hispanic 2.715173157 - - 
 
Describing how well the elastic net model predicts FRAX® is graphically shown as 
Figure 4.4. The intercept is -1.96 which indicates that the CFRI estimates are systematically too 
low, however the slope of 1.40 indicates that there are extreme estimates which accounts for the 
decent fit based on a low intercept. Although there were 18 patients who had a hip 10-year risk 
of >20% no characteristics identifiable in administrative claims that were more prevalent in this 
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group than in the population as a whole. This group primarily had at least at least one FRAX® 
risk factor, only 6 (4.4%) did not have a single FRAX® risk factor, and a t-score <-2.5.  
The model has difficultly predicting larger values, and overall seems to do a relatively 
poor job of continuously predicting the 10-year hip risk, which wouldn’t have been expected 
with an aR2 of less than 0.2. In a clinical sense, a 3% threshold is important due to its inclusion 
in the NOF guidelines as the threshold for treatment of a FRAX® 10-year hip risk. Although the 
model may not be sufficiently calibrated to predict the continuous score, it may sufficiently 
discriminate between those who should and should not be treated. This is examined in Figure 
4.5. 
Figure 4.4 Scatterplot of Best Hip compared to FRAX 
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Figure 4.5 Receiver Operating Curve CFRI compared to 3% treatment threshold 
 
Based on the ROC curve it appears that CFRI hip does a reasonable job of discriminating 
between those who are high and low risk (3% threshold). The area under the curve for CFRI hip 
is 85.4% (95% CI 82.3, 87.9). The AUC indicates that if you were to randomly draw one patient 
from the predicted dataset, 85% of the time they would correctly be identified as high-risk. In 
terms of the ability to predict above and below the NOF threshold of 3%, the test sample had 383 
(45.6%) patients with a score >3, while the predicted score placed 635 (75.6%) patients above 
the 3% threshold. Additionally 556 (66.2%) of patients were classified correctly of <3 or ≥3% by 
CFRI compared to their FRAX® score. It appears that in terms of utility the CFRI hip score may 
be useable both as a continuous and categorical response. However the majority of the CFRI 
predictions themselves are below the 3% threshold. 
4.2.1.1.5 High-Dimensional Variable Selection 
To evaluate the value of adding additional variables through a high-dimensional selection 
process of all variables with a prevalence of ≥1%, all four elastic net models were re-fit with the 
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additional covariates. For Hip with BMD, the high-dimensional variable selection approach 
included 135 medication classes, 129 different diagnoses, and 713 procedural classes. When 
these were added to the 87 content variables there were 1,063 different variables for the elastic 
net model to evaluate. After evaluation, the MAE λ minimum model was found to be the 
superior elastic net model, selecting 7 variables with no medication classes, no diagnosis codes, 
and 3 procedure codes (primarily associated with office visits). However the aR2 for this model 
was 0.2125 which was less than the chosen elastic net model, suggesting that the high-
dimensional approach did not improve model performance.  
4.2.1.2 Continuous Prediction of Major Osteoporotic Fracture with BMD Fracture Risk 
Models were built for the prediction of the MOF with BMD FRAX® score. In both the 
training and test samples the distribution of the MOF score was approximately normal, but 
highly skewed with a small number of extreme values. The mean score in the training sample is 
12.8 (SD 7.7) median 13.0 (IQR 9.10, 18.00) while it is 12.8 (SD 7.6) median 13.00 (IQR 9.10, 
18.00) in the test sample. A kernel density plot is presented as Figure 4.6 which shows that the 
spread of values is similar to that of the hip score (range 1.62 to 68.7), however the cluster of 
scores are much less spread as evidenced by the maximum density only reaching 0.08. As was 
presented in the Hip with BMD section, all analyses were done with both the untransformed and 
log transformed scores.  
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Figure 4.6 Density Plots of Test and Training Sample for MOF with BMD 
 
4.2.1.2.1 Basic Linear Regression Models for MOF with BMD 
The same methods including the interaction terms as the hip with BMD model (Section 
4.2.1.1.1) were used for the MOF with BMD models. A null model was created taking the mean 
actual value subtracted by the actual value for the MAE and RMSE of the null model. 
Multivariable, as well as backwards stepwise models were fit for both the untransformed and 
log-transformed outcome. Models results including aR2 are presented as Table 4.7. The model 
with only age at DXA produced an aR2 of 0.09 and when log transformed an aR2 of 0.04 
indicating poorer performance than the other models (Table 4.7). The model with only age at 
DXA produced an aR2 of 0.09 and when log transformed an aR2 of 0.04 indicating a poorer 
performance than the other models.  
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Table 4.7 MOF with BMD Linear Model Error Terms 
Analysis # var RMSE MAE R2 aR2 Slope 
Best Guess - 8.88 6.44 - - - 
Linear Model 80 7.07 4.89 0.34 0.27 0.93 
LN Linear Model 80 6.99 4.54 0.35 0.29 1.09 
Backwards Stepwise 28 7.03 4.89 0.35 0.32 0.94 
LN Backwards Stepwise  32 6.96 4.51 0.36 0.33 1.10 
# var: Number of variables used in the model 
RMSE: Root Mean Squared Error 
MAE: Mean Absolute Error 
aR2: Adjusted R2 
 
As was done in the hip models a best guess scenario was undertaken to determine what 
minimum RMSE and MAE were for improvement. The RMSE of the best guess model is 8.9 and 
MAE is 6.4, indicating that for a model to be viewed as useful their RMSE and MAE must be 
less than these values. The RMSE and MAE for the MOF model are nearly double that of the hip 
model. With all 80 variables used (including dummy variables for race and year of DXA) the 
linear (aR2: 0.27) and log-linear (aR2: 0.29) models had a better predictive ability than the 
optimal hip model. The backwards stepwise regression procedures produced better fitting 
models, linear aR2 0.32, and log-linear aR2 0.33 while taking 52 and 48 fewer variables 
respectively. The backwards stepwise models also reduced RMSE and MAE compared to the 
best guess model. Based on the highest aR2 value, the optimal model from the basic linear 
models would be the backwards stepwise model, with greater than 30% of the variation in the 
FRAX® 10-year risk of MOF with BMD explained by the model.  
4.2.1.2.2 LASSO Models for MOF with BMD 
The error terms of the LASSO models predicting the MOF with BMD FRAX® score are 
presented as Table 4.8.  
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Table 4.8 LASSO MOF with BMD Model Results 
Analysis # var RMSE MAE R2 aR2 Slope 
LASSO MSE 1se 7 7.19 5.16 0.32 0.309737 1.54 
LASSO MSE λ minimum 34 6.93 4.84 0.37 0.338342 1.09 
LASSO MAE 1se 8 7.05 5.02 0.34 0.33591 1.39 
LASSO MAE λ minimum 27 6.93 4.85 0.36 0.3432393 1.12 
LN LASSO MSE 1se 10 7.09 4.63 0.33 0.326905 1.39 
LN LASSO MSE λ min 44 6.90 4.50 0.37 0.335453 1.20 
LN LASSO MAE 1se 10 7.04 4.59 0.34 0.336219 1.36 
LN LASSO MAE λ min 46 6.90 4.50 0.37 0.333775 1.20 
 
Compared to the best guess model, all of the LASSO models represent a decrease in 
RMSE and MAE. However based on aR2 the best fitting model is MAE λ minimum with an aR2 
of 0.282. All RMSE and MAE for the non-transformed models are within 0.3 of each other. In 
this model the 25 additional variables chosen from the MAE λ minimum are more useful in 
explaining the model, compared to the 1se model, as evidenced by aR2 being the greatest in the 
MAE λ minimum model, even after taking account for the additional variables. The MAE λ 
minimum model would be chosen as the best of the 8 models based on the optimal aR2. 
Compared to the best guess model, all of the log-transformed LASSO models represent 
decreases in RMSE and MAE. However based on aR2 the best fitting model is MAE 1se with an 
aR2 of 0.268. This model appears to have performed the best based on a small number of 
included variables and a lower error than the MSE 1se. The two λ minimum models suffer from 
the inclusion of too many variables, which causes their aR2 to decrease past the MAE 1se. 
However if not for the penalization of selecting too many variables the log-transformed MAE λ 
actually represented the best R2 of all 8 models with 0.306. 
4.2.1.2.3 Elastic Net MOF with BMD 
The error terms of the elastic net models predicting MOF with BMD FRAX® score are 
presented as Table 4.9. 
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Table 4.9 Elastic Net MOF with BMD untransformed model results 
Analysis # 
var 
RMSE MAE R2 aR2 Intercept 
Enet MSE 1se 7 7.19 5.16 0.32 0.311228 1.54 
Enet MSE λ min 29 6.93 4.84 0.37 0.34235 1.10 
Enet MAE 1se 8 7.05 5.02 0.34 0.336134 1.39 
Enet MAE λ min 27 6.93 4.85 0.36 0.3432784 1.12 
LN Enet MSE 1se 10 7.09 4.63 0.34 0.327023 1.39 
LN Enet MSE λ min 46 6.90 4.50 0.37 0.333782 1.20 
LN Enet MAE 1se 10 7.05 4.60 0.34 0.334553 1.37 
LN Enet MAE λ min 46 6.90 4.50 0.37 0.333775 1.20 
 
The elastic net untransformed model results all represent a decrease in RMSE and MAE 
to the best guess model. The error terms are very similar to that of the LASSO model, with each 
of these models increasing the aR2 by a marginal amount. The MAE λ minimum model is the 
optimal model with an aR2 of 0.282 indicating an ability to account for ~28% of all of the 
variability in the FRAX® 10-year MOF. 
The elastic net log-transformed model results all represent a decrease in RMSE and MAE 
to the best guess model. Similar to the LASSO model, the MAE 1se model was the best model 
with an aR2 of 0.269. This model has 23 variables, and had high RMSE and MAE compared to 
the λ minimum models. The results of the elastic net log transformed model are very similar to 
the LASSO model, as well as the density plot (not presented). In the log-transformed Elastic net 
model, the third hump of the distribution again appears to be smoothed. With the aR2 used as the 
criteria for selecting the best model, we would view the MAE 1se as the best fitting of the log-
transformed elastic net models.  
The best elastic net model without transformation is the MAE 1se model with an aR2 of 
0.282, while the best log-transformed model is the MAE 1se model with an aR2 of 0.269. These 
are the same models which were found to be the best LASSO models. Based on the criterion of 
largest aR2, we will accept the untransformed MAE 1se model as the optimal elastic-net model. 
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4.2.1.2.4 Comparison of the best linear MOF with BMD models 
The three types of model which produced the best MOF with BMD estimates are 
presented as Table 4.10. The best performing models for MOF with BMD were the same as the 
Hip with BMD, except for the log-transformed chosen over the untransformed backwards 
stepwise model. The models are backwards stepwise regression, LASSO with MAE λ minimum, 
and Elastic net with MAE λ minimum. The model which represents the highest aR2 is the elastic 
net model and based on our methodology it would be accepted as the best model. Based on the 
density plot (Figure 4.7), none of these models are able to accurately predict the maximum 
observed scores. The elastic net model only classified 322 patients as having an MOF of ≥20% 
while the backwards stepwise model predicted 235 patients with that score which is the NOF 
threshold for treatment. The test model in total has 310 patients who have a MOF of ≥20%. A 
scatter plot of the predicted values compared to the actual values is presented as Figure 4.8. The 
intercept is -5.31 indicating that systematically the estimates are much lower than they should be. 
However with a slope of 1.33 the predictions had a tendency to be higher than expected. The 
other thing that the scatter plot shows us is that the majority of the predictions fall between 10 
and 20 with the model not doing a good job of identifying extreme scores. Those patients at the 
highest MOF values, similar to the hip estimates didn’t have any characteristics that were 
significantly different than the general population, other than FRAX® risk factors and BMD 
scores. 
Table 4.10 Best linear MOF with BMD models 
Analysis # 
var 
RMSE MAE R2 aR2 Slope 
Backwards Stepwise  32 6.96 4.51 0.36 0.3340581 1.10 
LASSO MAE λ minimum 27 6.93 4.85 0.36 0.3432393 1.12 
Enet MAE λ minimum 27 6.93 4.85 0.36 0.3432784 1.12 
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Figure 4.7 Density Plot of Best 3 Linear MOF with BMD models 
 
Figure 4.8 Scatterplot of best MOF with BMD model 
 
The model coefficients for the 3 best models are presented as Table 4.10. All 3 models 
included the intercept and linear age. Similar to the hip with BMD model, Cushing’s syndrome 
was the strongest predictor in the model. The next most influential variable was cystic fibrosis 
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and Hispanic race, each of these increasing the risk by >5%. As neither of these are FRAX® 
variables the most influential variable which is measured in the FRAX® algorithm was 
glucocorticoid use, but it (as well as rheumatoid arthritis diagnosis) increased a score by less than 
2%. The models also all included race. Differently from the Hip with BMD estimates, all 3 
include rheumatoid arthritis as predictor. Vertebral fracture is the variable with the largest effect 
on the CFRI estimate other than variables including age (linear age and osteoporosis*age) based 
on their multiplicative effects. 
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Table 4.11 Model coefficients for the best 3 linear MOF with BMD models 
Attribute  Backwards Stepwise LASSO Elastic Net 
Intercept   656107.4739 -4.793618214 -4.825318605 
Linear Age   0.597352024 0.213689987 0.213882754 
Age*Age   1.007664994 - - 
Age*Age*Age   0.999964141 - - 
Age*Osteoporosis   - 0.065007596 0.06501777 
In 365-days prior to index     
Osteoporosis   1.32712879 - - 
Lifestyle Factors      
Vitamin D insufficiency 0.963579158 -0.011273041 -0.013289971 
Genetic factors      
Hypophosphatasia  - 0.008092342 0.009540193 
Hypogonadal states      
Endocrine disorders      
Diabetes mellitus 
(Type 1 & 2) 
 0.96018752 -0.009055322 -0.010675466 
Cushing's syndrome  2.532662798 29.94834646 30.00819577 
Hyperparathyroidism  1.095685332 0.492861044 0.498923702 
Central Adiposity  0.948061336 - - 
Gastrointestinal disorders     
Inflammatory Bowel Disease 1.187847198 1.546359531 1.554882759 
Hematologic disorders     
 Hemophilia  0.883463892 - - 
Rheumatologic and autoimmune 
diseases  
   
Ankylosing 
spondylitis 
 1.106222719 - - 
Lupus  - 0.717620602 0.726900325 
Rheumatoid arthritis  1.207422619 2.811289734 2.813412897 
Polymyalgia 
Rheumatica 
 1.176553885 1.443967256 1.449502678 
Central nervous system disorders    
Epilepsy  1.120652167 - - 
Spinal cord injury  1.48000584 1.053226296 1.093297267 
Miscellaneous conditions and 
diseases 
   
Depression  - 0.018531661 0.021357651 
End stage renal disease 1.173995164 - - 
Sarcoidosis  1.212139726 0.463805842 0.481572939 
Chronic metabolic 
acidosis 
 1.310222847 1.657934364 1.667854978 
Idiopathic scoliosis  1.075165666 0.993030423 0.996848535 
Kyphosis  1.195302682 0.082614896 0.090356929 
Renaulds  1.087214457 1.234849999 1.239561619 
Medications      
Proton pump inhibitors 1.028449649 0.054361967 0.056608238 
Anticonvulsants  0.95012885 - - 
Methotrexate  1.126143755 0.834020516 0.841853825 
Glucocorticoids  1.068881586 0.965086179 0.965996066 
Hormone Replacement Therapy - 0.203410172 0.208072152 
Non-MOF Fractures  1.17657041 2.164282235 2.169086603 
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Race     
White  0.838004021 2.259054019 2.266392607 
African-American  0.321281092 -6.778268151 -6.775158983 
Hispanic  - 2.631780414 2.662589671 
Asian  0.598366463 - - 
Other  0.553936103 -0.003499407 -0.004125508 
 
In a clinical sense it is important for models to be able to differentiate between high and 
low risk patients. For MOF we will use the 20% threshold as this is the value at which all 
patients are recommended treatment based on the NOF guidelines. A receiver operating curve 
has been created investigating the elastic net MAE 1se CFRI predictions ability to discriminate 
between high and low risk patients (Figure 4.9). The model is able to discriminate well between 
low risk and high risk patients, with a c-statistic of 0.81 (95% CI 0.78, 0.85), indicating that 
patients with a higher CFRI are more likely to have had a FRAX® MOF with BMD ≥20%. 
However CFRI does a poorer job of predicting treatable patients based on MOF than hip 10-year 
risks. 
Based on raw statistics, 899 (76.9%) of patients were correctly classified using CFRI into 
above or below the 20% threshold. There were 334 patients who were listed as ≥20% based on 
their FRAX® score, while CFRI listed 288 patients at this level. Based on these findings the 
MOF with BMD CFRI score should be valid in the general population. 
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Figure 4.9 Receiver Operating Curve for MOF with BMD 20% Threshold 
 
4.2.1.2.5 High-Dimensional Variable Selection 
Using the high-dimensional variable selection approach for MOF with BMD there were 
135 medication classes, 129 different diagnoses, and 713 procedural classes added to the model. 
When these were added to the 87 content variables there were 1,063 different variables for the 
elastic net model to evaluate. After evaluation the MAE λ minimum model was found to be the 
superior elastic net model, selecting 40 variables with 4 medication classes (glipizide, 
methylprednisone, metronidazole, and motelukast), 8 diagnosis codes (goiter, bronchitis, 
blindness, intestinal obstruction, intestinal malabsorption, renal failure, and uterine disorders), 
and 16 procedure codes (primarily associated with office visits). However the aR2 for this model 
was 0.3431 which was less than the chosen elastic net model. Therefore the choice of the best 
model does not change the choice of model for MOF with BMD. 
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4.2.2 Without BMD Cohort 
There were 2,860 patients who met all entrance criteria for the study. Basic demographics 
of the overall population as well as the test and training samples are presented as Table 4.12. 
Based on a 70/30 split there were 2,001 patients in the training sample and 859 in the test 
sample. The demographics are similar to those of the with BMD population (Section 1.2.1). The 
only covariates out of balance between the test and training sample were lupus and SSRI use. 
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Table 4.12 Basic Demographics of the without BMD population 
Characteristic Test Train All 
N 
 
859 2001 2860 
Mean Age 74.0 74.2 74.2 
Year of DXA  
  2009 49 (5.7) 115 (5.7) 164 (5.7) 
  2010 147 (17.1) 318 (15.9) 465 (16.3) 
  2011 216 (25.1) 595 (29.7) 811 (28.4) 
  2012 224 (26.1) 479 (23.9) 703 (24.6) 
  2013 223 (26.0) 494 (24.7) 717 (25.1) 
In 365-days prior to index  
 
Osteoporosis, N (%)  364 (42.4) 888 (44.4) 1252 (43.8) 
Non-MOF Fracture 56 (6.5) 102 (5.1) 158 (5.5) 
Lifestyle Factors, N (%)  
   
  Alcohol Abuse <11 <11 <11 
  Falling 47 (5.5) 104 (5.2) 151 (5.3) 
  Vitamin D insufficiency 258 (30.0) 557 (27.8) 815 (28.5) 
Genetic factors, N (%)  
  
  Homocystinuria <11 <11 <11 
  Hypophosphatasia <11 11 (0.5) 14 (0.5) 
  Gaucher's disease <11 <11 <11 
  Porphyria <11 <11 <11 
  Hemochromatosis <11 <11 <11 
Hypogonadal states, N (%)  
  
  Anorexia nervosa and bulimia <11 17 (0.8) 25 (0.9) 
  Hyperprolactinemia <11 <11 <11 
  Premature ovarian failure <11 <11 <11 
  Athletic amenorrhea <11 <11 <11 
Endocrine disorders, N (%)  
  
  Adrendal insufficiency <11 <11 <11 
  Diabetes mellitus (Type 1 & 2) 186 (21.7) 398 (19.9) 584 (20.4) 
  Cushing's syndrome <11 <11 <11 
  Hyperparathyroidism 41 (4.8) 93 (4.6) 134 (4.7) 
  Central Adiposity 60 (7.0) 146 (7.3) 206 (7.2) 
  Thyrotoxicosis 15 (1.7) 31 (1.5) 46 (1.6) 
Gastrointestinal disorders, N (%)  
 
  Celiac disease <11 14 (0.7) 21 (0.7) 
  Gastric bypass <11 <11 <11 
  Inflammatory Bowel Disease 17 (2.0) 38 (1.9) 55 (1.9) 
  Malabsorption 12 (1.4) 34 (1.7) 46 (1.6) 
  Pancreatic disease <11 29 (1.4) 38 (1.3) 
  Primary biliary cirrhosis <11 <11 13 (0.5) 
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Characteristic Test Train All 
  Crohn’s Disease 45 (5.2) 94 (4.7) 139 (4.9) 
Hematologic disorders, N (%)  
   
  Hemophilia 17 (2.0) 33 (1.6) 50 (1.7) 
  Thalassemia <11 <11 <11 
  Systemic mastocytosis <11 <11 <11 
Rheumatologic and autoimmune diseases, N (%)  
 
  Ankylosing spondylitis <11 37 (1.8) 40 (1.4) 
  Lupus 16 (1.9) 18 (0.9) 34 (1.2) 
  Rheumatoid arthritis 53 (6.2) 148 (7.4) 201 (7.0) 
  Gout 30 (3.5) 52 (2.6) 82 (2.9) 
  Polymyalgia Rheumatica 26 (3.0) 55 (2.7) 81 (2.8) 
Central nervous system disorders, N (%)  
 
  Epilepsy <11 36 (1.8) 45 (1.6) 
  Parkinson's disease 13 (1.5) <11 22 (0.8) 
  Stroke 87 (10.1) 186 (9.3) 273 (9.5) 
  Multiple sclerosis <11 14 (0.7) 23 (0.8) 
  Spinal cord injury <11 <11 <11 
  Alzheimer’s disease 52 (6.1) 101 (5.0) 153 (5.3) 
Miscellaneous conditions and diseases, N (%)  
  Congestive Heart Failure 64 (7.5) 140 (7.0) 204 (7.1) 
  Liver Disease 49 (5.7) 90 (4.5) 139 (4.9) 
  Depression 134 (15.6) 324 (16.2) 458 (16.0) 
  Amyloidosis <11 <11 <11 
  End stage renal disease <11 11 (0.5) 21 (0.7) 
  Sarcoidosis <11 <11 17 (0.6) 
  Chronic metabolic acidosis <11 22 (1.1) 28 (1.0) 
  Asthma/Chronic obstructive lung 
disease 
191 (22.2) 427 (21.3) 618 (21.6) 
  Idiopathic scoliosis 48 (5.6) 74 (3.7) 122 (4.3) 
  Cataracts 401 (46.7) 958 (47.9) 1359 (47.5) 
  Glaucoma 136 (15.8) 291 (14.5) 427 (14.9) 
  Kyphosis 815 (94.9) 1914 (95.7) 2729 (95.4) 
  Obesity 60 (7.0) 146 (7.3) 206 (7.2) 
  Disorders of the eye* 549 (63.9) 1284 (64.2) 1833 (64.1) 
  Osteoarthritis 363 (42.3) 866 (43.3) 1229 (43.0) 
  Renauld's syndrome 37 (4.3) 75 (3.7) 112 (3.9) 
Medications, N (%)  
  Cyclosporine A and tacrolimus <11 <11 16 (0.6) 
  Proton pump inhibitors 263 (30.6) 567 (28.3) 830 (29.0) 
  Anticoagulants 81 (9.4) 169 (8.4) 250 (8.7) 
  Selective serotonin reuptake inhibitors 151 (17.6) 330 (16.5) 481 (16.8) 
  Anticonvulsants 121 (14.1) 266 (13.3) 387 (13.5) 
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Characteristic Test Train All 
  Aromatase inhibitors 27 (3.1) 61 (3.0) 88 (3.1) 
  Thiazolidinediones 13 (1.5) 19 (0.9) 32 (1.1) 
  Barbiturates <11 <11 <11 
  Lithium <11 <11 <11 
  Methotrexate 27 (3.1) 61 (3.0) 88 (3.1) 
  Glucocorticoids 182 (21.2) 450 (22.5) 632 (22.1) 
  Hormone Replacement Therapy 93 (10.8) 249 (12.4) 342 (12.0) 
Race  
  
  White 743 (86.5) 1718 (85.9) 2461 (86.0) 
  African-American 93 (10.8) 240 (12.0) 333 (11.6) 
  Hispanic <11 <11 13 (0.5) 
  Asian <11 12 (0.6) 22 (0.8) 
  Other <11 16 (0.8) 21 (0.7) 
All Cells with a total of 0 were suppressed; *: Includes Cataracts and Glaucoma <11: CMS does not allow 
cells with less than 11 patients to be presented 
 
4.2.2.1 Continuous Prediction of Hip without BMD Fracture Risk 
Models were built for the prediction of hip without BMD FRAX® score. All patients 
were utilized for this prediction as everyone had all FRAX® risk factors, even if they didn’t have 
a femoral neck BMD. The mean score of the training sample was 6.7 (SD 7.4) median 3.73 (IQR 
1.90, 7.44), while the mean of the test sample was 7.0 (SD 7.8) median 3.79 (IQR 2.11, 7.44). A 
kernel density plot of the distribution of hip without BMD FRAX® for the training and test 
sample is presented as Figure 4.10. The hip without BMD scores range from 0.04 to 74.37 with 
both of the extremes being present in the test sample. Once again, a hand check was made of the 
most extreme values and they were found to be valid. Models will be built for basic linear 
models, LASSO, and elastic net models with the best models from each of the categories 
compared. The best model will be defined as the one with the greatest adjusted R-squared (aR2). 
Additionally we will present the number of covariates, RMSE, MAE, R2, aR2, and calibration 
slope for each model. We will present the model coefficient values for best model in each of the 
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three categories. Finally, we will investigate the utility of the best model to predict a 3% FRAX® 
threshold based on the actual FRAX® without BMD score. 
Figure 4.10 Density Plot of FRAX® Hip without BMD 
 
4.2.2.1.1 Basic Linear Regression Models 
A null model was fit to the data by taking the mean of the actual FRAX® scores and 
comparing it to the actual values to calculate the RMSE and MAE. A linear regression model 
using both an untransformed outcome as well as a log-transformed (LN) outcome were fit, as 
well as backwards stepwise regression models for both the untransformed and log-transformed 
outcomes. The model error terms are presented as Table 4.13. Additionally we tested only age in 
the model which produced an aR2 of 0.29 with an untransformed FRAX® score and a aR2 of 
0.09 when log transformed. The null model produced a RMSE of 7.38 and a MAE of 4.94 which 
means that for a model to be more informative than a random guess they must have a lower error 
term than these values. The linear and LN linear models have very similar RMSE, but the LN 
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model has a much lower MAE. These correspond to very similar R2 and aR2 values with the LN 
model having a superior aR2. The untransformed model has a better calibration slope, but the LN 
model is only 0.17 away from a perfect slope. The backwards stepwise models are similar to the 
basic models in that the untransformed and LN have very similar results. Echoing the basic 
models, it is LN model which achieves the best aR2, with a value of 0.3736 the largest aR2, 
however this model includes 7 more variables than the untransformed model, which may indicate 
a need for a more intensive evaluation if this model is found to be better than the LASSO and 
elastic net models. 
Table 4.13 Hip without BMD Linear Model Error Terms 
Analysis # var RMSE MAE R2 aR2 Slope 
Null Model - 7.05 4.52 - - - 
Linear Model 71 4.64 2.97 0.37 0.32 0.86 
LN Linear Model 71 4.41 2.41 0.43 0.38 0.98 
Backwards Stepwise 28 4.66 2.95 0.37 0.34 0.86 
LN Backwards Stepwise 31 4.44 2.40 0.42 0.40 1.00 
# var: Number of variables used in the model 
RMSE: Root Mean Squared Error 
MAE: Mean Absolute Error 
aR2: Adjusted R2 
 
4.2.2.1.2 LASSO Models for Hip without BMD 
The error terms for the LASSO models predicting hip without BMD both untransformed 
and LN are presented as Table 4.14 
. 
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Table 4.14 LASSO Hip without BMD Model Results 
Analysis # var RMSE MAE R2 aR2 Slope 
LASSO MSE 1se 5 4.82 3.06 0.32 0.319713 1.26 
LASSO MSE λ minimum 26 4.60 2.87 0.38 0.363651 0.95 
LASSO MAE 1se 5 4.69 2.95 0.36 0.353706 1.17 
LASSO MAE λ minimum 19 4.59 2.86 0.39 0.37312 0.98 
LN LASSO MSE 1se 59 4.76 2.52 0.34 0.291101 0.82 
LN LASSO MSE λ min 70 4.45 2.41 0.42 0.372676 0.99 
LN LASSO MAE 1se 56 4.67 2.49 0.36 0.318562 0.86 
LN LASSO MAE λ min 71 4.44 2.41 0.43 0.373555 0.99 
 
Compared to the null model all 8 LASSO models represent a decrease in RMSE and MAE. 
The models with the least number of variables are the untransformed 1se models (6 variables in 
both), while the LN λ minimum models retain the most variables (75 and 81). The LN MAE λ 
minimum model represents the smallest RMSE and the smallest MAE. This model also 
represents the largest R2, but the use of 81 variables allows the untransformed MSE λ minimum 
model to produce a superior aR2 (0.362 compared to 0.360). In the LN models it appears that 
overfitting did occur as the models with the most variables did produce the largest R2 values. As 
opposed to both with BMD models, for the first time a λ minimum has been chosen as the 
optimal model, but the use of MAE shrinkage parameter has held constant. Based on the optimal 
aR2, the untransformed λ minimum MAE model is the optimal LASSO model. 
4.2.2.1.3 Elastic Net Hip without BMD 
The error terms for the elastic net models predicting hip without BMD are presented as 
Table 4.15. The best model is chosen by a maximum aR2.  
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Table 4.15 Elastic Net Hip without BMD Model Results 
Analysis # 
var 
RMSE MAE R2 aR2 Intercept 
Enet MSE 1se 4 4.84 3.09 0.32 0.312698 1.27 
Enet MSE λ min 28 4.60 2.88 0.38 0.36154 0.94 
Enet MAE 1se 5 4.69 2.94 0.36 0.355607 1.17 
Enet MAE λ min 19 4.59 2.86 0.39 0.373274 0.98 
LN Enet MSE 1se 59 4.81 2.53 0.33 0.275869 0.80 
LN Enet MSE λ min 70 4.45 2.41 0.42 0.372893 0.99 
LN Enet MAE 1se 56 4.70 2.50 0.35 0.309951 0.85 
LN Enet MAE λ min 71 4.44 2.41 0.42 0.37312 0.99 
 
All 8 elastic net models represent a decrease in RMSE and MAE compared to the null 
model. The number of variables retained by the models range from 6 to 81 with an optimal 
choice of 21 variables in the MAE λ minimum model. The smallest RMSE and MAE were found 
in the LN λ minimum models. The largest R2 was found in the same models, however their 
retention of 40 more variables than the MAE λ minimum model reduced their aR2. The best 
elastic net model would be the LN MAES λ minimum with an aR2 of 0.37380. 
4.2.2.1.4 Comparison of the best linear hip without BMD models 
The three models with the best aR2, log transformed backwards stepwise, LASSO MAE λ 
minimum, and Elastic Net MAE λ minimum are compared in this section. The model error 
results are presented as Table 4.16. Additionally a kernel density plot of the predicted values 
compared to the actual values is presented as Figure 4.11.  
Table 4.16 Comparison of the best linear hip without BMD models 
Analysis # 
var 
RMSE MAE R2 aR2 Slope 
LN Backwards Stepwise 31 4.44 2.40 0.42 0.40 1.00 
LN LASSO MAE λ min 71 4.4460 2.414.3 0.43 0.373555 0.99 
LN Enet MAE λ min 71 4.44 2.41 0.42 0.37312 0.99 
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Figure 4.11 Kernel Density plot of best 3 linear hip without BMD models 
 
Based on the optimal aR2 the LN backwards stepwise model would be chosen as the 
optimal model. This model also results in a smaller RMSE and MAE compared to the LASSO 
and Elastic Net models, but a larger slope. The inclusion of 42 variables may make this model 
more difficult to implement than the LASSO and Elastic Net models which include 21 variables. 
A scatter plot comparing CFRI values to FRAX® values for the LN backwards stepwise model 
are presented as Figure 4.12. Much like the with BMD models, this model does a poor job of 
predicting larger values. However, there are more values >20% predicted by the without BMD 
model than the with BMD model. The calibration equation is an intercept of 0.18 indicating 
systematic over prediction, and a slope of 1.18 indicating more extremely high predictions. 
The model coefficients for the three optimal models are presented as Table 4.17. The 
LASSO and Elastic Net models produce very similar model coefficients, while the LN 
backwards model chose a much larger proportion of variables. The LN backwards model has a 
very small intercept and does not choose the basic linear age variable, only choosing the 
interaction terms. Osteoporosis was only chosen by the LN backwards model; however other 
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rheumatologic conditions were chosen by all 3 models. Both RA and glucocorticoid use were 
retained by the backwards stepwise model, important as both of these are FRAX variables. 
Vertebral fractures were not chosen by the LN Backwards model which is surprising as this has 
been a covariate with a lot of importance in the other models. 
Table 4.17 Model Coefficients for Best Linear Hip without BMD 
Attribute LN 
Backwards 
LASSO Elastic Net 
Intercept  13.17578348 -14.64248951 -14.66588037 
Linear Age  -0.866260403 0.27164329 0.272105604 
Age*Age  0.015398691 - - 
Age*Age*Age  -7.90E-05 -1.01E-05 -1.01E-05 
Osteoporosis, N (%)  0.229939204 0.222514387 0.222569808 
Lifestyle Factors, N (%)        
  Alcohol Abuse - 0.122297091 0.122448237 
  Falling - -0.026516442 -0.026598521 
  Vitamin D insufficiency - -0.014849375 -0.014874305 
Genetic factors, N (%)       
  Hypophosphatasia 0.524734704 0.537278564 0.537600674 
  Porphyria - 0.237003518 0.237474064 
  Hemochromatosis - -0.383729672 -0.384098864 
Hypogonadal states, N (%)       
  Anorexia nervosa and bulimia - 0.036913963 0.037275547 
  Premature ovarian failure -0.290420231 -0.283755078 -0.283977476 
Endocrine disorders, N (%)       
  Diabetes mellitus (Type 1 & 2) -0.159199428 -0.151566746 -0.151581912 
  Cushing's syndrome - 0.555982822 0.557516197 
  Hyperparathyroidism - 0.023518619 0.023590833 
  Central Adiposity -0.264133914 -0.247525444 -0.247545026 
  Thyrotoxicosis - -0.002949795 -0.002960049 
Gastrointestinal disorders, N (%)       
  Celiac disease - -0.047753991 -0.048415943 
  Inflammatory Bowel Disease - -0.130820793 -0.131246614 
  Malabsorption 0.201816013 0.214086422 0.214472907 
  Pancreatic disease 0.18872779 0.114123204 0.114351762 
  Primary biliary cirrhosis - -0.064469809 -0.06495293 
  Crohn's Disease 0.168869922 0.230157155 0.230508762 
Hematologic disorders, N (%)       
  Hemophilia -0.200298838 -0.165713083 -0.165919394 
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Attribute LN 
Backwards 
LASSO Elastic Net 
  Thalassemia - -0.194978508 -0.195106538 
Rheumatologic and autoimmune diseases, N (%)       
  Ankylosing spondylitis - -0.041700591 -0.041807668 
  Lupus 0.207871113 0.21903413 0.219306833 
  Rheumatoid arthritis 0.342872904 0.35306675 0.353169056 
  Gout - 0.033198394 0.033256117 
  Polymyalgia Rheumatica 0.141430641 0.145797399 0.145918519 
Central nervous system disorders, N (%)       
  Epilepsy 0.192915433 0.23073996 0.230959668 
  Parkinson's disease - 0.145371534 0.145546936 
  Stroke -0.079886673 -0.068076657 -0.068175056 
  Multiple sclerosis - -0.146151049 -0.146393999 
  Spinal cord injury - 0.29836054 0.298972168 
  Alzheimer's disease - 0.005265918 0.005484316 
Miscellaneous conditions and diseases, N (%)      
  Congestive Heart Failure - -0.004329417 -0.004410815 
  Liver Disease 0.105682215 0.089888081 0.089980881 
  Depression - 0.006727432 0.006786355 
  Amyloidosis 0.630966755 0.476481045 0.476922038 
  End stage renal disease - -0.011448349 -0.011725172 
  Sarcoidosis - 0.175679785 0.17580929 
  Chronic metabolic acidosis 0.347989776 0.335727973 0.335885424 
  Asthma/Chronic obstructive 
lung disease 
- 0.000365177 0.000465412 
  Idiopathic scoliosis - 0.059342503 0.059460451 
  Cataracts - 0.040081371 0.040034303 
  Glaucoma - -0.002327282 -0.002430932 
  Kyphosis 0.093857352 0.088096049 0.088190437 
  Disorders of the eye - 0.002000466 0.002046483 
  Osteoarthritis       
  Renauld's syndrome - -0.050327517 -0.05058248 
Medications, N (%)       
  Cyclosporine A and tacrolimus - 0.019318383 0.019777256 
  Proton pump inhibitors -0.045768346 -0.041372602 -0.04140867 
  Anticoagulants - 0.01146825 0.011518812 
  Selective serotonin reuptake 
inhibitors 
- 0.00331476 0.003358391 
  Aromatase inhibitors - -0.077371264 -0.077473724 
  Thiazolidinediones - -0.130218783 -0.130354479 
  Barbiturates - -0.274449874 -0.275247521 
  Lithium - -0.335272217 -0.335507472 
  Methotrexate 0.272679731 0.262703651 0.262745281 
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Attribute LN 
Backwards 
LASSO Elastic Net 
  Glucocorticoids 0.103682447 0.106835672 0.10679937 
  Hormone Replacement Therapy 0.169297399 0.158392457 0.158442204 
Fractures       
  Other Sites 0.255680069 0.235075732 0.235262231 
Race         
  African-American -0.926065479 -0.904729485 -0.904716208 
  Hispanic -0.622755009 -0.573563018 -0.574002918 
  Asian -0.431379367 -0.410321297 -0.410296945 
  Other -0.538443005 -0.501412749 -0.501542105 
 
Figure 4.12 Best Hip without BMD model scatterplot 
 
To determine the model’s ability to determine the patients who truly should be treated 
(Hip ≥3%) based on the NOF guidelines we calculated a receiver operating curve and area under 
the curve (Figure 4.13). Overall the model seems to do a very good job of predicting who had a 
FRAX® hip without BMD score of ≥3% as evidenced by an AUC of 0.912 (95% 0.896, 0.927). 
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Although the model requires 42 variables, 91% of the time it is able to correctly identify patients 
who had a treatment level Hip without BMD FRAX® score. 
Figure 4.13 Receiver Operating Curve for Hip without BMD 
 
4.2.2.1.5 High-Dimensional Variable Selection 
For hip without BMD the high-dimensional variable selection added 134 medication 
classes, 145 different diagnoses, and 702 procedural classes. When combined with the 87 content 
variables, there were 1,068 different variables for the elastic net model to evaluate. After 
evaluation the MAE λ minimum model was found to be the superior elastic net model, selecting 
44 variables with 7 medication classes, 8 diagnosis codes, and 15 procedure codes. However the 
aR2 for this model was 0.338 which was less than the LN backwards stepwise model. Therefore 
the choice of the best model does not change the choice of model for Hip without BMD. 
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4.2.2.2 Continuous Prediction of Major Osteoporotic Fracture without BMD 
Models were built for the prediction of MOF without BMD FRAX® score. All patients 
were utilized for this prediction as everyone had all FRAX® risk factors, even if they didn’t have 
a femoral neck BMD. The mean score of the training sample was 16.5 (SD 9.7) median 14.19 
(IQR 9.98, 20.64), while the mean of the test sample was 16.2 (SD 8.8) median 13.82 (IQR 
10.22, 20.40). A kernel density plot of the distribution of hip without BMD FRAX® for the 
training and test sample is presented as Figure 4.14. The hip without BMD scores range from 
0.96 to 58.48 with both of the extremes being present in the test sample. Similar methods were 
used to evaluate model fit for the continuous score. We also evaluate model performance for 
predicting a 20% FRAX® threshold based on the actual FRAX® without BMD score. 
Figure 4.14 Density Plot of FRAX® MOF without BMD 
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4.2.2.2.1 Basic Linear Regression Models 
A null model was fit to the data by taking the mean of the actual FRAX® scores and 
comparing it to the actual values to calculate the RMSE and MAE. A linear regression model 
using both an untransformed outcome as well as a log-transformed (LN) outcome were fit, as 
well as backwards stepwise regression models for both the untransformed and log-transformed 
outcomes. The model error terms are presented as Table 4.18. When only age is introduced into 
the model an aR2 of 0.20 is produced for the untransformed and 0.16 for the log-transformed 
model. The null model produced a RMSE of 10.2 and a MAE of 7.8. The linear and 
untransformed backwards stepwise model have very similar results for all error terms other than 
the backwards stepwise model using 46 less variables and producing a marginally better aR2. 
The LN models have less error and a greater aR2 compared to their untransformed counterparts. 
The backwards stepwise model out performs the linear LN model producing an aR2 of 0.44, the 
best basic linear model. The slopes for all 4 models are nearly 1 with the untransformed less than 
1, and the LN slightly more than 1. 
Table 4.18 MOF without BMD Basic Linear Model Error Terms 
Analysis # var RMSE MAE R2 aR2 Slope 
Null Model NA 9.66 7.21 NA NA NA 
Linear Model 71 6.62 4.99 0.43 0.38 0.93 
LN Linear Model 71 6.51 4.52 0.45 0.40 0.96 
Backwards Stepwise 26 6.64 4.97 0.43 0.41 0.93 
LN Backwards Stepwise 28 6.56 4.54 0.44 0.43 0.97 
# var: Number of variables used in the model 
RMSE: Root Mean Squared Error 
MAE: Mean Absolute Error 
aR2: Adjusted R2 
 
173 
 
4.2.2.2.2 LASSO Models for MOF without BMD 
The error terms for the LASSO models predicting hip without BMD both untransformed 
and LN are presented as Table 4.19. 
Table 4.19 LASSO MOF without BMD Model Results 
Analysis # var RMSE MAE R2 aR2 Slope 
LASSO MSE 1se 9 6.85 5.15 0.39 0.387622 1.22 
LASSO MSE λ minimum 30 6.64 4.97 0.43 0.411414 1.02 
LASSO MAE 1se 12 6.73 5.04 0.42 0.406755 1.13 
LASSO MAE λ minimum 35 6.63 4.96 0.43 0.40825 1.01 
LN LASSO MSE 1se 16 6.80 4.64 0.40 0.39167 1.07 
LN LASSO MSE λ min 57 6.66 4.59 0.43 0.386494 0.96 
LN LASSO MAE 1se 26 6.74 4.61 0.41 0.395688 1.03 
LN LASSO MAE λ min 70 6.52 4.54 0.45 0.40339 0.98 
 
Compared to the null model, all 8 LASSO models represent a decrease in RMSE and 
MAE. The models with the least number of variables was the MSE 1se model with 9 variables, 
while the LN λ minimum models both nearly retained all variables. The LN λ minimum models 
represent the smallest error terms, but their high number of variables retained cause their aR2 to 
be less than untransformed MAE 1se. Based on MAE, and slope the MAE 1se model only 
outperforms the MSE 1se model, however its retention of 15 variables seems to be the factor 
which is most associated with a superior aR2. 
4.2.2.2.3 Elastic Net Hip without BMD 
The error terms for the elastic net models predicting MOF without BMD are presented as 
Table 4.20. The best model is chosen by a maximum aR2.  
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Table 4.20 Elastic Net MOF without BMD Model Results 
Analysis # 
var 
RMSE MAE R2 aR2 Intercept 
Enet MSE 1se 9 6.86 5.16 0.39 0.386481 1.22 
Enet MSE λ min 30 6.64 4.97 0.43 0.411434 1.02 
Enet MAE 1se 12 6.73 5.04 0.42 0.407091 1.13 
Enet MAE λ min 37 6.63 4.96 0.43 0.406835 1.01 
LN Enet MSE 1se 16 6.81 4.64 0.40 0.391296 1.07 
LN Enet MSE λ min 59 6.66 4.59 0.43 0.385339 0.96 
LN Enet MAE 1se 26 6.74 4.61 0.41 0.395865 1.03 
LN Enet MAE λ min 70 6.52 4.54 0.45 0.403456 0.98 
 
All 8 elastic net models represent a decrease in RMSE and MAE compared to the null 
model. The number of variables retained by the models range from 11 to 84 with an optimal 
choice of 15 variables in the MAE 1se model. The smallest RMSE and MAE were found in the 
LN λ minimum models. The largest R2 was found in the same models, however their retention of 
40 more variables than the MAE λ minimum model reduced their aR2. The best elastic net model 
would be the MAE λ minimum with an aR2 of 0.42. It appears that the penalization can create 
models with a better fit, however the retention of a large number of variables causes the 
predictive ability to suffer. 
4.2.2.2.4 Comparison of the best linear MOF without BMD models 
The three models with the best aR2, log transformed backwards stepwise, LASSO MAE 
1se, and Elastic Net MAE 1se are compared in this section. The model error results are presented 
as Table 4.21. Additionally a kernel density plot of the predicted values compared to the actual 
values is presented as Figure 4.15.  
Table 4.21 Comparison of the best linear MOF without BMD models 
Analysis # 
var 
RMSE MAE R2 aR2 Slope 
LN Backwards Stepwise 28 6.56 4.54 0.44 0.43 0.97 
LASSO MSE λ minimum 30 6.64 4.97 0.43 0.41 1.02 
Enet MSE λ min 30 6.64 4.97 0.43 0.41 1.02 
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Figure 4.15 Kernel Density plot of best 3 linear MOF without BMD models 
 
Based on the optimal aR2 the LN backwards stepwise model would be chosen as the 
optimal model. The LN backwards stepwise model outperforms the LASSO and elastic net 
models in all aspects. Similar to the Hip without BMD model, 42 variables are necessary to 
calculate the model. A scatter plot comparing CFRI values to FRAX® values for the LN 
backwards stepwise model are presented as Figure 4.16. This model seems to do the best job in 
predicting larger values, however with an intercept of 0.73 and slope of 1.03 the estimates are 
likely to be higher than expected. This is evident in the lower value predictions, which account 
for the model under predicting the larger values.  
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Figure 4.16 Best MOF without BMD model scatterplot 
 
The coefficients for the three optimal linear models are presented as Table 4.22. Unlike 
the Hip without BMD, the intercept in the LN backwards model is large, and it retains age as 
well as age2 and age3. In the MOF with BMD model’s osteoporosis was only retained by the LN 
backwards stepwise model, however RA and glucocorticoids were retained by all 3 models. 
Fractures again were important variables, although the LN backwards model did not retain 
vertebral fractures. Overall within the LN backwards model most coefficients were very close to 
1, while the LASSO and elastic net gave large weights to certain variables. In the end retaining 
more variables created a more harmonious model. 
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Table 4.22 Model Coefficients for Linear MOF without BMD 
Attribute LN 
Backwards 
LASSO Elastic Net 
Intercept  22.25687045 -34.75496345 -34.79540886 
Linear Age  -0.914502808 0.631668782 0.632320338 
Age*Age  0.013336948 - - 
Age*Age*Age  -6.15E-05 - - 
Age*Osteoporosis  0.001681857 0.031372562 0.031419748 
In 365-days prior to index       
Genetic factors        
  Hypophosphatasia 0.281333375 2.471804805 2.518598059 
Endocrine disorders       
  Diabetes mellitus (Type 1 & 2) -0.075335158 -0.538547956 -0.550364407 
  Central Adiposity -0.109487081 -0.630311366 -0.649100307 
Gastrointestinal disorders       
  Inflammatory Bowel Disease -0.108489108 - - 
  Malabsorption 0.126877713 - 0.018374218 
  Crohn's Disease 0.142616646 0.969026877 0.985987218 
Hematologic disorders       
  Hemophilia -0.119944794 - - 
Rheumatologic and autoimmune diseases       
  Lupus 0.183524351 4.224023436 4.273632872 
  Rheumatoid arthritis 0.205507803 3.678520605 3.682881305 
  Gout - 0.131721248 0.160127861 
  Polymyalgia Rheumatica 0.107395123 1.921607036 1.940065485 
Central nervous system disorders      
  Epilepsy 0.105167629 0.262548636 0.29712851 
  Stroke -0.064792173 -0.621698485 -0.643372224 
Miscellaneous conditions and diseases       
  Liver Disease 0.077038137 0.77347816 0.791006586 
  Amyloidosis 0.532356113 7.206598946 7.340628687 
  Chronic metabolic acidosis 0.269888216 2.361874215 2.387891671 
  Idiopathic scoliosis - 0.215785508 0.233170932 
  Obesity - -0.017332243 -0.017848227 
  Disorders of the eye - 0.055497184 0.063399475 
  Osteoarthritis - 0.032683451 0.037207593 
Medications       
  Selective serotonin reuptake 
inhibitors 
- 0.199330688 0.211959154 
  Anticonvulsants - 0.032115648 0.040350409 
  Methotrexate 0.208599974 2.954033763 2.975039838 
  Glucocorticoids 0.063924749 1.223561653 1.224988434 
  Hormone Replacement Therapy 0.098549558 1.341015845 1.353681926 
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Attribute LN 
Backwards 
LASSO Elastic Net 
Fractures       
  Non-MOF 0.210669732 2.777596 2.794245798 
Race        
  White - 4.045799614 4.023977424 
  African-American -0.852807121 -5.353985077 -5.382784744 
  Hispanic -0.491561947 -0.198996407 -0.299415187 
  Asian -0.438087007 - - 
  Other -0.497591055 - -0.030258459 
To determine the model’s ability to identify patients who truly should be treated (MOF 
≥20%) based on the NOF guidelines we calculated a receiver operating curve and area under the 
curve (Figure 4.17). Overall the model seems to do a very good job of predicting who had a 
FRAX® MOF without BMD score of ≥20% as evidenced by an AUC 0.825 (0.794, 0.855). 
However the without BMD model increases the AUC over the with BMD model by only 0.03 
indicating a similar fit for both.  
Figure 4.17 Receiver Operating Curve for MOF without BMD 
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4.2.2.2.5 High-Dimensional Variable Selection 
For MOF without BMD there were 134 medication classes, 145 different diagnoses, and 
702 procedural classes. When these were added to the 87 content variables there were 1,068 
different variables for the elastic net model to evaluate. After evaluation the MAE 1se model was 
found to be the superior elastic net model, selecting 20 variables, however the aR2 for this model 
was 0.397 which was less than the LN backwards stepwise model. Therefore the choice of the 
best model does not change the choice of model for MOF without BMD. 
4.3 Summary 
Overall the regression techniques were able to predict FRAX® at a fair rate. The with 
BMD models produced much lower aR2 with fewer variables than the without BMD models. 
Age was the variable which was most influential in each of the models, which confirms other 
studies findings of the influence of age on fracture. In the without BMD cohorts as well as the 
without BMD MOF cohort age, RA, and glucocorticoids which are all FRAX® variables were 
also variables in CFRI. However in the with BMD hip prediction only age was similar between 
FRAX® and CFRI. Age was the most influential variable overall, and the variables which could 
reliably be identified in claims which also appeared in FRAX® were included in 3/4 models. It is 
likely that the small variation in hip with BMD score caused the non-inclusion of any additional 
variables including the FRAX® variables which the other models expressed. More descriptive 
summaries of each of the models follow this section. 
All four models appear to do a similar job at predicting the appropriate FRAX® threshold 
(3% in hip and 20% for MOF). It could be argued that due to the models high c-statistics in 
predicting the thresholds, they should only be used for this purpose, however this is greatly 
reduces the utility of the score. Therefore in Aim 2 we will determine how well CFRI actually 
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predicts fractures which will provide us with a better context of if it should be limited to only 
thresholds. 
4.3.1 Hip with BMD 
The model which produced the best hip with BMD CFRI score was elastic net model 
based on the 1se penalty. This model marginally outperformed the LASSO model of the same 
penalization method, and was able to account for 21% of all variation in the FRAX® score after 
adjustment for the number of variables included in the final model (aR2). The final scores had a 
similar density distribution to the actual FRAX® scores, if only increased by a score of 3. Based 
on the scatterplot it appears that when the FRAX® score was low, the model did a good job of 
predicting, but was unable to predict extremely large scores. We are unaware of any models 
which this performance can be compared to. 
When we evaluated the predictive ability of the CFRI score based on a 3% threshold 
(which is the Hip FRAX® treatment threshold from the NOF), a c-statistic of 0.85 was produced. 
This demonstrates that 85% of the time a CFRI score of 3% would have predicted a high or low 
risk patient in the same risk group as their actual FRAX® score. These findings suggest that a 
3% threshold may be the appropriate threshold in a policy context to identify patients who 
should receive anti-osteoporosis medication. 
4.3.2 MOF with BMD 
When predicting MOF with BMD the same model, the elastic net model with the 1se 
penalty produced the best predictive model. MOF has a much wider spread of predictable values, 
however the model chosen only had 27 variables, so there could be much less variation in the 
estimates than in the real values. This is particularly evident by looking at the scatterplot of the 
predicted compared to actual scores, where the data points repeat themselves frequently in the 
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10-20% range. The small number of variables also prevents the model from making extreme 
predictions in the same range as the actual values, as other than Cushing’s syndrome there are no 
variables which if present would be able to drive an estimate to an extreme value. 
The MOF with BMD score based on the NOF threshold of 20% was associated with a c-
statistic of 0.81 which indicates that 81% of the time patients were correctly identified as above 
or below the 20% threshold in CFRI compared to FRAX®. This suggests that the threshold of 
20% can be used based on CFRI to identify high and low-risk patients based on NOF treatment 
thresholds. 
4.3.3 Hip without BMD 
The model which produced the best hip without BMD CFRI score was backwards 
stepwise model which was log transformed. Although this model wasn’t able to deal with 
extreme predictions, its calibration slope of ~1 indicates that with enough data points it should be 
able to give good predictions. The aR2 of 0.40 indicates that 40% of the variation in FRAX® hip 
without BMD could be accounted for by the predictive model, which was only 0.02 less than the 
without BMD MOF CFRI which was the highest aR2. The rationale behind better prediction for 
the without BMD compared to the with-BMD is first the spread of the data, although the means 
were similar the distribution of hip without BMD scores was much wider than with BMD. 
Second the increased n because we were able to use all women who were in the dataset rather 
than just the selection who had a femoral neck BMD. Lastly, this model included more variables 
31 compared to 4 in the with BMD model, which allowed for more variation in scores, 
increasing the predictive ability. In some regards it says something about how few variables are 
really needed to predict FRAX®, but when used appropriately the increase in predictive ability is 
substantial. 
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When we evaluated the predictive ability of the CFRI score based on a 3% threshold 
(which is the Hip FRAX® treatment threshold from the NOF), a c-statistic of 0.89 was produced. 
This demonstrates that 89% of the time a CFRI score of 3% would have predicted a high or low 
risk patient in the same risk group as their actual FRAX® score. These findings suggest that a 
3% threshold may be the appropriate threshold in a policy context to identify patients who 
should receive anti-osteoporosis medication. This c-statistic is better than the with BMD statistic 
of 0.84, based on these findings the without BMD score should be preferred over the with BMD 
score. 
4.3.4 MOF with BMD 
When predicting MOF without BMD the log-transformed backwards stepwise model 
produced the best aR2 of 0.43 which incidentally was the best predictive ability for any of the 
four variations. The model used 28 variables which was one more than the hip without BMD 
model, and had a similar predictive ability. The spread of MOF without was similar to the hip 
without in that it was larger than the with BMD estimates. This offers some explanation for 
better predictions. Based on visual inspection the density distribution is more similar for these 
predictions than for any other variation. 
Although the aR2 is greater for the MOF without BMD, the hip without BMD had the 
best c-statistic, as the MOF without only produced a score of 0.83. This was 2% better than the 
with BMD estimate, so based on the increased aR2 and c-statistic, the MOF without BMD CFRI 
score would be preferred to the with-BMD. 
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 AIM 2 RESULTS 
Aim 2: Externally validate CFRI in a 20% random sample of Medicare beneficiaries 
by comparing the performance of CFRI and FRAX® to predict incident fractures.  
Hypothesis 2: There will be no significant difference between FRAX® and CFRI to 
predict incident fractures as a continuous variable (calibration) between the linked and random 
sample.  
Hypothesis 3: CFRI will identify fractures at a similar rate based on c-statistics in the 
random sample as FRAX® in the linked sample (discrimination). 
5.1 Study Population  
The Aim 2 population is comprised of two separate cohorts from two different data 
sources, herein referred to as the linked and random populations. The linked population is the 
same cohort used from Aim 1. Specific details on this population and methods for linkage can be 
found in Section 3.1.3.  
The random population is comprised of Medicare eligible females (age ≥65) who had at 
least 365-days continuous Medicare Parts A, B, and D enrollment prior to an office visit between 
2008 and 2012. When an office visit met this criterion it was kept as an eligible date, however 
only the first office visit of any given calendar year could then be used to define the index date. 
If a woman had multiple years which met the enrollment criterion we randomly chose one year 
for the analysis. Additionally we required patients to be AOM naïve (bisphosphonate,  
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Raloxifene, Teriparatide, Calcitonin) and no inpatient or outpatient claims for a MOF in the 365-
day wash-out period. A flowchart detailing exclusions is presented as Figure 5.1. Overall there 
were 1,448,815 women who met all inclusion criteria.  
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Figure 5.1 Aim 2 Random Population Selection Flowchart 
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For the comparison of the linked population, the model coefficients from the four optimal 
models from Aim 1, were culled and predicted values were created for everyone in the linked 
cohort, thereby dissolving the test and training samples. However the with (n=2,798) and without 
BMD (n=2,860) populations were preserved.  
In the random population, all available patients were used to create the ROC curves for 
CFRI both with and without BMD. Model coefficients from the 4 relevant models from the Aim 
1 results were used to calculate the CFRI score (Table 4.6, Table 4.10, Table 4.17, Table 4.22). 
The outcomes of interest were hip fracture or MOF within 1 year of the index date (index date = 
DXA for the linked population and an office visit for the random population). The algorithms 
used to evaluate the fractures are presented in Table 3.3. Patients were followed up to one year 
after their index office visit until occurrence of fracture, death, or loss continuous enrollment. If 
death, loss of continuous enrollment, or 365-days from index occurred prior to a fracture then the 
patient was administratively censored. 
5.1.1 Characteristics of the Random Population 
There were 1,444,815 women who met all inclusion criteria previously specified. 
Specifics of the random population are presented as Table 5.1. The mean age of the population 
was 76.0 (SD 8.2). The population was predominantly white (83.6%), and the index dates were 
relatively evenly spread between 2008 and 2012 with 16.9% in 2010 representing the smallest 
number and 26.2% in 2012 the highest. The most prevalent characteristic in the random 
population was disorders of the eye (53.5%), cataracts (36.4%), diabetes (32.1%), osteoarthritis 
(29.8%), use of a proton pump inhibitor (27.3%), kyphosis (24.4%), and asthma/COPD (21.3%).   
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Table 5.1. Population Characteristics of the Random Population 
Attribute Random Population 
(n=1,444,815) 
Linked without BMD 
Population (n=2,860) 
 Mean Age 76.0 (8.2) 75.4 (7.7) 
Year of DXA   
 2008 300,076 (20.7) - 
 2009 250,133 (17.3) 164 (5.7) 
 2010 245,034 (16.9) 465 (16.3) 
 2011 274,074 (18.9) 811 (28.4) 
 2012 379,498 (26.2) 703 (24.6) 
In 365-days prior to index  
Osteoporosis, N (%)  164772 (11.4) 1252 (43.8) 
Lifestyle Factors, N (%)  
  Alcohol Abuse 4589 (0.3) 9 (0.3) 
  Falling 67499 (4.7) 151 (5.3) 
  Vitamin D insufficiency 112862 (7.8) 815 (28.5) 
  Excess Vitamin A 67 (<0.1) <11 
Genetic factors, N (%)  
  Cystic fibrosis 360 (<0.1) <11 
  Homocystinuria 1580 (0.1) <11 
  Osteogenesis imperfecta 106 (<0.1) <11 
  Hypophosphatasia 4803 (0.3) 14 (0.5) 
  Gaucher's disease 2200 (0.2) <11 
  Idiopathic hypercalciuria 4 (<0.1) <11 
  Porphyria 228 (<0.1) <11 
  Glycogen storage diseases 128 (<0.1) <11 
  Marfan syndrome 47 (<0.1) <11 
  Riley-Day syndrome 37 (<0.1) <11 
  Hemochromatosis 390 (<0.1) <11 
Hypogonadal states, N (%)   
  Androgen insensitivity 40 (<0.1) <11 
  Anorexia nervosa and bulimia 15901 (1.1) 25 (0.9) 
  Hyperprolactinemia 292 (<0.1) <11 
  Premature ovarian failure 807 (0.1) <11 
  Athletic amenorrhea 853 (0.1) <11 
  Turner and Klinefelters's syndromes 30 (<0.1) <11 
  Panhypopituitarism 92 (<0.1) <11 
Endocrine disorders, N (%)   
  Adrendal insufficiency 525 (<0.1) <11 
  Diabetes mellitus (Type 1 & 2) 465292 (32.1) 584 (20.4) 
  Cushing's syndrome 617 (<0.1) <11 
  Hyperparathyroidism 13700 (0.9) 134 (4.7) 
  Central Adiposity 82981 (5.7) 206 (7.2) 
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  Thyrotoxicosis 29324 (2.0) 46 (1.6) 
Gastrointestinal disorders, N (%)   
  Celiac disease 2244 (0.2) 21 (0.7) 
  Gastric bypass 0 (<0.1) <11 
  Inflammatory Bowel Disease 11925 (0.8) 55 (1.9) 
  Malabsorption 6224 (0.4) 46 (1.6) 
  Pancreatic disease 15713 (1.1) 38 (1.3) 
  Primary biliary cirrhosis 1355 (0.1) 13 (0.5) 
  Crohn's Disease 54925 (3.8) 139 (4.9) 
Hematologic disorders, N (%)   
  Hemophilia 31298 (2.2) 50 (1.7) 
  Thalassemia 734 (0.1) <11 
  Sickle cell anemia 290 (<0.1) <11 
  Systemic mastocytosis 150 (<0.1) <11 
Rheumatologic and autoimmune diseases, N (%)   
  Ankylosing spondylitis 16064 (1.1) 40 (1.4) 
  Lupus 6706 (0.5) 34 (1.2) 
  Rheumatoid arthritis 51970 (3.6) 201 (7.0) 
  Gout 45961 (3.2) 82 (2.9) 
  Polymyalgia Rheumatica 11961 (0.8) 81 (2.8) 
Central nervous system disorders, N (%)   
  Epilepsy 17014 (1.2) 45 (1.6) 
  Parkinson's disease 21173 (1.5) 22 (0.8) 
  Stroke 162004 (11.2) 273 (9.5) 
  Multiple sclerosis 4263 (0.3) 23 (0.8) 
  Spinal cord injury 1157 (0.1) <11 
  Alzheimer's disease 159783 (11.0) 153 (5.3) 
Miscellaneous conditions and diseases, N (%)   
  AIDS/HIV 927 (0.1) <11 
  Congestive Heart Failure 203151 (14.0) 204 (7.1) 
  Muscular dystrophy 408 (<0.1) <11 
  Liver Disease 57151 (3.9) 139 (4.9) 
  Depression 206798 (14.3) 458 (16.0) 
  Amyloidosis 422 (<0.1) <11 
  End stage renal disease 17938 (1.2) 21 (0.7) 
  Sarcoidosis 2647 (0.2) 17 (0.6) 
  Chronic metabolic acidosis 8682 (0.6) 28 (1.0) 
  Asthma/Chronic obstructive lung 
disease 
307970 (21.3) 618 (21.6) 
  Idiopathic scoliosis 27901 (1.9) 122 (4.3) 
  Cataracts 527811 (36.4) 1359 (47.5) 
  Glaucoma 216032 (14.9) 427 (14.9) 
  Kyphosis 353679 (24.4) 2729 (95.4) 
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  Obesity 82981 (5.7) 206 (7.2) 
  Disorders of the eye 774859 (53.5) 1833 (64.1) 
  Osteoarthritis 431348 (29.8) 1229 (43.0) 
  Renauld's syndrome 71213 (4.9) 112 (3.9) 
Medications, N (%)   
  Cyclosporine A and tacrolimus 1759 (0.1) 16 (0.6) 
  Proton pump inhibitors 395799 (27.3) 830 (29.0) 
  Anticoagulants 159834 (11.0) 250 (8.7) 
  Selective serotonin reuptake inhibitors 275156 (19.0) 481 (16.8) 
  Anticonvulsants 181120 (12.5) 387 (13.5) 
  Aromatase inhibitors 21560 (1.5) 88 (3.1) 
  GnRH (Gonadotropin releasing 
hormone) antagonists and agonists 
1 (<0.1) <11 
  Thiazolidinediones 52990 (3.7) 32 (1.1) 
  Barbiturates 184 (<0.1) <11 
  Lithium 3105 (0.2) <11 
  Methotrexate 14478 (1.0) 88 (3.1) 
  Glucocorticoids 209563 (14.5) 632 (22.1) 
  Hormone Replacement Therapy 129708 (9.0) 342 (12.0) 
  Calcium 1 (<0.1) <11 
  Vitamin D 11 (<0.1) <11 
Non-MOF, N (%) 53076 (3.7) 158 (5.5) 
Race, N (%) 
 
 
  White 1211099 (83.6 2461 (86.0) 
  African-American 152101 (10.5) 333 (11.6) 
  Hispanic 34128 (2.4) 13 (0.5) 
  Asian 25397 (1.8) 22 (0.8) 
  Other 17051 (1.2) 21 (0.7) 
All Cells with a total of 0 were suppressed; *: Includes Cataracts and Glaucoma <11: CMS does not allow 
cells with less than 11 patients to be presented 
 
Comparing the random population to the linked population reveals that the linked 
population had characteristics typically associated with fracture in greater quantities than the 
general (random) population. The largest difference was in kyphosis where 95.4% of the linked 
and only 24.4% of the random population had a claim. Next was osteoporosis, where 43.8% of 
the linked and only 11.4% of the random population had a claim, vitamin D insufficiently was 
28.5% in the linked and only 7.8% in the random population, osteoarthritis was 43.0% in the 
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linked and only 29.8% in the random, and glucocorticoid use was 22.1% in the linked and 14.5% 
in the random. These conditions are all common in the population seen by CCF Rheumatologists, 
but not necessarily for the population as a whole. This may suggest that the random population is 
healthier in regards to bone health compared to the linked population.  
However if evaluating general health, the random population was older (76.0 compared 
to 73.5 years of age), had more prevalent cases of diabetes (32.1% compared to 20.4%), 
Alzheimer’s disease (11.0% compared to 5.3%), as well as CHF (14.0% compared to 7.1%). The 
majority of the other attributes were very similar between the random and linked populations. 
With a greater age and more diabetes, it may be that the random population was at a greater risk 
for death in the 365-days following index, compared to the linked population being at a greater 
risk for fracture.  
5.2 Analysis 
5.2.1 Hip with BMD CFRI score 
The table of coefficients used to calculate CFRI Hip with BMD is presented as Table 5.2. If a 
researcher was interested in using the CFRI score they would need to multiply the dummy 
variable (0/1) for absence/presence of the covariate in the data and sum the score.   
Table 5.2 Hip with BMD CFRI Model Coefficients 
Attribute Hip with BMD CFRI 
Intercept -7.78430299 
Linear Age 0.154623293 
Age*Osteoporosis 0.032028816 
 
Cushing's syndrome 21.48856957 
 
African-American -1.366183288 
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5.2.1.1 Comparison in Linked Population 
The hip with BMD CFRI score was calculated based on the presence of the covariates 
used in the model multiplied by their coefficient. The table used for the calculation was Table 
4.6, column 4, Elastic Net. There were 14/2,798 (0.5%) women who had a femoral neck BMD 
value, and a hip fracture in the linked population within 1 year of their DXA (index date). The 
FRAX® and CFRI scores are relative to the 10-year risk of hip fracture for the individual. The 
mean hip with BMD FRAX® score was 4.4 (SD 5.7) and the mean hip with BMD CFRI score 
was 4.5 (SD 1.9).  
Calibration was assessed using the Hosmer-Lemeshow test which is a variation on the 
chi-square by testing deciles of the risk score to determine if observed and expected event rates 
match each other (where a higher p-value indicates a better fit). In the linked population the 
FRAX® 10-year risk of hip fracture produces a p-value of 0.97 while the CFRI hip with BMD 
produces a p-value of 0.67. These both indicate a relatively good fit of prediction to fracture. We 
also evaluated calibration using the brier score, which is a measure of the accuracy of predicted 
probabilities. The brier score ranges from 0 (the best score) to 1 (the worst score). FRAX® had a 
brier score of 0.005 while CFRI also had a brier score of 0.005, both of these scores indicate 
nearly optimal predictive ability. 
A paired De-Long test for equality of ROC curves was calculated with a p≤0.05 
indicating a statistically significant difference between the two ROC curves (32, 420). The AUC 
for the FRAX® ROC was 58.75 (95% CI 41.20, 81.19), while for the CFRI curve the AUC was 
65.53 (95% CI 50.72, 80.34). The paired De-Long test had a p-value of 0.33 indicating a lack of 
statistically significant difference between the two ROC curves (32, 420) (Figure 5.2).  
192 
 
Comparing the calibration of the two predictions based on HL and brier without much 
difference, hypothesis 2 would be confirmed. Hypothesis 2 in brief stated that there would be no 
significant difference in calibration between CFRI and FRAX®. The equality of the De-Long 
test supports hypothesis 3 for hip with BMD, as there is no statistically significant difference in 
the ability to predict fractures between FRAX® and CFRI in the linked population.  
Figure 5.2 ROC Comparison for Hip with BMD in Linked Population 
 
After visual inspection of Figure 5.2 the ROC curves for CFRI does not move from a 
sensitivity of 0% until the specificity is nearly 90%. The CFRI values which were associated 
with fractures were at lowest 2.1 and a highest 8.8, while the FRAX® values ranged from 0.2 to 
29. There was no discernable difference in the ages of the patients who had fractures than those 
who did not (i.e., performance did not vary by age group); instead patients with a very low CFRI 
score did not fracture. This also is likely compounded by the small sample size, with only 14 hip 
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fractures, it may be that CFRI did poorly at finding those in the linked group who were most 
likely to fracture. 
5.2.1.2 Comparison among the Linked FRAX®, Linked CFRI, and Random CFRI 
There were 12,801/1,448,815 (0.9%) women who had a hip fracture by 365 days after 
index in the 20% random population. The mean hip with BMD CFRI score was 4.1 (SD 1.7). 
This score is lower and with a smaller standard deviation than in the linked population and likely 
represents a healthier population. The HL for the random population was <0.001 indicating that 
it was a very poor fit for the hip fracture outcome. However the brier score was 0.009 which 
although less predictive than the linked population demonstrates good predictive performance.  
The AUC for the random population was 0.74 (95% CI 0.68, 0.79). Using a two sample 
DeLong test for equality, the difference between the FRAX® estimate and CFRI estimate was 
not statistically significant (Random AUC 74.2, FRAX® AUC 58.7, p= 0.10. Additionally the 
two sample De-Long test did not show a statistically significant difference between the CFRI in 
the random and linked populations (Random 74.2, Linked 65.5, p= 0.28). Graphical 
representation of the three curves is presented as Figure 5.3.  
Hypothesis 2 was concerned with if there was a significant difference in calibration 
between CFRI and FRAX®. Although the HL test is vastly different for the linked and random 
population, the brier scores are very similar which would support the acceptance of the null 
hypothesis from hypothesis 2 of a similar calibration between estimates. Based on the statistical 
significance of the De-Long test, there is no difference between FRAX® in the linked and CFRI 
in the random populations ability to predict fractures at one year, this finding does not reject the 
null hypothesis of hypothesis 3.  
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Figure 5.3 ROC Comparison for Hip with BMD in Linked and Random Populations 
 
The mean CFRI score for hip fractures in the random population was 5.4% (SD 1.6%), 
which is statistically significantly greater than those who did not have fractures 4.1% (SD 1.7%), 
p<0.001, but follows what we would expect with a higher score being more indicative of a higher 
chance of fracture. The age of those with fractures in the random population was 83.3 (SD 8.0), 
which when compared to that of those who didn’t have a fracture 75.9 (SD 8.2) (p<0.001). 
Although fractures increased with age, the algorithm did not only assign high scores to older 
persons. Overall CFRI was able to better identify those persons who would have hip fractures in 
the random population than in the linked population. This was found even though patient 
characteristics in the linked population suggested that they were at a greater risk for fracture than 
the general population.  
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5.2.2 Major Osteoporotic Fracture with BMD CFRI Score 
The table of coefficients used to calculate CFRI Hip with BMD is presented as Table 5.3. 
If a researcher was interested in using the CFRI score they would need to multiply the dummy 
variable (0/1) for absence/presence of the covariate in the data and sum the score.   
Table 5.3 MOF with BMD CFRI Model Coefficients 
Variable MOF with BMD CFRI 
Intercept -4.825318605 
Linear Age 0.213882754 
Age*Osteoporosis 0.06501777 
Vitamin D insufficiency -0.013289971 
Hypophosphatasia 0.009540193 
Diabetes mellitus (Type 1 & 2) -0.010675466 
Cushing's syndrome 30.00819577 
Hyperparathyroidism 0.498923702 
Inflammatory Bowel Disease 1.554882759 
Lupus 0.726900325 
Rheumatoid arthritis 2.813412897 
Polymyalgia Rheumatica 1.449502678 
Spinal cord injury 1.093297267 
Depression 0.021357651 
Sarcoidosis 0.481572939 
Chronic metabolic acidosis 1.667854978 
Idiopathic scoliosis 0.996848535 
Kyphosis 0.090356929 
Renaulds 1.239561619 
Proton pump inhibitors 0.056608238 
Methotrexate 0.841853825 
Glucocorticoids 0.965996066 
Hormone Replacement Therapy 0.208072152 
Non-MOF Fractures 2.169086603 
White 2.266392607 
African-American -6.775158983 
Hispanic 2.662589671 
Other -0.004125508 
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5.2.2.1 Comparison in Linked Population 
The MOF with BMD CFRI score was calculated based on the presence of the covariates 
used in the model multiplied by their coefficient. The table used for the calculation was Table 
4.10, column 4, Elastic Net. There were 84/2798 (3.0%) MOF in the linked population with 
BMD within 1 year of their DXA. The mean MOF with BMD FRAX® score was 15.0 (SD 8.8) 
and the mean MOF with BMD CFRI score was 15.1 (SD 4.6). The HL for FRAX® MOF was 
0.11, while CFRI produced a p-value of 0.08 indicating similar predictive abilities based on 
deciles of expected to observed fracture rate. The brier score was 0.0287 for FRAX® and 0.0289 
for CFRI indicating very good predictive performance for both risk scores.  
A paired De-Long test for equality of ROC curves was calculated with a p≤0.05 
indicating a statistically significant difference between the two ROC curves. The AUC for the 
FRAX® ROC was 0.6658 (95% CI 0.6038, 0.7277), while for the CFRI curve the AUC was 
0.6960 (95% CI 0.6386, 0.7534) (Figure 5.4). The paired De-Long test had a p-value of 0.26 
indicating no significant difference between the two ROC curves. The equivalence of the De-
Long test supports that there is no significant difference in the ability to predict fractures 
between FRAX® and CFRI in the linked population, using the MOF without BMD CFRI score. 
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Figure 5.4 ROC Comparison for MOF with BMD in Linked Population 
 
 
5.2.2.2 Comparison between the Linked FRAX®, Linked CFRI, and Random CFRI 
population 
There were 45,414/1,448,815 (3.1%) women in the random population who had a MOF 
within 365-days of their index date. The mean MOF without BMD CFRI score was 13.8 (SD 
4.0). The HL for MOF with BMD was <0.001 indicating a poor fit for expected to observed 
fracture rate. The brier score was 0.03, indicating in the random population CFRI was a better 
predictor than FRAX® or CFRI in the linked population. A De-Long test for equality of ROC 
curves was calculated with a p≤0.05 indicating a statistically significant difference between the 
two ROC curves. The AUC for CFRI in the random population was 0.667 (95% CI 0.664, 
0.669). Comparing the random AUC to the FRAX® AUC indicated no significant differences 
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(p=0.98), while the comparison to the linked CFRI also did not show a statistically significant 
difference (p=0.31).  Graphical representation of the three curves is presented as Figure 5.5.  
Although the HL test is vastly different for the linked and random population, the brier 
scores are very similar which would support the acceptance of the null hypothesis from 
hypothesis 2 of a similar calibration between estimates. The non-statically significant differences 
between the ROC curves using the De-Long test, supports the null of hypothesis 3 for MOF with 
BMD, of no difference between the three curves.  
Figure 5.5 ROC Comparison for MOF with BMD in Linked and Random Populations 
 
In women who had a MOF, the mean CFRI was 15.8% (SD 3.8) while those without a 
fracture had a mean CFRI of 13.7% (SD 4.0). These are smaller differences than fractures 
compared to non-fractures using the hip with BMD CFRI score. Women who had fractures were 
only slightly older than those who did not, 80.4 years (SD 8.6) compared to 75.9 years (SD 8.2). 
This is much less of a variation than in hip fractures, and may be an artifact of the covariate for 
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age being smaller in MOF algorithm than in the hip. It should be noted how closely the FRAX 
and random CFRI values are, although the linked have fewer fractures overall, the c-statistics are 
nearly identical.  
5.2.3 Hip without BMD 
The table of coefficients used to calculate CFRI Hip with BMD is presented as Table 5.4. 
If a researcher was interested in using the CFRI score they would need to multiply the dummy 
variable (0/1) for absence/presence of the covariate in the data and sum the score.   
Table 5.4 Hip without BMD CFRI Coefficients 
Attribute Hip without BMD CFRI 
Intercept 13.17578348 
Linear Age -0.866260403 
Age*Age 0.015398691 
Age*Age*Age -7.90E-05 
Osteoporosis 0.229939204 
Hypophosphatasia 0.524734704 
Premature ovarian failure -0.290420231 
Diabetes mellitus (Type 1 & 2) -0.159199428 
Central Adiposity -0.264133914 
Malabsorption 0.201816013 
Pancreatic disease 0.18872779 
Crohn's Disease 0.168869922 
Hemophilia -0.200298838 
Lupus 0.207871113 
Rheumatoid arthritis 0.342872904 
Polymyalgia Rheumatica 0.141430641 
Epilepsy 0.192915433 
Stroke -0.079886673 
Liver Disease 0.105682215 
Amyloidosis 0.630966755 
Chronic metabolic acidosis 0.347989776 
Kyphosis 0.093857352 
Proton pump inhibitors -0.045768346 
Methotrexate 0.272679731 
Glucocorticoids 0.103682447 
Hormone Replacement Therapy 0.169297399 
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Non-MOF Fracture 0.255680069 
African-American -0.926065479 
Hispanic -0.622755009 
Asian -0.431379367 
Other -0.538443005 
 
5.2.3.1 Comparison in the Linked Population 
The hip without BMD CFRI score was calculated based on the presence of the covariates 
used in the model multiplied by their coefficient. The table used for the calculation was Table 
4.17, column 2, LN Backwards. There were 15/2860 (0.5%) women who had a hip fracture in 
the linked population within 1 year of their DXA. The mean hip without BMD FRAX® score 
was 5.1 (SD 4.0) and the mean hip without BMD CFRI score was 5.9 (SD 6.7). The HL for 
FRAX® 10-year risk of hip fracture without BMD had a p-value of 0.67 and a brier score of 
0.005, while CFRI’s HL had a p-value of 0.86 and a brier score of 0.005. These calibration tests 
demonstrate that both risk scores are good predictors of future fracture, but CFRI has a greater 
predictive ability based on a higher HL p-value. A paired De-Long test for equality of ROC 
curves was calculated with a p≤0.05 indicating a statistically significant difference between the 
two ROC curves. The AUC for the FRAX® ROC was 0.6761 (95% CI 0.5404, 0.8119), while 
for the CFRI curve the AUC was 0.6418 (95% CI 0.5063, 0.7773). The paired De-Long test had 
a p-value of 0.49 indicating no statistically significant difference between the two ROC curves 
(Figure 5.6). The equality of the De-Long test supports hypothesis 3 for hip without BMD, as 
there is no difference in the ability to predict fractures between FRAX® and CFRI in the linked 
population. 
201 
 
Figure 5.6 ROC Comparison for Hip without BMD in Linked Population 
 
5.2.3.2 Comparison between the Linked FRAX®, Linked CFRI, and Random CFRI 
population 
There were 12,801/1,448,815 (0.9%) women who had hip fractures by 365-days after 
index in the 20% random population. The mean hip without BMD CFRI score was 4.1 (SD 1.7). 
This score is lower and with a smaller standard deviation than in the linked population and likely 
represents a healthier population. The HL for the random population is associated with a p-value 
<0.001 indicating poor predictive ability, however the brier score is 0.009 which indicates the 
opposite. Based on the HL doing poorly with large sample sizes, we will defer to the brier score 
(437, 438). The AUC for the random population was 0.742 (95% CI 0.694, 0.790). Using a two 
sample DeLong test for equality, the difference between the FRAX® estimate and CFRI estimate 
was not statistically significant (Random AUC 0.742, FRAX® AUC 0.587, p= 0.09677), likely 
due to the small number of patients and events in the linked sample. Additionally the two sample 
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De-Long test did not show a statistically significant difference between the CFRI in the random 
and linked populations (Random 0.742, Linked 0.655, p= 0.2769) (Figure 5.7).  
Although the HL test is vastly different for the linked and random population, the brier 
scores are very similar which would support the acceptance of the null hypothesis from 
hypothesis 2 of a similar calibration between estimates. Based on the statistical significance of 
the De-Long test, there is no difference in FRAX® ability to predict fractures in the linked 
population, as CFRI in the random population, this finding does not reject the null hypothesis of 
hypothesis 3.  
Figure 5.7 ROC Comparison for Hip without BMD in Linked and Random Populations 
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5.2.4 MOF without BMD 
The table of coefficients used to calculate CFRI Hip with BMD is presented as Table 5.5. 
If a researcher was interested in using the CFRI score they would need to multiply a dummy 
variable (0/1) for absence/presence of the covariate in the data and sum the score.   
Table 5.5 MOF without BMD CFRI Model Coefficients 
Attribute MOF without BMD CFRI 
Intercept 22.25687045 
Linear Age -0.914502808 
Age*Age 0.013336948 
Age*Age*Age -6.15E-05 
Age*Osteoporosis 0.001681857 
Hypophosphatasia 0.281333375 
Diabetes mellitus (Type 1 & 2) -0.075335158 
Central Adiposity -0.109487081 
Inflammatory Bowel Disease -0.108489108 
Malabsorption 0.126877713 
Crohn's Disease 0.142616646 
Hemophilia -0.119944794 
Lupus 0.183524351 
Rheumatoid arthritis 0.205507803 
Polymyalgia Rheumatica 0.107395123 
Epilepsy 0.105167629 
Stroke -0.064792173 
Liver Disease 0.077038137 
Amyloidosis 0.532356113 
Chronic metabolic acidosis 0.269888216 
Methotrexate 0.208599974 
Glucocorticoids 0.063924749 
Hormone Replacement Therapy 0.098549558 
Non-MOF 0.210669732 
African-American -0.852807121 
Hispanic -0.491561947 
Asian -0.438087007 
Other -0.497591055 
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5.2.4.1 Comparison in the Linked Population 
The hip without BMD CFRI score was calculated based on the presence of the covariates 
used in the model multiplied by their coefficient. The table used for the calculation was Table 
4.22, column 2, LN Backwards. There were 86/2860 (3.0%) MOF in the linked population 
within 1 year of their DXA. The mean MOF without BMD FRAX® score was 16.5 (SD 9.4) and 
the mean MOF without BMD CFRI score was 15.5 (SD 6.3). The calibration of FRAX® based 
on HL was p-value 0.41 and brier score of 0.028, while CFRI produced a HL of 0.48 and brier 
score of 0.027. Both of the calibration scores indicate a superior predictive ability of CFRI 
compared to FRAX® in the linked sample.  
A paired De-Long test for equality of ROC curves was calculated with a p≤0.05 
indicating a statistically significant difference between the two ROC curves. The AUC for the 
FRAX® ROC was 0.6509 (95% CI 0.5898, 0.7121), while for the CFRI curve the AUC was 
0.6674 (95% CI 0.6079, 0.7269) (Figure 5.8). The paired De-Long test had a p-value of 0.49 
indicating no statistically significant difference between the two ROC curves. The equality of the 
De-Long test supports hypothesis 3 for MOF without BMD, as there is no significant difference 
in the ability to predict fractures between FRAX® and CFRI in the linked population. 
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Figure 5.8 ROC Comparison for MOF without BMD in Linked Population 
 
 
5.2.4.2 Comparison between the Linked FRAX®, Linked CFRI, and Random CFRI 
population 
There were 45,414/1,448,815 (3.1%) women who had a MOF within 365-days of their 
index date. The mean MOF without BMD CFRI score was 15.4 (SD 6.1). The calibration of 
CFRI in the random population as measured by HL was <0.001 while the brier score was 0.03. 
Although the HL test indicates a poor fit and a worse fit than either risk score in the linked 
population, the brier score is similar to the linked sample, and indicates that based on one of two 
measures CFRI has a similar calibration. 
A two sample De-Long test for equality of ROC curves was calculated with a p≤0.05 
indicating a statistically significant difference between the two ROC curves. The AUC for CFRI 
in the random population was 0.666 (95% CI 0.663, 0.668). Comparing the random AUC to the 
FRAX® AUC indicated no significant differences (p=0.6341), while the comparison to the 
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linked CFRI also did not show a statistically significant difference (p=0.958).  Graphical 
representation of the three curves are presented as Figure 5.9.  
Although the HL test is vastly different for the linked and random population, the brier 
scores are very similar which would support the acceptance of the null hypothesis from 
hypothesis 2 of a similar calibration between estimates. The non-statically significant differences 
between the ROC curves using the De-Long test, supports the null of hypothesis 3 for MOF with 
BMD, of no difference between the three curves.  
Figure 5.9 ROC Comparison for MOF without BMD in Linked and Random Populations 
 
In women who had a MOF, the mean CFRI was 19.0% (SD 6.3) while those who did not 
have a fracture had a mean CFRI of 15.3% (SD 6.1). This represents a much larger difference in 
CFRI than for the with BMD score. As the fractures are the same as the with BMD population, 
there was a small variation in age (4.5 years) between those with and without fractures. Because 
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the patients who had fractures were the same population and it is only the covariates in the 
algorithm which changed, it appears that for MOF the log-normal backwards stepwise model 
was better able to predict a comparable score than the elastic net model. With all of the c-
statistics being very similar for this score, it would be reasonable to extrapolate that they are 
predicting similar outcomes with their scores. However a higher CFRI score would be necessary 
to have the same dichotomous split as the NOF guidelines recommended FRAX® score of 20%. 
5.3 Sensitivity Analysis 
The planned sensitivity analyses for this aim involve identifying patients based on the 
receipt of DXA, rather than on an office visit to more closely resemble the linked population. 
Women were identified as receiving a DXA by CPT codes 76075 or 77080, the date of the DXA 
was then used as the index date. The same requirements of 365-days continuous enrollment prior 
to index in Medicare Parts A, B, and D were used. The patients were also required to be naïve to 
AOMs and be without a diagnosis of MOF during the 365-days prior to index.  
There were 502,965 women who met the entrance criterion. The mean age was 74.2 (SD 
6.6), with a similar distribution of patients in each year to the office visit cohort. The sensitivity 
population had a much lower percentage of patients with osteoporosis 5.8% compared to 11.4% 
in the full random population. All other characteristics are similar to the full population.  
5.3.1 CFRI with BMD 
The hip and MOF results will be present simultaneously. Using DXA as the index date 
there were 2572/502,965 (0.5%) women who had hip fractures within 1 year and 17,533/502,965 
(3.5%) women who had a MOF within 1 year of index. The ROC curves for the two outcomes 
are presented as Figure 5.10. The HL for hip with BMD was <0.001, however its chi-square was 
closer to the null than in the main analysis indicating a better fit. The brier score was 0.005 
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which is the same score as the linked population indicating a good predictive ability. The HL for 
MOF with BMD also was <0.001 indicating a poor fit, but the test statistic in the sensitivity 
analysis indicated a better fit than in the full analysis.  
For the CFRI Hip with BMD analysis, the sensitivity cohort underperformed compared to 
the full population as evidenced by a c-statistic of 0.722 (95% CI 0.712, 0.732) compared to the 
full cohort c-statistic 0.732 (95% CI 0.728, 0.736). This is with both cohorts having 0.5% of the 
population with a hip fracture. There is more of a difference between those with and without a 
hip fracture 4.4% compared to 7.2% than in the full population where hip fractures had a mean 
CFRI of 5.4%. There was no significant difference between the c-statistic for the full population 
and the sensitivity population, suggesting that CFRI is as effective in the population with DXA 
as in those who only had an office visit. 
For the CFRI MOF with BMD analysis, the sensitivity cohort had a lower c-statistic than 
the full population, although the difference was not statistically significantly different. The 
sensitivity cohort had a c-statistic of 0.659 (95% CI 0.654, 0.663) compared to the full 
population with a c-statistic of 0.667 (95% CI 0.664, 0.669). There was a smaller difference 
between the CFRI score for those who had an MOF and those who did not, 14.8% compared to 
13.3% in the sensitivity cohort and 15.8% compared to 13.7% in the full cohort. This indicates 
that there isn’t large difference between those patients who have fractures and who do not. With 
no significant difference between the sensitivity analysis and the full cohort, CFRI appears valid 
for use without mandating a DXA. 
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Figure 5.10 Sensitivity Analysis with BMD 
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5.3.2 CFRI without BMD 
There was no difference in the percentage or number of fractures in sensitivity cohort 
regardless of if the with or without BMD CFRI score was used. CFRI hip without BMD 
population had 0.5% fractures while 3.5% of the sensitivity analysis population had an MOF 
within 1 year of their DXA. ROC for the without BMD population are presented as Figure 5.11. 
For both the hip and MOF CFRI scores, the full population outperformed the DXA population. 
The calibration of hip without BMD HL had a p-value <0.001 but an X2 closer to the null than 
the full population, indicative of a better predictive ability. The brier score was 0.005 which was 
less than the full population also indicating a superior predictive ability. The calibration of MOF 
without BMD is as follows, HL p-value <0.001 and brier score 0.03, which are both marginally 
better than the main population. 
Specifically the CFRI Hip without BMD score in the DXA population was 0.722 (95% 
CI 0.712, 0.732) while in the full population the c-statistic was 0.732 (95% CI 0.728, 0.736), the 
difference between the two curves was not statistically significantly different. The actual CFRI 
scores had a similar difference in the without population as in the with BMD population, 0.5% of 
women had a fracture with a mean CFRI of 7.2% and those without a fracture had a mean score 
of 4.4%. The women who had fractures were older 79.9 years to 74.2 years, and had osteoporosis 
more often 10.4% compared to 7.2% which were similar to the overall population. Based on the 
similar ROC and characteristics it appears that CFRI may be better used in the full population 
than in a subset of patients with DXAs. 
In the CFRI MOF without BMD analysis no significant differences were found in ROC 
when the full and sensitivity analysis were compared. As with all of the other analyses there 
were no striking differences between the sensitivity analysis results and those of the main 
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analysis. The difference in CFRI scores 17.8% compared to 14.9% for those with and without a 
MOF is similar to the main analysis as is the difference in age, 77.4 compared to 74.1 years of 
age. With the sensitivity results being so similar to the main analysis, the CFRI for MOF without 
BMD appears to be calibrated for both any office visit or tying it specifically to a DXA. 
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Figure 5.11 Sensitivity Analysis without BMD 
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5.4 Summary 
Overall CFRI performed as well as FRAX® in both the linked and random population for 
all four outcomes. The goal of Aim 2 was to externally validate CFRI based on one year fracture 
rates between the linked and random populations. Calibration was intended to be assessed by 
both the Hosmer-Lemeshow test and the Brier score, however the HL was found to not be valid 
in this population. Discrimination was evaluated using the AUC (c-statistic). Lastly AUCs were 
compared using a De-Long test. Broadly we found that CFRI in the random population was as 
well calibrated and had a similar ability to discriminate between those who would and would not 
have a fracture. 
The AUCs for the random population ranged from 74.2 in hip with BMD, to 66.7 in 
MOF with BMD, to 73.2 in hip without BMD, and finally to 0.667 in MOF without BMD. It was 
odd that MOF with and without BMD essentially had identical discriminatory abilities, even 
though they had different mean scores. Additionally discrimination for the hip scores were only 
different by 1.0. This supports the idea from Kanis that in a general population the with and 
without BMD scores should be similar, as although the variables used to calculate the scores 
were different they were as able to determine who would go on to have a fracture (170).  
The two hypotheses in this aim were concerned with the calibration (hypothesis 2) and 
discrimination (hypothesis 3). For each of the four outcomes confirmed both hypothesis 2 and 
hypothesis 3 that there were no significant differences in calibration or discrimination between 
the FRAX® linked sample and CFRI in the random population. Our sensitivity analysis 
demonstrated that not only when we used office visits, but when the index date was DXAs the  
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hypotheses were still confirmed. This not only demonstrates that there is little to no difference in 
FRAX® and CFRI in their ability to predict one year fractures, but that even though the linked 
population was created based on DXAs, in the general population CFRI behaves similarly.  
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 AIM 3 RESULTS 
Aim 3: Evaluate the utility of CFRI and restriction in a comparative effectiveness 
research study of alendronate users to non-users.  
Hypothesis: Comparative effectiveness estimates will most closely approximate Fracture 
Intervention Trial results after restricting by trial inclusion criteria and incorporating CFRI, 
then estimates generated without CFRI. 
6.1 Overview 
6.1.1 Study Population  
The study population for Aim 3 is a collection of three different study populations based 
on how a non-user is defined (described in detail in Chapter 3). Approach 1 defines new users as 
a woman with new use of any drug within 30-days of an office visit, after 365-days continuous 
enrollment in Medicare Parts A, B, and D. Approach 2 uses the same idea as approach 1, but 
restricts new non-users to those starting a drug within the diabetes or hypertension classes or a 
statin. Approach 3 does not require any drug use, and index dates are chosen based on any office 
visit after the 365-days continuous enrollment requirement has been met. These three approaches 
allow our study to investigate how using CFRI in practical analysis can reduce confounding. For 
all three approaches we will be comparing alendronate users to non-users using CFRI, the 
composite fracture risk score created in Aim 1, and tested in Aim 2.  
Additionally we will restrict the study populations to resemble to inclusion/exclusion 
criterion from the FIT trial. In brief the FIT trial was the only large scale alendronate versus 
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placebo randomized controlled trial (RCT) for post-menopausal women. The characteristics 
which can be measured in claims from the FIT trial include age, CFRI scores less than 9.1% 
MOF and/or 1.0% hip fracture, hip replacement, GERD, major illnesses, and specific medication 
classes. The algorithms for restriction are presented as Table 3.6. 
The goal of Aim 3 is to determine if CFRI and restriction can reduce confounding in an 
observational comparative effectiveness study of alendronate versus non-users and produce 
effect estimates similar to those achieved in the FIT trial. While the unrestricted population is 
likely to suffer from confounding by indication, including CFRI as a fracture risk score should 
reduce some of this confounding. However CFRI alone may not completely reduce this bias 
when selecting non-users. However once the population is restricted to look the same as the RCT 
population we will better be able to determine if this technique and population are comparable 
and in fact reduce confounding. FIT had a clinical fracture HR of 0.72 at three years. 
6.1.2 Use of CFRI 
CFRI for this aim will be used as a covariate in regression as well as part of the 
restriction to the FIT trial. We will use both the with and without BMD MOF CFRI in the 
analysis, and will specify which score has been used. The primary outcome of the aim is 
vertebral fracture as this was the outcome which showed a protective effect in the FIT trial, and a 
secondary outcome of MOF. The two CFRI score are hip and MOF, but we will only use the 
MOF in this aim as vertebral fracture and MOF are to be predicted based on the score.  
6.1.3 Outcomes 
The primary outcome of Aim 3 is an incident vertebral fracture with a secondary outcome 
of major osteoporotic fracture (MOF). The Aim 3 analysis will use these sites as well as the 
pelvis tibia/fibula, clavicle, thoracic, and lumbar spine. The algorithm and applicable ICD-9, and 
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CPT codes for this definition are presented as Table 3.4. Follow-up will begin 30-days after 
index to allow all patients the same amount of time to fill a medication. Outcomes will be 
measured at one and three years’ post-index, prior to the outcome patients can be 
administratively censored for losing Medicare A, B, D coverage, death, or initiation of an AOM. 
6.2 Approach 1 
6.2.1 Study Population 
Two groups are compared in this analysis: alendronate users and non-users. For approach 
1, non-users were required to have new use of any non-AOM drug (without prior use of the same 
drug in the preceding 365-days). Specific inclusion exclusion criterion for the population are 
presented as Figure 6.1. Overall 1,276,813 women filled any drug including alendronate with an 
office visit within 30-days prior to the fill. Of these women, 897,611 were continuous enrolled 
for at least 365-days prior to the office visit in Medicare Parts A, B, and D. Additional exclusions 
resulted in a final sample size of 718,117 women, of whom 29,772 were alendronate users, and 
688,345 were classified as non-users. 
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Figure 6.1 Approach 1 (All New Users) Study Population Flowchart 
 
From this cohort, when restricting further based on the FIT criteria, 149,570 were 
excluded for an inpatient stay in the 180 days prior to index. An additional 123,265 were 
excluded for medical diagnoses (77,437 for GERD, 51,969 for cancer diagnosis, and 5,233 for 
metabolic bone disease). Next, we excluded 114,922 for being outside of the trial age range, 
38,627 for glucocorticoid use, 34,800 for HRT use, and 2,610 for history of a total hip 
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arthroplasty. This left 254,869 patients as eligible prior to exclusions based on CFRI score. The 
without BMD CFRI cohort resulted in 20,734 patients; 1,203 alendronate users and 19,504 non-
users, while the with-BMD cohort had 3,951 patients with 268 alendronate users and 3,683 non-
users. 
The characteristics of the unrestricted study population are presented as Table 6.1. A 
second analysis will be performed with a population after FIT exclusions. In the unrestricted 
population there was a significant difference between users and non-users in regard to 
osteoporosis diagnosis with alendronate users having a greater proportion of the population with 
osteoporosis (37.2% compared to 10.7%) and kyphosis (55% compared to 24%). There were 
many more diabetics in the non-users than in the alendronate users (53.9% compared to 23.9%). 
The non-user population had a larger percentage of anti-convulsant, and SSRI fills in the 365-
days prior to index. Otherwise the characteristics appear to be reasonably similar although some 
differences did reach statistical significance which can be attributed to the large sample size. 
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Table 6.1 Approach 1 (All New Users), Characteristics of the Study Population before 
Restricting to FIT Criteria  
Attribute Non-Users 
(n=688,345) 
Users 
(n=29,772) 
Total 
(n=718,117) 
 Mean Age 75.8 (8.1) 74.3 (7.5) 75.7 (8.1) 
In 365-days prior to index       
Osteoporosis, N (%)  4873 (10.7) 7621 (37.2) 12494 (19.0) 
Lifestyle Factors, N (%)       
  Alcohol Abuse 143 (0.3) 78 (0.4) 221 (0.3) 
  Falling 2246 (4.9) 802 (3.9) 3048 (4.6) 
  Vitamin D insufficiency 4010 (8.8) 964 (4.7) 4974 (7.5) 
  Excess Vitamin A <11 <11 <11 
Genetic factors, N (%)  
   
  Cystic fibrosis 15 (<0.1) <11 22 (<0.1) 
  Homocystinuria 73 (0.2) 25 (0.1) 98 (0.1) 
  Osteogenesis imperfecta <11 <11 <11 
  Hypophosphatasia 311 (0.7) 52 (0.3) 363 (0.6) 
  Gaucher's disease 77 (0.2) 39 (0.2) 116 (0.2) 
  Porphyria <11 <11 <11 
  Glycogen storage diseases <11 <11 <11 
  Marfan syndrome <11 <11 <11 
  Riley-Day syndrome <11 <11 <11 
  Hemochromatosis <11 <11 <11 
Hypogonadal states, N (%)       
  Androgen insensitivity <11 <11 <11 
  Anorexia nervosa and bulimia 582 (1.3) 175 (0.9) 757 (1.1) 
  Hyperprolactinemia 12 (<0.1) <11 15 (<0.1) 
  Premature ovarian failure 30 (0.1) 34 (0.2) 64 (0.1) 
  Athletic amenorrhea 17 (<0.1) 19 (0.1) 36 (0.1) 
  Turner and Klinefelters's syndromes <11 <11 <11 
  Panhypopituitarism <11 <11 <11 
Endocrine disorders, N (%)       
  Adrendal insufficiency <11 11 (0.1) 18 (<0.1) 
  Diabetes mellitus (Type 1 & 2) 24476 (53.9) 6739 (32.9) 31215 (47.4) 
  Cushing's syndrome 29 (0.1) 13 (0.1) 42 (0.1) 
  Hyperparathyroidism 528 (1.2) 290 (1.4) 818 (1.2) 
  Central Adiposity 4606 (10.1) 1015 (5.0) 5621 (8.5) 
  Thyrotoxicosis 1001 (2.2) 538 (2.6) 1539 (2.3) 
Gastrointestinal disorders, N (%)       
  Celiac disease 55 (0.1) 39 (0.2) 94 (0.1) 
  Gastric bypass <11 <11 <11 
  Inflammatory Bowel Disease 302 (0.7) 127 (0.6) 429 (0.7) 
  Malabsorption 182 (0.4) 81 (0.4) 263 (0.4) 
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  Pancreatic disease 593 (1.3) 167 (0.8) 760 (1.2) 
  Primary biliary cirrhosis 21 (<0.1) <11 30 (<0.1) 
  Crohn's Disease 1786 (3.9) 685 (3.3) 2471 (3.7) 
Hematologic disorders, N (%)       
  Hemophilia 979 (2.2) 337 (1.6) 1316 (2.0) 
  Thalassemia 28 (0.1) 12 (0.1) 40 (0.1) 
  Sickle cell anemia <11 <11 <11 
  Systemic mastocytosis <11 <11 <11 
Rheumatologic and autoimmune diseases, N (%)       
  Ankylosing spondylitis 459 (1.0) 211 (1.0) 670 (1.0) 
  Lupus 203 (0.4) 118 (0.6) 321 (0.5) 
  Rheumatoid arthritis 1670 (3.7) 1003 (4.9) 2673 (4.1) 
  Gout 1792 (3.9) 480 (2.3) 2272 (3.4) 
  Polymyalgia Rheumatica 341 (0.8) 297 (1.4) 638 (1.0) 
Central nervous system disorders, N (%)       
  Epilepsy 639 (1.4) 212 (1.0) 851 (1.3) 
  Parkinson's disease 550 (1.2) 206 (1.0) 756 (1.1) 
  Stroke 6873 (15.1) 2166 (10.6) 9039 (13.7) 
  Multiple sclerosis 119 (0.3) 61 (0.3) 180 (0.3) 
  Spinal cord injury 44 (0.1) 20 (0.1) 64 (0.1) 
  Alzheimer's disease 5004 (11.0) 1424 (6.9) 6428 (9.8) 
Miscellaneous conditions and diseases, N (%)       
  AIDS/HIV 38 (0.1) 20 (0.1) 58 (0.1) 
  Congestive Heart Failure 7732 (17.0) 1902 (9.3) 9634 (14.6) 
  Muscular dystrophy 15 (<0.1) <11 18 (<0.1) 
  Liver Disease 2121 (4.7) 757 (3.7) 2878 (4.4) 
  Depression 6932 (15.3) 2620 (12.8) 9552 (14.5) 
  Amyloidosis 16 (<0.1) <11 20 (<0.1) 
  End stage renal disease 902 (2.0) 96 (0.5) 998 (1.5) 
  Sarcoidosis 86 (0.2) 44 (0.2) 130 (0.2) 
  Chronic metabolic acidosis 700 (1.5) 107 (0.5) 807 (1.2) 
  Asthma/Chronic obstructive lung disease 10039 (22.1) 4120 (20.1) 14159 (21.5) 
  Idiopathic scoliosis 760 (1.7) 492 (2.4) 1252 (1.9) 
  Cataracts 15769 (34.7) 7537 (36.8) 23306 (35.4) 
  Glaucoma 6390 (14.1) 2949 (14.4) 9339 (14.2) 
  Kyphosis 10677 (23.5) 11172 (54.5) 21849 (33.2) 
  Obesity 4606 (10.1) 1015 (5.0) 5621 (8.5) 
  Disorders of the eye* 23517 (51.8) 10705 (52.2) 34222 (51.9) 
  Osteoarthritis 13725 (30.2) 6238 (30.4) 19963 (30.3) 
  Renauld's syndrome 4583 (10.1) 801 (3.9) 5384 (8.2) 
Medications, N (%)       
  Cyclosporine A and tacrolimus 51 (0.1) 21 (0.1) 72 (0.1) 
  Proton pump inhibitors 11868 (26.1) 5146 (25.1) 17014 (25.8) 
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  Anticoagulants 4300 (9.5) 1619 (7.9) 5919 (9.0) 
  Selective serotonin reuptake inhibitors 7664 (16.9) 3407 (16.6) 11071 (16.8) 
  Anticonvulsants 5660 (12.5) 2225 (10.9) 7885 (12.0) 
  Aromatase inhibitors 563 (1.2) 448 (2.2) 1011 (1.5) 
  GnRH  antagonists and agonists <11 <11 <11 
  Thiazolidinediones 3420 (7.5) 1105 (5.4) 4525 (6.9) 
  Barbiturates <11 <11 <11 
  Lithium 58 (0.1) 35 (0.2) 93 (0.1) 
  Methotrexate 379 (0.8) 327 (1.6) 706 (1.1) 
  Glucocorticoids 6163 (13.6) 2875 (14.0) 9038 (13.7) 
  Hormone Replacement Therapy 2745 (6.0) 1181 (5.8) 3926 (6.0) 
Fractures       
  Other Sites 1726 (3.8) 988 (4.8) 2714 (4.1) 
Race       
  White 34911 (76.9) 15821 (77.2) 50732 (77.0) 
  African-American 6426 (14.2) 1855 (9.1) 8281 (12.6) 
  Hispanic 1793 (3.9) 1170 (5.7) 2963 (4.5) 
  Asian 1177 (2.6) 1057 (5.2) 2234 (3.4) 
  Other 767 (1.7) 459 (2.2) 1226 (1.9) 
Non-users are defined as any new-use of any drug in any class 
All Cells with a total of 0 were suppressed; *: Includes Cataracts and Glaucoma <11: CMS does not allow 
cells with less than 11 patients to be presented 
6.2.2 Unrestricted Population Results 
The primary outcome of this aim is vertebral fracture, since the MOF includes these 
fractures, the CFRI score which is most applicable is the MOF rather than hip score. However 
there are two different ways to account for the score, both with and without BMD. The results 
for the unrestricted population using both with and without BMD MOF CFRI at 365-days post-
index are presented in Table 6.2. 
 
Table 6.2 Unrestricted Population for Approach 1 (All New Users), Hazard Ratio for MOF at 
365-days comparing alendronate use to non-use 
Type of Analysis MOF Hazard Ratio Vertebral Hazard Ratio 
Null 1.26 (1.18,1.34) 1.33 (1.23,1.43) 
Only MOF CFRI without BMD 1.23 (1.15,1.30) 1.30 (1.21,1.40) 
Only MOF CFRI with BMD 1.08 (1.02,1.15) 1.14 (1.06,1.23) 
Fully Adjusted 1.25 (1.17,1.32) 1.26 (1.17,1.36) 
SIPTW 1.57 (1.49,1.66) 0.63 (0.17,2.41) 
SMRW 1.29 (1.17,1.41) 0.58 (0.10,3.25) 
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For reference in the FIT trial any clinical fracture hazard ratio at three years was (HR 
0.72, 95% CI [0.58, 0.90]). At one year 1,068 (3.6%) of alendronate users and 18,678 (2.7%) of 
non-users had a major osteoporotic fracture, while 732 (2.5%) of alendronate users and 12,091 
(1.8%) of non-users had vertebral fractures. The naïve model produced a hazard ratio of 1.26 
which was similar to the fully-adjusted model (HR 1.25). The propensity score inverse 
probability of treatment weights (SIPTW) model produced a HR of 1.57. The most conservative 
estimate was when the model only included CFRI MOF with BMD (HR 1.08) which was non-
significant and 0.13 less than the without BMD estimate (1.23). The vertebral estimates followed 
a similar pattern with the estimate only including the with BMD CFRI score being closest to the 
null. However the fully adjusted model was closer to the null than the without BMD naïve 
estimate which may suggest that for vertebral fracture outcomes the with-BMD score is most 
appropriate. 
In regards to the propensity score based approaches neither produced estimates which 
were less than the simple model with CFRI. The overlap of the propensity scores are presented 
as Figure 6.2. The propensity score for both the treated and untreated follow similar distributions 
with approximately four spikes, however there is very little similar overlap in the distribution 
other than approximately between 0.05 and 0.1 propensity for use of alendronate. The covariates 
appeared to be balanced between the two groups (results not shown), and the addition of the 
CFRI score did not improve the hazard ratios or the distribution of the propensity score. 
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Figure 6.2 Kernel Density Plot for Propensity Scores in Approach 1 (All New Users) 
 
 
The results for the unrestricted population using both with and without BMD MOF CFRI 
with all available time are presented in Table 6.3. 
Table 6.3 Unrestricted Population for Approach 1 (All New Users), Hazard Ratio for MOF 
using all available time 
Type of Analysis MOF Hazard Ratio Vertebral Hazard Ratio 
Null 1.44 (1.39,1.49) 1.36 (1.30,1.42) 
Only MOF CFRI without BMD 1.38 (1.33,1.43) 1.31 (1.25,1.36) 
Only MOF CFRI with BMD 1.23 (1.19,1.27) 1.16 (1.11,1.21) 
Fully Adjusted 1.38 (1.33,1.43) 1.26 (1.20,1.31) 
SIPTW 1.89 (1.40,2.54) 0.63 (0.17,2.41) 
SMRW 1.66 (1.02,2.69) 0.58 (0.10,3.25) 
 
Using all available time, alendronate users had a mean of 1286.6 (SD 646.5), median 
1402 (IQR 737, 1863) days and non-users were followed for a mean of 909.2 (SD 597.0), 
median 810 (IQR 442, 1364) days. During this time period 3,632 (12.2%) MOF and 2,308 
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(7.8%) vertebral fractures in alendronate users and 43,347 (6.3%) MOF and 28,358 (4.1%) 
vertebral fractures for non-users had a major osteoporotic fracture. The naïve model which only 
includes the grouping indicator produced a hazard ratio of 1.44 which is more than the when the 
model used all of the content variables (HR 1.38), but smaller than the propensity score inverse 
probability of treatment weights (SIPTW) model which produced a HR of 1.89. The most 
conservative estimate was when the model only included CFRI MOF with BMD (HR 1.23) 
which was significant showing an increased fracture risk for alendronate users, but was 0.15 less 
than the without BMD estimate (1.38). Additionally the propensity score methods (SIPTW and 
SMRW) again produced increased hazard ratios compared to the regression based approaches. 
For the vertebral fracture outcome, the with BMD estimate and the fully adjusted estimate were 
closest to the null, however neither crossed 1 as such demonstrated a statistically significant 
increase in fracture risk for alendronate users. 
Our estimates do not reach those of the FIT trial at 3 years (HR 0.72, 95% CI [0.58, 
0.90]) even with the alendronate and non-user group were followed for around 3 years. Our 
results indicate that CFRI in the general population is not able to reduce confounding by 
indication of a sufficient amount. 
6.2.3 FIT restricted population results 
The population characteristics generally were very different within the FIT restricted 
population compared to the unrestricted population. The largest difference was in the with BMD 
population where there were only Black patients included. The reason for only including black 
patients was the combination of the with-BMD intercept and age coefficient. Unless a patient 
was <57 they had to have Black race to have a MOF <9.1% There are no patients in the with 
BMD population who had a diagnosis of osteoporosis, this is due to the inclusion of the age * 
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osteoporosis variable in CFRI hip with BMD which similar to the age variable increases the hip 
CFRI score to >1, which excludes the patient from the analysis. Both of these factors make the 
with BMD population very different from the unrestricted population and question the 
generalizability of their results. In the end there were 20,734 patients in the without BMD CFRI 
population, 1,230 (5.9%) alendronate users and 19,504 (94.1%) who were non-users, while there 
were 3,951 patients in the with-BMD CFRI restricted population and 268 (6.8%) of these were 
alendronate users and the other 3683 (93.2%) were classified as non-users. 
The distribution of characteristics seems to be reasonably well balanced between users 
and non-users, other than osteoporosis in the without BMD CFRI group. There were significant 
differences in some population characteristics, however many of these were due to sample size 
rather than a clinical difference. Central adiposity, COPD, and the use of anticonvulsants differed 
by >1-2% between the users and non-users. Particularly in the with BMD CFRI population and 
for the most part in the without BMD population these population characteristics are not 
representative of the general population. This makes it difficult to claim any generalizability to 
the general population from these results. However these characteristics may be similar to those 
of the highly restricted RCT population. 
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Table 6.4 Population Characteristics of Restricted Population in Approach 1 (All New 
Users) 
Attribute Non-User 
BMD 
(n=3683) 
User 
BMD 
(n=268) 
Total 
BMD 
(n=3951) 
Non-User 
No BMD 
(n=19504) 
User No 
BMD 
(n=1230) 
Total No 
BMD 
(n=20734) 
Mean Age 64.4 (0.5) 64.2 (0.4) 64.4 (0.5) 66.6 (2.0) 65.7 (1.8) 66.6 (2.0) 
In 365-days prior to index 
    
Osteoporosis, N (%)  <11 <11 <11 267 (1.4) 105 (8.5) 372 (1.8) 
Lifestyle Factors, N (%) 
   
  Alcohol Abuse <11 <11 <11 37 (0.2) <11 39 (0.2) 
  Falling 23 (0.6) <11 24 (0.6) 224 (1.1) <11 233 (1.1) 
  Vitamin D insufficiency 64 (1.7) <11 65 (1.6) 579 (3.0) 29 (2.4) 608 (2.9) 
  Excess Vitamin A <11 <11 <11 <11 <11 <11 
Genetic factors, N (%) 
   
  Cystic fibrosis <11 <11 <11 <11 <11 <11 
  Homocystinuria <11 <11 <11 <11 <11 <11 
  Hypophosphatasia <11 <11 <11 15 (0.1) <11 16 (0.1) 
  Gaucher's disease <11 <11 <11 19 (0.1) <11 20 (0.1) 
  Glycogen storage diseases <11 <11 <11 <11 <11 <11 
  Riley-Day syndrome <11 <11 <11 <11 <11 <11 
  Hemochromatosis <11 <11 <11 <11 <11 <11 
Hypogonadal states, N (%) 
   
  Anorexia nervosa and 
bulimia 
<11 <11 <11 46 (0.2) <11 48 (0.2) 
  Hyperprolactinemia <11 <11 <11 <11 <11 <11 
  Premature ovarian failure <11 <11 <11 <11 <11 <11 
  Athletic amenorrhea <11 <11 <11 <11 <11 <11 
  Panhypopituitarism <11 <11 <11 <11 <11 <11 
Endocrine disorders, N (%) 
   
  Adrendal insufficiency <11 <11 <11 <11 <11 <11 
  Diabetes mellitus (Type 1 
& 2) 
856 (23.2) 27 (10.1) 883 (22.3) 7949 (40.8) 391 (31.8) 8340 (40.2) 
  Cushing's syndrome <11 <11 <11 <11 <11 <11 
  Central Adiposity 178 (4.8) 3 (1.1) 181 (4.6) 2414 (12.4) 90 (7.3) 2504 (12.1) 
  Thyrotoxicosis 22 (0.6) <11 23 (0.6) 227 (1.2) 20 (1.6) 247 (1.2) 
Gastrointestinal disorders, N (%) 
   
  Celiac disease <11 <11 <11 <11 <11 <11 
  Inflammatory Bowel 
Disease 
<11 <11 <11 24 (0.1) <11 26 (0.1) 
  Malabsorption <11 <11 <11 18 (0.1) <11 20 (0.1) 
  Pancreatic disease <11 <11 11 (0.3) 57 (0.3) <11 59 (0.3) 
  Primary biliary cirrhosis <11 <11 <11 <11 <11 <11 
  Crohn's Disease 19 (0.5) 1 (0.4) 20 (0.5) 158 (0.8) <11 163 (0.8) 
Hematologic disorders, N (%) 
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  Hemophilia 17 (0.5) <11 17 (0.4) 181 (0.9) <11 189 (0.9) 
  Thalassemia <11 <11 <11 14 (0.1) <11 14 (0.1) 
  Sickle cell anemia <11 <11 <11 <11 <11 <11 
  Systemic mastocytosis <11 <11 <11 <11 <11 <11 
Rheumatologic and autoimmune diseases, N (%) 
   
  Ankylosing spondylitis <11 <11 12 (0.3) 62 (0.3) <11 67 (0.3) 
  Lupus 20 (0.5) <11 21 (0.5) 47 (0.2) <11 51 (0.2) 
  Rheumatoid arthritis 40 (1.1) <11 44 (1.1) 150 (0.8) <11 158 (0.8) 
  Gout 48 (1.3) <11 48 (1.2) 428 (2.2) 11 (0.9) 439 (2.1) 
  Polymyalgia Rheumatica <11 <11 <11 <11 <11 <11 
Central nervous system disorders, N (%) 
   
  Epilepsy 38 (1.0) <11 41 (1.0) 109 (0.6) <11 117 (0.6) 
  Parkinson's disease <11 <11 <11 56 (0.3) <11 60 (0.3) 
  Stroke 76 (2.1) <11 76 (1.9) 852 (4.4) 38 (3.1) 890 (4.3) 
  Multiple sclerosis 6 (0.2) <11 7 (0.2) 36 (0.2) 3 (0.2) 39 (0.2) 
  Spinal cord injury <11 <11 <11 <11 <11 <11 
  Alzheimer's disease 42 (1.1) <11 43 (1.1) 405 (2.1) <11 415 (2.0) 
Miscellaneous conditions and diseases, N (%) 
   
  AIDS/HIV 22 (0.6) <11 24 (0.6) 67 (0.3) <11 71 (0.3) 
  Congestive Heart Failure 132 (3.6) <11 140 (3.5) 1106 (5.7) 38 (3.1) 1144 (5.5) 
  Liver Disease 47 (1.3) <11 49 (1.2) 359 (1.8) 25 (2.0) 384 (1.9) 
  Depression 180 (4.9) <11 189 (4.8) 1290 (6.6) 91 (7.4) 1381 (6.7) 
  End stage renal disease 145 (3.9) <11 150 (3.8) 394 (2.0) 13 (1.1) 407 (2.0) 
  Sarcoidosis <11 <11 <11 54 (0.3) <11 58 (0.3) 
  Chronic metabolic acidosis <11 <11 <11 22 (0.1) <11 22 (0.1) 
  Asthma/Chronic obstructive 
lung disease 
221 (6.0) <11 231 (5.8) 1932 (9.9) 87 (7.1) 2019 (9.7) 
  Idiopathic scoliosis 11 (0.3) <11 11 (0.3) 76 (0.4) <11 78 (0.4) 
  Cataracts 153 (4.2) <11 161 (4.1) 2418 (12.4) 132 (10.7) 2550 (12.3) 
  Glaucoma 111 (3.0) <11 118 (3.0) 1440 (7.4) 70 (5.7) 1510 (7.3) 
  Kyphosis 90 (2.4) <11 100 (2.5) 1177 (6.0) 212 (17.2) 1389 (6.7) 
  Obesity 178 (4.8) <11 181 (4.6) 2414 (12.4) 90 (7.3) 2504 (12.1) 
  Disorders of the eye* 309 (8.4) 12 (4.5) 321 (8.1) 4012 (20.6) 220 (17.9) 4232 (20.4) 
  Osteoarthritis 315 (8.6) 11 (4.1) 326 (8.3) 2908 (14.9) 161 (13.1) 3069 (14.8) 
  Renauld's syndrome 147 (4.0) <11 150 (3.8) 927 (4.8) 30 (2.4) 957 (4.6) 
Medications, N (%) 
   
  Cyclosporine A and 
tacrolimus 
<11 <11 <11 15 (0.1) <11 16 (0.1) 
  Proton pump inhibitors 670 (18.2) 40 (14.9) 710 (18.0) 3956 (20.3) 217 (17.6) 4173 (20.1) 
  Anticoagulants 154 (4.2) <11 164 (4.2) 850 (4.4) 34 (2.8) 884 (4.3) 
  Selective serotonin reuptake 
inhibitors 
333 (9.0) 20 (7.5) 353 (8.9) 2058 (10.6) 127 (10.3) 2185 (10.5) 
  Anticonvulsants 467 (12.7) 30 (11.2) 497 (12.6) 2377 (12.2) 133 (10.8) 2510 (12.1) 
  Aromatase inhibitors <11 <11 13 (0.3) 50 (0.3) <11 55 (0.3) 
  Thiazolidinediones 122 (3.3) <11 126 (3.2) 1264 (6.5) 59 (4.8) 1323 (6.4) 
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  Lithium <11 <11 <11 31 (0.2) <11 32 (0.2) 
  Methotrexate 23 (0.6) <11 29 (0.7) 52 (0.3) 11 (0.9) 63 (0.3) 
  Glucocorticoids <11 <11 <11 <11 <11 <11 
  Calcitonin <11 <11 <11 <11 <11 <11 
  Hormone Replacement 
Therapy 
<11 <11 <11 <11 <11 <11 
  Raloxifene <11 <11 <11 <11 <11 <11 
  Calcium <11 <11 <11 <11 <11 <11 
  Vitamin D <11 <11 <11 <11 <11 <11 
Fractures 
   
  Vertebral <11 <11 <11 <11 <11 <11 
  Non-Vertebral <11 <11 <11 <11 <11 <11 
  Other Sites 17 (0.5) <11 17 (0.4) 139 (0.7) <11 141 (0.7) 
Race 
   
  White <11 <11 <11 1579 (8.1) 115 (9.3) 1694 (8.2) 
  African-American 3683 (100) 268 (100) 3951 
(100) 
13661 (70.0 603 (49.0) 14264 
(68.8 
  Hispanic <11 <11 <11 2337 (12.0) 276 (22.4) 2613 (12.6) 
  Asian <11 <11 <11 854 (4.4) 148 (12.0) 1002 (4.8) 
  Other <11 <11 <11 1040 (5.3) 85 (6.9) 1125 (5.4) 
All Cells with a total of 0 were suppressed; *: Includes Cataracts and Glaucoma <11: CMS does not allow cells 
with less than 11 patients to be presented 
 
After restriction to only the FIT population based on with BMD CFRI the study 
population was significantly smaller with only 3951 patients in. At 365-days of follow-up there 
were <11 patients who had a MOF fracture in the alendronate group and 29/3683 (0.8%) patients 
who had a MOF in the non-users, as well as <11 vertebral fracture in the alendronate and 22 
(0.6%) vertebral fractures in the non-users group. The results of the with and without BMD 
CFRI restricted analyses are presented as Table 6.5. While FIT restricted hazard ratios were 
lower than estimates from the full population, the model including only CFRI continued to 
produce the lowest HR. 
When the CFRI population is restricted based on the without BMD CFRI population, the 
study population (n=20,734) is larger than the with BMD population. In this population at 365-
days there were 13 (1.1%) MOF fractures and 11 (0.9%) vertebral fractures in the alendronate 
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group and 148 (0.8%) MOF fractures as well as 99 (0.5%) vertebral fractures in the non-user 
group (0 spine fractures in either group). Incidentally the naïve estimates in this population are 
only ~0.1 greater than those of the general population, and a similar amount greater than the 
without BMD population, which may be due to the small sample size and event count observed.  
The results suggest that although the population can be restricted to mimic the FIT trial, 
the claims-based sample ultimately does not reflect the trial population. This is particularly 
evident by the protective estimates for the with BMD cohort, as they did not have enough events 
for a realistic result. Based simply on the hazard ratios produced by these analyses, none showed 
the expected direction of statistically significantly less than 1. 
Table 6.5 FIT-restricted population using CFRI at one year, Approach 1 (All New Users) 
Analysis Type MOF Hazard Ratio Vertebral Hazard Ratio 
With BMD 
 
 
  FIT Null 0.52 (0.07,3.87) 0.68 (0.09,5.08) 
  FIT with only CFRI 0.55 (0.08,4.09) 0.72 (0.10,5.39) 
  Fully Adjusted 0.50 (0.06,4.00) 0.84 (0.11,6.43) 
  FIT SIPTW 1.09 (0.26,4.54) 1.41 (0.33,5.96) 
  SMRW 0.49 (0.04,5.34) 0.61 (0.05,7.39) 
Without BMD 
 
 
  FIT Null 1.25 (0.68,2.31) 1.64 (0.86,3.15) 
  FIT with only CFRI 1.14 (0.62,2.11) 1.48 (0.77,2.85) 
  Fully Adjusted 1.02 (0.54,1.93) 1.25 (0.63,2.50) 
  FIT SIPTW 1.02 (0.53,1.99) 1.23 (0.59,2.56) 
  SMRW 0.97 (0.42,2.23) 1.23 (0.49,3.09) 
 
Using all available time for follow-up the tables for the without and with BMD estimates 
have been combined in Table 6.6. There were 25 (1.6%) patients with a MOF and <11 vertebral 
fractures in the alendronate group and 180 (0.7%) MOF and 61 (1.7%) vertebral fractures in the 
non-user group based on with BMD CFRI, and the mean follow-up times for the alendronate 
group was 1082.8 (SD 659.0) days and 909.9 (SD 567.3) days in the non-users. There were 48 
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(3.9%) MOF and 36 (2.9%) vertebral fractures in the alendronate group and 347 (1.8%) MOF 
and 230 (1.2%) vertebral fractures in the non-user group based on without BMD CFRI, and the 
mean follow-up times for the alendronate group was 1043.9 (SD 652.2), median 1009.5 (IQR 
460, 1628) days and mean of 889.4 (SD 555.9), median 760 (IQR 474, 1273) days in the non-
users.   
Compared to the full populations the FIT restricted populations either saw their estimates 
increase (for the without BMD population) or become non-significant due to small event counts 
in the with-BMD population. In both cases the estimates did not get close to the protective effect 
of alendronate found in the FIT trial. This suggests that any new user is too broad of a non-user 
comparison group. Also the restricted populations are not similar to the general population which 
makes it difficult to claim with any certainty that these results should be generalizable to a larger 
population, or are interpretable in the broader context. These results were similar to the results at 
one year and indicate that there may be a decrease in hazard when you restrict based on the with-
BMD score, but none of the estimates reached statistical significance. 
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Table 6.6 FIT-Restricted Population All Available time, Approach 1 (All New Users) 
Analysis Type Hazard Ratio Spine Hazard Ratio 
With BMD    
  FIT naïve 0.96 (0.35,2.65) 0.59 (0.14,2.41) 
  FIT with only CFRI 0.98 (0.36,2.71) 0.60 (0.15,2.47) 
  Fully Adjusted 1.04 (0.36,2.95) 0.58 (0.14,2.43) 
  FIT SIPTW 2.73 (1.43,5.20) 0.65 (0.17,2.50) 
  SMRW 1.03 (0.26,4.08) 0.58 (0.10,3.31) 
Without BMD 
 
 
  FIT naïve 1.91 (1.40,2.60) 2.17 (1.52,3.10) 
  FIT with only CFRI 1.73 (1.27,2.36) 2.00 (1.40,2.87) 
  Fully Adjusted 1.61 (1.16,2.23) 1.79 (1.22,2.61) 
  FIT SIPTW 1.93 (1.43,2.60) 2.15 (1.51,3.04) 
  SMRW 1.62 (0.99,2.65) 1.85 (1.03,3.35) 
 
6.2.4 Conclusions 
Evaluating the results of the approach 1 results, we find that classifying non-users as any 
new-use of a drug is not sufficient to reduce confounding to the level of a placebo compared to 
alendronate trial. When the population is restricted based on the with CFRI score the study 
population becomes very small and with a small number of events which create very large 
confidence intervals. Even when the without BMD CFRI score is used, the number of events are 
very small, which indicates that the analysis is underpowered and restriction of the study 
population based on CFRI may not be an appropriate use in a research context.  
In general it appears that the any new-use categorization provides a large non-user base 
for evaluation. However the patients within this population aren’t very similar to the users, and 
when propensity score weighting is used the estimates prior to CFRI exclusions do not follow the 
normal direction of towards the null. With the populations being so different, propensity scores 
may not be enough to create similar populations. As CFRI was created using advanced selection 
methods with the ability to increase error terms to improve prediction ability, it appears that 
CFRI may do a better job of reducing confounding between users and non-users than propensity 
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scores. Approach 2 will investigate if restricting the non-users to specific groups will increase 
CFRIs ability to reduce confounding. 
6.3 Approach 2: Non-Users are New Initiators of Statins, Hypertensives and 
Diabetes Drugs 
6.3.1 Study Population 
The approach 2 non-user population was restricted to only patients who had either a new 
use of alendronate or a statin, hypertensive, or diabetes related drug. Specific inclusion and 
exclusion criterion are presented as Figure 6.3. Overall 149,678 women filled either alendronate 
or one of the non-use drug categories (statin, hypertension, or diabetes drug) with an office visit 
within 30-days prior to the fill. Of these women, 85,765 were continuous enrolled for at least 
365-days prior to the office visit. Additional exclusions including use of an AOM (prior to 
index), or a diagnosis code relating to a MOF resulted in the inclusion of 63,882 women, of 
whom 20,492 were alendronate users, and 45,407 were classified as non-users. 
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Figure 6.3 Approach 2 Study Population Flowchart 
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Using the FIT criteria, 12,151 were excluded for an inpatient stay in the 180 days prior to 
index. An additional 12,604 were excluded for medical diagnoses (8,199 for GERD, 4,732 for 
cancer, and 766 for metabolic bone disease). Next, we excluded 8,210 for being >80 years old, 
3,053 for glucocorticoid use, 2,012 for HRT use, and 210 for history of a total hip arthroplasty. 
This left 27,661 patients as eligible prior to exclusions based on CFRI score. The without BMD 
CFRI cohort resulted in 3,221 patients; 859 alendronate users and 2,362 non-users, while the 
with-BMD cohort had 585 patients with 160 alendronate users and 425 non-users. 
Characteristics of the unrestricted study population are presented as Table 6.7. A second 
analysis will be performed after applying FIT exclusions. In the unrestricted population there 
was a significant difference between users and non-users in regard to osteoporosis diagnosis with 
alendronate users having a greater proportion of the population with osteoporosis and kyphosis. 
Non-users (those initiating statins, antihypertensive or antidiabetic agents) had a larger 
percentage of diabetes, and congestive heart failure. Otherwise the characteristics appear to be 
reasonably similar although some differences did reach statistical significance. 
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Table 6.7 Unrestricted-population Characteristics of Approach 2, Alendronate Users and 
Diabetes, Hypertension, and Statin Users (Non-Users) 
Attribute Non-Users 
(n=45,407) 
Users 
(n=20,492) 
Total 
(n=65,899) 
 Mean Age 74.6 (7.6) 74.4 (7.2) 74.5 (7.5) 
In 365-days prior to index 
  
Osteoporosis, N (%)  4873 (10.7) 7621 (37.2) 12494 (19.0) 
Lifestyle Factors, N (%) 
  
  Alcohol Abuse 143 (0.3) 78 (0.4) 221 (0.3) 
  Falling 2246 (4.9) 802 (3.9) 3048 (4.6) 
  Vitamin D insufficiency 4010 (8.8) 964 (4.7) 4974 (7.5) 
  Excess Vitamin A <11 <11 <11 
Genetic factors, N (%) 
  
  Cystic fibrosis 15 (<0.1) <11 22 (<0.1) 
  Homocystinuria 73 (0.2) 25 (0.1) 98 (0.1) 
  Osteogenesis imperfecta <11 <11 <11 
  Hypophosphatasia 311 (0.7) 52 (0.3) 363 (0.6) 
  Gaucher's disease 77 (0.2) 39 (0.2) 116 (0.2) 
  Idiopathic hypercalciuria <11 <11 <11 
  Porphyria <11 <11 <11 
  Glycogen storage diseases <11 <11 <11 
  Marfan syndrome <11 <11 <11 
  Riley-Day syndrome <11 <11 <11 
  Hemochromatosis <11 <11 <11 
Hypogonadal states, N (%) 
  
  Androgen insensitivity <11 <11 <11 
  Anorexia nervosa and bulimia 582 (1.3) 175 (0.9) 757 (1.1) 
  Hyperprolactinemia 12 (<0.1) <11 15 (<0.1) 
  Premature ovarian failure 30 (0.1) 34 (0.2) 64 (0.1) 
  Athletic amenorrhea 17 (<0.1) 19 (0.1) 36 (0.1) 
  Turner and Klinefelters's syndromes <11 <11 <11 
  Panhypopituitarism <11 <11 <11 
Endocrine disorders, N (%) 
  
  Adrendal insufficiency <11 11 (0.1) 18 (<0.1) 
  Diabetes mellitus (Type 1 & 2) 24476 (53.9) 6739 (32.9) 31215 (47.4) 
  Cushing's syndrome 29 (0.1) 13 (0.1) 42 (0.1) 
  Hyperparathyroidism 528 (1.2) 290 (1.4) 818 (1.2) 
  Central Adiposity 4606 (10.1) 1015 (5.0) 5621 (8.5) 
  Thyrotoxicosis 1001 (2.2) 538 (2.6) 1539 (2.3) 
Gastrointestinal disorders, N (%) 
  
  Celiac disease 55 (0.1) 39 (0.2) 94 (0.1) 
  Inflammatory Bowel Disease 302 (0.7) 127 (0.6) 429 (0.7) 
  Malabsorption 182 (0.4) 81 (0.4) 263 (0.4) 
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  Pancreatic disease 593 (1.3) 167 (0.8) 760 (1.2) 
  Primary biliary cirrhosis 21 (<0.1) <11 30 (<0.1) 
  Crohn's Disease 1786 (3.9) 685 (3.3) 2471 (3.7) 
Hematologic disorders, N (%) 
  
  Hemophilia 979 (2.2) 337 (1.6) 1316 (2.0) 
  Thalassemia 28 (0.1) 12 (0.1) 40 (0.1) 
  Sickle cell anemia <11 <11 <11 
  Systemic mastocytosis <11 <11 <11 
Rheumatologic and autoimmune diseases, N (%) 
 
  Ankylosing spondylitis 459 (1.0) 211 (1.0) 670 (1.0) 
  Lupus 203 (0.4) 118 (0.6) 321 (0.5) 
  Rheumatoid arthritis 1670 (3.7) 1003 (4.9) 2673 (4.1) 
  Gout 1792 (3.9) 480 (2.3) 2272 (3.4) 
  Polymyalgia Rheumatica 341 (0.8) 297 (1.4) 638 (1.0) 
Central nervous system disorders, N (%) 
 
  Epilepsy 639 (1.4) 212 (1.0) 851 (1.3) 
  Parkinson's disease 550 (1.2) 206 (1.0) 756 (1.1) 
  Stroke 6873 (15.1) 2166 (10.6) 9039 (13.7) 
  Multiple sclerosis 119 (0.3) 61 (0.3) 180 (0.3) 
  Spinal cord injury 44 (0.1) 20 (0.1) 64 (0.1) 
  Alzheimer's disease 5004 (11.0) 1424 (6.9) 6428 (9.8) 
Miscellaneous conditions and diseases, N (%) 
  
  AIDS/HIV 38 (0.1) 20 (0.1) 58 (0.1) 
  Congestive Heart Failure 7732 (17.0) 1902 (9.3) 9634 (14.6) 
  Muscular dystrophy 15 (<0.1) <11 18 (<0.1) 
  Liver Disease 2121 (4.7) 757 (3.7) 2878 (4.4) 
  Depression 6932 (15.3) 2620 (12.8) 9552 (14.5) 
  Amyloidosis 16 (<0.1) <11 20 (<0.1) 
  End stage renal disease 902 (2.0) 96 (0.5) 998 (1.5) 
  Sarcoidosis 86 (0.2) 44 (0.2) 130 (0.2) 
  Chronic metabolic acidosis 700 (1.5) 107 (0.5) 807 (1.2) 
  Asthma/Chronic obstructive lung disease 10039 (22.1) 4120 (20.1) 14159 (21.5) 
  Idiopathic scoliosis 760 (1.7) 492 (2.4) 1252 (1.9) 
  Cataracts 15769 (34.7) 7537 (36.8) 23306 (35.4) 
  Glaucoma 6390 (14.1) 2949 (14.4) 9339 (14.2) 
  Kyphosis 10677 (23.5) 11172 (54.5) 21849 (33.2) 
  Obesity 4606 (10.1) 1015 (5.0) 5621 (8.5) 
  Disorders of the eye 23517 (51.8) 10705 (52.2) 34222 (51.9) 
  Osteoarthritis 13725 (30.2) 6238 (30.4) 19963 (30.3) 
  Renauld's syndrome 4583 (10.1) 801 (3.9) 5384 (8.2) 
Medications, N (%) 
  
  Cyclosporine A and tacrolimus 51 (0.1) 21 (0.1) 72 (0.1) 
  Proton pump inhibitors 11868 (26.1) 5146 (25.1) 17014 (25.8) 
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  Anticoagulants 4300 (9.5) 1619 (7.9) 5919 (9.0) 
  Selective serotonin reuptake inhibitors 7664 (16.9) 3407 (16.6) 11071 (16.8) 
  Anticonvulsants 5660 (12.5) 2225 (10.9) 7885 (12.0) 
  Aromatase inhibitors 563 (1.2) 448 (2.2) 1011 (1.5) 
  GnRH (Gonadotropin releasing hormone) 
antagonists and agonists 
<11 <11 <11 
  Thiazolidinediones 3420 (7.5) 1105 (5.4) 4525 (6.9) 
  Barbiturates <11 <11 <11 
  Lithium 58 (0.1) 35 (0.2) 93 (0.1) 
  Methotrexate 379 (0.8) 327 (1.6) 706 (1.1) 
  Glucocorticoids 6163 (13.6) 2875 (14.0) 9038 (13.7) 
  Hormone Replacement Therapy 2745 (6.0) 1181 (5.8) 3926 (6.0) 
Fractures 
  
  Other Sites 1726 (3.8) 988 (4.8) 2714 (4.1) 
Race 
  
  White 34911 (76.9) 15821 (77.2) 50732 (77.0) 
  African-American 6426 (14.2) 1855 (9.1) 8281 (12.6) 
  Hispanic 1793 (3.9) 1170 (5.7) 2963 (4.5) 
  Asian 1177 (2.6) 1057 (5.2) 2234 (3.4) 
  Other 767 (1.7) 459 (2.2) 1226 (1.9) 
All Cells with a total of 0 were suppressed; *: Includes Cataracts and Glaucoma <11: CMS does not allow 
cells with less than 11 patients to be presented 
 
6.3.2 Unrestricted Population Results 
The primary outcome of this aim is major osteoporotic fracture, as such the CFRI score 
which is most applicable is the MOF rather than hip score. However there are two different ways 
to account for the score, both with and without BMD. The results for the unrestricted population 
using both with and without BMD MOF CFRI at 365-days post-index are presented in Table 6.8. 
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Table 6.8 Hazard Ratios of the Unrestricted Population at 365-days comparing 
Alendronate Users to Non-Users, Approach 2 (Diabetes, Hypertension, and Statin Users) 
Type of Analysis MOF Hazard Ratio Vertebral Hazard Ratio 
Null 1.41 (1.28,1.55) 1.84 (1.61,2.09) 
Only MOF CFRI without BMD 1.28 (1.16,1.41) 1.68 (1.48,1.91) 
Only MOF CFRI with BMD 1.20 (1.09,1.32) 1.57 (1.38,1.79) 
Fully Adjusted 1.45 (1.30,1.61) 1.84 (1.60,2.12) 
SIPTW 1.51 (1.37,1.65) 1.95 (1.72,2.20) 
SMRW 1.35 (1.20,1.51) 1.54 (1.32,1.79) 
At one year 721 (3.5%) alendronate users and 1,059 (2.3%) non-users had a major 
osteoporotic fracture. While 437 (2.1%) of alendronate users and 492 (1.1%) of non-users had a 
vertebral fracture. The null model produced a hazard ratio of 1.4. This was similar and slightly 
lower than the fully adjusted model using all of the content variables (HR 1.44), as well as the 
SIPTW model (HR 1.49). The most conservative estimate was the model of CFRI MOF with 
BMD (HR 1.198).  
In regards to the propensity score based approaches neither produced estimates which 
were less than the simple model with CFRI. The overlap of the propensity scores are presented 
as Figure 6.4. The propensity score for both the treated and untreated follow similar distributions 
with approximately four spikes, however there is very little similar overlap in the distribution 
other than at ~0.3 score. The covariates appeared to be relatively well balanced between the two 
groups (results not shown), and the addition of the CFRI score did not improve the hazard ratios 
or the distribution of the propensity score. 
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Figure 6.4 Density Plot of the Unrestricted-populations Propensity Scores Approach 2 
(Diabetes, Hypertension, and Statin Users) 
 
When all available time was used there were 2,517 (12.3%) MOF and 1,439 (7.0%) 
vertebral fractures in the alendronate users and 2,648 (5.8%) MOF and 1,271 (2.8%) vertebral 
fractures in the non-users. The mean follow-up time in the alendronate users was 1350.8 (SD 
625.3), median 1478 (IQR 864, 1901) days and in the non-users was 919.2 (SD 581.2), median 
872 (IQR 456, 1373) days; a nearly 3-year follow-up period for non-users and a 4-year follow-up 
period for alendronate users. The results of the all available time analysis are presented as Table 
6.9. All estimates using all available follow-up demonstrate increases over the one year estimate. 
The estimates for vertebral fracture continued to be greater than those for MOF with all available 
time, possibly due to fewer events. 
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Table 6.9 Hazard Ratios of the Unrestricted Population using all available time comparing 
Alendronate Users to Non-Users, Approach 2 (Diabetes, Hypertension, and Statin Users) 
Type of Analysis MOF Hazard Ratio Vertebral Hazard Ratio 
Null 1.44 (1.36,1.52) 1.71 (1.58,1.85) 
Only MOF CFRI without BMD 1.30 (1.23,1.38) 1.55 (1.43,1.67) 
Only MOF CFRI with BMD 1.23 (1.16,1.30) 1.45 (1.34,1.57) 
Fully Adjusted 1.43 (1.34,1.52) 1.62 (1.49,1.77) 
SIPTW 1.49 (1.41,1.57) 1.70 (1.58,1.83) 
SMRW 1.33 (1.24,1.42) 1.40 (1.28,1.54) 
 
6.3.3 FIT restricted population results 
The population characteristics generally were very different within the FIT restricted 
population compared to the unrestricted population, as both of these populations comprised less 
than 10% of the unrestricted cohort. The distribution of population characteristics was also very 
different from the unrestricted including the proportion of patients with osteoporosis, though you 
wouldn’t have expected any of these patients to have osteoporosis based on the FIT inclusion 
criteria only including osteopenic woman. There was a large proportion of patients with diabetes 
and hypertension in the FIT restricted population, however with these conditions being 
associated with the non-user drug classes, this is logical. Overall it does not appear that the 
restricted population either using the with or without BMD CFRI score is really representative of 
the general population who are using alendronate, which makes it difficult to generalize the 
results of this analysis to the overall alendronate-using population. 
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Table 6.10 Population Characteristics of Restricted Population in Approach 2 (Diabetes, 
Hypertension, and Statin Users) 
Attribute Non-User 
BMD 
(n=425) 
User 
BMD 
(n=160) 
Total 
BMD 
(n=585) 
Non-User 
No BMD 
(n=2362) 
User No 
BMD 
(n=859) 
Total No 
BMD 
(n=3221) 
Mean Age 
 
64.4 (0.5) 64.2 (0.4) 64.3 (0.5) 66.5 (2.1) 65.8 (1.9) 66.3 (2.1) 
In 365-days prior to index 
   
Lifestyle Factors, N (%) 
   
  Alcohol Abuse <11 <11 <11 <11 <11 <11 
  Falling 23 (0.6) <11 24 (0.6) 23 (0.6) <11 24 (0.6) 
  Vitamin D insufficiency 64 (1.7) <11 65 (1.6) 64 (1.7) <11 65 (1.6) 
  Excess Vitamin A <11 <11 <11 <11 <11 <11 
Genetic factors, N (%) 
   
  Hypophosphatasia <11 <11 <11 <11 <11 <11 
  Gaucher's disease <11 <11 <11 <11 <11 <11 
  Riley-Day syndrome <11 <11 <11 <11 <11 <11 
  Hemochromatosis <11 <11 <11 <11 <11 <11 
Hypogonadal states, N (%) 
   
  Anorexia nervosa / bulimia <11 <11 <11 <11 <11 <11 
Endocrine disorders, N (%) 
   
  Diabetes mellitus (Type 1 
& 2) 
856 (23.2) 27 (10.1) 883 (22.3) 856 (23.2) 27 (10.1) 883 (22.3) 
  Central Adiposity 178 (4.8) <11 181 (4.6) 178 (4.8) <11 181 (4.6) 
  Thyrotoxicosis 22 (0.6) <11 23 (0.6) 22 (0.6) <11 23 (0.6) 
Gastrointestinal disorders, N (%) 
   
  Celiac disease <11 <11 <11 <11 <11 <11 
  Inflammatory Bowel 
Disease 
<11 <11 <11 <11 <11 <11 
  Malabsorption <11 <11 <11 <11 <11 <11 
  Pancreatic disease <11 <11 11 (0.3) <11 <11 11 (0.3) 
  Crohn's Disease 19 (0.5) <11 20 (0.5) 19 (0.5) <11 20 (0.5) 
Hematologic disorders, N (%) 
   
  Hemophilia 17 (0.5) <11 17 (0.4) 17 (0.5) <11 17 (0.4) 
  Thalassemia <11 <11 <11 <11 <11 <11 
  Sickle cell anemia <11 <11 <11 <11 <11 <11 
Rheumatologic and autoimmune diseases, N (%) 
   
  Ankylosing spondylitis <11 <11 12 (0.3) <11 <11 12 (0.3) 
  Lupus 20 (0.5) <11 21 (0.5) 20 (0.5) <11 21 (0.5) 
  Rheumatoid arthritis 40 (1.1) <11 44 (1.1) 40 (1.1) <11 44 (1.1) 
  Gout 48 (1.3) <11 48 (1.2) 48 (1.3) <11 48 (1.2) 
  Polymyalgia Rheumatica <11 <11 <11 <11 <11 <11 
Central nervous system disorders, N (%) 
   
  Epilepsy 38 (1.0) <11 41 (1.0) 38 (1.0) <11 41 (1.0) 
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  Parkinson's disease <11 <11 <11 <11 <11 <11 
  Stroke 76 (2.1) <11 76 (1.9) 76 (2.1) <11 76 (1.9) 
  Multiple sclerosis <11 <11 <11 <11 <11 <11 
  Spinal cord injury <11 <11 <11 <11 <11 <11 
  Alzheimer's disease 42 (1.1) <11 43 (1.1) 42 (1.1) <11 43 (1.1) 
Miscellaneous conditions and diseases, N (%) 
   
  AIDS/HIV 22 (0.6) <11 24 (0.6) 22 (0.6) <11 24 (0.6) 
  Congestive Heart Failure 132 (3.6) <11 140 (3.5) 132 (3.6) <11 140 (3.5) 
  Liver Disease 47 (1.3) <11 49 (1.2) 47 (1.3) <11 49 (1.2) 
  Depression 180 (4.9) <11 189 (4.8) 180 (4.9) <11 189 (4.8) 
  End stage renal disease 145 (3.9) <11 150 (3.8) 145 (3.9) <11 150 (3.8) 
  Sarcoidosis <11 <11 <11 <11 <11 <11 
  Chronic metabolic acidosis <11 <11 <11 <11 <11 <11 
  Asthma/Chronic obstructive 
lung disease 
221 (6.0) <11 231 (5.8) 221 (6.0) <11 231 (5.8) 
  Idiopathic scoliosis 11 (0.3) <11 11 (0.3) 11 (0.3) <11 11 (0.3) 
  Cataracts 153 (4.2) <11 161 (4.1) 153 (4.2) <11 161 (4.1) 
  Glaucoma 111 (3.0) <11 118 (3.0) 111 (3.0) <11 118 (3.0) 
  Kyphosis 90 (2.4) <11 100 (2.5) 90 (2.4) <11 100 (2.5) 
  Obesity 178 (4.8) <11 181 (4.6) 178 (4.8) <11 181 (4.6) 
  Disorders of the eye 309 (8.4) 12 (4.5) 321 (8.1) 309 (8.4) 12 (4.5) 321 (8.1) 
  Osteoarthritis 315 (8.6) 11 (4.1) 326 (8.3) 315 (8.6) 11 (4.1) 326 (8.3) 
  Renauld's syndrome 147 (4.0) <11 150 (3.8) 147 (4.0) <11 150 (3.8) 
Medications, N (%) 
   
  Cyclosporine A and 
tacrolimus 
<11 <11 <11 <11 <11 <11 
  Proton pump inhibitors 670 (18.2) 40 (14.9) 710 (18.0) 670 (18.2) 40 (14.9) 710 (18.0) 
  Anticoagulants 154 (4.2) <11 164 (4.2) 154 (4.2) <11 164 (4.2) 
  Selective serotonin reuptake 
inhibitors 
333 (9.0) 20 (7.5) 353 (8.9) 333 (9.0) 20 (7.5) 353 (8.9) 
  Anticonvulsants 467 (12.7) 30 (11.2) 497 (12.6) 467 (12.7) 30 (11.2) 497 (12.6) 
  Aromatase inhibitors <11 <11 13 (0.3) <11 <11 13 (0.3) 
  Thiazolidinediones 122 (3.3) <11 126 (3.2) 122 (3.3) <11 126 (3.2) 
  Lithium <11 <11 <11 <11 <11 <11 
  Methotrexate 23 (0.6) <11 29 (0.7) 23 (0.6) <11 29 (0.7) 
Fractures 
   
  Other Sites 17 (0.5) <11 17 (0.4) 17 (0.5) <11 17 (0.4) 
Race 
   
  African-American 3683 (100) 268 (100) 3951 
(100) 
3683 
(100) 
268 (100) 3951 (100) 
All Cells with a total of 0 were suppressed; *: Includes Cataracts and Glaucoma <11: CMS 
does not allow cells with less than 11 patients to be presented 
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There are 585 women who are eligible for inclusion based on their with BMD CFRI 
score. Within this population at one year there were 0 spine fractures and 0 MOF for alendronate 
users, and <11 MOF and <11 spine fractures for non-users. Based on 0 events for the alendronate 
group, hazard ratios cannot be estimated. When the restricted population uses the without BMD 
CFRI score there are 3,221 eligible women. There were <11 MOF and <11 vertebral fractures in 
the alendronate users as well as 22 (0.9%) MOF and <11 vertebral fractures in the non-users 
(Table 6.11). 
Table 6.11 Hazard Ratios for FIT-restricted population using MOF without BMD CFRI at 
one year, Approach 2 (Diabetes, Hypertension, and Statin Users) 
Analysis Type MOF Hazard Ratio Vertebral Hazard Ratio 
Without BMD 
 
 
  FIT Null 1.07 (0.49,2.31) 2.28 (0.82,6.29) 
  FIT with only CFRI 1.01 (0.47,2.20) 2.11 (0.77,5.82) 
  Fully Adjusted 0.75 (0.30,1.89) 1.52 (0.45,5.18) 
  FIT SIPTW 0.81 (0.35,1.87) 1.66 (0.58,4.76) 
  SMRW 0.83 (0.34,2.04) 1.58 (0.47,5.26) 
 
Since there are no events in the with BMD group it is impossible to compare their estimates 
to the with BMD group. However the without BMD group produced MOF HR near one, with the 
fully adjusted models resulting in the lowest HR (this was true for both MOF and vertebral). The 
estimates for the without BMD CFRI group are ~0.5 lower than in the full population which 
suggests that if there were more events and these HR would hold, it may be possible to get to the 
same estimates as FIT for the MOF. However this does not hold true for the vertebral, as these 
estimates have increased compared to the general population. These results suggest that the 
selected population may not be generalizable to the groups of interest. Also CFRI reduced, but 
did not eliminate the confounding inherent in alendronate compared to non-users analyses.  
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Using all available time for follow-up the tables for the without and with BMD estimates 
have been combined in Table 6.12. In the with-BMD group there were <11 MOF and <11 
vertebral fractures in the alendronate group as well as <11 MOF and <11 vertebral fractures in 
non-users by the end of follow-up. The mean follow-up time for the alendronate group was 994.6 
(SD 585.6), median 988 (IQR 587, 1418.5) days and mean 796.4 (SD 554.2), median 698 (IQR 
423, 1068) days in the non-users. In the without-BMD group there were 36 (4.2%) patients with 
a MOF and 24 (2.8%) vertebral fractures in the alendronate group and 36 (1.5%) MOF and 14 
(0.6%) vertebral fractures for non-users using all available follow-up time. The mean follow-up 
time for the alendronate group was 1190.9 (SD 626.4), median 1126 (IQR 694, 1764) days and 
867.9 (SD 556.3), median 743 (IQR 456, 1270) days in the non-users. Full results of the with and 
without BMD CFRI restricted analysis for MOF and vertebral fracture utilizing all available time 
are presented as Table 6.12. 
 
Table 6.12 FIT-Restricted Population All Available time, Approach 2 (Diabetes, 
Hypertension, and Statin Users) 
Analysis Type MOF Hazard Ratio Vertebral Hazard Ratio 
With BMD 
 
 
  FIT Null 0.90 (0.17,4.65) 1.07 (0.10,11.95) 
  FIT with only CFRI 0.85 (0.16,4.44) 1.03 (0.09,11.51) 
  Fully Adjusted 0.71 (0.07,7.32) 7.51 (0.000,9999.99) 
  FIT SIPTW 0.74 (0.11,4.88) 0.34 (0.01,18.74) 
  SMRW 1.23 (0.14,11.06) 1.65 (0.06,48.65) 
Without BMD 
 
 
  FIT Null 2.075 (1.301,3.310) 3.49 (1.79,6.80) 
  FIT with only CFRI 1.934 (1.212,3.087) 3.24 (1.66,6.31) 
  Fully Adjusted 1.381 (0.801,2.382) 2.15 (0.96,4.78) 
  FIT SIPTW 1.759 (1.096,2.823) 2.86 (1.48,5.52) 
  SMRW 1.636 (0.906,2.956) 2.44 (1.05,5.66) 
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Similar to the estimates at one year, the with-BMD estimates are unstable due to such 
small event counts. HRs increased in the without BMD CFRI restricted population compared to 
the one year estimates. The difference between fracture counts caused the majority of the without 
BMD estimates to be statistically significant indicating that alendronate is associated with an 
increase in fractures, which demonstrates that we were unable to sufficiently reduce 
confounding. The takeaway from the restricted analysis is that once this population is restricted, 
it is not generalizable, and there are so few events that any estimate is highly unstable. Therefore 
any generalizability based on these findings should be questioned. This indicates that the aim 
hypothesis was wrong, although in some cases the CFRI restricted estimates are closer to the 
null, they are unstable and should not be used as applicable to the general population.  
6.3.4 Conclusions 
Evaluating the approach 2 results, we find that classifying non-users as users of statins, 
diabetes, and hypertension drugs does not sufficiently reduce confounding to comparable levels 
of the FIT RCT (HR 0.72). When restriction is used, rather than following the hypothesis of 
creating the most harmonious estimates, the hazard ratios created are unstable due to small n’s 
and event counts. This suggests that restriction based on all of the FIT criterion is likely not 
appropriate in this context. The most common reason women were excluded from this analysis 
were CFRI scores which corresponded to the BMD values from FIT, ergo if the acceptable CFRI 
scores are expanded restriction may still be a useful research tool, though in its current context 
the FIT restricted analyses are underpowered.  
Overall it appears that the three medication classes may be appropriate comparison 
groups, if additional steps are taken. This is more apparent in this analysis compared to approach 
1 where there were large discrepancies between the users and non-users. The user and non-user 
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groups appeared relatively well matched based on population characteristics, however propensity 
score methods increased HR compared to more standard methods. This likely is a result of 
imbalanced covariates, as evidenced by little to no overlap in the propensity score distributions. 
But in the case of the CFRI score, its simple inclusion in a regression equation was shown to 
bring the hazard ratios closer to the null which was the anticipated goal, as these were the 
findings from the FIT trial. 
Based on these findings, non-users cannot be classified based on drug use alone in the 
context of alendronate compared to non-users. Approach 3 will investigate if the use of a DXA 
as the index event will improve estimates, rather than including individuals based on non-
alendronate drug use. 
6.4 Approach 3 
6.4.1 Study Population 
The approach 3 non-user population is defined as women who had a DXA (CPT 70675, 
777080, 77081), and the alendronate users are those who were fully eligible in approach 1. The 
specific inclusion and exclusion criterion are specified in Figure 6.5, however these exclusions 
only include the non-user population. Overall 911,830 women had a DXA between 2008 and 
2013. Of these 894,857 were continuous enrolled in Medicare Parts A, B, & D for at least 365-
days before the DXA. Women were excluded for not filling a medication in the 365-days prior to 
DXA, as well as filling an AOM (bisphosphonate, calcitonin, Raloxifene, or Denosumab) during 
the same time period resulting in 623,391. Further exclusions included vertebral and non-
vertebral fracture, as well as death, resulting in 597,827 non-users and 29,772 alendronate users 
for this analysis. 
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Figure 6.5 Approach 3 (DXA visit as non-user) Study Population Flowchart 
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Using the FIT criteria, 45,085 were excluded for an inpatient stay in the 180 days prior to 
index. An additional 78,041 were excluded for medical diagnoses (44,155 for GERD, 35,946 for 
cancer, and 3,835 for metabolic bone disease). Next, we excluded 74,892 for being >80 years of 
age, 45,270 for glucocorticoid use, 50,149 for HRT use, and 3,740 for history of a total hip 
arthroplasty. This left 273,793 patients as eligible prior to exclusions based on CFRI score. The 
without BMD CFRI cohort resulted in 16,531 patients; 1,401 alendronate users and 15,130 non-
users, while the with-BMD cohort had 1,459 patients with 293 alendronate users and 1,166 non-
users. 
The characteristics of the unrestricted study population are presented in Table 6.13. A 
second analysis will be performed with a population after FIT exclusions. In the unrestricted 
population the population characteristics were largely similar. There were slight imbalances in 
asthma/COPD as well as HRT use, but generally very similar. 
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Table 6.13 Approach 3 (DXA visit as non-user) Characteristics of the Study Population 
Attribute Non-Users 
(n=527,254) 
Users 
(n=43,716) 
Total 
(n=570,970) 
Mean Age 73.6 (6.5) 74.9 (6.9) 73.7 (6.5) 
Osteoporosis, N (%)  26631 (5.1) 2338 (5.3) 28969 (5.1) 
Lifestyle Factors, N (%)        
  Alcohol Abuse 876 (0.2) 109 (0.2) 985 (0.2) 
  Falling 6436 (1.2) 770 (1.8) 7206 (1.3) 
  Vitamin D insufficiency 21348 (4.0) 1297 (3.0) 22645 (4.0) 
  Excess Vitamin A 11 (<0.1) <11 11 (<0.1) 
Genetic factors, N (%)        
  Cystic fibrosis 39 (<0.1) <11 45 (<0.1) 
  Homocystinuria 215 (<0.1) <11 223 (<0.1) 
  Osteogenesis imperfecta 11 (<0.1) <11 11 (<0.1) 
  Hypophosphatasia 773 (0.1) 62 (0.1) 835 (0.1) 
  Gaucher's disease 169 (<0.1) 11 (<0.1) 180 (<0.1) 
  Porphyria 50 (<0.1) <11 55 (<0.1) 
  Glycogen storage diseases 22 (<0.1) <11 22 (<0.1) 
  Marfan syndrome 13 (<0.1) <11 13 (<0.1) 
  Riley-Day syndrome <11 <11 <11 
  Hemochromatosis 117 (<0.1) <11 125 (<0.1) 
Hypogonadal states, N (%)        
  Androgen insensitivity <11 <11 <11 
  Anorexia nervosa and bulimia 1468 (0.3) 172 (0.4) 1640 (0.3) 
  Hyperprolactinemia 41 (<0.1) <11 41 (<0.1) 
  Premature ovarian failure 40 (<0.1) <11 44 (<0.1) 
  Athletic amenorrhea 86 (<0.1) 13 (<0.1) 99 (<0.1) 
  Turner and Klinefelters's syndromes <11 <11 <11 
  Panhypopituitarism 21 (<0.1) <11 22 (<0.1) 
Endocrine disorders, N (%)        
  Adrendal insufficiency 77 (<0.1) <11 80 (<0.1) 
  Diabetes mellitus (Type 1 & 2) 84245 (16.0) 7006 (16.0) 91251 (16.0) 
  Cushing's syndrome 138 (<0.1) 11 (<0.1) 149 (<0.1) 
  Hyperparathyroidism 3405 (0.6) 225 (0.5) 3630 (0.6) 
  Central Adiposity 19086 (3.6) 1271 (2.9) 20357 (3.6) 
  Thyrotoxicosis 4738 (0.9) 424 (1.0) 5162 (0.9) 
Gastrointestinal disorders, N (%)       
  Celiac disease 522 (0.1) 26 (0.1) 548 (0.1) 
  Inflammatory Bowel Disease 2161 (0.4) 171 (0.4) 2332 (0.4) 
  Malabsorption 1182 (0.2) 76 (0.2) 1258 (0.2) 
  Pancreatic disease 3171 (0.6) 265 (0.6) 3436 (0.6) 
  Primary biliary cirrhosis 372 (0.1) 20 (<0.1) 392 (0.1) 
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  Crohn's Disease 8523 (1.6) 805 (1.8) 9328 (1.6) 
Hematologic disorders, N (%)       
  Hemophilia 2643 (0.5) 242 (0.6) 2885 (0.5) 
  Thalassemia 210 (<0.1) 13 (<0.1) 223 (<0.1) 
  Sickle cell anemia 40 (<0.1) <11 44 (<0.1) 
  Systemic mastocytosis 17 (<0.1) <11 17 (<0.1) 
Rheumatologic and autoimmune diseases, N (%)       
  Ankylosing spondylitis 1375 (0.3) 102 (0.2) 1477 (0.3) 
  Lupus 1866 (0.4) 107 (0.2) 1973 (0.3) 
  Rheumatoid arthritis 11594 (2.2) 982 (2.2) 12576 (2.2) 
  Gout 7256 (1.4) 568 (1.3) 7824 (1.4) 
  Polymyalgia Rheumatica 2859 (0.5) 295 (0.7) 3154 (0.6) 
Central nervous system disorders, N (%)       
  Epilepsy 2632 (0.5) 288 (0.7) 2920 (0.5) 
  Parkinson's disease 2279 (0.4) 272 (0.6) 2551 (0.4) 
  Stroke 14961 (2.8) 1460 (3.3) 16421 (2.9) 
  Multiple sclerosis 846 (0.2) 82 (0.2) 928 (0.2) 
  Spinal cord injury 79 (<0.1) 12 (<0.1) 91 (<0.1) 
  Alzheimer's disease 11359 (2.2) 1474 (3.4) 12833 (2.2) 
Miscellaneous conditions and diseases, N (%)       
  AIDS/HIV 142 (<0.1) <11 150 (<0.1) 
  Congestive Heart Failure 21716 (4.1) 2337 (5.3) 24053 (4.2) 
  Muscular dystrophy 64 (<0.1) <11 68 (<0.1) 
  Liver Disease 10165 (1.9) 793 (1.8) 10958 (1.9) 
  Depression 29086 (5.5) 2830 (6.5) 31916 (5.6) 
  Amyloidosis 102 (<0.1) <11 107 (<0.1) 
  End stage renal disease 2358 (0.4) 160 (0.4) 2518 (0.4) 
  Sarcoidosis 768 (0.1) 64 (0.1) 832 (0.1) 
  Chronic metabolic acidosis 1606 (0.3) 160 (0.4) 1766 (0.3) 
  Asthma/Chronic obstructive lung disease 51315 (9.7) 5446 (12.5) 56761 (9.9) 
  Idiopathic scoliosis 6012 (1.1) 579 (1.3) 6591 (1.2) 
  Cataracts 17777 (3.4) 1608 (3.7) 19385 (3.4) 
  Glaucoma 7916 (1.5) 676 (1.5) 8592 (1.5) 
  Kyphosis 56392 (10.7) 4755 (10.9) 61147 (10.7) 
  Obesity 19086 (3.6) 1271 (2.9) 20357 (3.6) 
  Disorders of the eye 36397 (6.9) 3242 (7.4) 39639 (6.9) 
  Osteoarthritis 61725 (11.7) 5192 (11.9) 66917 (11.7) 
  Renauld's syndrome 14154 (2.7) 1196 (2.7) 15350 (2.7) 
Medications, N (%)       
  Cyclosporine A and tacrolimus 817 (0.2) 46 (0.1) 863 (0.2) 
  Proton pump inhibitors 140874 (26.7 11984 (27.4 152858 (26.8 
  Anticoagulants 44817 (8.5) 4067 (9.3) 48884 (8.6) 
  Selective serotonin reuptake inhibitors 87327 (16.6) 7704 (17.6) 95031 (16.6) 
252 
 
  Anticonvulsants 62458 (11.8) 5512 (12.6) 67970 (11.9) 
  Aromatase inhibitors 15584 (3.0) 994 (2.3) 16578 (2.9) 
  Thiazolidinediones 14383 (2.7) 1502 (3.4) 15885 (2.8) 
  Barbiturates 137 (<0.1) 11 (<0.1) 148 (<0.1) 
  Lithium 1085 (0.2) 81 (0.2) 1166 (0.2) 
  Methotrexate 8495 (1.6) 660 (1.5) 9155 (1.6) 
  Glucocorticoids 86617 (16.4) 7560 (17.3) 94177 (16.5) 
  Hormone Replacement Therapy 66397 (12.6) 2983 (6.8) 69380 (12.2) 
  Vitamin D <11 <11 <11 
Fractures       
  Other Sites 10045 (1.9) 1197 (2.7) 11242 (2.0) 
Race        
  White 460912 (87.4 36131 (82.7) 497043 (87.1 
  African-American 38938 (7.4) 3222 (7.4) 42160 (7.4) 
  Hispanic 10541 (2.0) 1864 (4.3) 12405 (2.2) 
  Asian 7705 (1.5) 1500 (3.4) 9205 (1.6) 
  Other 6602 (1.3) 706 (1.6) 7308 (1.3) 
Non-users are defined as any new-use of any drug in any class 
All Cells with a total of 0 were suppressed; *: Includes Cataracts and Glaucoma 
6.4.2 Unrestricted Population Results 
The primary outcome of this aim is vertebral fracture, and the MOF score includes vertebral 
fractures, therefore the MOF CFRI scores will be used in adjustments for this analysis. The 
results for the unrestricted population using both with and without BMD MOF CFRI at 365-days 
post-index are presented in Table 6.14. 
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Table 6.14 Unrestricted Population for Approach 3 (DXA visit as non-user), Hazard Ratio 
for MOF at 365-days comparing Alendronate Users to Non-Users 
Type of Analysis MOF Hazard Ratio Vertebral Hazard Ratio 
Null 1.39 (1.31,1.47) 1.34 (1.26,1.46) 
Only MOF CFRI without BMD 1.31 (1.24,1.38) 1.28 (1.18,1.37) 
Only MOF CFRI with BMD 1.34 (1.27,1.42) 1.31 (1.21,1.41) 
Fully Adjusted 1.24 (1.17,1.31) 1.20 (1.11,1.29) 
SIPTW 1.26 (1.19,1.34) 1.23 (1.14,1.33) 
SMRW 1.22 (1.12,1.32) 1.18 (1.06,1.31) 
 
At one year 1,360 (3.1%) alendronate users and 11,520 (2.2%) non-users had a major 
osteoporotic fracture while 782 (1.8%) alendronate and 6,757 (1.3%) non-users had a vertebral 
fracture. The null model produced a hazard ratio of 1.4 for both MOF and vertebral fractures 
which represented the highest estimate in both groups. The most conservative estimate was the 
SMRW models followed by fully adjusted model for both groups, which was different than the 
other two approaches where this estimate was greater than when only the CFRI variable was 
included in the model. None of the estimates were less than 1 or crossed 1. Therefore at one year 
DXA users are not a sufficient comparison group. 
In regards to the propensity score based approaches, for the first time in this analysis 
produced realistic estimates. The kernel density plot of the propensity scores is presented as 
Figure 6.6.  These two distributions are very similar with the user group having a lower peak and 
less smooth distribution, however they nearly cover each other entirely. When the groups were 
compared after weighting the characteristics for the most part were not similar which is 
surprising based on the estimates being similar to those of the standard regression approaches. 
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Figure 6.6 Kernel Density Plot for Propensity Scores in Approach 3 (DXA visit as non-
user) 
 
The results for the unrestricted population using both with and without BMD MOF CFRI 
using all available time post-index are presented in Table 6.15. 
Table 6.15 Unrestricted Population for Approach 3 (DXA visit as non-user), Hazard Ratio 
for MOF using all available time 
Type of Analysis MOF Hazard Ratio Vertebral Hazard Ratio 
Null 1.41 (1.37,1.46) 1.39 (1.34,1.45) 
Only MOF CFRI without BMD 1.35 (1.31,1.40) 1.33 (1.28,1.39) 
Only MOF CFRI with BMD 1.37 (1.33,1.42) 1.35 (1.30,1.41) 
Fully Adjusted 1.30 (1.26,1.34) 1.27 (1.22,1.32) 
SIPTW 1.29 (1.25,1.34) 1.27 (1.22,1.33) 
SMRW 1.26 (1.21,1.32) 1.24 (1.17,1.31) 
 
Using all available time, alendronate users had a mean of 1078.9 (SD 697.3), median 
1024 (IQR 464, 1648) days and non-users were followed for a mean of 979.0 (SD 696.5), 
median 851 (IQR 375, 1525) days. During this time period 4,697 (10.7%) of alendronate users 
and 36,375 (6.9%) of non-users had a major osteoporotic fracture and 2664 (6.1%) of 
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alendronate users and 20,741 (3.9%) of non-users had a vertebral fracture. The null model which 
only includes the grouping indicator produced a MOF and vertebral hazard ratio of 1.4, which 
was similar to at 365-days. The most conservative estimates were the SMRW estimates, which is 
the same as at 365-days. The with-BMD estimates were greater than the without BMD estimates 
in approach 3 which was different than the first two approaches.  
Comparing these estimate to the FIT trial clinical fracture hazard ratio at three years 
shows that even the lowest estimate at one year is greater than the FIT estimate. Both the 
alendronate and non-user group were followed for around 3 years, and our results indicate that 
CFRI in the general population is not able to reduce confounding by indication by a sufficient 
amount. 
6.4.3 FIT restricted population results 
The population characteristics generally were very different within the FIT restricted 
population compared to the unrestricted population. The characteristics of the population are 
presented as Table 6.16. The largest difference was in the with BMD population where there 
were only Black patients who were included. This was due to the Hip with BMD intercept being 
-7.8 and for most patients the only other variable which would be used in the algorithm was age, 
which to have a score <1.0 a patient would have needed to have had to have been under the age 
of 57, all of whom would have not been included in the population based on the Medicare age 
population being ≥65. There are no patients in the with BMD population who had a diagnosis of 
osteoporosis, this is due to the inclusion of the age * osteoporosis variable in CFRI hip with 
BMD which similar to the age variable increases the hip CFRI score to >1, which excludes the 
patient from the analysis.  
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The distribution of characteristics seems to be reasonably well balanced between users 
and non-users, other than osteoporosis in the without BMD CFRI group. There were significant 
differences in some population characteristics, however many of these were due to sample size 
rather than a clinical difference. Diabetes had an interesting spread across the groups with the 
alendronate users having a substantially lower percentage of patients with diabetes than non-
users in the with-BMD, but the inverse in the without-BMD. The miscellaneous conditions all 
seemed to have large discrepancies in proportions between the with and without-BMD 
population which additionally leads credence to these populations not being sufficiently similar 
to the general population. This makes it difficult to claim any generalizability to the general 
population from these results. However these characteristics may be similar to those of the 
highly restricted RCT population. 
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Table 6.16 Population Characteristics of Restricted Population in Approach 3 (DXA visit 
as non-user) 
Attribute Non-User 
BMD 
(n=1043) 
User 
BMD 
(n=84) 
Total 
BMD 
(n=1127) 
Non-User 
No BMD 
(n=13332) 
User No 
BMD 
(n=1110) 
Total No 
BMD 
(n=14442) 
 Mean Age 64.6 (0.5) 64.6 (0.5) 64.6 (0.5) 67.2 (1.8) 67.0 (1.6) 67.2 (1.8) 
Osteoporosis, N (%)  <11 <11 <11 121 (0.9) 17 (1.5) 138 (1.0) 
Lifestyle Factors, N (%) 
   
  Alcohol Abuse <11 <11 <11 14 (0.1) <11 18 (0.1) 
  Falling <11 <11 <11 80 (0.6) <11 87 (0.6) 
  Vitamin D insufficiency 33 (3.2) 2 (2.4) 35 (3.1) 516 (3.9) 24 (2.2) 540 (3.7) 
  Excess Vitamin A <11 <11 <11 <11 <11 <11 
Genetic factors, N (%) 
   
  Cystic fibrosis <11 <11 <11 <11 <11 <11 
  Homocystinuria <11 <11 <11 <11 <11 <11 
  Hypophosphatasia <11 <11 <11 <11 <11 <11 
  Gaucher's disease <11 <11 <11 11 (0.1) <11 13 (0.1) 
Hypogonadal states, N (%) 
   
  Anorexia nervosa and 
bulimia 
<11 <11 <11 25 (0.2) <11 28 (0.2) 
  Hyperprolactinemia <11 <11 <11 <11 <11 <11 
  Premature ovarian failure <11 <11 <11 <11 <11 <11 
  Athletic amenorrhea <11 <11 <11 <11 <11 <11 
Endocrine disorders, N (%) 
   
  Adrendal insufficiency <11 <11 <11 <11 <11 <11 
  Diabetes mellitus (Type 1 & 
2) 
295 (28.3) 16 (19.0) 311 
(27.6) 
4068 (30.5) 278 
(25.0) 
4346 
(30.1) 
  Cushing's syndrome <11 <11 <11 <11 <11 <11 
  Central Adiposity 65 (6.2) <11 67 (5.9) 1253 (9.4) 71 (6.4) 1324 (9.2) 
  Thyrotoxicosis 12 (1.2) <11 12 (1.1) 142 (1.1) 13 (1.2) 155 (1.1) 
Gastrointestinal disorders, N (%) 
   
  Celiac disease <11 <11 <11 <11 <11 <11 
  Inflammatory Bowel 
Disease 
<11 <11 <11 13 (0.1) <11 14 (0.1) 
  Malabsorption <11 <11 <11 <11 <11 <11 
  Pancreatic disease <11 <11 <11 21 (0.2) <11 26 (0.2) 
  Primary biliary cirrhosis <11 <11 <11 <11 <11 <11 
  Crohn's Disease <11 <11 <11 65 (0.5) <11 73 (0.5) 
Hematologic disorders, N (%) 
   
  Hemophilia <11 <11 <11 57 (0.4) <11 63 (0.4) 
  Thalassemia <11 <11 <11 <11 <11 <11 
  Sickle cell anemia <11 <11 <11 <11 <11 <11 
  Systemic mastocytosis <11 <11 <11 <11 <11 <11 
Rheumatologic and autoimmune diseases, N (%) 
   
258 
 
  Ankylosing spondylitis <11 <11 <11 13 (0.1) <11 14 (0.1) 
  Lupus <11 <11 <11 30 (0.2) <11 30 (0.2) 
  Rheumatoid arthritis 15 (1.4) <11 16 (1.4) 64 (0.5) <11 67 (0.5) 
  Gout 11 (1.1) <11 13 (1.2) 181 (1.4) <11 190 (1.3) 
  Polymyalgia Rheumatica <11 <11 <11 <11 <11 <11 
Central nervous system disorders, N (%) 
    
  Epilepsy <11 <11 <11 41 (0.3) <11 47 (0.3) 
  Parkinson's disease <11 <11 <11 20 (0.2) <11 22 (0.2) 
  Stroke 21 (2.0) <11 23 (2.0) 266 (2.0) 18 (1.6) 284 (2.0) 
  Multiple sclerosis <11 <11 <11 20 (0.2) <11 23 (0.2) 
  Spinal cord injury <11 <11 <11 <11 <11 <11 
  Alzheimer's disease <11 <11 <11 120 (0.9) 11 (1.0) 131 (0.9) 
Miscellaneous conditions and diseases, N (%) 
   
  AIDS/HIV <11 <11 <11 28 (0.2) <11 31 (0.2) 
  Congestive Heart Failure 35 (3.4) <11 39 (3.5) 407 (3.1) 29 (2.6) 436 (3.0) 
  Muscular dystrophy <11 <11 <11 <11 <11 <11 
  Liver Disease <11 <11 <11 190 (1.4) 17 (1.5) 207 (1.4) 
  Depression 62 (5.9) 6 (7.1) 68 (6.0) 640 (4.8) 61 (5.5) 701 (4.9) 
  Amyloidosis <11 <11 <11 <11 <11 <11 
  End stage renal disease 40 (3.8) <11 43 (3.8) 187 (1.4) <11 197 (1.4) 
  Sarcoidosis <11 <11 <11 28 (0.2) <11 28 (0.2) 
  Chronic metabolic acidosis <11 <11 <11 11 (0.1) <11 14 (0.1) 
  Asthma/Chronic obstructive 
lung disease 
68 (6.5) <11 78 (6.9) 819 (6.1) 72 (6.5) 891 (6.2) 
  Idiopathic scoliosis <11 <11 <11 40 (0.3) <11 44 (0.3) 
  Cataracts 33 (3.2) <11 35 (3.1) 519 (3.9) 37 (3.3) 556 (3.8) 
  Glaucoma 28 (2.7) <11 29 (2.6) 314 (2.4) 19 (1.7) 333 (2.3) 
  Kyphosis 31 (3.0) <11 33 (2.9) 539 (4.0) 45 (4.1) 584 (4.0) 
  Obesity 65 (6.2) <11 67 (5.9) 1253 (9.4) 71 (6.4) 1324 (9.2) 
  Disorders of the eye 75 (7.2) <11 78 (6.9) 1050 (7.9) 79 (7.1) 1129 (7.8) 
  Osteoarthritis 93 (8.9) <11 97 (8.6) 1294 (9.7) 88 (7.9) 1382 (9.6) 
  Renauld's syndrome 43 (4.1) <11 45 (4.0) 440 (3.3) 25 (2.3) 465 (3.2) 
Medications, N (%) 
   
  Cyclosporine A and 
tacrolimus 
<11 <11 <11 20 (0.2) <11 21 (0.1) 
  Proton pump inhibitors 269 (25.8) 14 (16.7) 283 
(25.1) 
3241 (24.3) 303 
(27.3) 
3544 
(24.5) 
  Anticoagulants 53 (5.1) 6 (7.1) 59 (5.2) 578 (4.3) 39 (3.5) 617 (4.3) 
  Selective serotonin reuptake 
inhibitors 
145 (13.9) 14 (16.7) 159 
(14.1) 
1406 (10.5) 137 
(12.3) 
1543 
(10.7) 
  Anticonvulsants 178 (17.1) 15 (17.9) 193 
(17.1) 
1673 (12.5) 136 
(12.3) 
1809 
(12.5) 
  Aromatase inhibitors 13 (1.2) <11 16 (1.4) 138 (1.0) <11 145 (1.0) 
  Thiazolidinediones 56 (5.4) <11 61 (5.4) 793 (5.9) 75 (6.8) 868 (6.0) 
  Barbiturates <11 <11 <11 <11 <11 <11 
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  Lithium <11 <11 <11 22 (0.2) <11 23 (0.2) 
  Methotrexate 11 (1.1) <11 13 (1.2) 57 (0.4) <11 61 (0.4) 
Fractures, N (%) 
   
  Other Sites <11 <11 <11 95 (0.7) <11 104 (0.7) 
Race, N (%) 
   
  White <11 <11 <11 613 (4.6) 38 (3.4) 651 (4.5) 
  African-American 1043 (100) 84 (100) 1127 
(100) 
9584 (71.9) 599 
(54.0) 
10183 
(70.5 
  Hispanic <11 <11 <11 1590 (11.9) 272 
(24.5) 
1862 
(12.9) 
  Asian <11 <11 <11 606 (4.5) 118 
(10.6) 
724 (5.0) 
  Other <11 <11 <11 930 (7.0) 82 (7.4) 1012 (7.0) 
Cells with 0 persons were suppressed. <11: CMS does not allow cells with less than 11 patients to be 
presented 
 
After restriction to only the CFRI population based on with BMD CFRI, the study 
population was significantly smaller with only 1127 patients. At 365-days of follow-up there 
were 0 (0.0%) patients who had an MOF fracture in the alendronate group and <11 patients who 
had a MOF in the non-users, as well as 0 (0.0%) vertebral fracture in the alendronate and <11 
vertebral fractures in the non-users group. Because there were no fractures in the alendronate 
group, the with-BMD hazard ratios could not be estimated. The results of the with and without-
BMD CFRI restricted analyses are presented as Table 6.17. All of the FIT restricted estimates 
are less than those of the full population, though the same finding of the only inclusion of CFRI 
in the model producing the lowest HR also held true in this population. 
When the CFRI population is restricted based on the without BMD CFRI population, the 
study population (n=16,531) is larger than the with BMD population. In this population at 365 
days there were 22 (1.6%) MOF fractures and 17 (1.2%) vertebral fractures in the alendronate 
group and 63 (0.4%) MOF fractures as well as 38 (0.3%) vertebral fractures in the non-user 
group. Incidentally the null estimates in this population are only ~0.1 greater than greater than 
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those of the general population, and a similar amount greater than the without BMD population 
as well which may be due to the small sample size and event count for this population.  
The results from both populations suggest that the selected population are not 
generalizable to the larger population. This is particularly evident by the protective estimates for 
the with BMD cohort, as they did not have enough events for a realistic result. Based simply on 
the hazard ratios produced by these analyses, none showed the expected direction of an estimate 
which was statistically significantly less than 1. 
Table 6.17 FIT-restricted population at one year, Approach 3 (DXA visit as non-user) 
Analysis Type MOF Hazard Ratio Vertebral Hazard 
Ratio 
Without BMD 
 
 
  FIT Null 2.25 (1.21,4.17) 2.32 (1.03,5.23) 
  FIT with only CFRI 2.06 (1.11,3.83) 2.14 (0.95,4.82) 
  Fully Adjusted 2.07 (1.09,3.93) 2.22 (0.95,5.20) 
  FIT SIPTW 2.48 (1.37,4.50) 2.43 (1.09,5.40) 
  SMRW 2.08 (0.76,5.67) 2.16 (0.57,8.17) 
 
Using all available time for follow-up the tables for the without and with BMD estimates 
have been combined in Table 6.18. There were 0 (0.0%) MOF and 0 (0.0%) vertebral fractures in 
the alendronate group and <11 MOF and 3 <11 vertebral fractures in the non-user group based 
on with BMD CFRI, and the mean follow-up times for the alendronate group was 911.3 (SD 
662.6), median 654 (IQR 385, 1417.5) days and mean of 899.1 (SD 671.6), median 727 (IQR 
298, 1362) days in the non-users. There were 12 (1.1%) MOF and <11 vertebral fractures in the 
alendronate group and 62 (0.5%) MOF and 35 (0.3%) in the non-user group based on without 
BMD CFRI, and the mean follow-up times for the alendronate group was 1025.6 (SD 713.2), 
median 890 (IQR 412, 1607) days and 897.2 (SD 692.1), median 733 (IQR 299, 1382) days in 
the non-users.   
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Compared to the full populations the FIT restricted populations either saw their estimates 
increase (for the without BMD population) or become non-significant due to small event counts 
in the with-BMD population. In both cases the estimates did not get close to the protective effect 
of alendronate found in the FIT trial. This suggests that any new user is too broad of a non-user 
comparison group. Also the restricted populations are not similar to the general population which 
makes it difficult to claim with any certainty that these results should be generalizable to a larger 
population, or are interpretable in the broader context. These results were similar to the results at 
one year and indicate that there may be a decrease in hazard when you restrict based on the with-
BMD score, but none of the estimates reached statistical significance. 
Table 6.18 FIT-Restricted Population All Available time, Approach 3 (DXA visit as non-
user) 
Analysis Type 
 
Hazard Ratio Spine Hazard Ratio 
With BMD    
  FIT null 1.62 (0.37,7.08) 2.04 (0.46,9.11) 
  FIT with only CFRI 1.65 (0.38,7.22) 2.04 (0.46,9.10) 
  Fully Adjusted 2.20 (0.41,11.86) 3.42 (0.67,17.35) 
  FIT SIPTW 2.68 (0.71,10.07) 3.35 (0.87,12.93) 
  SMRW 1.89 (0.18,19.80) 2.44 (0.19,31.47) 
Without BMD 
 
 
  FIT null 1.56 (1.11,2.19) 1.77 (1.16,2.70) 
  FIT with only CFRI 1.45 (1.03,2.04) 1.66 (1.09,2.55) 
  Fully Adjusted 1.41 (0.99,2.00) 1.66 (1.07,2.56) 
  FIT SIPTW 1.46 (1.03,2.08) 1.55 (0.99,2.44) 
  SMRW 1.41 (0.84,2.35) 1.62 (0.83,3.14) 
 
6.4.4 Conclusions 
Evaluating the results of the approach 3 results, we find that classifying non-users based 
solely on if they did or did not have a DXA is not sufficient to reduce confounding to the level of 
a placebo compared to alendronate trial. When the population is restricted based on the with 
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CFRI score the study population becomes very small and with a small number of events which 
create very large confidence intervals. This corresponds to the FIT restricted analyses being 
underpowered to detect the appropriate effect sizes. Even when the without CFRI score is used 
the number of events are very small, which indicates that the restriction of the study population 
based on CFRI may not be an appropriate use in a research context. The idea of using DXA as 
the non-use event of interest was to create a population which was comparable to our original 
cohort (ie had a DXA in Aim 1), however it appears that these patients are in many ways still 
dissimilar. Restricting the study population based on CFRI for the first time created populations 
which had a reasonable number of events, but the estimates continued to not reach those of the 
FIT trial. From a research standpoint CFRI cannot be used alone to control for confounding in 
osteoporosis research, however it appears useful to reduce confounding based on fracture risk.  
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 DISCUSSION 
Our goals for this project were to develop a claims-based algorithm to accurately measure 
FRAX® 10-year risks of fracture. To this end we have created the claims-based fracture risk 
index (CFRI) which we have shown is in many ways a comparable score. CFRI was shown to be 
as calibrated as FRAX® and of a similarly discriminatory ability for one-year fractures. 
Although the tool was not able to reduce confounding to the levels which we hoped for in a 
comparison of alendronate to non-users, CFRI should have merit as a tool in osteoporosis 
comparative effectiveness research going forward.  
To our knowledge this project is the first US based dataset which has combined both 
administrative claims and clinical data necessary to calculate FRAX®. We are aware of one 
Canadian dataset in Manitoba and a second project which may soon yield a similar data source in 
Quebec (220, 439). Data of this kind is necessary to evaluate fracture risk models on a 
population rather than cohort based population.  
Policy decisions continue to be made based on expert opinion as to the minimum fracture 
risk for which pharmaceutical therapy should be introduced without sufficient long-term 
evidence to demonstrate the thresholds effectiveness (37, 359). However one ongoing RCT the 
SCOOP trial in the United Kingdom aims to determine the effectiveness and cost-effective of a 
community based screening program utilizing FRAX® as a component (440). If the SCOOP trial 
finds a specific threshold to be optimal for screening or intervention it will increase the need for 
patients at or above this threshold to be identified and treated. CFRI would allow for 
retrospective in most cases, but possibly prospective identification of at-risk patients based on 
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claims data which would negate the need for collection of a baseline questionnaire as is currently 
being done in the SCOOP trial.  
One future direction from this project was to determine if a fracture risk score based on 
administrative claims data could be created to approximate FRAX® so these guidelines could be 
evaluated. We feel that these three aims demonstrate that CFRI offers a sufficient alternative to 
FRAX® when only administrative claims data is available from a policy context. However, 
CFRI alone cannot be used to eliminate non-user confounding in a research context, though its 
use along with other variables and methods may continue to elucidate the comparative 
effectiveness of anti-osteoporosis medications. 
The overall implications of this research study are that broadly it is possible to predict 
FRAX® using administrative claims. You may not be able to predict the linear value all that 
well, but that doesn’t mean that what you can predict isn’t useful and similar enough to FRAX® 
for it to be a reasonable claim based proxy. Broadly our results suggest that if FRAX® is 
available, then use FRAX® however if it is not and administrative claims are available then 
CFRI is a useful proxy. In the end CFRI will be useful for academic researchers as well as policy 
makers within insurance and healthcare environments where claims are readily available, but 
clinical data is not. CFRI is not a score which makes sense to calculate prior to a patient’s visit to 
alter a treatment decision, this should be done with FRAX®, however when accounting for 
possible decisions made based on FRAX® but without the FRAX® score itself CFRI appears to 
have utility. 
This study produced four models two for both with and without BMD estimating the 
FRAX® 10-year risk of fracture for both hip and major osteoporotic fracture. The with BMD 
models resulted in models with fewer variables and generally performed as well if not better than 
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the without BMD models. However the with BMD models had much lower statistics indicating 
their ability to account for variability in the associated FRAX® score. The without BMD models 
accounted for more of the variability which we have speculated is due to a wider variation in 
without compared to with BMD scores. Though when used in practice the with BMD scores 
tended to produce effect estimates closer to the null, which was the desired result. Broadly the 
models contained similar variables including race and age, with all but the with BMD hip model 
also containing other FRAX® variables previous fracture, rheumatoid arthritis, and 
glucocorticoid use. Although CFRI did not contain the same variables as FRAX® it did a 
passable job of predicting the continuous score, and did a far better job of discriminating 
between high and low risk patients.  
One may question if we pursued the wrong use of the CFRI score after the high rate of 
discrimination for the categorization of high v low risk patients based on NOF thresholds. In a 
random pull, CFRI would correctly identify between 81 and 89 out of 100 (based on CFRI type) 
patients as either high or low risk. Although one of the interests in this study was to be able to 
evaluate the NOF guidelines, we found it important to predict the continuous score rather than 
just dichotomizing it, particularly because if it could be used as a continuous score it would be 
more useful than as a single measure of high v low risk. That being said, most of the stakeholders 
who are likely to use this score going forward, particularly payers would be most interested in 
the dichotomous rather than the continuous.  
The ROC created in our study produced a small proportion of false positive and false 
negatives. If a prediction tool has a large proportion of false positives then it is likely that too 
many people would be screened/treated who would not benefit from it, however the inverse 
would be true if a large proportion of false negatives were present. The difficult part with the 
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ROC from Aim 1, is that the outcome that we are looking at isn’t actual fracture, but the FRAX® 
score, which could theoretically be a bad representation of a patient’s true fracture risk. However 
CFRI did not have a large proportion of false positives or false negatives, therefore should be a 
good proxy for FRAX® based on NOF thresholds. Since the continuous score performs well in 
Aim 2 in its ability to correctly predict fractures, this strengthens the idea that the categorical 
score would be useful in a context where identifying patients at high-risk would be important.  
We have produced tables of model coefficients which can be used to calculate CFRI in 
research outside of this project. The SAS code to accomplish this is available upon request, 
however it can be implemented by using the same ICD-9 codes listed in the methods for each of 
the variables listed in the four best models. We would speculate that the researcher should use a 
365-day lookback period for collection of covariates, as this would follow our method. The 
researcher then can multiply each of these 0/1 variable by the model coefficients from Aim 1 and 
sum all of the values to create CFRI in the four different variations. It was always a goal of this 
project to produce a model which could easily be reproduced by other researchers and if possible 
improved upon. 
Overall, we would view this project as a success. Although our models did not predict the 
continuous FRAX® score very well, the continuous scores were externally valid and reduced the 
effect size estimates in Aim 3 towards the null. Our models generally included the FRAX® 
variables which were measureable in administrative claims and although they are significantly 
more complex than the FRAX® score due to many more variable included, the discrimination of 
our 4 models generally was better than the FRAX® validation cohorts. For a research in 
administrative claims we have now produced a fracture risk score which is largely similar to 
FRAX® and likely can be used in the same way. We would view this as confirmation that you 
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can predict a continuous fracture risk score using only administrative claims data. In the 
following sections we discuss the broader implications of the findings from each of our aims. 
7.1 Aim 1 
There are two different populations for whom predictive models were created in this aim. 
When a patient receives a DXA there are times where a femoral neck BMD score is either not 
recorded or not valid. For a small proportion of our population (62 patients) no femoral neck 
BMD value was recorded in the CCF DXA registry, so these patients could only have their 
FRAX® calculated without BMD. Largely the characteristics between the with and without-
BMD cohorts were similar as they were comprised of the same patients. However the 
distribution of the FRAX® scores varied more widely in the without rather than with-BMD 
cohort. This is likely due to the fact that most of the patients who were getting DXAs were 
already viewed to be at risk for an osteoporosis related event, and likely had similar BMD 
values, which caused their FRAX® scores to be similar. Conversely because FRAX® without 
BMD is based on BMI rather than BMD a much wider spread of values was available for 
prediction which in turn created more predictive models. 
Overall it was surprising that the elastic net models only produced the best predictive 
models for the with BMD cohorts. Based on the known methodology it was expected that they 
would outperform a backwards stepwise model, as they would be able to modify the amount of 
error given to each coefficient (441, 442). To our knowledge there are no studies which have 
demonstrated in a similar context a backwards stepwise model outperforming either a LASSO or 
elastic net model in prediction of a continuous outcome. 
Also it was surprising that the inclusion of prevalence based HD covariates, rather than 
improving predictive ability, actually decreased the models predictive ability (31, 441, 443, 444). 
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Elastic net models are of a similar ilk to stepwise models, in that neither require any knowledge 
of the topic area, only the ability to measure and capture covariates and outcomes. The model 
performance based on content variables defined using theory (set in the framework of 
Andersen’s Model of Healthcare Utilization) increases the justification for the inclusion of these 
variables in the model. Although it would have been useful to find additional variables which 
could have improved the model’s predictive ability, it is reassuring that the variables chosen a 
priori as content variables and included in all subsequent aims were able to produce the most 
predictive parsimonious models. Although the elastic net models were supposed to be able to 
evaluate all of the variables and only choose those which were the best predictors, it may have 
been with ~1000 variables the models were overly saturated. 
In the four models deemed to be most predictive based on aR2 the only variables which 
were common across all 4 models were linear age and African-American race. This was largely 
due to the with-BMD hip model only including 4 variables. In the two with BMD models 
age*osteoporosis also remained in the model which is a variable which can be thought of a proxy 
for BMD in the FRAX® score. Both of these variables make sense for broad inclusion in the 
model as age is largely predictive of fracture risk and African-Americans have been shown to 
have better bone density than other races (445). For the without-BMD model’s rheumatologic 
conditions were common including rheumatoid arthritis (RA), lupus, and polymyalgia 
rheumatica all three of these conditions are commonly treated with glucocorticoids which have a 
deleterious effect on the bone and RA particularly has an effect on bone strength outside of 
glucocorticoid use, meriting RA and glucocorticoids its inclusion in the FRAX® calculation 
(176, 376). There were no other FRAX® factors which could be well measured in administrative 
claims, though non-MOF fractures did appear as a variable which increased risk in all but the hip 
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with-BMD model. In terms of medications which were predictive of FRAX® it is odd that 
hormone replacement therapy in the three non-Hip with-BMD model had a positive coefficient 
as normally it would have been assumed that the use of HRT would lessen a person’s fracture 
risk rather than raise it (283-286). However this may be indicative of women who already at a 
greater risk for fracture regardless of their HRT use. Outside of the one very small model at least 
one factor from each of the variable groups from Table 2.9 were included in the final predictive 
models. Some of the factors which were listed in Table 2.9 didn’t have a large enough n to be 
effectively utilized in the model, as such there may be variables which should have remained in 
the models but were excluded. 
Due to the inability to accurately measure most variables in FRAX® including BMD, 
parent fractured hip, smoking, alcohol use, and BMI our final CFRI model represents a departure 
from the variables which were included in their model. Broadly CFRI chose similar variables 
across the different outcomes, baring hip with BMD. The variables chosen by the models were 
factors which would be generally agreed upon to be associated with either fracture or 
osteoporosis. Though broadly there were very few conditions and medications which were 
associated with falling which were included in the model, only stroke appeared in both of the 
without-BMD models. 
Lastly, Kanis et al suggest that for a study population to be broadly representative of the 
general population their with and without BMD FRAX® scores should be similar (170). Broadly 
he states that the distributions for the study population should be equivalent with the extremes 
balancing each other out when the with and without BMD scores are compared. For both the hip 
and MOF with and without BMD scores, the means were similar, though the standard deviations 
were slightly different. Additionally all of the CFRI scores (comparison of with BMD to without 
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BMD) were similar. This suggests that although the study population in Aim 1 was highly 
specialized (only patients at one regional healthcare center who had DXAs), the results of the 
predictive model should be representative for the general population. 
The overall takeaway from the with BMD analyses is that although some of the 
predictive statistics, particularly aR2 are relatively low for CFRI, the models are able to 
differentiate high and low risk patients. This may be more relevant from a policy perspective 
where the interest would be identifying treatment eligible patients, rather than determining a 
precise risk-level for a patient.  
However the purpose of this project was to evaluate if a continuous score could be 
predicted, which we have demonstrated is possible. But none of the four models were able to do 
a very good job at predicting the extreme values, which seems to be more indicative of a lack of 
a specific condition or medication which was largely associated with those values. Although we 
couldn’t have expected that one variable would stick out as predictive of a very large score, 
overall, we our collection of variables is able to relatively accurately predict the majority of the 
scores. We also tested if only the inclusion of age would produce models similar to the best 
models, and in all four outcomes the age only model produced aR2 which were much less than 
even the best linear models. 
The elastic net models produced the best fitting models based on aR2 for the with BMD 
groups, while a log-transformed backwards stepwise model produced the best models for the 
without BMD groups. No model was able to explain more than 40% of the variation in the 
FRAX® scores. Likely due to the low number of events and small spread of actual FRAX® 
scores, notably when the scores were wider spread (MOF without BMD) the predictive power of 
CFRI was increased. However when NOF thresholds were applied to both FRAX® and CFRI, 
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our models were able to predict high or low risk FRAX® scores. There were very few variables 
which had a large effect on model building with the most important being age. Overall, we were 
able to predict FRAX® using CFRI for all four outcomes with moderate accuracy. Subsequent 
aims will address how well CFRI and FRAX® predict actual fractures, however based on aim 1, 
it is possible to predict a continuous FRAX® score using only administrative claims data. 
7.2 Aim 2 
The primary purpose of Aim 2 was to perform external validation of CFRI in a similar 
but separate population. To this end we used a 20% random sample of Medicare beneficiaries 
and compared calibration and discrimination between the CFRI and FRAX®. As a generalization 
we found that CFRI performed as well if not better than FRAX® in terms of discrimination, and 
predictive performance, but generally had a poor goodness of fit, due to an incorrect test (HL) 
being chosen. Based on these findings it can be argued that CFRI is able to similarly identify 
patients at risk for fracture using only data from administrative claims. Therefore the proxy score 
(CFRI) can be used to evaluate guideline concordant care in a policy context.  
We were also concerned with how well the models were calibrated to predict future 
fracture. Because there is evidence that the Hosmer-Lemeshow is not informative for large 
datasets when it was created using a small dataset (437, 438), we use of the brier score to 
determine the model calibration. The brier scores for all of the models were adequate to 
demonstrate predictive accuracy. Based on the limitations of the Hosmer-Lemeshow test as well 
as adequate brier scores, we would conclude that there is no statistically significant difference in 
calibration between the linked and random population in any of the 4 outcomes. Broadly CFRI 
was able to predict fractures as well as FRAX® for all four outcomes. Therefore we would 
accept the null hypothesis of no difference in calibration between CFRI and FRAX®. 
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Finally, we investigated the discrimination between the linked and random population. 
We evaluated discrimination using the AUC or c-statistic which is a graphically represented as 
the sensitivity (correctly identified true positive cases) compared to 1-specificity (correctly 
identified true negative cases). The basic definition of an AUC is the likelihood that a uniformly 
drawn positive is of a higher rank than a uniformly drawn negative. In aim 2 this would be 
explained as the likelihood that a patient would be correctly identified as high risk or low risk. In 
all 4 populations there were no significant differences in discrimination as measured by AUC 
and compared using De-Long test for ROC equality. Therefore we would accept the null 
hypothesis from of no difference in discriminatory ability between CFRI in the linked and 
random populations. Because we are not able to calculate FRAX® in any population other than 
the linked population, we are basing the interchangeability of the scores on a similar 
discriminatory ability for CFRI in both populations and lack of difference between 
discrimination between CFRI and FRAX in the linked population (446).  Because we could not 
calculate FRAX® in the random population, we are basing the exchangeability of the risk scores 
on similar abilities to predict one year fracture rate. 
Both the Yun et al model and the FRAX® model have evaluated their discrimination 
based on real fractures (18, 20). In both of the algorithms hip and major osteoporotic fracture 
were separately assessed. The hip model with the best AUC from Yun et al included 
demographic, fracture history, comorbidity and lifestyle questions, as well as a second model 
with included FRAX® hip finding similar predictive ability to CFRI. There was no designation 
for hip with or without BMD in the Yun et al model. In validation FRAX® gave AUC for each 
of the different validation cohorts, as well as an aggregate of the cohort used to create the model. 
Our AUC for hip with BMD CFRI in the random population was similar to the Yun et al model, 
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but less than the FRAX® AUC in their validation cohort. Our random population and the 
FRAX® validation cohort were not the same, therefore one could not expect that the AUC would 
be the same. Having a similar AUC in the linked population and a lack of statistically significant 
difference between the linked and random AUCs suggest that in similar cohorts CFRI is able to 
predict one year fractures at a similar rate to FRAX®. Ergo CFRI with BMD should be a 
reasonable proxy for FRAX® with BMD using administrative claims data.  
The FRAX® without hip BMD model from the original cohort produced an AUC lower 
than CFRI, but in the validation cohort a higher AUC was produced. Although our AUCs for the 
linked cohort were comparatively low, they increased by nearly .1 in the random cohort and were 
comparable to the FRAX® and Yun et al AUCs. It is interesting that for our study hip without 
BMDs AUC is increased over hip with BMD. We would speculate that this is due to more 
variables in the without-BMD model therefore allowing better distribution of the risk score, 
whereas FRAX® used BMD as a primary variable for its calculation. When BMD was removed 
from any of the FRAX® models their predictive ability was decreased, but CFRI selected more 
variables and increased its predictive power. It appears that CFRI is able to predict one year 
fracture as well as FRAX® was able predict fractures at 5 years using the hip without BMD 
score. Although the models with more variables in the without BMD categories were better able 
to predict fracture, we set out to create more parsimonious models, so including additional 
variables would not be feasible. 
In regards to MOF with BMD, all of the AUCs from both our study and from Yun et al 
outperformed the original cohort AUC from FRAX®, which suggests that in many ways 
FRAX® MOF with BMD is not an optimal model for predicting future fractures. However CFRI 
outperformed the original FRAX® and had the same performance as FRAX® in the linked 
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population. This suggests that CFRI should be relatively interchangeable with FRAX® based on 
its discriminatory ability to predict major osteoporotic fractures at one year. 
The last model assessed MOF without BMD, where we found that CFRI in both the 
linked and random populations outperformed FRAX® in the linked and in their original cohort. 
It is important to remember that FRAX® was based on 5-year fracture risk and our model is 
based on 1-year fracture risk which would likely change our AUC at a longer time interval. 
However with CFRI having a superior discriminatory ability based on the same data, we would 
encourage its use as a proxy for FRAX® when only administrative claims data is available. 
The external validation of the CFRI algorithm demonstrates the ability to predict 
fractures in a similar manner to the current gold standard of FRAX® using the same data, and 
subsequently in a population from a similar type data source. The populations for whom CFRI 
was tested in were largely similar which strengthens the claims that CFRI can be used as a proxy 
for FRAX® when only administrative claims data is available. Based on the internal validation 
from Aim 1, and the subsequent external validation in Aim 2, CFRI has demonstrated that it is a 
useful fracture risk prediction tool, and in many ways, may be interchanged with FRAX®.  
The AUC for all three variations of the models in Aim 2 were generally within 0.1 of 
each other. In terms of osteoporotic fracture it is unlikely that these are large enough differences 
to suggest that one risk score be used over another. However the argument could be made that 
because CFRI generally outperformed FRAX® that the small increase in precision if enough 
patients would be treated/evaluated a transition to CFRI could be warranted. But CFRI has been 
designed in this case as an alternative to FRAX® only when FRAX® cannot be calculated. It 
will be important in the future when other risk scores are available to determine how well CFRI 
performs compared to those, not only in the population where the other scores were created, but 
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in a truly random population as well. A small increase in discrimination can be important when 
all scores are similar as this may allow more patients to be correctly identified. 
7.3 Aim 3 
The primary purpose of Aim 3 was to evaluate the utility of CFRI in clinical research by 
evaluating if using CFRI we could find effect estimates similar to the placebo versus alendronate 
trial, the Fracture Intervention Trial (FIT). Soon after FIT’s publication, due to the benefits 
observed for alendronate over no treatment, it was judged to be unethical to not provide 
postmenopausal women with an active therapy when evaluating fracture risk (51, 62). To attempt 
to create similar effect sizes we employed CFRI in regression, in propensity score approaches, 
and finally through restriction to characteristics of patients included in the original FIT trial. We 
did not find that any of these techniques or the different ways that we defined new users were 
able to reduce our effect estimates to a similar level as those from the FIT trial. 
Our study, against expert guidance, used a non-user group comprised of patients based on 
any new use of a non-alendronate therapy as well as based solely on having a DXA (447-451). 
Approach 2 was the only approach which used an advised variation on the active comparator 
with 3 drug classes not associated with the outcome of interest. Approach 1, although using 
active users, was a very broad net to encompass all new users regardless of their possible 
association with fracture (447, 448). Approach 3 on the other hand didn’t require use of any 
drug, only use of the healthcare system which may suffer from bias (447-452).  
In our study we based the measurement of CFRI on when the physician would have had 
the opportunity to evaluate fracture risk (422), but began follow-up at the fill of the medication 
as the patient could only have a fracture after this point. Although not against methodologic 
guidance this may have had an effect on our results as some patients may have had a shorter time 
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period between their office visit and the fill of a medication. Another approach would have been 
to have used the entire period of 30-days after the office visit as an exposure period, and then 
began follow-up at that point, this is what was done with approach 3. In the first two approaches 
because they required a medication fill we began follow-up the day after the fill. 
Restriction of the administrative claims data by the characteristics of FIT trial participants 
was the a priori hypothesis for generating results that converge with trial estimates. This use of 
restriction, along with other methodologic techniques, have been identified as ways to emulate 
trial results (453, 454). Schneeweiss et al found that by restricting a study population in a similar 
manner to the RCT was sufficient to recreate RCT results (23). A second study of statin users 
was able to find similar protective results on par with the RCT as well, but when a true non-user 
group (ie no active comparator) was used the results were not to the level as the active 
comparators (455). Restriction has been used in other contexts and produced effect sizes similar 
to trial estimates (456).  
In each of these prior studies the variables necessary to correctly restrict the population 
were available including appropriate diagnoses, procedures, lab tests, and medications, unlike 
ours and many other possible studies. For example, because BMD is not measured in 
administrative claims, we restricted or sample based on CFRI, rather than BMD (the restriction 
criteria for the FIT trial). By doing this, we likely introduced selection bias because we were not 
able to correctly select patients based on BMD which may account for the difference between 
our results and those of the FIT trial. This also would account for the small number of patients 
(between 0.01% and 3% of the unrestricted populations) who could be used in the restricted 
analysis, which resulted in small event numbers which prevented the creation of useable effect 
estimates. The variables that were 
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When comparative effectiveness studies have included “non-users” (i.e., those who are 
not using an active comparator product) results have been mixed (455, 457). Expert opinion is 
that alendronate is superior to placebo in reduction of vertebral fracture, however meta-analyses 
are used to substantiate non-vertebral fracture reduction (247, 280, 293). Unfortunately, the 
confounding by indication could not be adjusted away in this study, regardless of our inclusion 
of CFRI. Disease risk scores are composite scores of conditions which approximate the severity 
of a condition. In approach 1 and 2, CFRI behaved in a similar manner to a traditional disease 
risk score by reducing confounding and reducing the variability of the estimate. Therefore we 
would suggest that CFRI could be used in a similar manner to a disease risk score by including it 
as a variable in regression or propensity score analyses (425). The score itself is a combination of 
the variables in the best models multiplied by their coefficients, this should be produced in a 
research context not a patient care context. 
In approach 1, we investigated if any new user could be an appropriate non-user group 
for alendronate. In both the 365-day and all available time estimate the inclusion of the with-
BMD CFRI score was responsible for the most conservative hazard ratio. However even the 
most conservative estimates were >0.3 and hazardous rather than protective compared to the FIT 
estimates. Also interestingly as the time increased (comparing 365-days to all available time) 
hazard ratios increased rather than decreased. In a clinical trial you would expect the fracture rate 
to improve over time because the patient would continue to take active therapy. However in a 
real-world analysis we did not have this same assumption and the women were unlikely taking 
alendronate throughout the entire study. After stopping alendronate the protective effects likely 
wore off, which is why the estimates increased with all available time. These findings were 
similar to those of approach 2, however when statins, anti-hypertension, and anti-diabetes drugs 
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were used as the referent group the hazard ratios were greater than the any new user referent 
group. Based on the increased hazard ratios, away from the FIT results, the any new user group 
is a better referent group when comparing alendronate to placebo.  
In approach 3 we intended to use any office visit as our non-user group, however that 
approach was found to be computationally and server space intensive, therefore we used the 
DXA which was listed as our sensitivity analysis as our primary analysis. At one year and using 
all available based on DXA, the SMRW estimate for the first time was the most conservative 
while the analyses only including the CFRI scores were greater than the fully adjusted analysis. 
Once the population was FIT restricted the n’s and fracture counts became too small in the with-
BMD population for accurate measurement. However the without BMD estimates were similar 
to the unrestricted population, if only farther from the null. As time increased the estimate 
generally increased rather than decreased. This is likely due to the study only requiring the fill of 
alendronate once, which was unlikely to confer a benefit if not consistently used.  
For all three approaches we can reject hypothesis 4 of the restricted population creating 
estimates which more closely resembled the FIT trial. Before the study we were unaware of how 
many women FIT would restrict out of the population, and how this would affect our estimates. 
Although no unrestricted estimate was close to the FIT estimates the unstable nature of the 
restricted estimates supports the rejection of the hypothesis. 
7.4 Strengths and Limitations 
Our study has several important limitations. First, this is an observational study and 
unmeasured confounding may bias our results, however we have presented an approach to 
attempt to address unmeasured confounding related to fracture risk. We only used women in our 
analysis, however men can also suffer from osteoporosis and osteoporotic fracture. Our project 
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uses a linked population which is restricted to a subset of all patients who had a DXA through 
the Cleveland Clinic Foundation sites. Most notably, individuals who were linked were those 
with fee-for-service Medicare excluding those who were insured by Medicare Advantage or 
other payers and the patient had to be using their Medicare benefits. Additionally we had a large 
proportion of the population which was of Medicare age, but we could not link to their Medicare 
claims. As such, our results may not be entirely generalizable to females in the general 
population. The linked sample only has FRAX® scores recorded for patients who receive DXAs 
within the Cleveland Clinic Health System, therefore our method to calculate CFRI may not be 
generalizable to office visits, but only applicable for DXA visits. Though our results in Aim 2 
suggest that CFRI does not have to measured only at DXA, as the comparability in fracture 
prediction was similar for office visits as it was for DXA. Because this is an analysis of Medicare 
eligible patients, we did not include anyone under the age of 65. 
In aim 1 we predict FRAX®, an imperfect measure of fracture risk. As such, our proxy 
for FRAX® (CFRI) is likely to be an imperfect estimation of future fracture risk. However 
FRAX® is the current gold standard for fracture risk prediction, making it useful for policy and 
quality measure applications. Although we were not able to predict fracture with high accuracy 
(as evidenced by low aR2) CFRI was similar in its discrimination and calibration to FRAX®.  
The linked population from Aim 1 is likely not broadly generalizable outside of its own 
population. However it is the only population which we had available to externally validate our 
model. The fact that the linked and random populations had similar calibration and 
discrimination statistics suggests that the population may be largely similar, or at least CFRI’s 
ability to predict fracture is largely similar. The one concerning factor about generalizability is 
the 95% kyphosis in the linked sample. This is likely a coding artifact; however this abnormality 
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alone doesn’t invalidate the method to determine external validity. Another concern to external 
validation was the small number of events in the linked sample, which likely under power the hip 
fracture estimates. However the fact that the predictive ability is similar to that of the random 
population lessens the worry that because this analysis was underpowered it is invalid. 
There is no accepted method for comparing users to non-users and generally this practice 
has been discouraged. The most common suggestion for researchers attempting to incorporate a 
non-user treatment arm is to do so by selecting users of a drug class thought to have no 
relationship to the outcome under study. We tested three different approaches to define non-users 
and found that anchoring our population based on a DXA with a 30-day treatment window 
produced the estimates most closely resembling the RCT. These likely were more similar 
patients than the other approaches as although AOM use other than alendronate was excluded, 
simply having a DXA may indicate a similar health profile.  
Our hazard ratios were never very similar to those of the FIT trial (FIT clinical fracture 
0.72 our lowest estimate ~1.1), however the difference between hazard and risk ratios would not 
be interpreted differently at this magnitude making our results directly comparable to FIT (458). 
Particularly, all of our FIT restricted population analyses were underpowered due to the extreme 
restrictions, this makes any conclusions based on the FIT restricted populations of questionable 
validity. Because adherence to therapy is a realistic explanation of the longer-term outcomes 
worsening compared to the one-year estimates, controlling for adherence to medication would 
have been a possibility. Noting this limitation we chose to leave the analysis as an intent to treat 
as this was the same model as the RCT. Also on the adherence piece we did not define 
alendronate populations based on their dosage, ie 10mg daily or 70 mg weekly as these two 
formulations were found to be of the same efficacy by Merck. Stratifying by dosage could have 
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provided some guidance on this, however due to small n’s this wasn’t feasible, though the 
different formulations may have affected our results 
Our study has some strengths that are unique to this project. First, we are the first 
research team to utilize this linked dataset of clinical and administrative data to evaluate 
osteoporosis care in the US. Second, we created an algorithm that only uses administrative 
claims data to predict a clinical risk score. Other attempts at calculating fracture risk scores in 
administrative claims have largely been focused on creating a separate measure rather than trying 
to recreate a current score. Although a new score could be useful within the data where it was 
created, they generally are not validated outside of that population. Our study performs the 
appropriate internal and external validation measures to establish the transferability of CFRI 
outside of our linked Medicare population. 
An additional strength of our analysis was the three different ways that we defined and 
measured new users. Methodologic guidance has largely stated that non-users should not be 
patients who do not use the medication of interest, but patients who are similar based on other 
characteristics. We found that defining non-users as any new user of a medication produced the 
best active comparator estimates but defining non-users based on DXAs produced estimates 
more closely resembling those from the FIT trial. Because we tested three different techniques 
and all three had results in a similar direction and magnitude this strengthens the validity of our 
findings that CFRI alone cannot be used to completely reduce confounding in osteoporosis 
research. 
7.5 Future Directions 
Osteoporotic fracture continues to demand a substantial amount of healthcare resources 
within the US. Therefore any strategies to reduce the occurrence and cost of fracture are likely to 
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be advisable from a public health standpoint. One of the main strategies to improve long term 
outcomes in medicine have been the introduction and enforcement of care based on quality 
measures. However in most medical disciplines, including osteoporosis, these measures are 
based on expert opinion rather than empirical evidence of their utility. Being able to use CFRI in 
claims-based research would allow an analysis of the longer-term effect of treatment based on 
these guidelines and better inform the threshold for treatment effectiveness. The intention of 
quality measures is to improve long term outcomes and patient care, hopefully CFRI will be 
useful improving these. This could be brought about by payers and policy makers helping to 
identify patients to be treated and monitoring if those patients actually receive an AOM. 
In this way if treatment based on a 10%, 30%, 40%, 50%, etc… threshold for major 
osteoporotic fracture or 6%, 9%, 12%, 20%, etc... hip fracture is actually found to be associated 
with a decrease in fracture, but the current thresholds are not, then either money could be saved 
by reducing over use of medications in a population for whom the benefit is less substantiated, or 
increase the use of medication in a population where its use will do the most good. Health care is 
a largely personal endeavor and with the increase in the want for “personalized medicine”, 
techniques and methods which are able to better drill down to the population which will most 
benefit from an intervention will continue to be desired by decision makers. 
Our study only evaluated alendronate compared to placebo. However most comparative 
effectiveness research is conducted with two active comparators. Since we excluded all non-
alendronate AOM users, future work should evaluate CFRI among other AOM users. Studies in 
glucocorticoid-induced osteoporosis have found contradictory results in the effect of AOMs in 
preventing future fracture, CFRI would likely be useful in reducing the inherent confounding in 
these studies (16, 17). Also future researchers may find that CFRI is more beneficial in reducing 
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confounding in one of these other populations, or in direct comparison to other osteoporosis 
medications rather than compared to new-users. 
Our study was restricted to women aged 65 years and older, however osteoporosis and 
osteoporotic fracture also effect men and younger women. Using our methodology for the 
creation of CFRI other researchers will either be able to create similar fracture risk scores in 
these populations or measure the utility of CFRI. In this way confounding in osteoporosis 
comparative effectiveness research can be moved forward to determine the best care for patients 
of all ages and genders.  
Our methods are reproducible as the codes used to measure the diseases and procedures 
of interest are presented within the methods section of this document. Additionally we provide 
model coefficients to 9 decimal places which will allow researchers and policy makers to 
produce CFRI in their own databases. Lastly the precise code used to measure the covariates and 
calculate CFRI including the model coefficients are available upon request. 
Overall, we found that we were able to sufficiently predict FRAX® using the CFRI score 
based on administrative claims. This will allow clinical researchers, policy makers, and payers to 
approximate a patient’s fracture risk score at the time of healthcare intervention to improve 
patient care and outcomes. We hope that CFRI will be a useful tool for others in this endeavor. 
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APPENDIX 
Table A1 Approach 1, MOF 365 no restriction, regression coefficients  
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.21907 0.0323 45.9977 <.0001 1.245 
Cystic Fibrosis 1 -0.12085 0.448 0.0728 0.7873 0.886 
Congestive Heart Failure 1 -0.12071 0.02066 34.1348 <.0001 0.886 
Ehlers-Danlos 1 8.34417 83.07385 0.0101 0.92 4205.593 
Epilepsy 1 -0.02086 0.05854 0.127 0.7216 0.979 
Osteogenesis Imperfecta 1 -0.59066 0.70787 0.6962 0.404 0.554 
Parkinson’s Disease 1 -0.0732 0.05147 2.0223 0.155 0.929 
Stroke 1 -0.07312 0.02269 10.3874 0.0013 0.929 
Adrenal insufficiency 1 0.1135 0.37852 0.0899 0.7643 1.12 
AIDS/HIV 1 0.02803 0.35392 0.0063 0.9369 1.028 
Alcoholism 1 -0.40196 0.09491 17.9378 <.0001 0.669 
Alzheimer’s 1 -0.09755 0.02225 19.2215 <.0001 0.907 
Amyloidosis 1 -0.33598 0.28906 1.351 0.2451 0.715 
Androgen insensitivity 1 -0.94235 1.00023 0.8876 0.3461 0.39 
Anorexia 1 -0.23454 0.05303 19.5579 <.0001 0.791 
Ankylosing spondylitis 1 -0.2856 0.06168 21.4389 <.0001 0.752 
COPD 1 -0.31892 0.01703 350.8698 <.0001 0.727 
Athletic amenorrhea 1 0.6195 0.44736 1.9176 0.1661 1.858 
Cataracts 1 0.06349 0.02254 7.937 0.0048 1.066 
Celiac 1 -0.32291 0.20856 2.3973 0.1215 0.724 
Central Adiposity 1 0.18779 0.03413 30.2764 <.0001 1.207 
Chronic metabolic acidosis 1 -0.1019 0.06208 2.6939 0.1007 0.903 
Crohn’s Disease 1 -0.11454 0.03736 9.4015 0.0022 0.892 
Cushing's 1 -0.58855 0.23623 6.2075 0.0127 0.555 
Depression 1 -0.054 0.02176 6.1588 0.0131 0.947 
DM 1 0.01508 0.01748 0.7443 0.3883 1.015 
ESRD 1 -0.44731 0.06257 51.1057 <.0001 0.639 
Disorders of the Eye 1 0.01661 0.02163 0.5892 0.4427 1.017 
Falling 1 -0.23655 0.0296 63.8714 <.0001 0.789 
Gaucher's Disease 1 -0.14397 0.18595 0.5995 0.4388 0.866 
Glaucoma 1 -0.01085 0.0257 0.1781 0.673 0.989 
Gout 1 0.12752 0.04252 8.9932 0.0027 1.136 
Glycogen storage diseases 1 0.70055 1.00016 0.4906 0.4837 2.015 
Hemochromatosis 1 1.12572 1.00007 1.2671 0.2603 3.082 
Hemophilia 1 -0.03609 0.04751 0.5771 0.4474 0.965 
Homocystinuria 1 -0.23237 0.18934 1.5063 0.2197 0.793 
285 
 
Hyperprolactinemia 1 -0.52384 0.40861 1.6435 0.1998 0.592 
Hyperparathyroidism 1 0.08646 0.07697 1.2617 0.2613 1.09 
Hyperthyroid 1 -0.00133 0.0519 0.0007 0.9795 0.999 
Hypophosphatasia 1 -0.31344 0.08782 12.7383 0.0004 0.731 
IBD 1 0.04219 0.0829 0.259 0.6108 1.043 
Idiopathic scoliosis 1 -0.23672 0.04221 31.4517 <.0001 0.789 
Idiopathic hypercalciuria 1 8.30935 147.06175 0.0032 0.9549 4061.69 
Kyphosis 1 -0.0133 0.02441 0.2968 0.5859 0.987 
Liver Disease 1 -0.168 0.03579 22.0283 <.0001 0.845 
Malabsorption 1 0.06413 0.14064 0.2079 0.6484 1.066 
Marfan syndrome 1 -0.42044 1.00084 0.1765 0.6744 0.657 
MS 1 -0.24893 0.12551 3.9334 0.0473 0.78 
Muscular dystrophy 1 -0.11688 0.40884 0.0817 0.775 0.89 
Obesity 0 0 . . . . 
Osteoarthritis 1 -0.01392 0.01651 0.7105 0.3993 0.986 
Osteoporosis 1 -1.5223 0.1859 67.0598 <.0001 0.218 
Other Fx 1 -0.24365 0.0317 59.058 <.0001 0.784 
Panhypopituitarism 1 -0.28356 0.70778 0.1605 0.6887 0.753 
Pancreatic Disease 1 -0.15854 0.05731 7.6535 0.0057 0.853 
Poly Rheumatica 1 -0.1932 0.06043 10.2223 0.0014 0.824 
Porphyria 1 8.15499 33.59426 0.0589 0.8082 3480.691 
Premature ovarian failure 1 2.1593 1.0001 4.6616 0.0308 8.665 
Primary biliary cirrhosis 1 -0.52893 0.18592 8.094 0.0044 0.589 
Riley-Day 1 7.82208 78.17641 0.01 0.9203 2495.088 
Renauld Disease 1 -0.01226 0.03035 0.1631 0.6863 0.988 
RA 1 -0.17666 0.03772 21.9383 <.0001 0.838 
Saccoidosis 1 -0.0717 0.1694 0.1791 0.6721 0.931 
Sickle Cell Anemia 1 0.01845 0.57782 0.001 0.9745 1.019 
Lupus 1 -0.44432 0.08312 28.5732 <.0001 0.641 
Spinal cord injury 1 -0.29998 0.18981 2.4976 0.114 0.741 
Systemic mastocytosis 1 0.40889 1.00009 0.1672 0.6826 1.505 
Turner’s & Klinefelter’s 
syndromes 
1 8.14346 92.1482 0.0078 0.9296 3440.814 
Thalassemia 1 0.10773 0.30173 0.1275 0.7211 1.114 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 8.12421 54.81031 0.022 0.8822 3375.196 
Vitamin D 1 0.05726 0.03498 2.6803 0.1016 1.059 
barb 1 -0.67316 0.37848 3.1633 0.0753 0.51 
lithium 1 0.42015 0.20067 4.3837 0.0363 1.522 
thiaz 1 -0.2459 0.0383 41.2142 <.0001 0.782 
gnrh 1 8.861 375.41413 0.0006 0.9812 7051.534 
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arom 1 -0.14618 0.05505 7.0511 0.0079 0.864 
convulsants 1 -0.1783 0.02012 78.5478 <.0001 0.837 
ssri 1 -0.21355 0.01806 139.8291 <.0001 0.808 
ppi 1 -0.1486 0.01565 90.2035 <.0001 0.862 
mtx 1 -0.30327 0.06155 24.2745 <.0001 0.738 
csa 1 -0.15734 0.18283 0.7406 0.3895 0.854 
coag 1 -0.1332 0.02207 36.4282 <.0001 0.875 
white 1 -0.2652 0.18592 2.0347 0.1537 0.767 
black 1 0.64993 0.18921 11.7985 0.0006 1.915 
other_race 1 -0.01643 0.20075 0.0067 0.9348 0.984 
asian 1 -0.01912 0.19453 0.0097 0.9217 0.981 
hispanic 1 0.05828 0.19167 0.0925 0.7611 1.06 
amnative 1 -0.35701 0.20774 2.9534 0.0857 0.7 
Age 1 -2.36703 0.19549 146.6019 <.0001 0.094 
Age*Age  1 0.03049 0.00244 156.3793 <.0001 1.031 
Age*Age*Age 1 -0.0001268 0.0000101 158.5881 <.0001 1 
Age*Osteoporosis 1 -0.01463 0.0023 40.5782 <.0001 0.985 
 
 
Table A2 Approach 1, MOF All available, no restriction, regression coefficients  
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.31973 0.01791 318.5363 <.0001 1.377 
Cystic Fibrosis 1 -0.30773 0.25037 1.5107 0.219 0.735 
Congestive Heart Failure 1 -0.11555 0.01377 70.4137 <.0001 0.891 
Ehlers-Danlos 1 -0.06718 1.0001 0.0045 0.9464 0.935 
Epilepsy 1 -0.05014 0.03952 1.6096 0.2045 0.951 
Osteogenesis Imperfecta 1 -0.40276 0.57805 0.4855 0.4859 0.668 
Parkinson’s Disease 1 -0.13851 0.03454 16.0769 <.0001 0.871 
Stroke 1 -0.07927 0.01447 29.9926 <.0001 0.924 
Adrenal insufficiency 1 -0.02193 0.22402 0.0096 0.922 0.978 
AIDS/HIV 1 0.32397 0.26747 1.4671 0.2258 1.383 
Alcoholism 1 -0.49186 0.06065 65.7726 <.0001 0.611 
Alzheimer’s 1 -0.04354 0.01548 7.9163 0.0049 0.957 
Amyloidosis 1 -0.37475 0.20027 3.5014 0.0613 0.687 
Androgen insensitivity 1 -0.08814 1.00007 0.0078 0.9298 0.916 
Anorexia 1 -0.1872 0.03787 24.4408 <.0001 0.829 
Ankylosing spondylitis 1 -0.26809 0.0372 51.9256 <.0001 0.765 
COPD 1 -0.29428 0.01103 712.312 <.0001 0.745 
Athletic amenorrhea 1 0.457 0.23581 3.756 0.0526 1.579 
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Cataracts 1 0.02214 0.01352 2.6809 0.1016 1.022 
Celiac 1 -0.04725 0.13616 0.1204 0.7286 0.954 
Central Adiposity 1 0.16259 0.02171 56.0639 <.0001 1.177 
Chronic metabolic acidosis 1 -0.08598 0.04515 3.6274 0.0568 0.918 
Crohn’s Disease 1 -0.07678 0.02434 9.9476 0.0016 0.926 
Cushing's 1 -0.43907 0.16261 7.2906 0.0069 0.645 
Depression 1 -0.05662 0.01442 15.4235 <.0001 0.945 
DM 1 0.02425 0.01126 4.6389 0.0313 1.025 
ESRD 1 -0.46274 0.04485 106.4566 <.0001 0.63 
Disorders of the Eye 1 -0.05735 0.01356 17.8797 <.0001 0.944 
Falling 1 -0.21456 0.01974 118.1112 <.0001 0.807 
Gaucher's Disease 1 0.01641 0.12055 0.0185 0.8917 1.017 
Glaucoma 1 0.01692 0.01526 1.2297 0.2675 1.017 
Gout 1 0.05983 0.02691 4.9437 0.0262 1.062 
Glycogen storage diseases 1 -0.12271 0.40841 0.0903 0.7638 0.885 
Hemochromatosis 1 1.61726 1.00003 2.6154 0.1058 5.039 
Hemophilia 1 -0.04363 0.03022 2.0849 0.1488 0.957 
Homocystinuria 1 0.19196 0.14161 1.8377 0.1752 1.212 
Hyperprolactinemia 1 -0.21522 0.3017 0.5089 0.4756 0.806 
Hyperparathyroidism 1 0.01205 0.0477 0.0638 0.8006 1.012 
Hyperthyroid 1 0.017 0.03272 0.27 0.6034 1.017 
Hypophosphatasia 1 -0.1835 0.06594 7.7457 0.0054 0.832 
IBD 1 -0.05112 0.05181 0.9733 0.3239 0.95 
Idiopathic scoliosis 1 -0.18381 0.02781 43.6913 <.0001 0.832 
Idiopathic hypercalciuria 1 6.30083 26.25653 0.0576 0.8104 545.026 
Kyphosis 1 -0.00875 0.01515 0.3336 0.5635 0.991 
Liver Disease 1 -0.12473 0.02319 28.9199 <.0001 0.883 
Malabsorption 1 -0.00794 0.08709 0.0083 0.9274 0.992 
Marfan syndrome 1 0.34461 1.00029 0.1187 0.7305 1.411 
MS 1 -0.17833 0.08606 4.2937 0.0383 0.837 
Muscular dystrophy 1 0.39845 0.35371 1.2689 0.26 1.49 
Obesity 0 0 . . . . 
Osteoarthritis 1 -0.01698 0.01047 2.6288 0.1049 0.983 
Osteoporosis 1 -1.19985 0.12261 95.7678 <.0001 0.301 
Other Fx 1 -0.27674 0.02069 178.9283 <.0001 0.758 
Panhypopituitarism 1 -0.73735 0.35395 4.3397 0.0372 0.478 
Pancreatic Disease 1 -0.14908 0.03827 15.1787 <.0001 0.862 
Poly Rheumatica 1 -0.15984 0.03863 17.1193 <.0001 0.852 
Porphyria 1 0.35662 0.40834 0.7627 0.3825 1.428 
Premature ovarian failure 1 0.5873 0.25836 5.1675 0.023 1.799 
Primary biliary cirrhosis 1 -0.48783 0.12517 15.1899 <.0001 0.614 
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Riley-Day 1 5.8241 20.36127 0.0818 0.7748 338.355 
Renauld Disease 1 -0.01843 0.02078 0.7871 0.375 0.982 
RA 1 -0.15129 0.0242 39.0842 <.0001 0.86 
Saccoidosis 1 -0.06055 0.10685 0.3212 0.5709 0.941 
Sickle Cell Anemia 1 0.27143 0.44759 0.3677 0.5442 1.312 
Lupus 1 -0.39125 0.05399 52.5184 <.0001 0.676 
Spinal cord injury 1 -0.25806 0.12749 4.0971 0.043 0.773 
Systemic mastocytosis 1 0.28805 0.57741 0.2489 0.6179 1.334 
Turner’s & Klinefelter’s 
syndromes 
1 -0.49704 0.70724 0.4939 0.4822 0.608 
Thalassemia 1 0.07424 0.19262 0.1486 0.6999 1.077 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 1.12958 1.00027 1.2753 0.2588 3.094 
Vitamin D 1 0.0399 0.02313 2.9744 0.0846 1.041 
barb 1 -0.39285 0.27759 2.0029 0.157 0.675 
lithium 1 0.29612 0.12092 5.9967 0.0143 1.345 
thiaz 1 -0.23351 0.02434 92.0717 <.0001 0.792 
gnrh 1 6.88978 64.38509 0.0115 0.9148 982.188 
arom 1 -0.13155 0.03595 13.3893 0.0003 0.877 
convulsants 1 -0.18733 0.01334 197.3425 <.0001 0.829 
ssri 1 -0.1923 0.01209 252.8766 <.0001 0.825 
ppi 1 -0.11419 0.01027 123.7055 <.0001 0.892 
mtx 1 -0.28953 0.04017 51.9543 <.0001 0.749 
csa 1 -0.21938 0.11129 3.8861 0.0487 0.803 
coag 1 -0.18764 0.01422 174.0544 <.0001 0.829 
white 1 -0.30793 0.1326 5.393 0.0202 0.735 
black 1 0.61511 0.13459 20.8883 <.0001 1.85 
other_race 1 -0.03575 0.14127 0.064 0.8002 0.965 
asian 1 -0.09508 0.13731 0.4795 0.4887 0.909 
hispanic 1 -0.00771 0.13594 0.0032 0.9548 0.992 
amnative 1 -0.38616 0.14585 7.0095 0.0081 0.68 
Age 1 -2.14582 0.13538 251.2509 <.0001 0.117 
Age*Age  1 0.02783 0.0017 269.2314 <.0001 1.028 
Age*Age*Age 1 -0.0001164 7.04E-06 273.2939 <.0001 1 
Age*Osteoporosis 1 -0.01116 0.00153 53.1422 <.0001 0.989 
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Table A3 Approach 1, MOF 365 days, CFRI Without BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.01524 0.32681 0.0022 0.9628 1.015 
Cystic Fibrosis 1 12.68328 9522 0 0.9989 322314.2 
Congestive Heart 
Failure 
1 0.07362 0.33977 0.0469 0.8285 1.076 
Epilepsy 1 -0.07802 1.05209 0.0055 0.9409 0.925 
Parkinson’s Disease 1 -0.53803 1.01391 0.2816 0.5957 0.584 
Stroke 1 -0.03809 0.35769 0.0113 0.9152 0.963 
Adrenal insufficiency 1 13.26799 8955 0 0.9988 578380.5 
AIDS/HIV 1 12.93149 1036 0.0002 0.99 413117.1 
Alcoholism 1 13.53055 1614 0.0001 0.9933 752045.9 
Alzheimers 1 0.24001 0.62351 0.1482 0.7003 1.271 
Anorexia 1 -1.47149 0.75414 3.8072 0.051 0.23 
Ankylosing spondylitis 1 -0.79749 1.01333 0.6194 0.4313 0.45 
COPD 1 -0.09248 0.26807 0.119 0.7301 0.912 
Athletic amenorrhea 1 13.9656 6579 0 0.9983 1161934 
Cataracts 1 0.68341 0.41784 2.6751 0.1019 1.981 
Celiac 1 -1.4186 5470 0 0.9998 0.242 
Central Adiposity 1 0.82906 0.30788 7.2514 0.0071 2.291 
Chronic metabolic 
acidosis 
1 13.85803 1809 0.0001 0.9939 1043436 
Crohn’s Disease 1 -0.1068 1.01168 0.0111 0.9159 0.899 
Cushing's 1 13.54194 4636 0 0.9977 760657.8 
Depression 1 -0.31955 0.27893 1.3125 0.252 0.726 
DM 1 -0.15384 0.20075 0.5872 0.4435 0.857 
ESRD 1 -0.29634 0.4929 0.3615 0.5477 0.744 
Disorders of the Eye 1 -0.09609 0.31501 0.093 0.7603 0.908 
Falling 1 -1.46812 0.41029 12.8038 0.0003 0.23 
Gaucher's Disease 1 13.5664 2184 0 0.995 779494.8 
Glaucoma 1 0.63359 0.50769 1.5575 0.212 1.884 
Gout 1 -0.62975 0.43674 2.0792 0.1493 0.533 
Glycogen storage 
diseases 
1 10.88815 7653 0 0.9989 53538.41 
Hemochromatosis 1 14.25968 5333 0 0.9979 1559192 
Hemophilia 1 -0.22839 0.57388 0.1584 0.6906 0.796 
Homocystinuria 1 13.39097 3872 0 0.9972 654069.3 
Hyperprolactinemia 1 13.99742 6429 0 0.9983 1199501 
Hyperthyrois 1 -0.6956 0.52513 1.7546 0.1853 0.499 
Hypophosphatasia 1 -2.27852 1.10243 4.2717 0.0388 0.102 
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IBD 1 13.50667 2291 0 0.9953 734299.5 
Idopathic scoliosis 1 12.62684 807.98255 0.0002 0.9875 304626.3 
Kyphosis 1 0.8155 0.5905 1.9072 0.1673 2.26 
Liver Disease 1 1.08168 1.00837 1.1507 0.2834 2.95 
Malabsorption 1 13.80847 1917 0.0001 0.9943 992982.8 
MS 1 13.541 1780 0.0001 0.9939 759945.1 
Obseity 0 0 . . . . 
Osteoarthritis 1 -0.16806 0.23294 0.5205 0.4706 0.845 
Osteoporosis 1 -35.22601 26.6008 1.7536 0.1854 0 
Other Fx 1 0.41494 1.02256 0.1647 0.6849 1.514 
Panhypopituitarism 1 12.98192 12344 0 0.9992 434487.5 
Pancreatic Disease 1 13.84892 1238 0.0001 0.9911 1033976 
Poly Rheumatica 1 13.85454 3627 0 0.997 1039799 
Premature ovarian 
failure 
1 12.9975 4914 0 0.9979 441309.6 
Primary bilary cirrhosis 1 11.82731 7166 0 0.9987 136941.8 
Riley-Day 1 15.07286 8827 0 0.9986 3516091 
Renauld Disease 1 -0.27144 0.36504 0.5529 0.4571 0.762 
RA 1 -0.76547 0.63854 1.4371 0.2306 0.465 
Saccoidosis 1 -0.68743 1.04717 0.4309 0.5115 0.503 
Sickle Cell Anemia 1 13.07443 3980 0 0.9974 476596.3 
Lupus 1 -0.78643 1.0317 0.5811 0.4459 0.455 
Spinal cord injury 1 11.6896 7599 0 0.9988 119324.1 
Systemic mastocytosis 1 13.21174 13174 0 0.9992 546748.2 
Thalassemia 1 13.29856 3018 0 0.9965 596337.1 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 13.57887 10477 0 0.999 789278.5 
Vitamin D 1 -0.85789 0.33588 6.5236 0.0106 0.424 
barb 1 14.31906 9214 0 0.9988 1654578 
lithium 1 14.02703 1726 0.0001 0.9935 1235557 
thiaz 1 -0.17605 0.30317 0.3372 0.5614 0.839 
arom 1 -0.67787 1.01121 0.4494 0.5026 0.508 
convulsants 1 -0.10094 0.23121 0.1906 0.6624 0.904 
ssri 1 -0.22882 0.23387 0.9573 0.3279 0.795 
ppi 1 -0.227 0.18806 1.4571 0.2274 0.797 
mtx 1 -0.546 1.03769 0.2769 0.5988 0.579 
csa 1 13.26812 2503 0 0.9958 578457.7 
coag 1 -0.63657 0.30907 4.242 0.0394 0.529 
white 1 -13.39172 4695 0 0.9977 0 
black 1 -12.54397 4695 0 0.9979 0 
other_race 1 -12.49572 4695 0 0.9979 0 
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asian 1 -12.65013 4695 0 0.9979 0 
hispanic 1 -13.40192 4695 0 0.9977 0 
amnative 1 -15.23315 4695 0 0.9974 0 
Age 1 70.03146 82.01864 0.7291 0.3932 2.60E+30 
Age*Age  1 -1.05795 1.21036 0.764 0.3821 0.347 
Age*Age*Age 1 0.00532 0.00595 0.7993 0.3713 1.005 
Age*Osteoporosis 1 -0.51582 0.4064 1.611 0.2044 0.597 
 
 
Table A4 Approach 1, MOF All available, CFRI Without BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.47697 0.16655 8.2018 0.0042 1.611 
Cystic Fibrosis 1 12.62001 3164 0 0.9968 302552 
Congestive Heart 
Failure 
1 0.15682 0.2201 0.5077 0.4761 1.17 
Epilepsy 1 -0.84314 0.47622 3.1347 0.0766 0.43 
Parkinson’s Disease 1 -0.34856 0.72149 0.2334 0.629 0.706 
Stroke 1 0.03851 0.22668 0.0289 0.8651 1.039 
Adrenal insufficiency 1 13.51705 3268 0 0.9967 741959.6 
AIDS/HIV 1 12.49987 505.10168 0.0006 0.9803 268301.2 
Alcoholism 1 -1.18529 0.71992 2.7107 0.0997 0.306 
Alzheimers 1 -0.07966 0.35065 0.0516 0.8203 0.923 
Anorexia 1 -1.78924 0.47293 14.3136 0.0002 0.167 
Ankylosing spondylitis 1 -0.41667 0.71629 0.3384 0.5608 0.659 
COPD 1 -0.06055 0.16663 0.132 0.7163 0.941 
Athletic amenorrhea 1 13.40077 2639 0 0.9959 660512.9 
Cataracts 1 0.2761 0.20748 1.7709 0.1833 1.318 
Celiac 1 12.60472 1828 0 0.9945 297961.3 
Central Adiposity 1 0.66137 0.1893 12.206 0.0005 1.937 
Chronic metabolic 
acidosis 
1 12.57209 569.27227 0.0005 0.9824 288397.2 
Crohn’s Disease 1 0.19611 0.71325 0.0756 0.7834 1.217 
Cushing's 1 12.57818 2019 0 0.995 290158.9 
Depression 1 0.02415 0.1902 0.0161 0.899 1.024 
DM 1 -0.25355 0.12672 4.0037 0.0454 0.776 
ESRD 1 -1.08624 0.26688 16.566 <.0001 0.337 
Disorders of the Eye 1 -0.16339 0.18073 0.8173 0.366 0.849 
Falling 1 -1.15038 0.27528 17.4631 <.0001 0.317 
Gaucher's Disease 1 12.75282 871.39009 0.0002 0.9883 345526.3 
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Glaucoma 1 0.24419 0.23017 1.1255 0.2887 1.277 
Gout 1 -0.62186 0.27317 5.1823 0.0228 0.537 
Glycogen storage 
diseases 
1 9.69309 3724 0 0.9979 16205.21 
Hemochromatosis 1 13.7444 2807 0 0.9961 931357.8 
Hemophilia 1 -0.10927 0.39 0.0785 0.7793 0.896 
Homocystinuria 1 12.60252 1530 0.0001 0.9934 297306.1 
Hyperprolactinemia 1 13.23109 4955 0 0.9979 557429.2 
Hyperthyrois 1 -0.16746 0.38826 0.186 0.6662 0.846 
Hypophosphatasia 1 -1.15365 1.03107 1.2519 0.2632 0.315 
IBD 1 -0.92513 1.23839 0.5581 0.455 0.396 
Idopathic scoliosis 1 12.03616 355.87643 0.0011 0.973 168748.3 
Kyphosis 1 0.48015 0.28849 2.7702 0.096 1.616 
Liver Disease 1 0.80683 0.5071 2.5315 0.1116 2.241 
Malabsorption 1 -0.3638 1.04871 0.1203 0.7287 0.695 
MS 1 12.91374 732.01321 0.0003 0.9859 405848.9 
Obseity 0 0 . . . . 
Osteoarthritis 1 -0.20227 0.1392 2.1114 0.1462 0.817 
Osteoporosis 1 -23.88161 16.34535 2.1347 0.144 0 
Other Fx 1 0.33841 0.59562 0.3228 0.5699 1.403 
Panhypopituitarism 1 12.43877 4588 0 0.9978 252398.6 
Pancreatic Disease 1 0.43381 1.01185 0.1838 0.6681 1.543 
Poly Rheumatica 1 13.18055 1617 0.0001 0.9935 529956.9 
Premature ovarian 
failure 
1 12.08439 1787 0 0.9946 177086.3 
Primary bilary cirrhosis 1 10.81919 3676 0 0.9977 49970.64 
Riley-Day 1 13.60338 7631 0 0.9986 808855.6 
Renauld Disease 1 -0.10611 0.23349 0.2065 0.6495 0.899 
RA 1 0.45967 0.62363 0.5433 0.4611 1.584 
Saccoidosis 1 0.06525 1.00767 0.0042 0.9484 1.067 
Sickle Cell Anemia 1 12.44513 1654 0.0001 0.994 254009.2 
Lupus 1 -1.28444 0.60366 4.5274 0.0334 0.277 
Spinal cord injury 1 11.2201 2817 0 0.9968 74615.03 
Systemic mastocytosis 1 12.68331 4612 0 0.9978 322323.7 
Thalassemia 1 12.49705 1125 0.0001 0.9911 267547.1 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 12.87641 5870 0 0.9982 390979.4 
Vitamin D 1 -0.51289 0.25926 3.9137 0.0479 0.599 
barb 1 13.78925 3251 0 0.9966 974078 
lithium 1 13.17088 800.76413 0.0003 0.9869 524858.7 
thiaz 1 -0.31773 0.17599 3.2594 0.071 0.728 
arom 1 -0.98352 0.58717 2.8057 0.0939 0.374 
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convulsants 1 -0.0639 0.15377 0.1727 0.6777 0.938 
ssri 1 -0.33227 0.15074 4.8585 0.0275 0.717 
ppi 1 0.02785 0.12752 0.0477 0.8271 1.028 
mtx 1 -0.65945 0.7414 0.7912 0.3738 0.517 
csa 1 12.42367 1026 0.0001 0.9903 248617.6 
coag 1 -0.48836 0.20848 5.4874 0.0192 0.614 
white 1 -12.48704 1953 0 0.9949 0 
black 1 -11.60629 1953 0 0.9953 0 
other_race 1 -12.00552 1953 0 0.9951 0 
asian 1 -12.00845 1953 0 0.9951 0 
hispanic 1 -12.46 1953 0 0.9949 0 
amnative 1 -13.42879 1953 0 0.9945 0 
Age 1 -6.97485 62.3686 0.0125 0.911 0.001 
Age*Age  1 0.08722 0.92385 0.0089 0.9248 1.091 
Age*Age*Age 1 -0.0003518 0.00456 0.006 0.9385 1 
Age*Osteoporosis 1 -0.35107 0.24866 1.9933 0.158 0.704 
 
 
Table A5 Approach 1, MOF 365 days, CFRI With BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 -0.69356 1.06123 0.4271 0.5134 0.5 
Congestive Heart 
Failure 
1 19.92888 1834 0.0001 0.9913 4.52E+08 
Epilepsy 1 15.18062 2648 0 0.9954 3916154 
Parkinson’s Disease 1 17.08062 11056 0 0.9988 26183002 
Stroke 1 -0.45959 1.12696 0.1663 0.6834 0.632 
AIDS/HIV 1 16.0586 7375 0 0.9983 9422441 
Alcoholism 1 20.78257 10035 0 0.9983 1.06E+09 
Alzheimers 1 -1.84643 1.10724 2.7809 0.0954 0.158 
Anorexia 1 16.99477 64062 0 0.9998 24028909 
Ankylosing spondylitis 1 15.82383 14577 0 0.9991 7450811 
COPD 1 -0.88173 0.68756 1.6445 0.1997 0.414 
Cataracts 1 -15.39971 1978 0.0001 0.9938 0 
Celiac 1 -50.16522 101892 0 0.9996 0 
Central Adiposity 1 16.07604 2863 0 0.9955 9588140 
Chronic metabolic 
acidosis 
1 -13.23647 68371 0 0.9998 0 
Crohn’s Disease 1 16.22309 10061 0 0.9987 11107057 
Depression 1 -0.21414 1.07345 0.0398 0.8419 0.807 
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DM 1 0.2845 0.53087 0.2872 0.592 1.329 
ESRD 1 0.32259 1.04361 0.0955 0.7572 1.381 
Disorders of the Eye 1 16.73025 1978 0.0001 0.9932 18444027 
Falling 1 -2.02602 1.18467 2.9248 0.0872 0.132 
Gaucher's Disease 1 16.01104 39579 0 0.9997 8984741 
Glaucoma 1 13.56844 2965 0 0.9963 781086.2 
Gout 1 14.9232 4291 0 0.9972 3027359 
Hemochromatosis 1 0.80805 79409 0 1 2.244 
Hemophilia 1 -2.9439 1.07878 7.4469 0.0064 0.053 
Hyperthyrois 1 -2.4697 1.07785 5.2501 0.0219 0.085 
Hypophosphatasia 1 -4.12193 1.40145 8.6506 0.0033 0.016 
IBD 1 1.16656 35196 0 1 3.211 
Idopathic scoliosis 1 0.75409 7521 0 0.9999 2.126 
Kyphosis 1 15.83765 4026 0 0.9969 7554451 
Liver Disease 1 15.81574 4450 0 0.9972 7390727 
Malabsorption 1 1.93971 57086 0 1 6.957 
MS 1 16.79441 16369 0 0.9992 19666191 
Obseity 0 0 . . . . 
Osteoarthritis 1 -0.03336 0.72196 0.0021 0.9631 0.967 
Other Fx 1 15.96891 6276 0 0.998 8614060 
Pancreatic Disease 1 16.45632 13661 0 0.999 14024573 
Poly Rheumatica 1 17.75901 40432 0 0.9996 51598891 
Riley-Day 1 -12.2099 49063 0 0.9998 0 
Renauld Disease 1 -1.43126 0.887 2.6037 0.1066 0.239 
RA 1 -2.48144 0.83109 8.9148 0.0028 0.084 
Saccoidosis 1 -3.45605 1.21108 8.1436 0.0043 0.032 
Sickle Cell Anemia 1 16.27301 26050 0 0.9995 11675619 
Lupus 1 16.17047 5588 0 0.9977 10537712 
Spinal cord injury 0 0 . . . . 
Thalassemia 1 -12.40982 70178 0 0.9999 0 
Thyrotoxicosis 0 0 . . . . 
Vitamin D 1 16.11881 4762 0 0.9973 10007111 
lithium 1 17.13334 14464 0 0.9991 27600327 
thiaz 1 -0.80602 0.80882 0.9931 0.319 0.447 
arom 1 16.4601 16317 0 0.9992 14077640 
convulsants 1 -0.49201 0.52994 0.862 0.3532 0.611 
ssri 1 0.45869 0.77397 0.3512 0.5534 1.582 
ppi 1 -0.82485 0.4409 3.5 0.0614 0.438 
mtx 1 -0.72015 1.1953 0.363 0.5469 0.487 
csa 1 16.32758 30697 0 0.9996 12330392 
coag 1 -1.0694 0.64758 2.727 0.0987 0.343 
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Age 1 0.33078 0.42428 0.6078 0.4356 1.392 
Age*Age  0 0 . . . . 
Age*Age*Age 0 0 . . . . 
Age*Osteoporosis 0 0 . . . . 
 
 
Table A6 Approach 1, MOF All Available, CFRI With BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.03677 0.53327 0.0048 0.945 1.037 
Congestive Heart 
Failure 
1 16.36058 936.23249 0.0003 0.9861 12744055 
Epilepsy 1 15.21591 2375 0 0.9949 4056805 
Parkinson’s Disease 1 14.7651 3519 0 0.9967 2584639 
Stroke 1 0.09488 0.90131 0.0111 0.9162 1.1 
AIDS/HIV 1 15.15211 2993 0 0.996 3806097 
Alcoholism 1 -0.28601 1.4678 0.038 0.8455 0.751 
Alzheimers 1 -1.88413 0.7666 6.0407 0.014 0.152 
Anorexia 1 1.23932 13202 0 0.9999 3.453 
Ankylosing spondylitis 1 15.47151 5428 0 0.9977 5238338 
COPD 1 -0.89941 0.45631 3.885 0.0487 0.407 
Cataracts 1 1.0122 1.78174 0.3227 0.57 2.752 
Celiac 1 -28.88026 24893 0 0.9991 0 
Central Adiposity 1 -0.25547 0.62831 0.1653 0.6843 0.775 
Chronic metabolic 
acidosis 
1 0.15048 15810 0 1 1.162 
Crohn’s Disease 1 14.76468 3352 0 0.9965 2583555 
Depression 1 1.19356 1.06284 1.2611 0.2614 3.299 
DM 1 -0.28767 0.33035 0.7583 0.3839 0.75 
ESRD 1 -1.03773 0.50646 4.1983 0.0405 0.354 
Disorders of the Eye 1 1.04524 1.04638 0.9978 0.3178 2.844 
Falling 1 -2.38019 0.68143 12.2007 0.0005 0.093 
Gaucher's Disease 1 15.17937 12563 0 0.999 3911241 
Glaucoma 1 14.42614 1527 0.0001 0.9925 1841587 
Gout 1 15.17013 2151 0 0.9944 3875288 
Hemochromatosis 1 -2.21412 41483 0 1 0.109 
Hemophilia 1 -1.12177 1.31315 0.7297 0.393 0.326 
Hyperthyrois 1 -1.575 1.0363 2.3099 0.1286 0.207 
Hypophosphatasia 1 -3.08298 1.41277 4.7621 0.0291 0.046 
IBD 1 1.86628 12680 0 0.9999 6.464 
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Idopathic scoliosis 1 -0.63508 3079 0 0.9998 0.53 
Kyphosis 1 15.1517 1582 0.0001 0.9924 3804533 
Liver Disease 1 14.95126 1838 0.0001 0.9935 3113519 
Malabsorption 1 13.94973 9286 0 0.9988 1143641 
MS 1 15.15946 7168 0 0.9983 3834159 
Obseity 0 0 . . . . 
Osteoarthritis 1 -0.33851 0.45132 0.5626 0.4532 0.713 
Other Fx 1 14.50604 2186 0 0.9947 1994779 
Pancreatic Disease 1 15.42138 5800 0 0.9979 4982192 
Poly Rheumatica 1 16.08604 11074 0 0.9988 9684540 
Riley-Day 1 1.88542 23441 0 0.9999 6.589 
Renauld Disease 1 -0.42566 0.61794 0.4745 0.4909 0.653 
RA 1 -0.53012 0.89966 0.3472 0.5557 0.589 
Saccoidosis 1 -2.0071 1.12153 3.2027 0.0735 0.134 
Sickle Cell Anemia 1 14.96295 8905 0 0.9987 3150111 
Lupus 1 -1.70915 1.07869 2.5105 0.1131 0.181 
Spinal cord injury 0 0 . . . . 
Thalassemia 1 1.12718 19285 0 1 3.087 
Thyrotoxicosis 0 0 . . . . 
Vitamin D 1 15.23514 2010 0.0001 0.994 4135606 
lithium 1 15.2486 6727 0 0.9982 4191615 
thiaz 1 0.24455 0.75187 0.1058 0.745 1.277 
arom 1 -2.08823 1.02754 4.13 0.0421 0.124 
convulsants 1 -0.04753 0.40142 0.014 0.9057 0.954 
ssri 1 0.21171 0.54058 0.1534 0.6953 1.236 
ppi 1 -0.21495 0.32543 0.4363 0.5089 0.807 
mtx 1 -0.54634 1.12669 0.2351 0.6277 0.579 
csa 1 15.84067 9286 0 0.9986 7577337 
coag 1 -0.38896 0.55644 0.4886 0.4845 0.678 
Age 1 0.0102 0.294 0.0012 0.9723 1.01 
Age*Age  0 0 . . . . 
Age*Age*Age 0 0 . . . . 
Age*Osteoporosis 0 0 . . . . 
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Table A7 Approach 1 Vertebral Fracture 365 days, no restriction, regression coefficients  
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.23059 0.03911 34.7657 <.0001 1.259 
Cystic Fibrosis 1 -0.01793 0.57812 0.001 0.9753 0.982 
Congestive Heart Failure 1 -0.10348 0.02589 15.977 <.0001 0.902 
Ehlers-Danlos 1 9.42058 172.16383 0.003 0.9564 12339.73 
Epilepsy 1 0.11701 0.07735 2.2885 0.1303 1.124 
Osteogenesis Imperfecta 1 -0.30079 1.00122 0.0903 0.7639 0.74 
Parkinson’s Disease 1 -0.09147 0.06508 1.9754 0.1599 0.913 
Stroke 1 -0.06715 0.02838 5.5991 0.018 0.935 
Adrenal insufficiency 1 0.01201 0.44786 0.0007 0.9786 1.012 
AIDS/HIV 1 -0.40009 0.35412 1.2765 0.2586 0.67 
Alcoholism 1 -0.47057 0.11289 17.3769 <.0001 0.625 
Alzheimers 1 0.08334 0.02926 8.1105 0.0044 1.087 
Amyloidosis 1 -0.63421 0.3168 4.0077 0.0453 0.53 
Androgen insensitivity 1 8.96563 166.74087 0.0029 0.9571 7829.341 
Anorexia 1 -0.27027 0.0656 16.9763 <.0001 0.763 
Ankylosing spondylitis 1 -0.37177 0.07177 26.833 <.0001 0.69 
COPD 1 -0.40223 0.0208 374.1083 <.0001 0.669 
Athletic amenorrhea 1 0.22207 0.44743 0.2463 0.6197 1.249 
Cataracts 1 0.04372 0.02789 2.4579 0.1169 1.045 
Celiac 1 -0.35186 0.26818 1.7214 0.1895 0.703 
Central Adiposity 1 0.15257 0.04161 13.4457 0.0002 1.165 
Chronic metabolic acidosis 1 -0.07713 0.07909 0.951 0.3295 0.926 
Crohn’s Disease 1 -0.13887 0.04575 9.216 0.0024 0.87 
Cushing's 1 -0.80611 0.25888 9.6961 0.0018 0.447 
Depression 1 -0.04152 0.02729 2.3142 0.1282 0.959 
DM 1 0.08842 0.02199 16.1708 <.0001 1.092 
ESRD 1 -0.3078 0.08303 13.743 0.0002 0.735 
Disorders of the Eye 1 0.00491 0.02692 0.0333 0.8552 1.005 
Falling 1 -0.22278 0.03748 35.3398 <.0001 0.8 
Gaucher's Disease 1 0.23198 0.27761 0.6983 0.4034 1.261 
Glaucoma 1 -0.00502 0.0318 0.0249 0.8746 0.995 
Gout 1 0.16713 0.05395 9.596 0.0019 1.182 
Glycogen storage diseases 1 9.21742 89.80673 0.0105 0.9183 10071.03 
Hemochromatosis 1 9.09615 65.56946 0.0192 0.8897 8920.887 
Hemophilia 1 -0.07097 0.05763 1.5165 0.2181 0.931 
Homocystinuria 1 -0.28669 0.22987 1.5554 0.2123 0.751 
Hyperprolactinemia 1 -0.24516 0.57777 0.1801 0.6713 0.783 
Hyperparathyroidism 1 0.13334 0.09809 1.8479 0.174 1.143 
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Hyperthyrois 1 0.03525 0.06531 0.2913 0.5894 1.036 
Hypophosphatasia 1 -0.40828 0.10777 14.3515 0.0002 0.665 
IBD 1 0.05588 0.10117 0.305 0.5807 1.057 
Idopathic scoliosis 1 -0.28909 0.05023 33.1247 <.0001 0.749 
Idiopathic hypercalciuria 1 9.34013 303.66494 0.0009 0.9755 11385.86 
Kyphosis 1 -0.03348 0.03019 1.2301 0.2674 0.967 
Liver Disease 1 -0.19932 0.04338 21.107 <.0001 0.819 
Malabsorption 1 0.18316 0.18333 0.9982 0.3178 1.201 
Marfan syndrome 1 -0.75561 1.00156 0.5692 0.4506 0.47 
MS 1 -0.16716 0.16076 1.0812 0.2984 0.846 
Muscular dystrophy 1 -0.14145 0.50062 0.0798 0.7775 0.868 
Obseity 0 0 . . . . 
Osteoarthritis 1 -0.00628 0.02051 0.0937 0.7596 0.994 
Osteoporosis 1 -0.91282 0.22662 16.2245 <.0001 0.401 
Other Fx 1 -0.24942 0.03948 39.9085 <.0001 0.779 
Panhypopituitarism 1 0.06828 1.00073 0.0047 0.9456 1.071 
Pancreatic Disease 1 -0.15344 0.07094 4.6787 0.0305 0.858 
Poly Rheumatica 1 -0.29932 0.07029 18.1337 <.0001 0.741 
Porphyria 1 9.1852 69.11667 0.0177 0.8943 9751.696 
Premature ovarian failure 1 1.78368 1.00015 3.1806 0.0745 5.952 
Primary bilary cirrhosis 1 -0.54118 0.22232 5.9257 0.0149 0.582 
Riley-Day 1 8.88134 172.62493 0.0026 0.959 7196.409 
Renauld Disease 1 0.03027 0.03872 0.6112 0.4343 1.031 
RA 1 -0.19308 0.04569 17.8567 <.0001 0.824 
Saccoidosis 1 -0.08144 0.20459 0.1585 0.6906 0.922 
Sickle Cell Anemia 1 -0.36523 0.57808 0.3992 0.5275 0.694 
Lupus 1 -0.45374 0.0996 20.7521 <.0001 0.635 
Spinal cord injury 1 -0.45368 0.21933 4.2786 0.0386 0.635 
Systemic mastocytosis 1 -0.01382 1.00015 0.0002 0.989 0.986 
Turner’s & Klinefelter’s 
syndromes 
1 9.23187 191.56562 0.0023 0.9616 10217.67 
Thalassemia 1 0.48943 0.44745 1.1964 0.274 1.631 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 9.11912 111.705 0.0067 0.9349 9128.152 
Vitamin D 1 0.04929 0.04306 1.3105 0.2523 1.051 
barb 1 -0.23222 0.5779 0.1615 0.6878 0.793 
lithium 1 0.21459 0.22454 0.9134 0.3392 1.239 
thiaz 1 -0.16883 0.04987 11.4592 0.0007 0.845 
gnrh 1 9.69473 773.04082 0.0002 0.99 16231.76 
arom 1 -0.05324 0.07087 0.5644 0.4525 0.948 
convulsants 1 -0.23104 0.0246 88.235 <.0001 0.794 
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ssri 1 -0.18967 0.02258 70.5868 <.0001 0.827 
ppi 1 -0.18092 0.01933 87.6412 <.0001 0.835 
mtx 1 -0.33785 0.07307 21.3807 <.0001 0.713 
csa 1 0.06626 0.25028 0.0701 0.7912 1.069 
coag 1 -0.18359 0.02708 45.9736 <.0001 0.832 
white 1 -0.11377 0.21851 0.2711 0.6026 0.892 
black 1 0.79639 0.22299 12.7546 0.0004 2.218 
other_race 1 -0.00436 0.23556 0.0003 0.9852 0.996 
asian 1 -0.0032 0.22851 0.0002 0.9888 0.997 
hispanic 1 0.19854 0.22611 0.771 0.3799 1.22 
amnative 1 -0.15429 0.24856 0.3853 0.5348 0.857 
Age 1 -2.58707 0.25038 106.7601 <.0001 0.075 
Age*Age  1 0.03341 0.00313 113.696 <.0001 1.034 
Age*Age*Age 1 -0.0001399 0.000013 116.0796 <.0001 1 
Age*Osteoporosis 1 -0.0062 0.0028 4.8985 0.0269 0.994 
 
 
Table A8 Approach 1 Vertebral Fracture All Available, no restriction, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.22861 0.02243 103.8331 <.0001 1.257 
Cystic Fibrosis 1 -0.34424 0.30193 1.2999 0.2542 0.709 
Congestive Heart Failure 1 -0.10813 0.01718 39.6297 <.0001 0.898 
Ehlers-Danlos 1 -0.42674 1.00014 0.1821 0.6696 0.653 
Epilepsy 1 0.05186 0.05101 1.0339 0.3093 1.053 
Osteogenesis Imperfecta 1 -0.4026 0.70814 0.3232 0.5697 0.669 
Parkinson’s Disease 1 -0.14475 0.04368 10.9795 0.0009 0.865 
Stroke 1 -0.06034 0.01812 11.0899 0.0009 0.941 
Adrenal insufficiency 1 0.04235 0.28912 0.0215 0.8835 1.043 
AIDS/HIV 1 0.23433 0.31651 0.5481 0.4591 1.264 
Alcoholism 1 -0.57307 0.07162 64.018 <.0001 0.564 
Alzheimers 1 0.1317 0.02036 41.8577 <.0001 1.141 
Amyloidosis 1 -0.57096 0.22981 6.1726 0.013 0.565 
Androgen insensitivity 1 7.89933 65.85558 0.0144 0.9045 2695.468 
Anorexia 1 -0.14514 0.04831 9.0264 0.0027 0.865 
Ankylosing spondylitis 1 -0.2935 0.04455 43.3948 <.0001 0.746 
COPD 1 -0.34656 0.01349 660.3969 <.0001 0.707 
Athletic amenorrhea 1 0.557 0.30164 3.4099 0.0648 1.745 
Cataracts 1 0.03154 0.01684 3.5076 0.0611 1.032 
Celiac 1 -0.1638 0.16766 0.9544 0.3286 0.849 
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Central Adiposity 1 0.12018 0.02641 20.7137 <.0001 1.128 
Chronic metabolic acidosis 1 -0.07819 0.05685 1.8916 0.169 0.925 
Crohn’s Disease 1 -0.08397 0.02993 7.8701 0.005 0.919 
Cushing's 1 -0.56927 0.18624 9.3432 0.0022 0.566 
Depression 1 -0.04585 0.01797 6.5132 0.0107 0.955 
DM 1 0.10164 0.01414 51.6819 <.0001 1.107 
ESRD 1 -0.36031 0.05879 37.5649 <.0001 0.697 
Disorders of the Eye 1 -0.0348 0.01684 4.2673 0.0389 0.966 
Falling 1 -0.21605 0.02477 76.0685 <.0001 0.806 
Gaucher's Disease 1 0.34432 0.17425 3.9046 0.0482 1.411 
Glaucoma 1 0.04858 0.01916 6.4251 0.0113 1.05 
Gout 1 0.08774 0.03393 6.6878 0.0097 1.092 
Glycogen storage diseases 1 0.1757 0.57751 0.0926 0.7609 1.192 
Hemochromatosis 1 8.06807 30.83918 0.0684 0.7936 3190.932 
Hemophilia 1 -0.06299 0.03677 2.9342 0.0867 0.939 
Homocystinuria 1 0.2639 0.18279 2.0842 0.1488 1.302 
Hyperprolactinemia 1 -0.18333 0.37823 0.2349 0.6279 0.832 
Hyperparathyroidism 1 0.08183 0.06109 1.7942 0.1804 1.085 
Hyperthyrois 1 0.01673 0.04046 0.1709 0.6793 1.017 
Hypophosphatasia 1 -0.26922 0.08084 11.0916 0.0009 0.764 
IBD 1 -0.0691 0.06272 1.2138 0.2706 0.933 
Idopathic scoliosis 1 -0.20155 0.03357 36.0396 <.0001 0.817 
Idiopathic hypercalciuria 1 8.30128 87.75497 0.0089 0.9246 4029.023 
Kyphosis 1 -0.03338 0.01872 3.1794 0.0746 0.967 
Liver Disease 1 -0.14157 0.02823 25.1523 <.0001 0.868 
Malabsorption 1 0.07446 0.11089 0.4509 0.5019 1.077 
Marfan syndrome 1 0.01958 1.00051 0.0004 0.9844 1.02 
MS 1 -0.16384 0.10581 2.3979 0.1215 0.849 
Muscular dystrophy 1 0.24875 0.40846 0.3709 0.5425 1.282 
Obseity 0 0 . . . . 
Osteoarthritis 1 -0.00117 0.01298 0.0081 0.9285 0.999 
Osteoporosis 1 -0.84085 0.14917 31.7743 <.0001 0.431 
Other Fx 1 -0.27271 0.02568 112.8012 <.0001 0.761 
Panhypopituitarism 1 -0.96119 0.3785 6.4489 0.0111 0.382 
Pancreatic Disease 1 -0.15964 0.04697 11.554 0.0007 0.852 
Poly Rheumatica 1 -0.28486 0.04462 40.7582 <.0001 0.752 
Porphyria 1 0.63902 0.57745 1.2246 0.2685 1.895 
Premature ovarian failure 1 0.84548 0.35374 5.7127 0.0168 2.329 
Primary bilary cirrhosis 1 -0.43125 0.15497 7.7441 0.0054 0.65 
Riley-Day 1 7.84587 72.11101 0.0118 0.9134 2555.15 
Renauld Disease 1 0.03377 0.02657 1.6148 0.2038 1.034 
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RA 1 -0.1564 0.02936 28.3736 <.0001 0.855 
Saccoidosis 1 -0.12186 0.12631 0.9308 0.3347 0.885 
Sickle Cell Anemia 1 0.08713 0.50052 0.0303 0.8618 1.091 
Lupus 1 -0.49144 0.06186 63.1063 <.0001 0.612 
Spinal cord injury 1 -0.31859 0.15314 4.328 0.0375 0.727 
Systemic mastocytosis 1 0.25696 0.70719 0.132 0.7163 1.293 
Turner’s & Klinefelter’s 
syndromes 
1 8.20592 67.39314 0.0148 0.9031 3662.57 
Thalassemia 1 0.1192 0.24274 0.2412 0.6234 1.127 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 8.13582 40.47546 0.0404 0.8407 3414.619 
Vitamin D 1 0.01034 0.0282 0.1344 0.7139 1.01 
barb 1 -0.40453 0.33362 1.4702 0.2253 0.667 
lithium 1 0.21482 0.14354 2.2397 0.1345 1.24 
thiaz 1 -0.15449 0.03162 23.8641 <.0001 0.857 
gnrh 1 8.70604 213.12861 0.0017 0.9674 6039.264 
arom 1 -0.06067 0.04576 1.7576 0.1849 0.941 
convulsants 1 -0.24006 0.01625 218.2315 <.0001 0.787 
ssri 1 -0.18893 0.01499 158.9214 <.0001 0.828 
ppi 1 -0.15827 0.01262 157.3921 <.0001 0.854 
mtx 1 -0.38201 0.04675 66.7679 <.0001 0.682 
csa 1 -0.08861 0.14454 0.3758 0.5399 0.915 
coag 1 -0.24102 0.01738 192.318 <.0001 0.786 
white 1 -0.18415 0.15829 1.3533 0.2447 0.832 
black 1 0.72948 0.16098 20.5356 <.0001 2.074 
other_race 1 -0.02414 0.16844 0.0205 0.8861 0.976 
asian 1 -0.14955 0.16352 0.8364 0.3604 0.861 
hispanic 1 0.07922 0.16256 0.2375 0.626 1.082 
amnative 1 -0.18767 0.17678 1.127 0.2884 0.829 
Age 1 -2.21617 0.17231 165.4213 <.0001 0.109 
Age*Age  1 0.02885 0.00216 177.6266 <.0001 1.029 
Age*Age*Age 1 -0.0001215 9.01E-06 181.8347 <.0001 1 
Age*Osteoporosis 1 -0.00583 0.00187 9.7636 0.0018 0.994 
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Table A9 Approach 1 Vertebral Fracture 365 days, CFRI Without BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.22446 0.35235 0.4058 0.5241 1.252 
Cystic Fibrosis 1 13.42767 17275 0 0.9994 678517.3 
Congestive Heart 
Failure 
1 0.12393 0.41981 0.0872 0.7678 1.132 
Epilepsy 1 -0.51644 1.10019 0.2203 0.6388 0.597 
Parkinson’s Disease 1 14.68519 2457 0 0.9952 2386134 
Stroke 1 -0.33824 0.4044 0.6996 0.4029 0.713 
Adrenal insufficiency 1 13.66081 15601 0 0.9993 856671.1 
AIDS/HIV 1 12.86624 1266 0.0001 0.9919 387024.9 
Alcoholism 1 14.54208 2690 0 0.9957 2067980 
Alzheimers 1 0.28062 0.76328 0.1352 0.7131 1.324 
Anorexia 1 13.89782 1491 0.0001 0.9926 1085787 
Ankylosing spondylitis 1 -1.0717 1.01858 1.107 0.2927 0.342 
COPD 1 -0.207 0.3111 0.4427 0.5058 0.813 
Athletic amenorrhea 1 14.24561 13000 0 0.9991 1537413 
Cataracts 1 0.3977 0.50328 0.6245 0.4294 1.488 
Celiac 1 -1.51083 7640 0 0.9998 0.221 
Central Adiposity 1 0.69789 0.3661 3.6338 0.0566 2.009 
Chronic metabolic 
acidosis 
1 14.49818 3776 0 0.9969 1979163 
Crohn’s Disease 1 -0.34102 1.02154 0.1114 0.7385 0.711 
Cushing's 1 14.34642 7991 0 0.9986 1700479 
Depression 1 -0.46031 0.32024 2.0661 0.1506 0.631 
DM 1 -0.04013 0.24097 0.0277 0.8677 0.961 
ESRD 1 0.09545 0.68909 0.0192 0.8898 1.1 
Disorders of the Eye 1 -0.09068 0.39145 0.0537 0.8168 0.913 
Falling 1 -1.31709 0.53732 6.0085 0.0142 0.268 
Gaucher's Disease 1 14.29963 4347 0 0.9974 1622746 
Glaucoma 1 1.15724 0.76036 2.3163 0.128 3.181 
Gout 1 -0.24202 0.62898 0.1481 0.7004 0.785 
Glycogen storage 
diseases 
1 12.30165 14117 0 0.9993 220058.7 
Hemochromatosis 1 15.29951 9154 0 0.9987 4410563 
Hemophilia 1 -0.67672 0.57178 1.4007 0.2366 0.508 
Homocystinuria 1 14.29415 6662 0 0.9983 1613884 
Hyperprolactinemia 1 14.77715 11547 0 0.999 2615976 
Hyperthyrois 1 0.19781 1.01806 0.0378 0.8459 1.219 
Hypophosphatasia 1 -2.82277 1.16098 5.9115 0.015 0.059 
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IBD 1 14.51044 3957 0 0.9971 2003572 
Idopathic scoliosis 1 11.82032 946.36057 0.0002 0.99 135987.1 
Kyphosis 1 1.59959 1.01221 2.4973 0.114 4.951 
Liver Disease 1 14.3819 909.34937 0.0003 0.9874 1761893 
Malabsorption 1 14.08019 3964 0 0.9972 1303014 
MS 1 14.26417 2998 0 0.9962 1566213 
Obseity 0 0 . . . . 
Osteoarthritis 1 -0.2533 0.27661 0.8386 0.3598 0.776 
Osteoporosis 1 -50.969 30.67919 2.7601 0.0966 0 
Other Fx 1 14.43621 1482 0.0001 0.9922 1860229 
Panhypopituitarism 1 1.17679 22938 0 1 3.244 
Pancreatic Disease 1 14.52086 2321 0 0.995 2024545 
Poly Rheumatica 1 14.62233 6380 0 0.9982 2240775 
Premature ovarian 
failure 
1 13.81262 8582 0 0.9987 997109.3 
Primary bilary cirrhosis 1 -0.71842 13092 0 1 0.488 
Riley-Day 1 15.2713 19064 0 0.9994 4287849 
Renauld Disease 1 -0.24643 0.46724 0.2782 0.5979 0.782 
RA 1 -1.26908 0.65794 3.7206 0.0537 0.281 
Saccoidosis 1 13.47593 1300 0.0001 0.9917 712069.7 
Sickle Cell Anemia 1 13.76344 7365 0 0.9985 949259.2 
Lupus 1 -0.91683 1.04849 0.7646 0.3819 0.4 
Spinal cord injury 1 12.05186 15211 0 0.9994 171418.1 
Systemic mastocytosis 1 14.31059 24828 0 0.9995 1640624 
Thalassemia 1 13.80997 5440 0 0.998 994472.4 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 14.75374 18181 0 0.9994 2555445 
Vitamin D 1 -0.69882 0.43003 2.6408 0.1041 0.497 
barb 1 16.05006 14618 0 0.9991 9342300 
lithium 1 14.87818 3128 0 0.9962 2894081 
thiaz 1 -0.24538 0.36434 0.4536 0.5006 0.782 
arom 1 14.72058 2561 0 0.9954 2472099 
convulsants 1 0.10049 0.28962 0.1204 0.7286 1.106 
ssri 1 -0.36843 0.26735 1.8991 0.1682 0.692 
ppi 1 -0.31592 0.22093 2.0449 0.1527 0.729 
mtx 1 -0.72748 1.05793 0.4729 0.4917 0.483 
csa 1 13.92998 4444 0 0.9975 1121280 
coag 1 -0.74166 0.35329 4.4071 0.0358 0.476 
white 1 -14.09551 8816 0 0.9987 0 
black 1 -13.20542 8816 0 0.9988 0 
other_race 1 -13.39167 8816 0 0.9988 0 
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asian 1 -13.52236 8816 0 0.9988 0 
hispanic 1 -14.02925 8816 0 0.9987 0 
amnative 1 -15.01976 8816 0 0.9986 0 
Age 1 -395.61366 229.81153 2.9635 0.0852 0 
Age*Age  1 5.90163 3.43732 2.9478 0.086 365.634 
Age*Age*Age 1 -0.02934 0.01713 2.9329 0.0868 0.971 
Age*Osteoporosis 1 -0.74453 0.47139 2.4946 0.1142 0.475 
 
 
Table A10 Approach 1 Vertebral Fracture All Available, CFRI Without BMD, regression 
coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.57988 0.19416 8.92 0.0028 1.786 
Cystic Fibrosis 1 13.77302 8025 0 0.9986 958400 
Congestive Heart 
Failure 
1 0.322 0.28472 1.279 0.2581 1.38 
Epilepsy 1 -0.69812 0.61049 1.3077 0.2528 0.498 
Parkinson’s Disease 1 -0.09159 1.01117 0.0082 0.9278 0.912 
Stroke 1 -0.07097 0.27162 0.0683 0.7939 0.931 
Adrenal insufficiency 1 14.92822 9625 0 0.9988 3042594 
AIDS/HIV 1 12.70566 667.12417 0.0004 0.9848 329609.6 
Alcoholism 1 -1.43645 0.73086 3.863 0.0494 0.238 
Alzheimers 1 0.13917 0.46677 0.0889 0.7656 1.149 
Anorexia 1 -1.02042 0.74143 1.8941 0.1687 0.36 
Ankylosing spondylitis 1 -0.81662 0.7215 1.281 0.2577 0.442 
COPD 1 -0.10356 0.20102 0.2654 0.6064 0.902 
Athletic amenorrhea 1 14.47326 7238 0 0.9984 1930437 
Cataracts 1 0.25683 0.26025 0.9739 0.3237 1.293 
Celiac 1 14.38651 4446 0 0.9974 1770033 
Central Adiposity 1 0.62553 0.23325 7.1919 0.0073 1.869 
Chronic metabolic 
acidosis 
1 14.23514 1582 0.0001 0.9928 1521395 
Crohn’s Disease 1 -0.17965 0.7159 0.063 0.8019 0.836 
Cushing's 1 13.68044 4101 0 0.9973 873656.8 
Depression 1 -0.07717 0.22851 0.114 0.7356 0.926 
DM 1 -0.0794 0.15296 0.2695 0.6037 0.924 
ESRD 1 -0.85634 0.3337 6.5856 0.0103 0.425 
Disorders of the Eye 1 -0.11594 0.22718 0.2604 0.6098 0.891 
Falling 1 -0.84601 0.37891 4.9852 0.0256 0.429 
305 
 
Gaucher's Disease 1 14.06614 2195 0 0.9949 1284832 
Glaucoma 1 0.22657 0.28943 0.6128 0.4337 1.254 
Gout 1 -0.49721 0.35197 1.9955 0.1578 0.608 
Glycogen storage 
diseases 
1 10.9326 8340 0 0.999 55971.39 
Hemochromatosis 1 15.30407 8015 0 0.9985 4430697 
Hemophilia 1 -0.51466 0.40061 1.6504 0.1989 0.598 
Homocystinuria 1 13.99656 3891 0 0.9971 1198475 
Hyperprolactinemia 1 14.83818 13802 0 0.9991 2780614 
Hyperthyrois 1 0.19977 0.58813 0.1154 0.7341 1.221 
Hypophosphatasia 1 -1.46908 1.05153 1.9518 0.1624 0.23 
IBD 1 -0.90919 1.24288 0.5351 0.4645 0.403 
Idopathic scoliosis 1 12.39725 503.65227 0.0006 0.9804 242135.4 
Kyphosis 1 0.3845 0.33072 1.3517 0.245 1.469 
Liver Disease 1 0.78111 0.58852 1.7615 0.1844 2.184 
Malabsorption 1 -0.62731 1.06077 0.3497 0.5543 0.534 
MS 1 14.40555 1815 0.0001 0.9937 1804066 
Obseity 0 0 . . . . 
Osteoarthritis 1 -0.34313 0.16581 4.2827 0.0385 0.71 
Osteoporosis 1 -37.28609 20.01037 3.472 0.0624 0 
Other Fx 1 -0.18211 0.60613 0.0903 0.7638 0.834 
Panhypopituitarism 1 14.1877 11522 0 0.999 1450913 
Pancreatic Disease 1 0.06647 1.01667 0.0043 0.9479 1.069 
Poly Rheumatica 1 14.69933 4116 0 0.9972 2420126 
Premature ovarian 
failure 
1 13.51051 4240 0 0.9975 737125.5 
Primary bilary cirrhosis 1 12.5511 8368 0 0.9988 282407 
Riley-Day 1 15.13239 19545 0 0.9994 3731773 
Renauld Disease 1 -0.39547 0.27305 2.0977 0.1475 0.673 
RA 1 0.16025 0.63281 0.0641 0.8001 1.174 
Saccoidosis 1 13.09963 763.46147 0.0003 0.9863 488762.1 
Sickle Cell Anemia 1 13.83732 4287 0 0.9974 1022052 
Lupus 1 -1.45402 0.61379 5.6118 0.0178 0.234 
Spinal cord injury 1 12.41521 6152 0 0.9984 246522.1 
Systemic mastocytosis 1 14.02618 11791 0 0.9991 1234508 
Thalassemia 1 13.74806 2686 0 0.9959 934771.6 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 14.46003 14906 0 0.9992 1905063 
Vitamin D 1 -0.60147 0.30053 4.0054 0.0454 0.548 
barb 1 15.72874 9151 0 0.9986 6774942 
lithium 1 14.12055 1654 0.0001 0.9932 1356685 
thiaz 1 -0.18957 0.22971 0.681 0.4092 0.827 
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arom 1 -0.34961 1.00738 0.1204 0.7286 0.705 
convulsants 1 0.10552 0.19628 0.289 0.5909 1.111 
ssri 1 -0.38524 0.18272 4.4452 0.035 0.68 
ppi 1 -0.06393 0.1519 0.1771 0.6739 0.938 
mtx 1 -0.89479 0.74592 1.439 0.2303 0.409 
csa 1 13.02466 1690 0.0001 0.9939 453459.7 
coag 1 -0.69275 0.23935 8.3766 0.0038 0.5 
white 1 -13.62097 4990 0 0.9978 0 
black 1 -12.95524 4990 0 0.9979 0 
other_race 1 -13.38614 4990 0 0.9979 0 
asian 1 -13.34897 4990 0 0.9979 0 
hispanic 1 -13.74245 4990 0 0.9978 0 
amnative 1 -14.34573 4990 0 0.9977 0 
Age 1 -134.51749 109.77553 1.5016 0.2204 0 
Age*Age  1 2.00064 1.63581 1.4958 0.2213 7.394 
Age*Age*Age 1 -0.00992 0.00812 1.4912 0.222 0.99 
Age*Osteoporosis 1 -0.55782 0.30592 3.3248 0.0682 0.572 
 
 
Table A11 Approach 1 Vertebral Fracture 365 days, CFRI With BMD, regression coefficients  
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 -0.17052 1.03674 0.0271 0.8694 0.843 
Congestive Heart 
Failure 
1 16.20557 2234 0.0001 0.9942 10914130 
Epilepsy 1 15.20043 3346 0 0.9964 3994498 
Parkinson’s Disease 1 16.65143 9809 0 0.9986 17046073 
Stroke 1 -0.24846 1.27293 0.0381 0.8452 0.78 
AIDS/HIV 1 15.88307 4784 0 0.9974 7905482 
Alcoholism 1 20.7782 8194 0 0.998 1.06E+09 
Alzheimers 1 -2.29952 1.11288 4.2695 0.0388 0.1 
Anorexia 1 4.21676 40887 0 0.9999 67.813 
Ankylosing spondylitis 1 14.98169 13659 0 0.9991 3209697 
COPD 1 -1.2873 0.68288 3.5536 0.0594 0.276 
Cataracts 1 0.04853 3545 0 1 1.05 
Celiac 1 -30.28138 93028 0 0.9997 0 
Central Adiposity 1 16.16266 2705 0 0.9952 10455676 
Chronic metabolic 
acidosis 
1 -1.2787 49097 0 1 0.278 
Crohn’s Disease 1 16.27383 10813 0 0.9988 11685190 
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Depression 1 -0.73551 1.05581 0.4853 0.486 0.479 
DM 1 -0.00619 0.58524 0.0001 0.9916 0.994 
ESRD 1 0.57447 1.29428 0.197 0.6571 1.776 
Disorders of the Eye 1 17.63102 2880 0 0.9951 45399941 
Falling 1 15.64558 5044 0 0.9975 6234310 
Gaucher's Disease 1 15.5225 39462 0 0.9997 5512357 
Glaucoma 1 -1.09212 4517 0 0.9998 0.336 
Gout 1 15.1723 5162 0 0.9977 3883719 
Hemochromatosis 1 -15.75932 90002 0 0.9999 0 
Hemophilia 1 -3.21122 1.10077 8.5103 0.0035 0.04 
Hyperthyrois 1 -2.73334 1.10651 6.102 0.0135 0.065 
Hypophosphatasia 1 -5.42681 1.15052 22.2487 <.0001 0.004 
IBD 1 1.05406 32005 0 1 2.869 
Idopathic scoliosis 1 -2.19341 7096 0 0.9998 0.112 
Kyphosis 1 15.8881 3880 0 0.9967 7945368 
Liver Disease 1 15.42408 4388 0 0.9972 4995679 
Malabsorption 1 0.14435 33734 0 1 1.155 
MS 1 16.41043 11017 0 0.9988 13395520 
Obseity 0 0 . . . . 
Osteoarthritis 1 -0.28861 0.79977 0.1302 0.7182 0.749 
Other Fx 1 14.07632 5156 0 0.9978 1297977 
Pancreatic Disease 1 16.31273 11686 0 0.9989 12148671 
Poly Rheumatica 1 17.33398 42340 0 0.9997 33732592 
Riley-Day 1 -12.25841 46491 0 0.9998 0 
Renauld Disease 1 -1.50847 1.01222 2.2209 0.1362 0.221 
RA 1 -2.48256 0.89345 7.7207 0.0055 0.084 
Saccoidosis 1 14.31583 6899 0 0.9983 1649252 
Sickle Cell Anemia 1 15.66724 24203 0 0.9995 6370846 
Lupus 1 16.00335 6950 0 0.9982 8915919 
Spinal cord injury 0 0 . . . . 
Thalassemia 1 0.86751 78764 0 1 2.381 
Thyrotoxicosis 0 0 . . . . 
Vitamin D 1 15.57106 3964 0 0.9969 5786625 
lithium 1 17.33315 10261 0 0.9987 33704894 
thiaz 1 -1.38213 0.79955 2.9882 0.0839 0.251 
arom 1 16.23052 14476 0 0.9991 11189916 
convulsants 1 0.43168 0.7858 0.3018 0.5828 1.54 
ssri 1 0.1987 0.78806 0.0636 0.8009 1.22 
ppi 1 -0.79525 0.51951 2.3432 0.1258 0.451 
mtx 1 -1.47218 1.22569 1.4427 0.2297 0.229 
csa 1 15.83201 30953 0 0.9996 7511998 
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coag 1 -1.32302 0.6802 3.7832 0.0518 0.266 
Age 1 0.1539 0.48779 0.0995 0.7524 1.166 
Age*Age  0 0 . . . . 
Age*Age*Age 0 0 . . . . 
Age*Osteoporosis 0 0 . . . . 
 
 
Table A12 Approach 1 Vert All Available, CFRI With BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 -0.55119 0.73395 0.564 0.4527 0.576 
Congestive Heart 
Failure 
1 16.16851 2146 0.0001 0.994 10517120 
Epilepsy 1 16.2782 4258 0 0.9969 11736350 
Parkinson’s Disease 1 15.94851 8710 0 0.9985 8440174 
Stroke 1 1.31702 1.51536 0.7554 0.3848 3.732 
AIDS/HIV 1 16.35833 4326 0 0.997 12715427 
Alcoholism 1 -1.12005 1.64462 0.4638 0.4958 0.326 
Alzheimers 1 -2.27915 0.7693 8.7773 0.0031 0.102 
Anorexia 1 1.28527 23387 0 1 3.616 
Ankylosing spondylitis 1 15.88333 10121 0 0.9987 7907541 
COPD 1 -0.63061 0.58868 1.1475 0.2841 0.532 
Cataracts 1 1.03069 3375 0 0.9998 2.803 
Celiac 1 -14.70279 48884 0 0.9998 0 
Central Adiposity 1 0.55479 1.04148 0.2838 0.5942 1.742 
Chronic metabolic 
acidosis 
1 -0.22353 28521 0 1 0.8 
Crohn’s Disease 1 15.43021 8808 0 0.9986 5026357 
Depression 1 0.76406 1.11365 0.4707 0.4927 2.147 
DM 1 -0.38731 0.38136 1.0314 0.3098 0.679 
ESRD 1 -0.854 0.62441 1.8705 0.1714 0.426 
Disorders of the Eye 1 16.87932 3024 0 0.9955 21408896 
Falling 1 -1.4954 1.14131 1.7168 0.1901 0.224 
Gaucher's Disease 1 15.26351 19951 0 0.9994 4254609 
Glaucoma 1 -0.14981 3852 0 1 0.861 
Gout 1 16.30049 3476 0 0.9963 12000870 
Hemochromatosis 1 -17.92489 78568 0 0.9998 0 
Hemophilia 1 -1.32241 1.4252 0.861 0.3535 0.266 
Hyperthyrois 1 -1.85091 1.04589 3.1318 0.0768 0.157 
Hypophosphatasia 1 -4.40281 1.02593 18.4171 <.0001 0.012 
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IBD 1 2.40582 21012 0 0.9999 11.088 
Idopathic scoliosis 1 -2.46875 5363 0 0.9996 0.085 
Kyphosis 1 16.1634 3239 0 0.996 10463471 
Liver Disease 1 16.00158 4116 0 0.9969 8900179 
Malabsorption 1 -0.49843 20136 0 1 0.607 
MS 1 16.05675 12682 0 0.999 9404968 
Obseity 0 0 . . . . 
Osteoarthritis 1 -0.19586 0.56908 0.1185 0.7307 0.822 
Other Fx 1 15.51281 6492 0 0.9981 5459179 
Pancreatic Disease 1 16.30309 9396 0 0.9986 12032090 
Poly Rheumatica 1 16.86626 22913 0 0.9994 21131278 
Riley-Day 1 -13.96877 44995 0 0.9998 0 
Renauld Disease 1 -0.48476 0.7533 0.4141 0.5199 0.616 
RA 1 -0.74841 0.97584 0.5882 0.4431 0.473 
Saccoidosis 1 14.8353 4645 0 0.9975 2772621 
Sickle Cell Anemia 1 16.15505 17148 0 0.9992 10376405 
Lupus 1 -1.98142 1.06697 3.4487 0.0633 0.138 
Spinal cord injury 0 0 . . . . 
Thalassemia 1 0.54758 40211 0 1 1.729 
Thyrotoxicosis 0 0 . . . . 
Vitamin D 1 15.99408 3648 0 0.9965 8833669 
lithium 1 16.6642 10373 0 0.9987 17265185 
thiaz 1 -0.1615 0.76087 0.0451 0.8319 0.851 
arom 1 -2.31785 1.03968 4.9702 0.0258 0.098 
convulsants 1 0.42034 0.54561 0.5935 0.4411 1.522 
ssri 1 0.19961 0.61934 0.1039 0.7472 1.221 
ppi 1 0.03313 0.407 0.0066 0.9351 1.034 
mtx 1 -1.21201 1.16639 1.0797 0.2988 0.298 
csa 1 16.6874 17050 0 0.9992 17670335 
coag 1 -0.68439 0.56845 1.4495 0.2286 0.504 
Age 1 -0.08383 0.338 0.0615 0.8041 0.92 
Age*Age  0 0 . . . . 
Age*Age*Age 0 0 . . . . 
Age*Osteoporosis 0 0 . . . . 
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Table A13 Approach 2 MOF 365 days, no restriction, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.36858 0.05452 45.6999 <.0001 1.446 
Cystic Fibrosis 1 -0.73017 1.0011 0.532 0.4658 0.482 
Congestive Heart Failure 1 -0.11012 0.06887 2.5567 0.1098 0.896 
Ehlers-Danlos 1 10.99121 1910 0 0.9954 59350 
Epilepsy 1 -0.04321 0.18858 0.0525 0.8188 0.958 
Osteogenesis Imperfecta 1 11.60901 670.10401 0.0003 0.9862 110085.3 
Parkinson’s Disease 1 -0.13996 0.17909 0.6108 0.4345 0.869 
Stroke 1 -0.01486 0.0674 0.0486 0.8255 0.985 
Adrenal insufficiency 1 -1.05216 0.71064 2.1921 0.1387 0.349 
AIDS/HIV 1 -0.58311 0.70919 0.6761 0.4109 0.558 
Alcoholism 1 -0.45331 0.32007 2.0059 0.1567 0.636 
Alzheimers 1 -0.16758 0.07566 4.9061 0.0268 0.846 
Amyloidosis 1 11.43135 445.87077 0.0007 0.9795 92165.97 
Androgen insensitivity 1 11.03792 1972 0 0.9955 62188.06 
Anorexia 1 -0.34179 0.16561 4.2592 0.039 0.711 
Ankylosing spondylitis 1 -0.50236 0.17268 8.4638 0.0036 0.605 
COPD 1 -0.22254 0.05712 15.1774 <.0001 0.8 
Athletic amenorrhea 1 11.58101 279.92818 0.0017 0.967 107045.2 
Cataracts 1 0.01072 0.0659 0.0265 0.8707 1.011 
Celiac 1 -0.23374 0.76528 0.0933 0.76 0.792 
Central Adiposity 1 0.18675 0.09882 3.5711 0.0588 1.205 
Chronic metabolic acidosis 1 0.13537 0.20802 0.4235 0.5152 1.145 
Crohn’s Disease 1 0.06131 0.12871 0.2269 0.6339 1.063 
Cushing's 1 -1.22122 0.50434 5.8632 0.0155 0.295 
Depression 1 0.04555 0.07248 0.3948 0.5298 1.047 
DM 1 -0.07089 0.05407 1.7188 0.1899 0.932 
ESRD 1 -0.59384 0.17573 11.4197 0.0007 0.552 
Disorders of the Eye 1 0.08188 0.06753 1.47 0.2253 1.085 
Falling 1 -0.37963 0.09074 17.5036 <.0001 0.684 
Gaucher's Disease 1 -0.1596 0.50153 0.1013 0.7503 0.852 
Glaucoma 1 0.09046 0.07648 1.3989 0.2369 1.095 
Gout 1 0.19117 0.13702 1.9464 0.163 1.211 
Glycogen storage diseases 1 11.45826 595.26769 0.0004 0.9846 94680.48 
Hemochromatosis 1 11.38766 593.94541 0.0004 0.9847 88226.28 
Hemophilia 1 -0.2411 0.13924 2.998 0.0834 0.786 
Homocystinuria 1 -0.61417 0.41388 2.2021 0.1378 0.541 
Hyperprolactinemia 1 -0.79095 1.01667 0.6053 0.4366 0.453 
Hyperparathyroidism 1 0.03077 0.20938 0.0216 0.8832 1.031 
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Hyperthyrois 1 0.03282 0.15527 0.0447 0.8326 1.033 
Hypophosphatasia 1 -0.05217 0.29201 0.0319 0.8582 0.949 
IBD 1 -0.01308 0.30493 0.0018 0.9658 0.987 
Idopathic scoliosis 1 -0.2845 0.14032 4.1105 0.0426 0.752 
Idiopathic hypercalciuria 1 11.72908 1673 0 0.9944 124129.7 
Kyphosis 1 0.12881 0.07493 2.9553 0.0856 1.137 
Liver Disease 1 0.06364 0.12076 0.2777 0.5982 1.066 
Malabsorption 1 0.22376 0.5021 0.1986 0.6559 1.251 
Marfan syndrome 1 11.74442 1475 0.0001 0.9936 126047.8 
MS 1 -0.21493 0.38111 0.318 0.5728 0.807 
Muscular dystrophy 1 11.70761 382.74851 0.0009 0.9756 121492.2 
Obseity 0 0 . . . . 
Osteoarthritis 1 -0.03661 0.05336 0.4706 0.4927 0.964 
Osteoporosis 1 -0.79851 0.55557 2.0658 0.1506 0.45 
Other Fx 1 -0.09201 0.10358 0.7892 0.3744 0.912 
Panhypopituitarism 1 11.48238 743.72735 0.0002 0.9877 96991.2 
Pancreatic Disease 1 -0.21986 0.18699 1.3824 0.2397 0.803 
Poly Rheumatica 1 0.14623 0.22221 0.4331 0.5105 1.157 
Porphyria 1 11.48693 662.38782 0.0003 0.9862 97434.16 
Premature ovarian failure 1 11.46338 225.91756 0.0026 0.9595 95166.27 
Primary bilary cirrhosis 1 -1.55742 0.59054 6.9553 0.0084 0.211 
Riley-Day 1 12.44159 1262 0.0001 0.9921 253113.3 
Renauld Disease 1 -0.23464 0.08732 7.2209 0.0072 0.791 
RA 1 0.00494 0.12729 0.0015 0.969 1.005 
Saccoidosis 1 -0.23609 0.50187 0.2213 0.6381 0.79 
Sickle Cell Anemia 1 11.07343 597.89352 0.0003 0.9852 64436.39 
Lupus 1 -0.76273 0.23501 10.5332 0.0012 0.466 
Spinal cord injury 1 -0.8781 0.41263 4.5286 0.0333 0.416 
Systemic mastocytosis 1 11.32435 662.88186 0.0003 0.9864 82814.2 
Turner’s & Klinefelter’s 
syndromes 
1 12.03053 1361 0.0001 0.9929 167801.1 
Thalassemia 1 0.12751 1.0017 0.0162 0.8987 1.136 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 11.3577 866.57779 0.0002 0.9895 85622.01 
Vitamin D 1 0.0426 0.09467 0.2025 0.6527 1.044 
barb 1 -2.11873 0.71907 8.6819 0.0032 0.12 
lithium 1 0.21051 0.7099 0.0879 0.7668 1.234 
thiaz 1 -0.13955 0.09517 2.1498 0.1426 0.87 
gnrh 1 11.7211 1583 0.0001 0.9941 123143.3 
arom 1 -0.25813 0.1714 2.268 0.1321 0.772 
convulsants 1 -0.2672 0.06875 15.1041 0.0001 0.766 
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ssri 1 -0.26154 0.06369 16.8656 <.0001 0.77 
ppi 1 -0.25684 0.05394 22.6767 <.0001 0.773 
mtx 1 -0.60638 0.19906 9.2796 0.0023 0.545 
csa 1 11.46811 206.24759 0.0031 0.9557 95616.95 
coag 1 -0.19316 0.07641 6.3897 0.0115 0.824 
white 1 -1.28427 1.00084 1.6466 0.1994 0.277 
black 1 -0.47536 1.00546 0.2235 0.6364 0.622 
other_race 1 -1.14693 1.01964 1.2653 0.2607 0.318 
asian 1 -1.07859 1.01059 1.1391 0.2858 0.34 
hispanic 1 -1.15994 1.00683 1.3273 0.2493 0.314 
amnative 1 -0.84505 1.08088 0.6112 0.4343 0.43 
Age 1 -2.8391 0.71308 15.8519 <.0001 0.058 
Age*Age  1 0.03576 0.00904 15.6445 <.0001 1.036 
Age*Age*Age 1 -0.0001463 0.000038 14.846 0.0001 1 
Age*Osteoporosis 1 -0.00789 0.00705 1.2519 0.2632 0.992 
 
 
Table A14 Approach 2 MOF All Available, no restriction, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.35524 0.03118 129.7853 <.0001 1.427 
Cystic Fibrosis 1 0.35528 1.0004 0.1261 0.7225 1.427 
Congestive Heart Failure 1 -0.08714 0.04161 4.3861 0.0362 0.917 
Ehlers-Danlos 1 8.70506 368.92716 0.0006 0.9812 6033.377 
Epilepsy 1 0.0465 0.12567 0.1369 0.7114 1.048 
Osteogenesis Imperfecta 1 9.20262 174.08619 0.0028 0.9578 9923.048 
Parkinson’s Disease 1 -0.24674 0.10762 5.2559 0.0219 0.781 
Stroke 1 -0.02343 0.03969 0.3485 0.555 0.977 
Adrenal insufficiency 1 -0.65177 0.44942 2.1032 0.147 0.521 
AIDS/HIV 1 0.57141 0.70962 0.6484 0.4207 1.771 
Alcoholism 1 -0.36787 0.20236 3.3048 0.0691 0.692 
Alzheimers 1 -0.05559 0.04775 1.3555 0.2443 0.946 
Amyloidosis 1 0.02465 1.00093 0.0006 0.9804 1.025 
Androgen insensitivity 1 8.7391 310.61133 0.0008 0.9776 6242.291 
Anorexia 1 -0.15569 0.11657 1.7838 0.1817 0.856 
Ankylosing spondylitis 1 -0.26661 0.10803 6.0912 0.0136 0.766 
COPD 1 -0.27332 0.03315 67.9864 <.0001 0.761 
Athletic amenorrhea 1 0.45844 0.57828 0.6285 0.4279 1.582 
Cataracts 1 -0.01404 0.03731 0.1417 0.7066 0.986 
Celiac 1 0.10813 0.36652 0.087 0.768 1.114 
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Central Adiposity 1 0.24223 0.06131 15.6077 <.0001 1.274 
Chronic metabolic acidosis 1 0.14796 0.14299 1.0706 0.3008 1.159 
Crohn’s Disease 1 -0.00527 0.07414 0.005 0.9434 0.995 
Cushing's 1 -0.83998 0.35579 5.5738 0.0182 0.432 
Depression 1 -0.05473 0.04307 1.6144 0.2039 0.947 
DM 1 -0.04402 0.03129 1.9791 0.1595 0.957 
ESRD 1 -0.59862 0.12118 24.4023 <.0001 0.55 
Disorders of the Eye 1 0.05434 0.03929 1.913 0.1666 1.056 
Falling 1 -0.32267 0.05588 33.3422 <.0001 0.724 
Gaucher's Disease 1 0.92459 0.44778 4.2635 0.0389 2.521 
Glaucoma 1 -0.00986 0.04178 0.0557 0.8135 0.99 
Gout 1 -0.00504 0.07609 0.0044 0.9472 0.995 
Glycogen storage diseases 1 -1.40616 0.71047 3.9172 0.0478 0.245 
Hemochromatosis 1 9.09928 123.72466 0.0054 0.9414 8948.861 
Hemophilia 1 -0.08271 0.0905 0.8353 0.3608 0.921 
Homocystinuria 1 0.25871 0.35483 0.5316 0.4659 1.295 
Hyperprolactinemia 1 -0.89801 0.71393 1.5822 0.2085 0.407 
Hyperparathyroidism 1 0.111 0.12485 0.7904 0.374 1.117 
Hyperthyrois 1 0.01572 0.08873 0.0314 0.8593 1.016 
Hypophosphatasia 1 -0.1633 0.1907 0.7333 0.3918 0.849 
IBD 1 -0.00812 0.17598 0.0021 0.9632 0.992 
Idopathic scoliosis 1 -0.27078 0.08064 11.2751 0.0008 0.763 
Idiopathic hypercalciuria 1 9.6526 251.6257 0.0015 0.9694 15562.25 
Kyphosis 1 0.12698 0.04258 8.8944 0.0029 1.135 
Liver Disease 1 -0.00786 0.06941 0.0128 0.9098 0.992 
Malabsorption 1 -0.25668 0.22553 1.2954 0.2551 0.774 
Marfan syndrome 1 9.97842 301.28879 0.0011 0.9736 21556.33 
MS 1 0.00599 0.26001 0.0005 0.9816 1.006 
Muscular dystrophy 1 9.77599 96.24069 0.0103 0.9191 17605.96 
Obseity 0 0 . . . . 
Osteoarthritis 1 -0.02031 0.03073 0.4368 0.5087 0.98 
Osteoporosis 1 -0.58701 0.32817 3.1996 0.0737 0.556 
Other Fx 1 -0.28766 0.05709 25.3853 <.0001 0.75 
Panhypopituitarism 1 -0.57668 1.00252 0.3309 0.5651 0.562 
Pancreatic Disease 1 -0.08663 0.12105 0.5122 0.4742 0.917 
Poly Rheumatica 1 -0.14121 0.10951 1.6626 0.1972 0.868 
Porphyria 1 -0.55807 1.00319 0.3095 0.578 0.572 
Premature ovarian failure 1 0.42263 0.50062 0.7127 0.3985 1.526 
Primary bilary cirrhosis 1 -1.05 0.45332 5.3651 0.0205 0.35 
Riley-Day 1 10.59561 493.44141 0.0005 0.9829 39959.15 
Renauld Disease 1 -0.15927 0.05536 8.2784 0.004 0.853 
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RA 1 -0.08967 0.07142 1.5765 0.2093 0.914 
Saccoidosis 1 0.0007375 0.31748 0 0.9981 1.001 
Sickle Cell Anemia 1 8.74962 113.28504 0.006 0.9384 6308.265 
Lupus 1 -0.32269 0.16733 3.719 0.0538 0.724 
Spinal cord injury 1 -0.66122 0.2696 6.0152 0.0142 0.516 
Systemic mastocytosis 1 8.98237 121.23387 0.0055 0.9409 7961.44 
Turner’s & Klinefelter’s 
syndromes 
1 10.10154 311.43824 0.0011 0.9741 24380.54 
Thalassemia 1 -1.0865 0.33526 10.5022 0.0012 0.337 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 -1.33217 1.00365 1.7618 0.1844 0.264 
Vitamin D 1 0.00579 0.05915 0.0096 0.922 1.006 
barb 1 -1.90778 0.58203 10.7438 0.001 0.148 
lithium 1 -0.1087 0.35569 0.0934 0.7599 0.897 
thiaz 1 -0.15881 0.05574 8.118 0.0044 0.853 
gnrh 1 9.86582 246.05715 0.0016 0.968 19260.67 
arom 1 -0.15032 0.10045 2.2394 0.1345 0.86 
convulsants 1 -0.24199 0.04129 34.3411 <.0001 0.785 
ssri 1 -0.20236 0.03811 28.1931 <.0001 0.817 
ppi 1 -0.09271 0.03217 8.3053 0.004 0.911 
mtx 1 -0.36606 0.11944 9.393 0.0022 0.693 
csa 1 0.78561 0.57823 1.8459 0.1743 2.194 
coag 1 -0.20879 0.04453 21.9822 <.0001 0.812 
white 1 -0.92521 0.50057 3.4163 0.0646 0.396 
black 1 -0.05625 0.50412 0.0124 0.9112 0.945 
other_race 1 -0.45408 0.51737 0.7703 0.3801 0.635 
asian 1 -0.5883 0.50751 1.3437 0.2464 0.555 
hispanic 1 -0.68 0.50525 1.8113 0.1783 0.507 
amnative 1 -0.79001 0.54073 2.1345 0.144 0.454 
Age 1 -3.64426 0.47551 58.736 <.0001 0.026 
Age*Age  1 0.04666 0.00607 59.1568 <.0001 1.048 
Age*Age*Age 1 -0.0001949 0.0000257 57.687 <.0001 1 
Age*Osteoporosis 1 -0.00545 0.00417 1.7065 0.1914 0.995 
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Table A15 Approach 2 MOF 365 days, CFRI Without BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 -0.28368 0.46857 0.3665 0.5449 0.753 
Cystic Fibrosis 1 16.12064 412857 0 1 10025433 
Congestive Heart 
Failure 
1 -1.60372 0.59356 7.3001 0.0069 0.201 
Epilepsy 1 16.91242 7150 0 0.9981 22129501 
Parkinson’s Disease 1 16.42408 12688 0 0.999 13579549 
Stroke 1 0.71451 1.05987 0.4545 0.5002 2.043 
AIDS/HIV 1 17.33938 11938 0 0.9988 33915559 
Alcoholism 1 15.67864 13345 0 0.9991 6443870 
Alzheimers 1 14.27532 2143 0 0.9947 1583770 
Anorexia 1 15.9626 16821 0 0.9992 8559916 
Ankylosing spondylitis 1 16.52575 9533 0 0.9986 15032879 
COPD 1 0.93074 0.78797 1.3952 0.2375 2.536 
Cataracts 1 0.1135 0.7571 0.0225 0.8808 1.12 
Central Adiposity 1 1.12081 0.79139 2.0058 0.1567 3.067 
Chronic metabolic 
acidosis 
1 16.02547 28929 0 0.9996 9115367 
Crohn’s Disease 1 15.76529 15939 0 0.9992 7027105 
Depression 1 0.74972 0.79546 0.8883 0.3459 2.116 
DM 1 -0.18855 0.47807 0.1556 0.6933 0.828 
ESRD 1 -0.21237 1.31065 0.0263 0.8713 0.809 
Disorders of the Eye 1 0.29768 0.67413 0.195 0.6588 1.347 
Falling 1 -1.69707 1.08592 2.4423 0.1181 0.183 
Gaucher's Disease 1 16.03658 13012 0 0.999 9217152 
Glaucoma 1 0.11751 0.8539 0.0189 0.8905 1.125 
Gout 1 -1.18307 1.07777 1.2049 0.2723 0.306 
Hemophilia 1 -1.76349 0.90087 3.832 0.0503 0.171 
Homocystinuria 1 16.52705 18487 0 0.9993 15052487 
Hyperprolactinemia 1 16.03455 31683 0 0.9996 9198491 
Hyperthyrois 1 -0.67518 1.04257 0.4194 0.5172 0.509 
Hypophosphatasia 1 15.07996 14331 0 0.9992 3541160 
IBD 1 0.37235 31302 0 1 1.451 
Idopathic scoliosis 1 16.6427 6597 0 0.998 16897928 
Kyphosis 1 1.02858 1.05763 0.9458 0.3308 2.797 
Liver Disease 1 14.64156 1325 0.0001 0.9912 2284266 
Malabsorption 1 15.53505 38961 0 0.9997 5581942 
MS 1 -2.12777 1.39964 2.3111 0.1285 0.119 
Obseity 0 0 . . . . 
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Osteoarthritis 1 -0.30568 0.49084 0.3878 0.5334 0.737 
Osteoporosis 1 -89.75277 57.35969 2.4484 0.1176 0 
Other Fx 1 12.05379 1225 0.0001 0.9922 171748.5 
Panhypopituitarism 1 16.84994 52848 0 0.9997 20789192 
Pancreatic Disease 1 15.87426 17830 0 0.9993 7836149 
Premature ovarian 
failure 
1 16.4424 18204 0 0.9993 13830737 
Renauld Disease 1 0.11501 0.93248 0.0152 0.9018 1.122 
RA 1 16.72904 5746 0 0.9977 18421739 
Saccoidosis 1 15.81459 17674 0 0.9993 7382290 
Lupus 1 15.84586 5471 0 0.9977 7616777 
Thalassemia 1 17.12619 30811 0 0.9996 27403615 
Thyrotoxicosis 0 0 . . . . 
Vitamin D 1 -0.44756 0.75754 0.3491 0.5546 0.639 
lithium 1 16.84089 12567 0 0.9989 20601726 
thiaz 1 -0.46093 0.64346 0.5131 0.4738 0.631 
arom 1 16.91942 39375 0 0.9997 22284984 
convulsants 1 -0.64841 0.52749 1.511 0.219 0.523 
ssri 1 -0.29111 0.58302 0.2493 0.6176 0.747 
ppi 1 -0.48027 0.45395 1.1193 0.2901 0.619 
mtx 1 15.54662 11071 0 0.9989 5646898 
csa 1 16.27488 27897 0 0.9995 11697467 
coag 1 0.77276 1.10446 0.4895 0.4841 2.166 
white 1 -17.57485 21770 0 0.9994 0 
black 1 -17.04869 21770 0 0.9994 0 
other_race 1 -18.40695 21770 0 0.9993 0 
asian 1 -17.06322 21770 0 0.9994 0 
hispanic 1 -18.81 21770 0 0.9993 0 
amnative 1 -19.95987 21770 0 0.9993 0 
Age 1 -900.82493 803.44941 1.2571 0.2622 0 
Age*Age  1 13.57082 12.09682 1.2585 0.2619 782943.2 
Age*Age*Age 1 -0.06813 0.06069 1.2602 0.2616 0.934 
Age*Osteoporosis 1 -1.35438 0.88521 2.3409 0.126 0.258 
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Table A16 Approach 2 MOF All Available, CFRI Without BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.32303 0.27804 1.3498 0.2453 1.381 
Cystic Fibrosis 1 13.74046 147206 0 0.9999 927693.5 
Congestive Heart 
Failure 
1 -0.63038 0.48205 1.7101 0.191 0.532 
Epilepsy 1 -1.54791 1.15964 1.7818 0.1819 0.213 
Parkinson’s Disease 1 15.50091 1762 0.0001 0.993 5394603 
Stroke 1 0.3265 0.57205 0.3258 0.5682 1.386 
AIDS/HIV 1 14.08168 2636 0 0.9957 1304956 
Alcoholism 1 14.00927 3377 0 0.9967 1213806 
Alzheimers 1 0.03536 1.04572 0.0011 0.973 1.036 
Anorexia 1 14.40483 5261 0 0.9978 1802766 
Ankylosing spondylitis 1 13.80979 2950 0 0.9963 994295.2 
COPD 1 -0.14988 0.3892 0.1483 0.7002 0.861 
Cataracts 1 -0.54796 0.5298 1.0697 0.301 0.578 
Central Adiposity 1 1.54823 0.57881 7.155 0.0075 4.703 
Chronic metabolic 
acidosis 
1 14.98971 6404 0 0.9981 3235561 
Crohn’s Disease 1 14.34443 3191 0 0.9964 1697103 
Depression 1 -0.00596 0.41864 0.0002 0.9886 0.994 
DM 1 -0.10394 0.32167 0.1044 0.7466 0.901 
ESRD 1 0.31514 1.14959 0.0752 0.784 1.37 
Disorders of the Eye 1 0.72026 0.51737 1.9381 0.1639 2.055 
Falling 1 -1.40288 0.76433 3.3688 0.0664 0.246 
Gaucher's Disease 1 14.56715 5841 0 0.998 2120481 
Glaucoma 1 -0.09522 0.55587 0.0293 0.864 0.909 
Gout 1 -1.85853 0.64405 8.3272 0.0039 0.156 
Hemophilia 1 -1.9291 0.80154 5.7924 0.0161 0.145 
Homocystinuria 1 15.21075 5334 0 0.9977 4035941 
Hyperprolactinemia 1 14.99699 13808 0 0.9991 3259204 
Hyperthyrois 1 -0.5923 0.73684 0.6462 0.4215 0.553 
Hypophosphatasia 1 13.01116 4850 0 0.9979 447379.3 
IBD 1 -0.5539 6634 0 0.9999 0.575 
Idopathic scoliosis 1 -0.84768 1.43322 0.3498 0.5542 0.428 
Kyphosis 1 1.26055 0.74909 2.8317 0.0924 3.527 
Liver Disease 1 14.51888 947.20809 0.0002 0.9878 2020545 
Malabsorption 1 12.91515 6697 0 0.9985 406424 
MS 1 -0.29133 1.23919 0.0553 0.8141 0.747 
Obseity 0 0 . . . . 
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Osteoarthritis 1 -0.25734 0.33174 0.6018 0.4379 0.773 
Osteoporosis 1 -56.37792 28.447 3.9278 0.0475 0 
Other Fx 1 13.78157 1983 0 0.9945 966633.2 
Panhypopituitarism 1 15.03757 14879 0 0.9992 3394167 
Pancreatic Disease 1 14.02736 4508 0 0.9975 1235962 
Premature ovarian 
failure 
1 14.69674 4076 0 0.9971 2413860 
Renauld Disease 1 -0.07913 0.60326 0.0172 0.8956 0.924 
RA 1 14.67354 1087 0.0002 0.9892 2358507 
Saccoidosis 1 13.69693 3444 0 0.9968 888176.1 
Lupus 1 -1.20133 1.15125 1.0889 0.2967 0.301 
Thalassemia 1 15.22605 9623 0 0.9987 4098161 
Thyrotoxicosis 0 0 . . . . 
Vitamin D 1 0.28931 0.73043 0.1569 0.692 1.336 
lithium 1 15.33033 4406 0 0.9972 4548590 
thiaz 1 -0.2983 0.4482 0.4429 0.5057 0.742 
arom 1 -3.33219 1.08761 9.3867 0.0022 0.036 
convulsants 1 -0.74182 0.33738 4.8345 0.0279 0.476 
ssri 1 -0.35919 0.37342 0.9252 0.3361 0.698 
ppi 1 0.06593 0.34 0.0376 0.8463 1.068 
mtx 1 -1.37102 1.11302 1.5173 0.218 0.254 
csa 1 14.76422 5510 0 0.9979 2582382 
coag 1 2.49805 1.13918 4.8086 0.0283 12.159 
white 1 -15.53144 7884 0 0.9984 0 
black 1 -14.38395 7884 0 0.9985 0 
other_race 1 -15.14385 7884 0 0.9985 0 
asian 1 -14.32086 7884 0 0.9986 0 
hispanic 1 -15.66853 7884 0 0.9984 0 
amnative 1 -16.97756 7884 0 0.9983 0 
Age 1 -423.55269 419.21729 1.0208 0.3123 0 
Age*Age  1 6.39307 6.29242 1.0322 0.3096 597.69 
Age*Age*Age 1 -0.03216 0.03147 1.0444 0.3068 0.968 
Age*Osteoporosis 1 -0.83541 0.43528 3.6835 0.055 0.434 
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Table A17 Approach 2 MOF 365 days, CFRI With BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 -18.80791 8021 0 0.9981 0 
Congestive Heart 
Failure 
1 13.10758 5565 0 0.9981 492662 
Epilepsy 1 0.53908 457476 0 1 1.714 
Parkinson’s Disease 1 18.52079 47805 0 0.9997 1.11E+08 
Stroke 1 20.5641 120081 0 0.9999 8.53E+08 
AIDS/HIV 1 20.97013 668206 0 1 1.28E+09 
Alcoholism 1 -32.03022 15400647 0 1 0 
Alzheimers 1 21.86311 620417 0 1 3.13E+09 
Anorexia 1 4.15658 8340429 0 1 63.853 
Ankylosing spondylitis 1 -14.57984 14931778 0 1 0 
COPD 1 14.95477 7522 0 0.9984 3124445 
Cataracts 1 -0.12984 2.00626 0.0042 0.9484 0.878 
Central Adiposity 1 22.09024 50065 0 0.9996 3.92E+09 
Chronic metabolic 
acidosis 
1 -5.42191 18966444 0 1 0.004 
Crohn’s Disease 1 -0.83807 3477073 0 1 0.433 
Depression 1 22.76158 77339 0 0.9998 7.68E+09 
DM 1 0.31862 1.47767 0.0465 0.8293 1.375 
ESRD 1 21.31495 216797 0 0.9999 1.81E+09 
Disorders of the Eye 1 -2.10283 1.60487 1.7168 0.1901 0.122 
Falling 1 3.51056 712887 0 1 33.467 
Gaucher's Disease 1 1.76246 23902434 0 1 5.827 
Glaucoma 1 -0.59487 1.75183 0.1153 0.7342 0.552 
Gout 1 18.7954 347157 0 1 1.45E+08 
Hemophilia 1 4.26968 1789414 0 1 71.499 
Hyperthyrois 1 2.2108 1834972 0 1 9.123 
Hypophosphatasia 1 -12.88784 5230623 0 1 0 
Idopathic scoliosis 1 -112.56166 323644682 0 1 0 
Kyphosis 1 21.00894 73168 0 0.9998 1.33E+09 
Liver Disease 1 2.41283 674246 0 1 11.166 
Malabsorption 1 -14.19792 4009633 0 1 0 
MS 1 -47.83553 58819289 0 1 0 
Obseity 0 0 . . . . 
Osteoarthritis 1 21.35183 43810 0 0.9996 1.87E+09 
Other Fx 1 22.86861 694132 0 1 8.55E+09 
Pancreatic Disease 1 -13.16066 13723930 0 1 0 
Renauld Disease 1 22.00549 69866 0 0.9997 3.60E+09 
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RA 1 2.18327 261487 0 1 8.875 
Saccoidosis 1 1.61984 1267216 0 1 5.052 
Lupus 1 20.1815 592006 0 1 5.82E+08 
Thyrotoxicosis 0 0 . . . . 
Vitamin D 1 17.33169 22571 0 0.9994 33655627 
lithium 1 -31.58284 18107120 0 1 0 
thiaz 1 -1.46474 1.50155 0.9516 0.3293 0.231 
arom 1 6.41079 1941730 0 1 608.372 
convulsants 1 -2.58918 1.61945 2.5562 0.1099 0.075 
ssri 1 19.74867 51955 0 0.9997 3.77E+08 
ppi 1 -0.12358 1.38725 0.0079 0.929 0.884 
mtx 1 22.2083 758071 0 1 4.42E+09 
coag 1 18.65417 22419 0 0.9993 1.26E+08 
Age 1 1.58787 1.50278 1.1165 0.2907 4.893 
Age*Age  0 0 . . . . 
Age*Age*Age 0 0 . . . . 
Age*Osteoporosis 0 0 . . . . 
 
 
Table A18 Approach 2 MOF All Available, CFRI With BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 -0.34216 1.19022 0.0826 0.7737 0.71 
Congestive Heart 
Failure 
1 17.82317 8215 0 0.9983 55017836 
Epilepsy 1 17.81151 39323 0 0.9996 54379934 
Parkinson’s Disease 1 18.32201 36146 0 0.9996 90603832 
Stroke 1 14.24532 5626 0 0.998 1536964 
AIDS/HIV 1 17.83429 69111 0 0.9998 55632991 
Alcoholism 1 -25.53775 173905 0 0.9999 0 
Alzheimers 1 13.80414 17738 0 0.9994 988697.6 
Anorexia 1 0.39927 285644 0 1 1.491 
Ankylosing spondylitis 1 1.51609 187740 0 1 4.554 
COPD 1 -1.12955 1.57093 0.517 0.4721 0.323 
Cataracts 1 -0.02912 1.84546 0.0002 0.9874 0.971 
Central Adiposity 1 17.7537 9632 0 0.9985 51325344 
Chronic metabolic 
acidosis 
1 -28.87295 115118 0 0.9998 0 
Crohn’s Disease 1 2.88154 80308 0 1 17.842 
Depression 1 29.84991 8000 0 0.997 9.20E+12 
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DM 1 -0.4323 1.05301 0.1685 0.6814 0.649 
ESRD 1 18.74658 21428 0 0.9993 1.39E+08 
Disorders of the Eye 1 -0.96714 1.29865 0.5546 0.4564 0.38 
Falling 1 -18.31916 4240 0 0.9966 0 
Gaucher's Disease 1 18.38577 294096 0 1 96568708 
Glaucoma 1 -0.0791 1.72241 0.0021 0.9634 0.924 
Gout 1 14.89705 27423 0 0.9996 2949208 
Hemophilia 1 0.2718 70564 0 1 1.312 
Hyperthyrois 1 4.48908 82627 0 1 89.04 
Hypophosphatasia 1 0.85861 212541 0 1 2.36 
Idopathic scoliosis 1 -97.79431 392621 0 0.9998 0 
Kyphosis 1 17.38027 9060 0 0.9985 35331124 
Liver Disease 1 0.88275 63889 0 1 2.418 
Malabsorption 1 -14.37341 80778 0 0.9999 0 
MS 1 -12.47286 174906 0 0.9999 0 
Obseity 0 0 . . . . 
Osteoarthritis 1 16.39664 4240 0 0.9969 13212020 
Other Fx 1 19.54016 48440 0 0.9997 3.06E+08 
Pancreatic Disease 1 1.28946 179831 0 1 3.631 
Renauld Disease 1 17.02273 8414 0 0.9984 24710357 
RA 1 14.84109 18593 0 0.9994 2788703 
Saccoidosis 1 0.77014 55927 0 1 2.16 
Lupus 1 15.81039 34782 0 0.9996 7351325 
Thyrotoxicosis 0 0 . . . . 
Vitamin D 1 16.4555 10326 0 0.9987 14013017 
lithium 1 -27.60796 36941 0 0.9994 0 
thiaz 1 -1.43116 1.55803 0.8438 0.3583 0.239 
arom 1 -2.81434 1.66151 2.8691 0.0903 0.06 
convulsants 1 -2.58737 1.00678 6.6046 0.0102 0.075 
ssri 1 16.95838 7231 0 0.9981 23170345 
ppi 1 -0.10395 1.32095 0.0062 0.9373 0.901 
mtx 1 12.90646 26234 0 0.9996 402906.4 
coag 1 15.39962 7704 0 0.9984 4874952 
Age 1 -0.14032 1.09398 0.0165 0.8979 0.869 
Age*Age  0 0 . . . . 
Age*Age*Age 0 0 . . . . 
Age*Osteoporosis 0 0 . . . . 
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Table A19 Approach 2 Vertebral Fracture 365 days, no restriction, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.60981 0.07285 70.0757 <.0001 1.84 
Cystic Fibrosis 1 -1.37604 1.00193 1.8862 0.1696 0.253 
Congestive Heart Failure 1 -0.11085 0.09416 1.3861 0.2391 0.895 
Ehlers-Danlos 1 11.54069 3600 0 0.9974 102815.2 
Epilepsy 1 0.11192 0.2696 0.1723 0.6781 1.118 
Osteogenesis Imperfecta 1 12.285 1419 0.0001 0.9931 216425 
Parkinson’s Disease 1 -0.39593 0.22078 3.2161 0.0729 0.673 
Stroke 1 -0.00731 0.09256 0.0062 0.9371 0.993 
Adrenal insufficiency 1 -0.99731 1.00491 0.9849 0.321 0.369 
AIDS/HIV 1 -1.15326 0.71102 2.6308 0.1048 0.316 
Alcoholism 1 -0.6345 0.38368 2.7348 0.0982 0.53 
Alzheimers 1 -0.03338 0.1069 0.0975 0.7549 0.967 
Amyloidosis 1 11.97897 837.47275 0.0002 0.9886 159367.7 
Androgen insensitivity 1 11.32153 3910 0 0.9977 82580.56 
Anorexia 1 -0.28013 0.23087 1.4722 0.225 0.756 
Ankylosing spondylitis 1 -0.47053 0.2289 4.2254 0.0398 0.625 
COPD 1 -0.32803 0.07605 18.6039 <.0001 0.72 
Athletic amenorrhea 1 12.18837 501.86246 0.0006 0.9806 196490.8 
Cataracts 1 -0.01058 0.08912 0.0141 0.9055 0.989 
Celiac 1 -0.89515 0.91527 0.9565 0.3281 0.409 
Central Adiposity 1 0.14214 0.13394 1.1262 0.2886 1.153 
Chronic metabolic acidosis 1 0.27722 0.31163 0.7914 0.3737 1.319 
Crohn’s Disease 1 0.02904 0.17096 0.0289 0.8651 1.029 
Cushing's 1 -1.09048 0.71175 2.3474 0.1255 0.336 
Depression 1 0.06269 0.0991 0.4002 0.527 1.065 
DM 1 0.00821 0.07395 0.0123 0.9116 1.008 
ESRD 1 -0.29767 0.27504 1.1713 0.2791 0.743 
Disorders of the Eye 1 0.04625 0.092 0.2528 0.6151 1.047 
Falling 1 -0.42026 0.1207 12.1243 0.0005 0.657 
Gaucher's Disease 1 0.64355 1.00141 0.413 0.5205 1.903 
Glaucoma 1 0.10439 0.10338 1.0196 0.3126 1.11 
Gout 1 0.35864 0.20196 3.1536 0.0758 1.431 
Glycogen storage diseases 1 11.92805 1082 0.0001 0.9912 151455.6 
Hemochromatosis 1 11.99174 1061 0.0001 0.991 161415.5 
Hemophilia 1 -0.36201 0.18309 3.9094 0.048 0.696 
Homocystinuria 1 -0.21143 0.7092 0.0889 0.7656 0.809 
Hyperprolactinemia 1 11.74529 838.3193 0.0002 0.9888 126158.5 
Hyperparathyroidism 1 0.58937 0.38313 2.3663 0.124 1.803 
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Hyperthyrois 1 0.25579 0.23281 1.2072 0.2719 1.291 
Hypophosphatasia 1 -0.41959 0.37591 1.2459 0.2643 0.657 
IBD 1 0.06681 0.41361 0.0261 0.8717 1.069 
Idopathic scoliosis 1 -0.47906 0.1704 7.9042 0.0049 0.619 
Idiopathic hypercalciuria 1 12.20653 3577 0 0.9973 200090.6 
Kyphosis 1 0.13766 0.10115 1.8522 0.1735 1.148 
Liver Disease 1 -0.06923 0.15486 0.1998 0.6549 0.933 
Malabsorption 1 0.32334 0.70982 0.2075 0.6487 1.382 
Marfan syndrome 1 12.8828 2773 0 0.9963 393484.4 
MS 1 -0.40645 0.45455 0.7995 0.3712 0.666 
Muscular dystrophy 1 11.79884 515.05537 0.0005 0.9817 133098.1 
Obseity 0 0 . . . . 
Osteoarthritis 1 -0.09748 0.07192 1.8374 0.1753 0.907 
Osteoporosis 1 0.03233 0.73934 0.0019 0.9651 1.033 
Other Fx 1 -0.25315 0.13104 3.7322 0.0534 0.776 
Panhypopituitarism 1 12.18312 1379 0.0001 0.993 195461.4 
Pancreatic Disease 1 -0.28093 0.24901 1.2728 0.2592 0.755 
Poly Rheumatica 1 0.00718 0.27326 0.0007 0.979 1.007 
Porphyria 1 12.21953 1112 0.0001 0.9912 202710 
Premature ovarian failure 1 12.12752 403.86823 0.0009 0.976 184890.6 
Primary bilary cirrhosis 1 -2.05436 0.59894 11.7647 0.0006 0.128 
Riley-Day 1 13.19721 2929 0 0.9964 538861.9 
Renauld Disease 1 -0.18441 0.12329 2.2372 0.1347 0.832 
RA 1 -0.02502 0.16469 0.0231 0.8792 0.975 
Saccoidosis 1 -0.08119 0.70967 0.0131 0.9089 0.922 
Sickle Cell Anemia 1 11.65146 1161 0.0001 0.992 114859.4 
Lupus 1 -0.96688 0.27611 12.2623 0.0005 0.38 
Spinal cord injury 1 -1.17826 0.45602 6.6758 0.0098 0.308 
Systemic mastocytosis 1 11.88555 1318 0.0001 0.9928 145153.9 
Turner’s & Klinefelter’s 
syndromes 
1 12.76621 2401 0 0.9958 350181.9 
Thalassemia 1 -0.44507 1.00311 0.1969 0.6573 0.641 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 12.00132 1705 0 0.9944 162970.5 
Vitamin D 1 0.04748 0.1323 0.1288 0.7197 1.049 
barb 1 -2.02045 1.01408 3.9697 0.0463 0.133 
lithium 1 11.95049 342.56761 0.0012 0.9722 154893.2 
thiaz 1 -0.10653 0.1335 0.6367 0.4249 0.899 
gnrh 1 12.44447 3287 0 0.997 253843.6 
arom 1 0.24349 0.29135 0.6984 0.4033 1.276 
convulsants 1 -0.34251 0.09116 14.1169 0.0002 0.71 
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ssri 1 -0.20991 0.08717 5.7984 0.016 0.811 
ppi 1 -0.32942 0.0724 20.6999 <.0001 0.719 
mtx 1 -0.68403 0.2492 7.5344 0.0061 0.505 
csa 1 11.27586 248.71516 0.0021 0.9638 78893.8 
coag 1 -0.16268 0.10477 2.4107 0.1205 0.85 
white 1 -0.56516 1.00149 0.3185 0.5725 0.568 
black 1 0.19753 1.01036 0.0382 0.845 1.218 
other_race 1 -0.89417 1.02349 0.7633 0.3823 0.409 
asian 1 -0.56001 1.01614 0.3037 0.5816 0.571 
hispanic 1 -0.40616 1.01289 0.1608 0.6884 0.666 
amnative 1 1.04611 1.41535 0.5463 0.4598 2.847 
Age 1 -2.83512 0.98463 8.2908 0.004 0.059 
Age*Age  1 0.03561 0.01251 8.1048 0.0044 1.036 
Age*Age*Age 1 -0.0001455 0.0000526 7.6419 0.0057 1 
Age*Osteoporosis 1 0.00262 0.00938 0.0778 0.7803 1.003 
 
 
Table A20 Approach 2 Vertebral Fracture All Available, no restriction, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.48367 0.04309 125.9881 <.0001 1.622 
Cystic Fibrosis 1 -0.35775 1.00074 0.1278 0.7207 0.699 
Congestive Heart Failure 1 -0.08887 0.05747 2.3912 0.122 0.915 
Ehlers-Danlos 1 9.38269 749.36844 0.0002 0.99 11880.87 
Epilepsy 1 0.16864 0.17658 0.9121 0.3396 1.184 
Osteogenesis Imperfecta 1 9.72898 332.77068 0.0009 0.9767 16797.46 
Parkinson’s Disease 1 -0.45651 0.13652 11.1812 0.0008 0.633 
Stroke 1 -0.02932 0.05484 0.2859 0.5929 0.971 
Adrenal insufficiency 1 -0.80106 0.58037 1.9051 0.1675 0.449 
AIDS/HIV 1 -0.01949 0.71207 0.0007 0.9782 0.981 
Alcoholism 1 -0.60099 0.23941 6.3015 0.0121 0.548 
Alzheimers 1 0.11034 0.06861 2.586 0.1078 1.117 
Amyloidosis 1 -0.65624 1.00184 0.4291 0.5124 0.519 
Androgen insensitivity 1 9.52044 627.80872 0.0002 0.9879 13635.63 
Anorexia 1 -0.21883 0.15293 2.0474 0.1525 0.803 
Ankylosing spondylitis 1 -0.36056 0.13683 6.9437 0.0084 0.697 
COPD 1 -0.37341 0.04465 69.9501 <.0001 0.688 
Athletic amenorrhea 1 0.26355 0.70856 0.1383 0.7099 1.302 
Cataracts 1 0.00268 0.05108 0.0028 0.9582 1.003 
Celiac 1 -0.34426 0.41972 0.6727 0.4121 0.709 
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Central Adiposity 1 0.23576 0.0851 7.6749 0.0056 1.266 
Chronic metabolic acidosis 1 0.25766 0.206 1.5644 0.211 1.294 
Crohn’s Disease 1 0.02594 0.10139 0.0654 0.7981 1.026 
Cushing's 1 -0.73661 0.50163 2.1563 0.142 0.479 
Depression 1 -0.10268 0.05853 3.0774 0.0794 0.902 
DM 1 0.04237 0.04357 0.9457 0.3308 1.043 
ESRD 1 -0.51835 0.17291 8.9866 0.0027 0.596 
Disorders of the Eye 1 -0.03886 0.05391 0.5195 0.471 0.962 
Falling 1 -0.33857 0.07563 20.0416 <.0001 0.713 
Gaucher's Disease 1 1.91252 1.0005 3.6541 0.0559 6.77 
Glaucoma 1 0.09139 0.05827 2.4601 0.1168 1.096 
Gout 1 -0.06827 0.10259 0.4428 0.5058 0.934 
Glycogen storage diseases 1 -1.41154 1.00461 1.9742 0.16 0.244 
Hemochromatosis 1 9.88555 245.33346 0.0016 0.9679 19644.53 
Hemophilia 1 -0.09183 0.12403 0.5482 0.4591 0.912 
Homocystinuria 1 0.99759 0.70819 1.9843 0.1589 2.712 
Hyperprolactinemia 1 9.51323 191.21187 0.0025 0.9603 13537.7 
Hyperparathyroidism 1 0.24468 0.18667 1.7181 0.1899 1.277 
Hyperthyrois 1 0.0368 0.12269 0.0899 0.7642 1.037 
Hypophosphatasia 1 -0.44768 0.24168 3.4312 0.064 0.639 
IBD 1 -0.10372 0.23098 0.2016 0.6534 0.901 
Idopathic scoliosis 1 -0.34364 0.10496 10.719 0.0011 0.709 
Idiopathic hypercalciuria 1 10.1778 485.70985 0.0004 0.9833 26312.56 
Kyphosis 1 0.13629 0.05911 5.3163 0.0211 1.146 
Liver Disease 1 -0.03768 0.09298 0.1643 0.6853 0.963 
Malabsorption 1 -0.34712 0.29141 1.4188 0.2336 0.707 
Marfan syndrome 1 10.71209 481.49676 0.0005 0.9823 44895.33 
MS 1 -0.17067 0.31967 0.285 0.5934 0.843 
Muscular dystrophy 1 10.32737 168.91635 0.0037 0.9512 30557.67 
Obseity 0 0 . . . . 
Osteoarthritis 1 -0.04119 0.04221 0.9523 0.3291 0.96 
Osteoporosis 1 -0.20367 0.44242 0.2119 0.6453 0.816 
Other Fx 1 -0.40505 0.07437 29.6663 <.0001 0.667 
Panhypopituitarism 1 -1.14018 1.00461 1.2881 0.2564 0.32 
Pancreatic Disease 1 -0.28267 0.15257 3.4324 0.0639 0.754 
Poly Rheumatica 1 -0.31155 0.13499 5.3264 0.021 0.732 
Porphyria 1 -1.04669 1.00626 1.082 0.2983 0.351 
Premature ovarian failure 1 0.1364 0.57841 0.0556 0.8136 1.146 
Primary bilary cirrhosis 1 -1.46948 0.50973 8.311 0.0039 0.23 
Riley-Day 1 10.59055 841.464 0.0002 0.99 39757.38 
Renauld Disease 1 -0.13662 0.07837 3.0386 0.0813 0.872 
326 
 
RA 1 -0.17294 0.09202 3.532 0.0602 0.841 
Saccoidosis 1 0.10481 0.44907 0.0545 0.8154 1.111 
Sickle Cell Anemia 1 9.41011 229.69518 0.0017 0.9673 12211.16 
Lupus 1 -0.50899 0.20088 6.4199 0.0113 0.601 
Spinal cord injury 1 -0.7726 0.33694 5.258 0.0218 0.462 
Systemic mastocytosis 1 9.60743 250.96746 0.0015 0.9695 14874.94 
Turner’s & Klinefelter’s 
syndromes 
1 10.5837 563.80589 0.0004 0.985 39486.05 
Thalassemia 1 -0.96987 0.45006 4.6439 0.0312 0.379 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 -2.03039 1.00683 4.0668 0.0437 0.131 
Vitamin D 1 0.16586 0.08828 3.53 0.0603 1.18 
barb 1 -2.00293 0.71345 7.8815 0.005 0.135 
lithium 1 0.63902 0.70901 0.8123 0.3674 1.895 
thiaz 1 -0.08729 0.0804 1.1786 0.2776 0.916 
gnrh 1 10.35542 450.6778 0.0005 0.9817 31427.04 
arom 1 0.08193 0.15264 0.2881 0.5915 1.085 
convulsants 1 -0.28703 0.05578 26.4766 <.0001 0.75 
ssri 1 -0.18213 0.05242 12.0725 0.0005 0.833 
ppi 1 -0.12701 0.04393 8.36 0.0038 0.881 
mtx 1 -0.37498 0.15258 6.0397 0.014 0.687 
csa 1 1.29262 1.00104 1.6674 0.1966 3.642 
coag 1 -0.19331 0.06158 9.8555 0.0017 0.824 
white 1 -0.88339 0.70789 1.5573 0.2121 0.413 
black 1 -0.00103 0.71319 0 0.9988 0.999 
other_race 1 -0.64404 0.72656 0.7857 0.3754 0.525 
asian 1 -0.85285 0.71501 1.4227 0.233 0.426 
hispanic 1 -0.72706 0.71378 1.0375 0.3084 0.483 
amnative 1 -0.56026 0.77555 0.5219 0.47 0.571 
Age 1 -3.15406 0.65743 23.0166 <.0001 0.043 
Age*Age  1 0.04034 0.00839 23.1149 <.0001 1.041 
Age*Age*Age 1 -0.0001682 0.0000355 22.4401 <.0001 1 
Age*Osteoporosis 1 0.0001064 0.00563 0.0004 0.9849 1 
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Table A21 Approach 2 Vertebral Fracture 365 days, CFRI Without BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.41921 0.625 0.4499 0.5024 1.521 
Cystic Fibrosis 0 0 . . . . 
Congestive Heart 
Failure 
1 -1.34929 0.94158 2.0535 0.1519 0.259 
Epilepsy 1 10.30987 2733 0 0.997 30027.61 
Parkinson’s Disease 1 16.67073 22788 0 0.9994 17378272 
Stroke 1 0.00659 1.09989 0 0.9952 1.007 
AIDS/HIV 1 18.964 48162 0 0.9997 1.72E+08 
Alcoholism 1 17.63052 31028 0 0.9995 45377252 
Alzheimers 1 16.47216 9701 0 0.9986 14248432 
Anorexia 1 17.2557 66809 0 0.9998 31192818 
Ankylosing spondylitis 1 18.49681 24987 0 0.9994 1.08E+08 
COPD 1 0.28083 0.94949 0.0875 0.7674 1.324 
Cataracts 1 -0.20578 0.94644 0.0473 0.8279 0.814 
Central Adiposity 1 1.61226 1.07202 2.2619 0.1326 5.014 
Chronic metabolic 
acidosis 
1 16.71124 86001 0 0.9998 18096677 
Crohn’s Disease 1 18.09184 38756 0 0.9996 71975814 
Depression 1 0.54272 1.02391 0.2809 0.5961 1.721 
DM 1 0.6147 0.76739 0.6416 0.4231 1.849 
ESRD 1 14.78519 9502 0 0.9988 2637107 
Disorders of the Eye 1 -0.39225 0.87196 0.2024 0.6528 0.676 
Falling 1 -2.16692 1.13057 3.6736 0.0553 0.115 
Gaucher's Disease 1 17.28224 37672 0 0.9996 32031744 
Glaucoma 1 0.58929 1.17222 0.2527 0.6152 1.803 
Gout 1 -1.93755 1.49429 1.6813 0.1948 0.144 
Hemophilia 1 -2.01114 1.20946 2.7651 0.0963 0.134 
Homocystinuria 1 18.7614 102535 0 0.9999 1.41E+08 
Hyperprolactinemia 1 20.15119 132831 0 0.9999 5.64E+08 
Hyperthyrois 1 18.13789 17944 0 0.9992 75367918 
Hypophosphatasia 1 16.79765 50473 0 0.9997 19729910 
IBD 1 -1.8744 102851 0 1 0.153 
Idopathic scoliosis 1 19.93594 8527 0 0.9981 4.55E+08 
Kyphosis 1 17.31603 2961 0 0.9953 33132605 
Liver Disease 1 16.99293 7939 0 0.9983 23984781 
Malabsorption 1 13.56798 82820 0 0.9999 780728.9 
MS 1 -2.19092 1.75212 1.5636 0.2111 0.112 
Obseity 0 0 . . . . 
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Osteoarthritis 1 -1.17627 0.60986 3.7202 0.0538 0.308 
Osteoporosis 1 -107.8273 2962 0.0013 0.971 0 
Other Fx 1 14.2905 7656 0 0.9985 1607995 
Panhypopituitarism 1 3.51203 251592 0 1 33.516 
Pancreatic Disease 1 17.35964 71313 0 0.9998 34609625 
Premature ovarian 
failure 
1 18.76865 98803 0 0.9998 1.42E+08 
Renauld Disease 1 15.64731 3682 0 0.9966 6245111 
RA 1 17.57874 14868 0 0.9991 43087387 
Saccoidosis 1 15.34089 37180 0 0.9997 4596879 
Lupus 1 17.92022 18841 0 0.9992 60624938 
Thalassemia 1 7.12439 150992 0 1 1241.896 
Thyrotoxicosis 0 0 . . . . 
Vitamin D 1 -0.69386 1.08172 0.4114 0.5212 0.5 
lithium 1 17.24014 56522 0 0.9998 30711382 
thiaz 1 -1.36926 0.86732 2.4924 0.1144 0.254 
arom 1 18.49956 183777 0 0.9999 1.08E+08 
convulsants 1 -0.88545 0.72672 1.4845 0.2231 0.413 
ssri 1 -0.63653 0.79018 0.6489 0.4205 0.529 
ppi 1 0.17138 0.74161 0.0534 0.8172 1.187 
mtx 1 17.43913 25427 0 0.9995 37473109 
csa 1 2.81256 99149 0 1 16.652 
coag 1 16.39138 2707 0 0.9952 13142783 
white 1 -20.76686 131646 0 0.9999 0 
black 1 -17.74349 131646 0 0.9999 0 
other_race 1 -20.55535 131646 0 0.9999 0 
asian 1 -1.49437 131912 0 1 0.224 
hispanic 1 -20.43646 131646 0 0.9999 0 
amnative 1 -1.3943 139673 0 1 0.248 
Age 1 -1280 1696 0.5693 0.4505 0 
Age*Age  1 19.35246 25.617 0.5707 0.45 2.54E+08 
Age*Age*Age 1 -0.09753 0.12895 0.5721 0.4494 0.907 
Age*Osteoporosis 1 -1.37491 0.98924 1.9317 0.1646 0.253 
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Table A22 Approach 2 Vertebral Fracture All Available, CFRI Without BMD, regression 
coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.76387 0.40801 3.5051 0.0612 2.147 
Cystic Fibrosis 0 0 . . . . 
Congestive Heart 
Failure 
1 -1.13098 0.62346 3.2907 0.0697 0.323 
Epilepsy 1 13.96177 5720 0 0.9981 1157497 
Parkinson’s Disease 1 13.8274 5362 0 0.9979 1011960 
Stroke 1 -0.21638 0.6608 0.1072 0.7433 0.805 
AIDS/HIV 1 15.13739 7181 0 0.9983 3750461 
Alcoholism 1 15.0151 9707 0 0.9988 3318755 
Alzheimers 1 14.96662 2716 0 0.9956 3161694 
Anorexia 1 15.35077 13536 0 0.9991 4642527 
Ankylosing spondylitis 1 14.56175 7979 0 0.9985 2109054 
COPD 1 -0.66151 0.49047 1.8191 0.1774 0.516 
Cataracts 1 -0.84162 0.72697 1.3403 0.247 0.431 
Central Adiposity 1 1.34695 0.71589 3.5401 0.0599 3.846 
Chronic metabolic 
acidosis 
1 14.86413 19813 0 0.9994 2853713 
Crohn’s Disease 1 15.34409 7354 0 0.9983 4611623 
Depression 1 -0.24319 0.54278 0.2007 0.6541 0.784 
DM 1 0.75453 0.46679 2.6128 0.106 2.127 
ESRD 1 16.30582 3429 0 0.9962 12064996 
Disorders of the Eye 1 0.64128 0.72257 0.7876 0.3748 1.899 
Falling 1 -0.87574 1.13556 0.5947 0.4406 0.417 
Gaucher's Disease 1 15.8881 14645 0 0.9991 7945406 
Glaucoma 1 0.08604 0.74084 0.0135 0.9075 1.09 
Gout 1 -2.00106 0.87776 5.1972 0.0226 0.135 
Hemophilia 1 -1.43897 1.13436 1.6092 0.2046 0.237 
Homocystinuria 1 16.42181 12578 0 0.999 13548769 
Hyperprolactinemia 1 17.22808 34227 0 0.9996 30343176 
Hyperthyrois 1 -0.65925 1.04941 0.3946 0.5299 0.517 
Hypophosphatasia 1 14.1518 11315 0 0.999 1399745 
IBD 1 -1.02585 16354 0 0.9999 0.358 
Idopathic scoliosis 1 0.50882 1.80202 0.0797 0.7777 1.663 
Kyphosis 1 1.60088 1.10346 2.1048 0.1468 4.957 
Liver Disease 1 16.59812 1991 0.0001 0.9933 16161178 
Malabsorption 1 12.42078 15901 0 0.9994 247900.3 
MS 1 -0.29956 1.48573 0.0407 0.8402 0.741 
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Obseity 0 0 . . . . 
Osteoarthritis 1 -0.48333 0.43638 1.2267 0.268 0.617 
Osteoporosis 1 -63.6157 30.9486 4.2252 0.0398 0 
Other Fx 1 14.2027 4226 0 0.9973 1472836 
Panhypopituitarism 1 16.29293 44068 0 0.9997 11910483 
Pancreatic Disease 1 15.12411 12479 0 0.999 3700995 
Premature ovarian 
failure 
1 16.33855 10665 0 0.9988 12466431 
Renauld Disease 1 -0.56996 0.78578 0.5261 0.4682 0.566 
RA 1 16.03262 2473 0 0.9948 9180777 
Saccoidosis 1 13.94207 6191 0 0.9982 1134919 
Lupus 1 -1.41418 1.35355 1.0916 0.2961 0.243 
Thalassemia 1 16.73552 28620 0 0.9995 18541437 
Thyrotoxicosis 0 0 . . . . 
Vitamin D 1 0.38292 1.05022 0.1329 0.7154 1.467 
lithium 1 16.31406 10266 0 0.9987 12164857 
thiaz 1 -0.96507 0.58599 2.7123 0.0996 0.381 
arom 1 -4.5724 1.19905 14.5416 0.0001 0.01 
convulsants 1 -0.47512 0.51836 0.8401 0.3594 0.622 
ssri 1 -0.33962 0.53662 0.4005 0.5268 0.712 
ppi 1 -0.05379 0.46889 0.0132 0.9087 0.948 
mtx 1 -2.16794 1.23366 3.0882 0.0789 0.114 
csa 1 15.73749 13847 0 0.9991 6834495 
coag 1 16.19736 1513 0.0001 0.9915 10824870 
white 1 -17.12683 25476 0 0.9995 0 
black 1 -14.98353 25476 0 0.9995 0 
other_race 1 -15.75829 25476 0 0.9995 0 
asian 1 -14.57665 25476 0 0.9995 0 
hispanic 1 -16.54522 25476 0 0.9995 0 
amnative 1 -0.33222 26869 0 1 0.717 
Age 1 -1999 1129 3.1391 0.0764 0 
Age*Age  1 30.26741 17.04205 3.1543 0.0757 1.40E+13 
Age*Age*Age 1 -0.15267 0.08576 3.169 0.075 0.858 
Age*Osteoporosis 1 -0.92969 0.4721 3.878 0.0489 0.395 
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Table A23 Approach 2 Vertebral Fracture 365 days, CFRI With BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 0 -14.67275 . . . . 
Congestive Heart 
Failure 
0 10.83239 . . . . 
Epilepsy 0 -44.16991 . . . . 
Parkinson’s Disease 0 -20.64949 . . . . 
Stroke 0 27.26695 . . . . 
AIDS/HIV 0 -20.91575 . . . . 
Alcoholism 0 -9.34805 . . . . 
Alzheimers 0 -17.53555 . . . . 
Anorexia 0 0.19984 . . . . 
Ankylosing spondylitis 0 272.54957 . . . . 
COPD 0 26.42629 . . . . 
Cataracts 0 0.53638 . . . . 
Central Adiposity 0 9.59947 . . . . 
Chronic metabolic 
acidosis 
0 54.58757 . . . . 
Crohn’s Disease 0 -4.13548 . . . . 
Depression 0 10.65813 . . . . 
DM 0 -1.66942 . . . . 
ESRD 0 -17.23292 . . . . 
Disorders of the Eye 0 17.40843 . . . . 
Falling 0 18.25968 . . . . 
Gaucher's Disease 0 -10.7636 . . . . 
Glaucoma 0 -43.72316 . . . . 
Gout 0 12.55679 . . . . 
Hemophilia 0 5.83458 . . . . 
Hyperthyrois 0 34.72215 . . . . 
Hypophosphatasia 0 7.19154 . . . . 
Idopathic scoliosis 0 -3.78129 . . . . 
Kyphosis 0 16.85857 . . . . 
Liver Disease 0 5.69325 . . . . 
Malabsorption 0 6.38849 . . . . 
MS 0 -17.24928 . . . . 
Obseity 0 0 . . . . 
Osteoarthritis 0 -15.83894 . . . . 
Other Fx 0 -1.42016 . . . . 
Pancreatic Disease 0 5.19293 . . . . 
Renauld Disease 0 5.05151 . . . . 
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RA 0 49.94904 . . . . 
Saccoidosis 0 -8.81972 . . . . 
Lupus 0 -25.74728 . . . . 
Thyrotoxicosis 0 0 . . . . 
Vitamin D 1 -4.48074 34558004 0 1 0.011 
lithium 0 -10.06346 . . . . 
thiaz 0 -37.92258 . . . . 
arom 0 -1.947 . . . . 
convulsants 0 10.46405 . . . . 
ssri 0 15.64561 . . . . 
ppi 0 9.50334 . . . . 
mtx 0 -19.86823 . . . . 
coag 0 -6.62971 . . . . 
Age 1 18.41333 1153543 0 1 99268098 
Age*Age  0 0 . . . . 
Age*Age*Age 0 0 . . . . 
Age*Osteoporosis 0 0 . . . . 
 
 
Table A24 Approach 2 Vertebral Fracture All Available, CFRI With BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 2.01615 160402 0 1 7.509 
Congestive Heart 
Failure 
1 174.65858 4367621 0 1 7.13E+75 
Epilepsy 1 56.11989 7134271 0 1 2.36E+24 
Parkinson’s Disease 1 -76.16294 5538680 0 1 0 
Stroke 1 -30.39157 4084802 0 1 0 
AIDS/HIV 1 -122.05827 114890285 0 1 0 
Alcoholism 1 -145.99136 443437919 0 1 0 
Alzheimers 1 -119.76494 10439068 0 1 0 
Anorexia 1 370.19929 1.74E+10 0 1 5.96E+160 
Ankylosing spondylitis 1 -162.85208 421495224 0 1 0 
COPD 1 -134.05357 697401 0 0.9998 0 
Cataracts 1 -12.24814 3647130 0 1 0 
Central Adiposity 1 45.39841 7780555 0 1 5.20E+19 
Chronic metabolic 
acidosis 
1 -255.46199 665324885 0 1 0 
Crohn’s Disease 1 -87.98374 1313874502 0 1 0 
Depression 1 -52.95248 3543682 0 1 0 
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DM 1 -4.3601 46120 0 0.9999 0.013 
ESRD 1 -0.12682 305603 0 1 0.881 
Disorders of the Eye 1 48.78054 5485488 0 1 1.53E+21 
Falling 1 -38.29993 3487709 0 1 0 
Gaucher's Disease 1 135.21054 566759921 0 1 5.26E+58 
Glaucoma 1 -75.33456 4121875 0 1 0 
Gout 1 -54.75707 26189145 0 1 0 
Hemophilia 1 -137.42218 188422408 0 1 0 
Hyperthyrois 1 -100.09263 6889757 0 1 0 
Hypophosphatasia 1 -95.10568 427781577 0 1 0 
Idopathic scoliosis 1 191.49709 1073638808 0 1 1.47E+83 
Kyphosis 1 4.4891 151255548 0 1 89.041 
Liver Disease 1 -114.79502 87066432 0 1 0 
Malabsorption 1 -133.33852 261920112 0 1 0 
MS 1 216.22443 465610060 0 1 8.04E+93 
Obseity 0 0 . . . . 
Osteoarthritis 1 49.32677 3517439 0 1 2.65E+21 
Other Fx 1 -127.22382 77307607 0 1 0 
Pancreatic Disease 1 -160.00767 500081197 0 1 0 
Renauld Disease 1 -45.16715 3640520 0 1 0 
RA 1 -78.24089 7135778 0 1 0 
Saccoidosis 1 -168.86541 116574792 0 1 0 
Lupus 1 -127.97522 24177620 0 1 0 
Thyrotoxicosis 0 0 . . . . 
Vitamin D 1 47.14258 4226531 0 1 2.98E+20 
lithium 1 -104.91797 916912 0 0.9999 0 
thiaz 1 -141.38471 684855 0 0.9998 0 
arom 1 -161.53417 700287 0 0.9998 0 
convulsants 1 25.61996 365857 0 0.9999 1.34E+11 
ssri 1 51.61049 3587043 0 1 2.60E+22 
ppi 1 47.29894 551103 0 0.9999 3.48E+20 
mtx 1 43.2768 7148669 0 1 6.24E+18 
coag 1 60.13062 3584770 0 1 1.30E+26 
Age 1 2.50468 155185 0 1 12.24 
Age*Age  0 0 . . . . 
Age*Age*Age 0 0 . . . . 
Age*Osteoporosis 0 0 . . . . 
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Table A25 Approach 3 MOF 365 days, no restriction, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.21107 0.02895 53.1574 <.0001 1.235 
Cystic Fibrosis 1 9.12079 79.88164 0.013 0.9091 9143.403 
Congestive Heart Failure 1 -0.19431 0.03511 30.6283 <.0001 0.823 
Ehlers-Danlos 1 -1.09372 1.0005 1.195 0.2743 0.335 
Epilepsy 1 -0.00174 0.10054 0.0003 0.9862 0.998 
Osteogenesis Imperfecta 1 9.45425 179.99448 0.0028 0.9581 12762.25 
Parkinson’s Disease 1 -0.46581 0.08274 31.6957 <.0001 0.628 
Stroke 1 -0.03044 0.04482 0.4612 0.497 0.97 
Adrenal insufficiency 1 -0.81009 0.37897 4.5693 0.0325 0.445 
AIDS/HIV 1 -1.28954 0.379 11.577 0.0007 0.275 
Alcoholism 1 -0.44915 0.15023 8.9383 0.0028 0.638 
Alzheimers 1 -0.16994 0.04347 15.2845 <.0001 0.844 
Amyloidosis 1 0.02783 0.5776 0.0023 0.9616 1.028 
Androgen insensitivity 1 9.47107 250.99625 0.0014 0.9699 12978.79 
Anorexia 1 -0.24693 0.11443 4.6568 0.0309 0.781 
Ankylosing spondylitis 1 -0.37724 0.12881 8.5773 0.0034 0.686 
COPD 1 -0.27807 0.02617 112.8662 <.0001 0.757 
Athletic amenorrhea 1 -0.57412 0.50019 1.3174 0.2511 0.563 
Cataracts 1 0.02486 0.06134 0.1643 0.6852 1.025 
Celiac 1 -0.50003 0.32646 2.346 0.1256 0.607 
Central Adiposity 1 0.06125 0.04972 1.5177 0.218 1.063 
Chronic metabolic acidosis 1 -0.10167 0.11966 0.7218 0.3955 0.903 
Crohn’s Disease 1 -0.20543 0.06345 10.4823 0.0012 0.814 
Cushing's 1 -0.79076 0.31707 6.2198 0.0126 0.453 
Depression 1 -0.09861 0.03466 8.0927 0.0044 0.906 
DM 1 -0.02831 0.02501 1.2806 0.2578 0.972 
ESRD 1 -0.64217 0.10522 37.2485 <.0001 0.526 
Disorders of the Eye 1 -0.03736 0.04693 0.6338 0.426 0.963 
Falling 1 -0.3455 0.05453 40.1448 <.0001 0.708 
Gaucher's Disease 1 -0.16085 0.44742 0.1292 0.7192 0.851 
Glaucoma 1 0.07215 0.07556 0.9119 0.3396 1.075 
Gout 1 0.07936 0.06955 1.302 0.2538 1.083 
Glycogen storage diseases 1 9.3876 161.93676 0.0034 0.9538 11939.38 
Hemochromatosis 1 -0.41132 0.50028 0.676 0.411 0.663 
Hemophilia 1 -0.08279 0.09451 0.7674 0.381 0.921 
Homocystinuria 1 0.0932 0.40858 0.052 0.8196 1.098 
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Hyperprolactinemia 1 8.90496 81.74789 0.0119 0.9133 7368.395 
Hyperparathyroidism 1 -0.0377 0.102 0.1366 0.7117 0.963 
Hyperthyrois 1 -0.10177 0.08191 1.5436 0.2141 0.903 
Hypophosphatasia 1 -0.2189 0.17025 1.6531 0.1985 0.803 
IBD 1 -0.11286 0.12466 0.8197 0.3653 0.893 
Idopathic scoliosis 1 -0.30763 0.0641 23.0319 <.0001 0.735 
Kyphosis 1 -0.0768 0.0391 3.8574 0.0495 0.926 
Liver Disease 1 -0.15342 0.06021 6.4925 0.0108 0.858 
Malabsorption 1 0.16589 0.24331 0.4649 0.4954 1.18 
Marfan syndrome 1 -1.0255 1.00071 1.0501 0.3055 0.359 
MS 1 -0.04979 0.21401 0.0541 0.816 0.951 
Muscular dystrophy 1 -0.12119 0.708 0.0293 0.8641 0.886 
Obseity 0 0 . . . . 
Osteoarthritis 1 0.03364 0.02636 1.6284 0.2019 1.034 
Osteoporosis 1 -1.49878 0.3126 22.9875 <.0001 0.223 
Other Fx 1 -0.23699 0.04875 23.6362 <.0001 0.789 
Panhypopituitarism 1 9.12389 124.16241 0.0054 0.9414 9171.841 
Pancreatic Disease 1 -0.17711 0.09081 3.804 0.0511 0.838 
Poly Rheumatica 1 -0.23995 0.08366 8.2252 0.0041 0.787 
Porphyria 1 0.24181 1.00036 0.0584 0.809 1.274 
Premature ovarian failure 1 8.53389 74.19095 0.0132 0.9084 5084.21 
Primary bilary cirrhosis 1 -0.38735 0.27387 2.0003 0.1573 0.679 
Riley-Day 1 9.86822 343.98611 0.0008 0.9771 19307 
Renauld Disease 1 -0.00508 0.05005 0.0103 0.9192 0.995 
RA 1 -0.17013 0.0545 9.7432 0.0018 0.844 
Saccoidosis 1 0.13526 0.24302 0.3098 0.5778 1.145 
Sickle Cell Anemia 1 -0.23357 1.0019 0.0544 0.8157 0.792 
Lupus 1 -0.58389 0.10571 30.5073 <.0001 0.558 
Spinal cord injury 1 -1.05573 0.33457 9.9573 0.0016 0.348 
Systemic mastocytosis 1 8.895 166.53875 0.0029 0.9574 7295.433 
Turner’s & Klinefelter’s 
syndromes 
1 9.50802 484.15546 0.0004 0.9843 13467.3 
Thalassemia 1 0.11724 0.44746 0.0687 0.7933 1.124 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 8.82345 207.70356 0.0018 0.9661 6791.625 
Vitamin D 1 0.15349 0.04793 10.2547 0.0014 1.166 
barb 1 -0.61044 0.40903 2.2273 0.1356 0.543 
lithium 1 0.20745 0.21427 0.9373 0.333 1.231 
thiaz 1 -0.24948 0.04867 26.273 <.0001 0.779 
arom 1 -0.0004823 0.05325 0.0001 0.9928 1 
convulsants 1 -0.33425 0.02447 186.5565 <.0001 0.716 
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ssri 1 -0.29322 0.02226 173.4605 <.0001 0.746 
ppi 1 -0.15232 0.01957 60.5746 <.0001 0.859 
mtx 1 -0.42294 0.06274 45.4456 <.0001 0.655 
csa 1 -0.18767 0.21864 0.7368 0.3907 0.829 
coag 1 -0.23607 0.02676 77.8041 <.0001 0.79 
white 1 -0.20037 0.24284 0.6808 0.4093 0.818 
black 1 0.82986 0.24836 11.1652 0.0008 2.293 
other_race 1 0.36676 0.2672 1.8841 0.1699 1.443 
asian 1 -0.06365 0.25434 0.0626 0.8024 0.938 
hispanic 1 0.07049 0.25046 0.0792 0.7784 1.073 
amnative 1 0.00833 0.29721 0.0008 0.9776 1.008 
Age 1 -1.83513 0.3409 28.9792 <.0001 0.16 
Age*Age 1 0.02425 0.00433 31.318 <.0001 1.025 
Age*Age*Age 1 -0.0001024 0.0000183 31.4318 <.0001 1 
Age*Osteoporosis 1 -0.01422 0.00395 12.9541 0.0003 0.986 
 
 
Table A26 Approach 3 MOF All Available Time, no restriction, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.25813 0.01559 274.1333 <.0001 1.295 
Cystic Fibrosis 1 8.11697 27.3571 0.088 0.7667 3350.837 
Congestive Heart Failure 1 -0.1421 0.02151 43.6545 <.0001 0.868 
Ehlers-Danlos 1 -0.91205 0.70728 1.6629 0.1972 0.402 
Epilepsy 1 -0.05247 0.0624 0.7072 0.4004 0.949 
Osteogenesis Imperfecta 1 8.48581 69.49969 0.0149 0.9028 4845.512 
Parkinson’s Disease 1 -0.38137 0.05227 53.2308 <.0001 0.683 
Stroke 1 -0.02167 0.0265 0.6685 0.4136 0.979 
Adrenal insufficiency 1 -0.5769 0.24303 5.6347 0.0176 0.562 
AIDS/HIV 1 -0.89733 0.27797 10.4208 0.0012 0.408 
Alcoholism 1 -0.48983 0.08768 31.2091 <.0001 0.613 
Alzheimers 1 -0.14181 0.02694 27.7084 <.0001 0.868 
Amyloidosis 1 -0.10881 0.33347 0.1065 0.7442 0.897 
Androgen insensitivity 1 8.37925 82.41239 0.0103 0.919 4355.724 
Anorexia 1 -0.23411 0.07174 10.6485 0.0011 0.791 
Ankylosing spondylitis 1 -0.3212 0.08173 15.4432 <.0001 0.725 
COPD 1 -0.2759 0.01547 317.8852 <.0001 0.759 
Athletic amenorrhea 1 0.10752 0.40834 0.0693 0.7923 1.114 
Cataracts 1 0.07487 0.03622 4.2733 0.0387 1.078 
Celiac 1 0.26799 0.19839 1.8247 0.1768 1.307 
337 
 
Central Adiposity 1 0.13969 0.03157 19.5852 <.0001 1.15 
Chronic metabolic acidosis 1 -0.1311 0.07642 2.9428 0.0863 0.877 
Crohn’s Disease 1 -0.0927 0.03943 5.5276 0.0187 0.911 
Cushing's 1 -0.5405 0.224 5.8226 0.0158 0.582 
Depression 1 -0.10954 0.021 27.2206 <.0001 0.896 
DM 1 -0.02952 0.01447 4.1639 0.0413 0.971 
ESRD 1 -0.61645 0.06643 86.1042 <.0001 0.54 
Disorders of the Eye 1 -0.03648 0.02774 1.7296 0.1885 0.964 
Falling 1 -0.22205 0.03404 42.5481 <.0001 0.801 
Gaucher's Disease 1 0.1673 0.30162 0.3077 0.5791 1.182 
Glaucoma 1 0.11378 0.04526 6.3185 0.0119 1.121 
Gout 1 0.05451 0.04172 1.707 0.1914 1.056 
Glycogen storage diseases 1 8.32746 53.77194 0.024 0.8769 4135.895 
Hemochromatosis 1 -0.11516 0.44735 0.0663 0.7968 0.891 
Hemophilia 1 -0.12916 0.05494 5.5264 0.0187 0.879 
Homocystinuria 1 -0.05677 0.2184 0.0676 0.7949 0.945 
Hyperprolactinemia 1 7.89711 30.82837 0.0656 0.7978 2689.486 
Hyperparathyroidism 1 -0.03401 0.06195 0.3015 0.5829 0.967 
Hyperthyrois 1 0.01432 0.05035 0.0809 0.776 1.014 
Hypophosphatasia 1 -0.03693 0.12421 0.0884 0.7662 0.964 
IBD 1 -0.1279 0.07854 2.6519 0.1034 0.88 
Idopathic scoliosis 1 -0.21223 0.04032 27.7125 <.0001 0.809 
Kyphosis 1 -0.02216 0.02359 0.8825 0.3475 0.978 
Liver Disease 1 -0.13917 0.03609 14.8699 0.0001 0.87 
Malabsorption 1 -0.31319 0.12264 6.5215 0.0107 0.731 
Marfan syndrome 1 -0.1607 1.00031 0.0258 0.8724 0.852 
MS 1 -0.04198 0.13062 0.1033 0.7479 0.959 
Muscular dystrophy 1 -0.31356 0.37864 0.6858 0.4076 0.731 
Obseity 0 0 . . . . 
Osteoarthritis 1 0.06299 0.01547 16.5899 <.0001 1.065 
Osteoporosis 1 -1.39359 0.19376 51.7278 <.0001 0.248 
Other Fx 1 -0.31914 0.0285 125.3768 <.0001 0.727 
Panhypopituitarism 1 0.46299 1.00032 0.2142 0.6435 1.589 
Pancreatic Disease 1 -0.07295 0.05651 1.6669 0.1967 0.93 
Poly Rheumatica 1 -0.18258 0.05119 12.7206 0.0004 0.833 
Porphyria 1 -0.14801 0.50015 0.0876 0.7673 0.862 
Premature ovarian failure 1 0.26729 0.70722 0.1428 0.7055 1.306 
Primary bilary cirrhosis 1 -0.11896 0.18912 0.3956 0.5294 0.888 
Riley-Day 1 8.90994 202.16984 0.0019 0.9648 7405.21 
Renauld Disease 1 -0.05454 0.0308 3.1361 0.0766 0.947 
RA 1 -0.24356 0.0323 56.8775 <.0001 0.784 
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Saccoidosis 1 0.14954 0.14459 1.0697 0.301 1.161 
Sickle Cell Anemia 1 0.61193 1.00088 0.3738 0.5409 1.844 
Lupus 1 -0.36458 0.07197 25.663 <.0001 0.694 
Spinal cord injury 1 -0.77074 0.22992 11.2374 0.0008 0.463 
Systemic mastocytosis 1 -0.48038 1.00016 0.2307 0.631 0.619 
Turner’s & Klinefelter’s 
syndromes 
1 8.37182 142.35415 0.0035 0.9531 4323.506 
Thalassemia 1 -0.32367 0.21838 2.1968 0.1383 0.723 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 -0.92627 1.00054 0.8571 0.3546 0.396 
Vitamin D 1 0.13017 0.03202 16.5203 <.0001 1.139 
barb 1 -0.37835 0.27764 1.857 0.173 0.685 
lithium 1 -0.06853 0.10676 0.4121 0.5209 0.934 
thiaz 1 -0.23814 0.02613 83.0815 <.0001 0.788 
arom 1 -0.06531 0.02987 4.7801 0.0288 0.937 
convulsants 1 -0.27388 0.01458 353.094 <.0001 0.76 
ssri 1 -0.26621 0.01281 431.5627 <.0001 0.766 
ppi 1 -0.14587 0.01115 171.2685 <.0001 0.864 
mtx 1 -0.3155 0.03784 69.5002 <.0001 0.729 
csa 1 -0.23846 0.12333 3.7383 0.0532 0.788 
coag 1 -0.23862 0.01546 238.0762 <.0001 0.788 
white 1 -0.17305 0.1476 1.3745 0.241 0.841 
black 1 0.73157 0.15022 23.7165 <.0001 2.078 
other_race 1 0.19498 0.15802 1.5224 0.2173 1.215 
asian 1 0.11243 0.15408 0.5325 0.4656 1.119 
hispanic 1 0.08082 0.15149 0.2846 0.5937 1.084 
amnative 1 -0.15619 0.17236 0.8212 0.3648 0.855 
Age 1 -1.52219 0.2005 57.6407 <.0001 0.218 
Age*Age 1 0.02046 0.00255 64.2584 <.0001 1.021 
Age*Age*Age 1 -0.0000872 0.0000108 65.5271 <.0001 1 
Age*Osteoporosis 1 -0.01277 0.00245 27.1417 <.0001 0.987 
 
Table A27 Approach 3 MOF 365 days, CFRI Without BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.72897 0.32683 4.9749 0.0257 2.073 
Cystic Fibrosis 1 -14.41108 50920 0 0.9998 0 
Congestive Heart 
Failure 
1 0.06347 0.63806 0.0099 0.9208 1.066 
Epilepsy 1 15.56033 4200 0 0.997 5724850 
Parkinson’s Disease 1 15.39725 6573 0 0.9981 4863388 
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Stroke 1 0.59113 1.02503 0.3326 0.5641 1.806 
Adrenal insufficiency 1 14.68664 18043 0 0.9994 2389609 
AIDS/HIV 1 -2.43472 1.02331 5.6609 0.0173 0.088 
Alcoholism 1 -2.46884 1.05905 5.4345 0.0197 0.085 
Alzheimers 1 15.05086 2057 0.0001 0.9942 3439592 
Amyloidosis 1 -0.6469 38162 0 1 0.524 
Anorexia 1 15.78787 6133 0 0.9979 7187630 
Ankylosing spondylitis 1 15.73893 7597 0 0.9983 6844316 
COPD 1 -0.01489 0.44751 0.0011 0.9735 0.985 
Athletic amenorrhea 1 16.18802 26599 0 0.9995 10724256 
Cataracts 1 0.3779 0.68779 0.3019 0.5827 1.459 
Celiac 1 -14.28856 43780 0 0.9997 0 
Central Adiposity 1 -0.56434 0.36924 2.3359 0.1264 0.569 
Chronic metabolic 
acidosis 
1 15.36887 7039 0 0.9983 4727326 
Crohn’s Disease 1 -1.24321 1.03201 1.4512 0.2283 0.288 
Cushing's 1 14.94257 38833 0 0.9997 3086568 
Depression 1 -0.59736 0.41933 2.0294 0.1543 0.55 
DM 1 -0.22043 0.2812 0.6145 0.4331 0.802 
ESRD 1 -1.25296 0.78658 2.5374 0.1112 0.286 
Disorders of the Eye 1 -0.89643 0.47952 3.4948 0.0616 0.408 
Falling 1 15.44987 2950 0 0.9958 5126149 
Gaucher's Disease 1 14.68729 8122 0 0.9986 2391171 
Glaucoma 1 15.98105 1544 0.0001 0.9917 8719261 
Gout 1 -0.90835 0.74228 1.4975 0.2211 0.403 
Hemophilia 1 14.70156 2213 0 0.9947 2425539 
Homocystinuria 1 14.58446 19300 0 0.9994 2157489 
Hyperprolactinemia 1 15.40618 27610 0 0.9996 4907051 
Hyperthyrois 1 -0.13588 1.02065 0.0177 0.8941 0.873 
Hypophosphatasia 1 15.7805 8974 0 0.9986 7134853 
IBD 1 -1.63769 1.47912 1.2259 0.2682 0.194 
Idopathic scoliosis 1 13.57227 3502 0 0.9969 784083.2 
Kyphosis 1 15.17617 1346 0.0001 0.991 3898774 
Liver Disease 1 15.29997 1923 0.0001 0.9937 4412563 
Malabsorption 1 15.35701 11880 0 0.999 4671580 
MS 1 15.95402 6839 0 0.9981 8486792 
Muscular dystrophy 1 15.81172 23149 0 0.9995 7361111 
Obseity 0 0 . . . . 
Osteoarthritis 1 -0.23343 0.34586 0.4555 0.4997 0.792 
Osteoporosis 1 -805.00724 50042 0.0003 0.9872 0 
Other Fx 1 -0.88563 1.02728 0.7432 0.3886 0.412 
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Pancreatic Disease 1 14.82909 3479 0 0.9966 2755451 
Poly Rheumatica 1 14.91041 22679 0 0.9995 2988886 
Premature ovarian 
failure 
1 15.52736 20138 0 0.9994 5539175 
Primary bilary cirrhosis 1 0.25527 14076 0 1 1.291 
Renauld Disease 1 1.80247 1.10336 2.6687 0.1023 6.065 
RA 1 -1.4604 1.03152 2.0044 0.1568 0.232 
Saccoidosis 1 15.45237 6351 0 0.9981 5139011 
Sickle Cell Anemia 1 13.53032 16488 0 0.9993 751869.2 
Lupus 1 -2.0513 1.03314 3.9422 0.0471 0.129 
Spinal cord injury 1 19.04181 29201 0 0.9995 1.86E+08 
Systemic mastocytosis 1 2.23657 29084 0 0.9999 9.361 
Thalassemia 1 16.00787 14992 0 0.9991 8956340 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 16.20872 16749 0 0.9992 10948530 
Vitamin D 1 0.2098 0.7255 0.0836 0.7724 1.233 
barb 1 16.34358 46462 0 0.9997 12529255 
lithium 1 16.1129 6549 0 0.998 9948131 
thiaz 1 -0.47551 0.37577 1.6014 0.2057 0.622 
arom 1 -0.32092 1.01477 0.1 0.7518 0.725 
convulsants 1 -0.44327 0.30254 2.1467 0.1429 0.642 
ssri 1 0.12728 0.35912 0.1256 0.723 1.136 
ppi 1 -0.01021 0.26878 0.0014 0.9697 0.99 
mtx 1 15.83101 3226 0 0.9961 7504483 
csa 1 14.79994 5889 0 0.998 2676285 
coag 1 0.84568 0.74555 1.2866 0.2567 2.33 
white 1 -16.57497 34071 0 0.9996 0 
black 1 -16.10006 34071 0 0.9996 0 
other_race 1 -16.72236 34071 0 0.9996 0 
asian 1 -16.31158 34071 0 0.9996 0 
hispanic 1 -16.69329 34071 0 0.9996 0 
amnative 1 -19.15879 34071 0 0.9996 0 
Age 1 -120.84015 116.12891 1.0828 0.2981 0 
Age*Age 1 1.71115 1.71198 0.999 0.3175 5.535 
Age*Age*Age 1 -0.00806 0.00841 0.918 0.338 0.992 
Age*Osteoporosis 1 -12.31983 781.6282 0.0002 0.9874 0 
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Table A28 Approach 3 MOF All Available, CFRI Without BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.34124 0.17884 3.641 0.0564 1.407 
Cystic Fibrosis 1 -13.72707 14203 0 0.9992 0 
Congestive Heart 
Failure 
1 -0.24602 0.29395 0.7005 0.4026 0.782 
Epilepsy 1 13.52436 482.17152 0.0008 0.9776 747399.4 
Parkinson’s Disease 1 13.21722 1130 0.0001 0.9907 549749.6 
Stroke 1 0.66437 0.5132 1.6759 0.1955 1.943 
Adrenal insufficiency 1 -3.10564 1.02818 9.1236 0.0025 0.045 
AIDS/HIV 1 -1.64362 0.72275 5.1716 0.023 0.193 
Alcoholism 1 -1.22986 1.01382 1.4716 0.2251 0.292 
Alzheimers 1 0.4449 0.72476 0.3768 0.5393 1.56 
Amyloidosis 1 0.45565 8414 0 1 1.577 
Anorexia 1 13.43929 1008 0.0002 0.9894 686448.3 
Ankylosing spondylitis 1 -1.39304 1.01911 1.8684 0.1717 0.248 
COPD 1 -0.0315 0.23895 0.0174 0.8951 0.969 
Athletic amenorrhea 1 13.15359 4845 0 0.9978 515857.3 
Cataracts 1 -0.19558 0.33425 0.3424 0.5585 0.822 
Celiac 1 -0.52122 10365 0 1 0.594 
Central Adiposity 1 0.10909 0.23847 0.2093 0.6473 1.115 
Chronic metabolic 
acidosis 
1 12.97857 1330 0.0001 0.9922 433032.9 
Crohn’s Disease 1 -0.80705 0.59796 1.8216 0.1771 0.446 
Cushing's 1 13.30528 5049 0 0.9979 600354.6 
Depression 1 -0.42929 0.23532 3.3279 0.0681 0.651 
DM 1 0.1012 0.1497 0.457 0.499 1.107 
ESRD 1 -0.66716 0.4006 2.7736 0.0958 0.513 
Disorders of the Eye 1 -0.51962 0.26861 3.7421 0.0531 0.595 
Falling 1 0.09942 0.72033 0.019 0.8902 1.105 
Gaucher's Disease 1 13.49569 1440 0.0001 0.9925 726278.2 
Glaucoma 1 0.43458 0.42827 1.0297 0.3102 1.544 
Gout 1 -0.22864 0.47093 0.2357 0.6273 0.796 
Hemophilia 1 -0.92864 0.49067 3.5819 0.0584 0.395 
Homocystinuria 1 12.99414 4283 0 0.9976 439826.9 
Hyperprolactinemia 1 12.88717 3056 0 0.9966 395210.9 
Hyperthyrois 1 0.39857 0.71312 0.3124 0.5762 1.49 
Hypophosphatasia 1 -1.70864 1.06166 2.5902 0.1075 0.181 
IBD 1 0.04517 1.20233 0.0014 0.97 1.046 
Idopathic scoliosis 1 0.31327 1.04638 0.0896 0.7646 1.368 
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Kyphosis 1 -0.30011 0.32803 0.837 0.3602 0.741 
Liver Disease 1 0.30907 0.59766 0.2674 0.6051 1.362 
Malabsorption 1 13.2118 1930 0 0.9945 546779.1 
MS 1 13.52665 1144 0.0001 0.9906 749118.9 
Muscular dystrophy 1 -2.38724 1.03889 5.2803 0.0216 0.092 
Obseity 0 0 . . . . 
Osteoarthritis 1 -0.03852 0.19401 0.0394 0.8426 0.962 
Osteoporosis 1 -32.07708 23.60046 1.8473 0.1741 0 
Other Fx 1 0.19387 0.72445 0.0716 0.789 1.214 
Pancreatic Disease 1 12.72077 1021 0.0002 0.9901 334625.6 
Poly Rheumatica 1 12.88873 4016 0 0.9974 395824.3 
Premature ovarian 
failure 
1 -2.80817 1.02446 7.5138 0.0061 0.06 
Primary bilary cirrhosis 1 13.11218 3001 0 0.9965 494933.7 
Renauld Disease 1 0.0814 0.33563 0.0588 0.8084 1.085 
RA 1 -0.80838 0.72107 1.2569 0.2622 0.446 
Saccoidosis 1 13.01672 1074 0.0001 0.9903 449873.3 
Sickle Cell Anemia 1 12.82174 4478 0 0.9977 370180.1 
Lupus 1 -1.32807 0.71832 3.4183 0.0645 0.265 
Spinal cord injury 1 13.50122 4227 0 0.9975 730308.9 
Systemic mastocytosis 1 10.69274 5676 0 0.9985 44034.94 
Thalassemia 1 13.18354 1971 0 0.9947 531540.8 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 12.82543 3415 0 0.997 371546 
Vitamin D 1 -0.12039 0.3686 0.1067 0.744 0.887 
barb 1 14.27867 12603 0 0.9991 1589083 
lithium 1 13.46455 841.52627 0.0003 0.9872 704012.4 
thiaz 1 -0.39526 0.18924 4.3626 0.0367 0.674 
arom 1 -0.17869 0.58249 0.0941 0.759 0.836 
convulsants 1 -0.26568 0.16647 2.547 0.1105 0.767 
ssri 1 -0.14595 0.17663 0.6828 0.4086 0.864 
ppi 1 -0.05877 0.13499 0.1895 0.6633 0.943 
mtx 1 13.13631 682.56811 0.0004 0.9846 507024.2 
csa 1 13.10293 1347 0.0001 0.9922 490375.8 
coag 1 -0.3649 0.23452 2.4211 0.1197 0.694 
white 1 -13.52158 9372 0 0.9988 0 
black 1 -12.76091 9372 0 0.9989 0 
other_race 1 -13.14185 9372 0 0.9989 0 
asian 1 -12.9572 9372 0 0.9989 0 
hispanic 1 -13.42598 9372 0 0.9989 0 
amnative 1 -15.46398 9372 0 0.9987 0 
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Age 1 -67.38977 82.67381 0.6644 0.415 0 
Age*Age 1 0.97795 1.22451 0.6378 0.4245 2.659 
Age*Age*Age 1 -0.00473 0.00604 0.6116 0.4342 0.995 
Age*Osteoporosis 1 -0.48042 0.36154 1.7657 0.1839 0.619 
 
Table A29 Approach 3 MOF 365 days, CFRI With BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 -18.62545 40798 0 0.9996 0 
Cystic Fibrosis 1 -8.39431 481008 0 1 0 
Congestive Heart 
Failure 
1 14.72638 10975 0 0.9989 2486481 
Epilepsy 1 13.0683 17434 0 0.9994 473687 
Parkinson’s Disease 1 -5.67966 1836524 0 1 0.003 
Stroke 1 14.12195 32994 0 0.9997 1358573 
AIDS/HIV 1 -0.80424 1015627 0 1 0.447 
Alcoholism 1 20.31555 143115 0 0.9999 6.65E+08 
Alzheimers 1 14.59562 174162 0 0.9999 2181707 
Amyloidosis 1 -54.77667 11400943 0 1 0 
Anorexia 1 -28.7664 5055631 0 1 0 
Ankylosing spondylitis 1 21.85591 524217 0 1 3.10E+09 
COPD 1 14.99373 11039 0 0.9989 3248590 
Cataracts 1 1.83327 59699 0 1 6.254 
Central Adiposity 1 13.68178 10228 0 0.9989 874822.6 
Crohn’s Disease 1 65.91109 65160156 0 1 4.22E+28 
Depression 1 -5.30127 2.37653 4.9759 0.0257 0.005 
DM 1 0.71043 1.37688 0.2662 0.6059 2.035 
ESRD 1 -5.63026 2.35952 5.6939 0.017 0.004 
Disorders of the Eye 1 17.36631 52774 0 0.9997 34841303 
Falling 1 12.88048 18354 0 0.9994 392572.3 
Gaucher's Disease 1 19.34989 1527793 0 1 2.53E+08 
Glaucoma 1 2.41809 102187 0 1 11.224 
Gout 1 18.45507 58113 0 0.9997 1.04E+08 
Hemophilia 1 4.9776 224468 0 1 145.126 
Hyperthyrois 1 15.3115 59200 0 0.9998 4463763 
Hypophosphatasia 1 22.71562 479169 0 1 7.33E+09 
Idopathic scoliosis 1 -12.53474 921771 0 1 0 
Kyphosis 1 16.99021 8571 0 0.9984 23919559 
Liver Disease 1 15.37602 18704 0 0.9993 4761223 
Malabsorption 1 5.15212 1592579 0 1 172.797 
MS 1 17.06398 474072 0 1 25750835 
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Muscular dystrophy 1 19.77781 1086252 0 1 3.89E+08 
Obseity 0 0 . . . . 
Osteoarthritis 1 1.76326 2.07177 0.7243 0.3947 5.831 
Other Fx 1 -7.69724 3.2207 5.7118 0.0169 0 
Pancreatic Disease 1 18.95434 630091 0 1 1.71E+08 
Premature ovarian 
failure 
0 0 . . . . 
Renauld Disease 1 21.50862 35402 0 0.9995 2.19E+09 
RA 1 17.21887 147804 0 0.9999 30064991 
Saccoidosis 1 -74.32117 65069052 0 1 0 
Lupus 1 10.42657 17636 0 0.9995 33744.35 
Thalassemia 1 19.57649 1665059 0 1 3.18E+08 
Thyrotoxicosis 0 0 . . . . 
Vitamin D 1 18.25388 43110 0 0.9997 84636809 
lithium 1 23.18492 135774 0 0.9999 1.17E+10 
thiaz 1 -4.48532 2.2754 3.8857 0.0487 0.011 
arom 1 19.58351 280055 0 0.9999 3.20E+08 
convulsants 1 -1.05558 1.32778 0.632 0.4266 0.348 
ssri 1 18.83648 5006 0 0.997 1.52E+08 
ppi 1 -2.31936 1.37667 2.8384 0.092 0.098 
mtx 1 19.15476 267886 0 0.9999 2.08E+08 
csa 1 4.16659 3005966 0 1 64.495 
coag 1 17.13922 13304 0 0.999 27763026 
Age 1 -0.05453 1.5625 0.0012 0.9722 0.947 
Age*Age  0 0 . . . . 
Age*Age*Age 0 0 . . . . 
Age*Osteoporosis 0 0 . . . . 
 
 
Table A30 Approach 3 MOF, All Available, CFRI With BMD, regression coefficients 
Label Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 0.78769 0.85978 0.8393 0.3596 2.198 
Cystic Fibrosis -15.61625 30424 0 0.9996 0 
Congestive Heart Failure -0.40583 1.30555 0.0966 0.7559 0.666 
Epilepsy 17.39171 3740 0 0.9963 35737340 
Parkinson’s Disease -1.86551 40920 0 1 0.155 
Stroke 15.01715 3626 0 0.9967 3325558 
AIDS/HIV 16.17611 8509 0 0.9985 10597287 
Alcoholism 15.16029 10585 0 0.9989 3837330 
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Alzheimers 12.99491 5474 0 0.9981 440167.6 
Amyloidosis -0.83412 48312 0 1 0.434 
Anorexia -16.01437 85947 0 0.9999 0 
Ankylosing spondylitis 15.64887 22401 0 0.9994 6254883 
COPD -0.22261 1.21798 0.0334 0.855 0.8 
Cataracts 0.40762 1.45246 0.0788 0.779 1.503 
Central Adiposity 0.42558 1.50777 0.0797 0.7777 1.53 
Crohn’s Disease 29.25709 80559 0 0.9997 5.08E+12 
Depression -1.21798 1.17909 1.0671 0.3016 0.296 
DM 1.18236 0.82337 2.0621 0.151 3.262 
ESRD -2.075 1.03273 4.0371 0.0445 0.126 
Disorders of the Eye -2.08999 1.12829 3.4312 0.064 0.124 
Falling 15.28744 4500 0 0.9973 4357623 
Gaucher's Disease 15.70676 46121 0 0.9997 6627649 
Glaucoma 0.47315 1.46104 0.1049 0.7461 1.605 
Gout -2.41852 1.74058 1.9307 0.1647 0.089 
Hemophilia 13.75073 17843 0 0.9994 937272.7 
Hyperthyrois 15.11004 4984 0 0.9976 3649292 
Hypophosphatasia 16.26318 8373 0 0.9985 11561414 
Idopathic scoliosis 16.12249 9941 0 0.9987 10044009 
Kyphosis -0.25243 1.42127 0.0315 0.859 0.777 
Liver Disease -1.50738 1.34252 1.2607 0.2615 0.221 
Malabsorption 14.79454 12057 0 0.999 2661878 
MS 16.4326 10091 0 0.9987 13695812 
Muscular dystrophy -2.6517 1.41415 3.5161 0.0608 0.071 
Obseity 0 . . . . 
Osteoarthritis 0.46456 1.06864 0.189 0.6638 1.591 
Other Fx -3.68769 1.27427 8.375 0.0038 0.025 
Pancreatic Disease 15.78466 12143 0 0.999 7164588 
Premature ovarian failure 0 . . . . 
Renauld Disease 1.35981 1.36564 0.9915 0.3194 3.895 
RA 16.03491 4945 0 0.9974 9201758 
Saccoidosis -15.07126 78864 0 0.9998 0 
Lupus 14.10817 8150 0 0.9986 1339989 
Thalassemia 15.74842 30756 0 0.9996 6909597 
Thyrotoxicosis 0 . . . . 
Vitamin D 15.20159 2900 0 0.9958 3999141 
lithium 16.40757 6621 0 0.998 13357216 
thiaz -1.48729 0.76117 3.818 0.0507 0.226 
arom 15.9346 6869 0 0.9981 8323521 
convulsants -0.43065 0.72984 0.3482 0.5552 0.65 
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ssri 0.98809 1.08069 0.836 0.3606 2.686 
ppi -0.34558 0.59786 0.3341 0.5633 0.708 
mtx 15.4625 6200 0 0.998 5191323 
csa 16.32858 63418 0 0.9998 12342733 
coag -0.2055 1.08895 0.0356 0.8503 0.814 
Age -0.15312 0.60787 0.0634 0.8011 0.858 
Age*Age  0 . . . . 
Age*Age*Age 0 . . . . 
Age*Osteoporosis 0 . . . . 
 
Table A31 Approach 3 Vertebral Fracture 365 Days, no restriction, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.17914 0.03828 21.8942 <.0001 1.196 
Cystic Fibrosis 1 9.09259 98.04542 0.0086 0.9261 8889.151 
Congestive Heart Failure 1 -0.14697 0.04624 10.101 0.0015 0.863 
Ehlers-Danlos 1 -1.56592 1.00102 2.4471 0.1177 0.209 
Epilepsy 1 0.23446 0.14158 2.7424 0.0977 1.264 
Osteogenesis Imperfecta 1 9.54645 253.01735 0.0014 0.9699 13994.88 
Parkinson’s Disease 1 -0.47032 0.1075 19.1424 <.0001 0.625 
Stroke 1 -0.0585 0.05776 1.0257 0.3112 0.943 
Adrenal insufficiency 1 -0.94405 0.44868 4.4272 0.0354 0.389 
AIDS/HIV 1 -1.65297 0.41011 16.2456 <.0001 0.191 
Alcoholism 1 -0.55226 0.1842 8.9889 0.0027 0.576 
Alzheimers 1 -0.09296 0.05852 2.5231 0.1122 0.911 
Amyloidosis 1 -0.53193 0.57776 0.8476 0.3572 0.587 
Androgen insensitivity 1 9.50966 332.77993 0.0008 0.9772 13489.39 
Anorexia 1 -0.08825 0.1596 0.3058 0.5803 0.916 
Ankylosing spondylitis 1 -0.44139 0.15921 7.6856 0.0056 0.643 
COPD 1 -0.37249 0.03324 125.6093 <.0001 0.689 
Athletic amenorrhea 1 0.29903 1.00017 0.0894 0.765 1.349 
Cataracts 1 0.0613 0.08011 0.5856 0.4441 1.063 
Celiac 1 -0.59871 0.46495 1.6581 0.1979 0.55 
Central Adiposity 1 0.08827 0.06566 1.8075 0.1788 1.092 
Chronic metabolic acidosis 1 -0.01511 0.16329 0.0086 0.9263 0.985 
Crohn’s Disease 1 -0.27165 0.07986 11.5707 0.0007 0.762 
Cushing's 1 -0.91916 0.37934 5.8712 0.0154 0.399 
Depression 1 -0.11346 0.04506 6.3391 0.0118 0.893 
DM 1 0.02819 0.03312 0.7243 0.3947 1.029 
ESRD 1 -0.37456 0.15586 5.7757 0.0162 0.688 
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Disorders of the Eye 1 -0.05251 0.0609 0.7434 0.3886 0.949 
Falling 1 -0.36726 0.07039 27.2249 <.0001 0.693 
Gaucher's Disease 1 -0.48831 0.50031 0.9526 0.3291 0.614 
Glaucoma 1 0.08058 0.09859 0.668 0.4138 1.084 
Gout 1 0.11942 0.09282 1.6553 0.1982 1.127 
Glycogen storage diseases 1 9.44522 206.91843 0.0021 0.9636 12647.6 
Hemochromatosis 1 -0.64243 0.57779 1.2363 0.2662 0.526 
Hemophilia 1 -0.26063 0.11268 5.3498 0.0207 0.771 
Homocystinuria 1 0.67761 0.70745 0.9174 0.3382 1.969 
Hyperprolactinemia 1 8.97511 110.34085 0.0066 0.9352 7903.919 
Hyperparathyroidism 1 0.12879 0.14601 0.7781 0.3777 1.137 
Hyperthyrois 1 0.01063 0.11278 0.0089 0.9249 1.011 
Hypophosphatasia 1 -0.3935 0.21294 3.4148 0.0646 0.675 
IBD 1 -0.04863 0.15941 0.093 0.7603 0.953 
Idopathic scoliosis 1 -0.3737 0.07957 22.0566 <.0001 0.688 
Kyphosis 1 -0.09953 0.05076 3.8446 0.0499 0.905 
Liver Disease 1 -0.25046 0.07462 11.2666 0.0008 0.778 
Malabsorption 1 0.42081 0.3545 1.4092 0.2352 1.523 
Marfan syndrome 1 9.57792 259.81308 0.0014 0.9706 14442.38 
MS 1 0.04032 0.2895 0.0194 0.8892 1.041 
Muscular dystrophy 1 9.25403 99.05132 0.0087 0.9256 10446.6 
Obseity 0 0 . . . . 
Osteoarthritis 1 0.067 0.03447 3.7782 0.0519 1.069 
Osteoporosis 1 -1.63254 0.39753 16.8652 <.0001 0.195 
Other Fx 1 -0.27824 0.06227 19.9653 <.0001 0.757 
Panhypopituitarism 1 9.08085 155.99908 0.0034 0.9536 8785.388 
Pancreatic Disease 1 -0.20563 0.11575 3.1557 0.0757 0.814 
Poly Rheumatica 1 -0.33269 0.1027 10.4933 0.0012 0.717 
Porphyria 1 -0.27004 1.0006 0.0728 0.7873 0.763 
Premature ovarian failure 1 8.53209 95.70322 0.0079 0.929 5075.031 
Primary bilary cirrhosis 1 -0.45455 0.32484 1.9581 0.1617 0.635 
Riley-Day 1 9.95695 449.82625 0.0005 0.9823 21098.44 
Renauld Disease 1 0.05625 0.06735 0.6974 0.4037 1.058 
RA 1 -0.26745 0.06729 15.7954 <.0001 0.765 
Saccoidosis 1 0.16796 0.31694 0.2808 0.5961 1.183 
Sickle Cell Anemia 1 -0.7624 1.00339 0.5773 0.4474 0.467 
Lupus 1 -0.67574 0.12814 27.8087 <.0001 0.509 
Spinal cord injury 1 -1.48676 0.33557 19.6297 <.0001 0.226 
Systemic mastocytosis 1 8.83735 207.18547 0.0018 0.966 6886.695 
Turner’s & Klinefelter’s 
syndromes 
1 9.42311 629.5518 0.0002 0.9881 12371 
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Thalassemia 1 -0.1946 0.5004 0.1512 0.6974 0.823 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 8.80783 277.096 0.001 0.9746 6686.394 
Vitamin D 1 0.25611 0.0653 15.3812 <.0001 1.292 
barb 1 -0.92564 0.44829 4.2635 0.0389 0.396 
lithium 1 0.57921 0.3345 2.9984 0.0833 1.785 
thiaz 1 -0.14228 0.06739 4.4571 0.0348 0.867 
arom 1 0.07911 0.07266 1.1856 0.2762 1.082 
convulsants 1 -0.41943 0.03118 180.9537 <.0001 0.657 
ssri 1 -0.23614 0.02945 64.2833 <.0001 0.79 
ppi 1 -0.21389 0.02538 71.0389 <.0001 0.807 
mtx 1 -0.45177 0.0785 33.121 <.0001 0.636 
csa 1 -0.24411 0.2779 0.7716 0.3797 0.783 
coag 1 -0.27675 0.03459 64.0316 <.0001 0.758 
white 1 -0.15118 0.31662 0.228 0.633 0.86 
black 1 0.88838 0.32427 7.5055 0.0062 2.431 
other_race 1 0.2428 0.34444 0.4969 0.4809 1.275 
asian 1 -0.26223 0.32885 0.6359 0.4252 0.769 
hispanic 1 -0.0174 0.32559 0.0029 0.9574 0.983 
amnative 1 -0.05719 0.38163 0.0225 0.8809 0.944 
Age 1 -2.45921 0.47394 26.9237 <.0001 0.086 
Age*Age  1 0.03282 0.00604 29.4877 <.0001 1.033 
Age*Age*Age 1 -0.0001413 0.0000256 30.5623 <.0001 1 
Age*Osteoporosis 1 -0.01481 0.00504 8.6481 0.0033 0.985 
 
 
Table A32 Approach 3 Vertebral Fracture All Available, no restriction, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.24011 0.02072 134.2844 <.0001 1.271 
Cystic Fibrosis 1 8.14466 36.19567 0.0506 0.822 3444.948 
Congestive Heart Failure 1 -0.12191 0.02835 18.4901 <.0001 0.885 
Ehlers-Danlos 1 -1.42861 0.7074 4.0785 0.0434 0.24 
Epilepsy 1 0.07463 0.08542 0.7634 0.3823 1.077 
Osteogenesis Imperfecta 1 8.63225 102.07437 0.0072 0.9326 5609.673 
Parkinson’s Disease 1 -0.35485 0.06941 26.1394 <.0001 0.701 
Stroke 1 -0.02714 0.03487 0.6057 0.4364 0.973 
Adrenal insufficiency 1 -0.6962 0.28934 5.7895 0.0161 0.498 
AIDS/HIV 1 -1.07115 0.3343 10.2664 0.0014 0.343 
Alcoholism 1 -0.56668 0.11002 26.5312 <.0001 0.567 
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Alzheimers 1 -0.00361 0.03743 0.0093 0.9232 0.996 
Amyloidosis 1 -0.27787 0.40844 0.4628 0.4963 0.757 
Androgen insensitivity 1 8.38833 112.52141 0.0056 0.9406 4395.452 
Anorexia 1 -0.16671 0.09666 2.975 0.0846 0.846 
Ankylosing spondylitis 1 -0.43251 0.09954 18.8811 <.0001 0.649 
COPD 1 -0.35358 0.01988 316.4659 <.0001 0.702 
Athletic amenorrhea 1 0.24369 0.57747 0.1781 0.673 1.276 
Cataracts 1 0.11153 0.04802 5.3937 0.0202 1.118 
Celiac 1 0.13651 0.27178 0.2523 0.6155 1.146 
Central Adiposity 1 0.14255 0.04167 11.7059 0.0006 1.153 
Chronic metabolic acidosis 1 0.00273 0.10714 0.0007 0.9796 1.003 
Crohn’s Disease 1 -0.11073 0.05104 4.7066 0.03 0.895 
Cushing's 1 -0.51781 0.28922 3.2053 0.0734 0.596 
Depression 1 -0.13918 0.02738 25.8333 <.0001 0.87 
DM 1 0.03258 0.01942 2.8148 0.0934 1.033 
ESRD 1 -0.38879 0.09799 15.7423 <.0001 0.678 
Disorders of the Eye 1 -0.03941 0.03653 1.1641 0.2806 0.961 
Falling 1 -0.22647 0.04468 25.6885 <.0001 0.797 
Gaucher's Disease 1 0.03265 0.37812 0.0075 0.9312 1.033 
Glaucoma 1 0.11708 0.05983 3.8294 0.0504 1.124 
Gout 1 0.15323 0.05755 7.0895 0.0078 1.166 
Glycogen storage diseases 1 8.35405 70.90078 0.0139 0.9062 4247.354 
Hemochromatosis 1 -0.43725 0.50021 0.7641 0.382 0.646 
Hemophilia 1 -0.18001 0.0695 6.7084 0.0096 0.835 
Homocystinuria 1 0.24505 0.33354 0.5398 0.4625 1.278 
Hyperprolactinemia 1 7.98169 43.36403 0.0339 0.854 2926.87 
Hyperparathyroidism 1 0.11656 0.08835 1.7405 0.1871 1.124 
Hyperthyrois 1 0.02735 0.06647 0.1693 0.6808 1.028 
Hypophosphatasia 1 -0.04129 0.16904 0.0597 0.807 0.96 
IBD 1 -0.09951 0.10205 0.9508 0.3295 0.905 
Idopathic scoliosis 1 -0.27118 0.05096 28.3153 <.0001 0.762 
Kyphosis 1 -0.01824 0.03123 0.3413 0.5591 0.982 
Liver Disease 1 -0.16854 0.04663 13.0653 0.0003 0.845 
Malabsorption 1 -0.11848 0.17468 0.4601 0.4976 0.888 
Marfan syndrome 1 8.34046 91.86795 0.0082 0.9277 4190.001 
MS 1 -0.05203 0.1696 0.0941 0.759 0.949 
Muscular dystrophy 1 -0.27696 0.50092 0.3057 0.5803 0.758 
Obseity 0 0 . . . . 
Osteoarthritis 1 0.05668 0.02022 7.853 0.0051 1.058 
Osteoporosis 1 -1.26232 0.24623 26.2812 <.0001 0.283 
Other Fx 1 -0.33519 0.03707 81.7789 <.0001 0.715 
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Panhypopituitarism 1 -0.0976 1.00055 0.0095 0.9223 0.907 
Pancreatic Disease 1 -0.13976 0.07181 3.7878 0.0516 0.87 
Poly Rheumatica 1 -0.31607 0.0621 25.9017 <.0001 0.729 
Porphyria 1 -0.38924 0.57763 0.4541 0.5004 0.678 
Premature ovarian failure 1 0.40599 1.00016 0.1648 0.6848 1.501 
Primary bilary cirrhosis 1 -0.26752 0.22835 1.3725 0.2414 0.765 
Riley-Day 1 9.02865 281.20821 0.001 0.9744 8338.634 
Renauld Disease 1 -0.00471 0.04176 0.0127 0.9103 0.995 
RA 1 -0.33196 0.0401 68.5198 <.0001 0.718 
Saccoidosis 1 0.16217 0.18934 0.7335 0.3917 1.176 
Sickle Cell Anemia 1 0.06021 1.00164 0.0036 0.9521 1.062 
Lupus 1 -0.48158 0.08712 30.5578 <.0001 0.618 
Spinal cord injury 1 -1.15471 0.24341 22.5038 <.0001 0.315 
Systemic mastocytosis 1 7.88444 85.75752 0.0085 0.9267 2655.635 
Turner’s & Klinefelter’s 
syndromes 
1 8.45738 196.53977 0.0019 0.9657 4709.689 
Thalassemia 1 -0.53934 0.25844 4.355 0.0369 0.583 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 -1.50791 1.00094 2.2695 0.1319 0.221 
Vitamin D 1 0.18265 0.04314 17.9241 <.0001 1.2 
barb 1 -0.54481 0.33374 2.6648 0.1026 0.58 
lithium 1 0.05137 0.14837 0.1199 0.7292 1.053 
thiaz 1 -0.15506 0.03613 18.4224 <.0001 0.856 
arom 1 0.03161 0.04154 0.5791 0.4466 1.032 
convulsants 1 -0.31196 0.01896 270.6494 <.0001 0.732 
ssri 1 -0.22969 0.01704 181.701 <.0001 0.795 
ppi 1 -0.22011 0.01456 228.6088 <.0001 0.802 
mtx 1 -0.41373 0.04659 78.8497 <.0001 0.661 
csa 1 -0.3457 0.15462 4.9991 0.0254 0.708 
coag 1 -0.29386 0.02007 214.399 <.0001 0.745 
white 1 -0.17621 0.2002 0.7747 0.3788 0.838 
black 1 0.73931 0.20382 13.1575 0.0003 2.094 
other_race 1 0.01476 0.21195 0.0049 0.9445 1.015 
asian 1 -0.13575 0.20703 0.4299 0.512 0.873 
hispanic 1 -0.00717 0.20494 0.0012 0.9721 0.993 
amnative 1 -0.11834 0.234 0.2557 0.6131 0.888 
Age 1 -1.6171 0.27519 34.5314 <.0001 0.198 
Age*Age  1 0.02208 0.00351 39.5647 <.0001 1.022 
Age*Age*Age 1 -0.000096 0.0000149 41.8096 <.0001 1 
Age*Osteoporosis 1 -0.00962 0.00311 9.5457 0.002 0.99 
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Table A33 Approach 3 Vertebral Fracture 365 Days, CFRI Without BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.79975 0.43348 3.4038 0.065 2.225 
Cystic Fibrosis 1 -30.63815 92868 0 0.9997 0 
Congestive Heart 
Failure 
1 0.02981 0.79818 0.0014 0.9702 1.03 
Epilepsy 1 16.03403 6119 0 0.9979 9193681 
Parkinson’s Disease 1 15.47026 9523 0 0.9987 5231757 
Stroke 1 0.01473 1.04008 0.0002 0.9887 1.015 
Adrenal insufficiency 1 15.25963 28242 0 0.9996 4238130 
AIDS/HIV 1 15.31237 10048 0 0.9988 4467650 
Alcoholism 1 -2.88182 1.11378 6.6948 0.0097 0.056 
Alzheimers 1 14.98305 2553 0 0.9953 3214069 
Amyloidosis 1 0.2712 52805 0 1 1.312 
Anorexia 1 15.91434 8526 0 0.9985 8156615 
Ankylosing spondylitis 1 16.06285 10694 0 0.9988 9462494 
COPD 1 -0.2104 0.55665 0.1429 0.7055 0.81 
Athletic amenorrhea 1 16.21254 41883 0 0.9997 10990435 
Cataracts 1 1.13584 1.18305 0.9218 0.337 3.114 
Celiac 1 -29.10185 80019 0 0.9997 0 
Central Adiposity 1 -0.46251 0.50417 0.8416 0.359 0.63 
Chronic metabolic 
acidosis 
1 16.30068 10271 0 0.9987 12003170 
Crohn’s Disease 1 -1.67533 1.06517 2.4738 0.1158 0.187 
Cushing's 1 16.04969 51993 0 0.9998 9338807 
Depression 1 -0.78342 0.50852 2.3734 0.1234 0.457 
DM 1 -0.29034 0.37145 0.6109 0.4344 0.748 
ESRD 1 -0.65686 1.13087 0.3374 0.5613 0.518 
Disorders of the Eye 1 -0.8232 0.64138 1.6473 0.1993 0.439 
Falling 1 15.49304 3689 0 0.9966 5352297 
Gaucher's Disease 1 14.99006 12553 0 0.999 3236683 
Glaucoma 1 16.0154 2173 0.0001 0.9941 9024007 
Gout 1 -0.86614 1.03822 0.696 0.4041 0.421 
Hemophilia 1 15.44611 2707 0 0.9954 5106945 
Homocystinuria 1 15.40877 33016 0 0.9996 4919741 
Hyperprolactinemia 1 15.81201 39038 0 0.9997 7363272 
Hyperthyrois 1 -0.71269 1.04803 0.4624 0.4965 0.49 
Hypophosphatasia 1 16.02008 14887 0 0.9991 9066353 
IBD 1 -1.56275 1.54329 1.0254 0.3112 0.21 
Idopathic scoliosis 1 13.56312 5660 0 0.9981 776940.3 
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Kyphosis 1 15.21857 1840 0.0001 0.9934 4067610 
Liver Disease 1 15.51007 2802 0 0.9956 5444226 
Malabsorption 1 14.88152 14654 0 0.9992 2903775 
MS 1 16.20915 8757 0 0.9985 10953320 
Muscular dystrophy 1 16.17629 32066 0 0.9996 10599247 
Obseity 0 0 . . . . 
Osteoarthritis 1 0.35137 0.55523 0.4005 0.5268 1.421 
Osteoporosis 1 -850.23432 58432 0.0002 0.9884 0 
Other Fx 1 15.50041 4182 0 0.997 5391908 
Pancreatic Disease 1 16.35724 6812 0 0.9981 12701571 
Poly Rheumatica 1 15.7202 30994 0 0.9996 6717302 
Premature ovarian 
failure 
1 15.68312 32312 0 0.9996 6472794 
Primary bilary cirrhosis 1 0.5312 20960 0 1 1.701 
Renauld Disease 1 0.93922 1.14733 0.6701 0.413 2.558 
RA 1 -1.85513 1.05933 3.0668 0.0799 0.156 
Saccoidosis 1 15.85688 9134 0 0.9986 7701112 
Sickle Cell Anemia 1 13.7788 24475 0 0.9996 963956 
Lupus 1 -2.5625 1.04406 6.0239 0.0141 0.077 
Spinal cord injury 1 2.93232 41856 0 0.9999 18.771 
Systemic mastocytosis 1 1.83335 35028 0 1 6.255 
Thalassemia 1 16.14933 22467 0 0.9994 10317260 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 16.20928 29695 0 0.9996 10954733 
Vitamin D 1 0.28887 1.02105 0.08 0.7772 1.335 
barb 1 16.30723 51875 0 0.9997 12082021 
lithium 1 16.29604 8250 0 0.9984 11947609 
thiaz 1 0.1278 0.62018 0.0425 0.8367 1.136 
arom 1 15.67845 4016 0 0.9969 6442672 
convulsants 1 -0.55846 0.38338 2.1219 0.1452 0.572 
ssri 1 -0.06866 0.43996 0.0244 0.876 0.934 
ppi 1 -0.37388 0.33666 1.2333 0.2668 0.688 
mtx 1 16.35972 4658 0 0.9972 12733129 
csa 1 15.31082 10306 0 0.9988 4460716 
coag 1 0.24639 0.76989 0.1024 0.7489 1.279 
white 1 -16.38061 41712 0 0.9997 0 
black 1 -16.07785 41712 0 0.9997 0 
other_race 1 -16.69215 41712 0 0.9997 0 
asian 1 -16.32919 41712 0 0.9997 0 
hispanic 1 -16.28262 41712 0 0.9997 0 
amnative 1 0.36688 46192 0 1 1.443 
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Age 1 -102.39872 158.88923 0.4153 0.5193 0 
Age*Age  1 1.43345 2.34535 0.3736 0.5411 4.193 
Age*Age*Age 1 -0.00667 0.01153 0.3343 0.5631 0.993 
Age*Osteoporosis 1 -13.01796 912.54594 0.0002 0.9886 0 
 
 
Table A34 Approach 3 Vertebral Fracture All Available, CFRI Without BMD, regression 
coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 0.50515 0.22214 5.1709 0.023 1.657 
Cystic Fibrosis 1 -14.41815 19750 0 0.9994 0 
Congestive Heart 
Failure 
1 -0.36744 0.35553 1.0681 0.3014 0.693 
Epilepsy 1 14.13946 680.36975 0.0004 0.9834 1382580 
Parkinson’s Disease 1 13.23065 1563 0.0001 0.9932 557184.5 
Stroke 1 0.0606 0.52114 0.0135 0.9074 1.062 
Adrenal insufficiency 1 -3.60292 1.04637 11.856 0.0006 0.027 
AIDS/HIV 1 -1.41497 1.02369 1.9105 0.1669 0.243 
Alcoholism 1 -1.5965 1.03248 2.391 0.122 0.203 
Alzheimers 1 -0.11219 0.7363 0.0232 0.8789 0.894 
Amyloidosis 1 0.81559 11637 0 0.9999 2.261 
Anorexia 1 13.46841 1434 0.0001 0.9925 706731.6 
Ankylosing spondylitis 1 -2.05399 1.03044 3.9733 0.0462 0.128 
COPD 1 -0.1305 0.29913 0.1903 0.6626 0.878 
Athletic amenorrhea 1 13.39539 7084 0 0.9985 656965.8 
Cataracts 1 0.25275 0.46814 0.2915 0.5893 1.288 
Celiac 1 -0.64031 14824 0 1 0.527 
Central Adiposity 1 0.01296 0.31574 0.0017 0.9672 1.013 
Chronic metabolic 
acidosis 
1 13.07401 1725 0.0001 0.994 476400.8 
Crohn’s Disease 1 -1.36465 0.61375 4.9438 0.0262 0.255 
Cushing's 1 13.60222 6897 0 0.9984 807921 
Depression 1 -0.18709 0.33243 0.3167 0.5736 0.829 
DM 1 0.14596 0.19627 0.553 0.4571 1.157 
ESRD 1 -0.41799 0.56837 0.5408 0.4621 0.658 
Disorders of the Eye 1 -0.54715 0.34853 2.4646 0.1164 0.579 
Falling 1 0.09401 1.01833 0.0085 0.9264 1.099 
Gaucher's Disease 1 13.0736 2063 0 0.9949 476203.7 
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Glaucoma 1 0.10553 0.53534 0.0389 0.8437 1.111 
Gout 1 -0.49598 0.54283 0.8348 0.3609 0.609 
Hemophilia 1 -1.16462 0.56622 4.2306 0.0397 0.312 
Homocystinuria 1 13.33371 6495 0 0.9984 617670.6 
Hyperprolactinemia 1 12.97114 4205 0 0.9975 429825.8 
Hyperthyrois 1 -0.2201 0.71767 0.0941 0.7591 0.802 
Hypophosphatasia 1 13.44478 2319 0 0.9954 690228.4 
IBD 1 0.25439 1.25329 0.0412 0.8392 1.29 
Idopathic scoliosis 1 -0.52376 1.09561 0.2285 0.6326 0.592 
Kyphosis 1 0.2033 0.50713 0.1607 0.6885 1.225 
Liver Disease 1 0.16859 0.73081 0.0532 0.8176 1.184 
Malabsorption 1 13.2355 2502 0 0.9958 559892.4 
MS 1 13.51432 1525 0.0001 0.9929 739936.8 
Muscular dystrophy 1 -2.86495 1.05862 7.3241 0.0068 0.057 
Obseity 0 0 . . . . 
Osteoarthritis 1 -0.03414 0.2554 0.0179 0.8937 0.966 
Osteoporosis 1 -31.32001 23.48582 1.7784 0.1823 0 
Other Fx 1 0.46073 1.02345 0.2027 0.6526 1.585 
Pancreatic Disease 1 12.85983 1430 0.0001 0.9928 384549.7 
Poly Rheumatica 1 13.02795 5705 0 0.9982 454952.6 
Premature ovarian 
failure 
1 13.56857 4534 0 0.9976 781187 
Primary bilary cirrhosis 1 13.25328 4351 0 0.9976 569938 
Renauld Disease 1 0.04158 0.42996 0.0094 0.923 1.042 
RA 1 -0.62849 1.01569 0.3829 0.5361 0.533 
Saccoidosis 1 13.2138 1429 0.0001 0.9926 547874.3 
Sickle Cell Anemia 1 12.87381 6171 0 0.9983 389963 
Lupus 1 -1.81965 0.7284 6.2407 0.0125 0.162 
Spinal cord injury 1 14.16103 5700 0 0.998 1412718 
Systemic mastocytosis 1 10.00681 7071 0 0.9989 22177.03 
Thalassemia 1 13.30288 2675 0 0.996 598919.1 
Thyrotoxicosis 0 0 . . . . 
Vitamin A 1 13.09577 4712 0 0.9978 486878.3 
Vitamin D 1 -0.35756 0.43364 0.6799 0.4096 0.699 
barb 1 14.09933 16472 0 0.9993 1328192 
lithium 1 13.40253 1085 0.0002 0.9901 661676.1 
thiaz 1 -0.02316 0.28326 0.0067 0.9348 0.977 
arom 1 -0.32193 0.71416 0.2032 0.6521 0.725 
convulsants 1 -0.27188 0.21555 1.5909 0.2072 0.762 
ssri 1 -0.18118 0.22935 0.624 0.4296 0.834 
ppi 1 -0.14871 0.17473 0.7244 0.3947 0.862 
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mtx 1 13.26722 947.48806 0.0002 0.9888 577935.6 
csa 1 13.13592 1868 0 0.9944 506823.1 
coag 1 -0.614 0.28331 4.6969 0.0302 0.541 
white 1 -13.32041 12981 0 0.9992 0 
black 1 -13.00333 12981 0 0.9992 0 
other_race 1 -13.46292 12981 0 0.9992 0 
asian 1 -13.40495 12981 0 0.9992 0 
hispanic 1 -13.48089 12981 0 0.9992 0 
amnative 1 0.38176 13282 0 1 1.465 
Age 1 -136.63286 118.77701 1.3233 0.25 0 
Age*Age  1 1.9988 1.76294 1.2855 0.2569 7.38 
Age*Age*Age 1 -0.00974 0.00872 1.2488 0.2638 0.99 
Age*Osteoporosis 1 -0.45465 0.35961 1.5984 0.2061 0.635 
 
 
Table A35 Approach 3 Vertebral Fracture 365 days, CFRI With BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 -18.53473 31721 0 0.9995 0 
Cystic Fibrosis 1 1.58472 14332319 0 1 4.878 
Congestive Heart 
Failure 
1 19.6868 99815 0 0.9998 3.55E+08 
Epilepsy 1 2.80638 141349 0 1 16.55 
Parkinson’s Disease 1 -11.90702 5447458 0 1 0 
Stroke 1 1.237 107136 0 1 3.445 
AIDS/HIV 1 -16.19229 756745 0 1 0 
Alcoholism 1 20.48625 108957 0 0.9998 7.89E+08 
Alzheimers 1 1.06987 190427 0 1 2.915 
Amyloidosis 1 -45.49631 86947041 0 1 0 
Anorexia 1 -62.06101 16962722 0 1 0 
Ankylosing spondylitis 1 23.5922 682069 0 1 1.76E+10 
COPD 1 17.68133 32307 0 0.9996 47742262 
Cataracts 1 1.61924 55529 0 1 5.049 
Central Adiposity 1 0.2491 32031 0 1 1.283 
Crohn’s Disease 1 74.67985 203513342 0 1 2.71E+32 
Depression 1 -21.0892 5458 0 0.9969 0 
DM 1 0.55534 1.29761 0.1832 0.6687 1.743 
ESRD 1 -20.95346 5458 0 0.9969 0 
Disorders of the Eye 1 17.54286 39793 0 0.9996 41568943 
Falling 1 1.70748 146480 0 1 5.515 
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Gaucher's Disease 1 5.51945 2804446 0 1 249.498 
Glaucoma 1 3.81352 121900 0 1 45.309 
Gout 1 16.56229 37140 0 0.9996 15592265 
Hemophilia 1 0.76951 207022 0 1 2.159 
Hyperthyrois 1 2.99441 250956 0 1 19.974 
Hypophosphatasia 1 25.47689 1418950 0 1 1.16E+11 
Idopathic scoliosis 1 -34.92226 253366 0 0.9999 0 
Kyphosis 1 18.85663 21846 0 0.9993 1.55E+08 
Liver Disease 1 21.43191 299070 0 0.9999 2.03E+09 
Malabsorption 1 -27.57887 5451409 0 1 0 
MS 1 2.98279 656804 0 1 19.743 
Muscular dystrophy 1 5.49478 1740904 0 1 243.419 
Obseity 0 0 . . . . 
Osteoarthritis 1 34.99556 9846 0 0.9972 1.58E+15 
Other Fx 1 1.481 372352 0 1 4.397 
Pancreatic Disease 1 4.89266 1102600 0 1 133.307 
Premature ovarian 
failure 
0 0 . . . . 
Renauld Disease 1 38.04764 40708 0 0.9993 3.34E+16 
RA 1 3.44589 241518 0 1 31.371 
Saccoidosis 1 -85.64362 203370461 0 1 0 
Lupus 1 2.34432 573318 0 1 10.426 
Thalassemia 1 5.81667 2708899 0 1 335.853 
Thyrotoxicosis 0 0 . . . . 
Vitamin D 1 16.30444 19670 0 0.9993 12048414 
lithium 1 22.40185 108947 0 0.9998 5.36E+09 
thiaz 1 -20.24671 5458 0 0.997 0 
arom 1 5.01584 467642 0 1 150.783 
convulsants 1 -0.56239 1.34623 0.1745 0.6761 0.57 
ssri 1 35.37991 8557 0 0.9967 2.32E+15 
ppi 1 -1.72701 1.29565 1.7767 0.1826 0.178 
mtx 1 4.99487 471933 0 1 147.654 
csa 1 -10.7067 6167317 0 1 0 
coag 1 17.87794 21105 0 0.9993 58115268 
Age 1 -0.36655 1.41501 0.0671 0.7956 0.693 
Age*Age  0 0 . . . . 
Age*Age*Age 0 0 . . . . 
Age*Osteoporosis 0 0 . . . . 
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Table A36 Approach 3 Vertebral Fracture All Available, CFRI With BMD, regression coefficients 
Label DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Alendronate 1 1.2293 0.82864 2.2008 0.1379 3.419 
Cystic Fibrosis 1 -33.19787 80625 0 0.9997 0 
Congestive Heart 
Failure 
1 -0.75775 1.41677 0.2861 0.5928 0.469 
Epilepsy 1 18.62315 3604 0 0.9959 1.22E+08 
Parkinson’s Disease 1 -2.85721 38839 0 0.9999 0.057 
Stroke 1 14.86032 3584 0 0.9967 2842868 
AIDS/HIV 1 12.81816 9194 0 0.9989 368855.5 
Alcoholism 1 14.15385 9864 0 0.9989 1402619 
Alzheimers 1 11.75539 5403 0 0.9983 127438.1 
Amyloidosis 1 -2.21341 44416 0 1 0.109 
Anorexia 1 -16.99787 72364 0 0.9998 0 
Ankylosing spondylitis 1 15.27267 19846 0 0.9994 4293757 
COPD 1 -0.88796 1.18928 0.5575 0.4553 0.411 
Cataracts 1 1.06603 1.64351 0.4207 0.5166 2.904 
Central Adiposity 1 0.59233 1.77288 0.1116 0.7383 1.808 
Crohn’s Disease 1 27.14337 60510 0 0.9996 6.14E+11 
Depression 1 -1.24775 1.27837 0.9527 0.329 0.287 
DM 1 1.27133 1.03541 1.5076 0.2195 3.566 
ESRD 1 -0.63197 1.52439 0.1719 0.6785 0.532 
Disorders of the Eye 1 -2.54422 1.23342 4.2549 0.0391 0.079 
Falling 1 15.98108 5369 0 0.9976 8719576 
Gaucher's Disease 1 15.37863 42731 0 0.9997 4773673 
Glaucoma 1 0.58455 1.52336 0.1472 0.7012 1.794 
Gout 1 -4.23213 2.00876 4.4388 0.0351 0.015 
Hemophilia 1 13.84087 17528 0 0.9994 1025684 
Hyperthyrois 1 14.92506 6874 0 0.9983 3032986 
Hypophosphatasia 1 14.00401 8040 0 0.9986 1207434 
Idopathic scoliosis 1 17.11756 9528 0 0.9986 27168306 
Kyphosis 1 -1.04056 1.60221 0.4218 0.516 0.353 
Liver Disease 1 14.66245 4173 0 0.9972 2332502 
Malabsorption 1 13.04945 13059 0 0.9992 464838.9 
MS 1 16.3843 9530 0 0.9986 13050020 
Muscular dystrophy 1 -2.35726 1.67665 1.9767 0.1597 0.095 
Obseity 0 0 . . . . 
Osteoarthritis 1 1.63476 1.63965 0.994 0.3188 5.128 
Other Fx 1 13.99555 7007 0 0.9984 1197270 
Pancreatic Disease 1 15.96706 11800 0 0.9989 8598167 
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Premature ovarian 
failure 
0 0 . . . . 
Renauld Disease 1 0.8523 1.68516 0.2558 0.613 2.345 
RA 1 15.72298 4775 0 0.9974 6736021 
Saccoidosis 1 -12.79544 58326 0 0.9998 0 
Lupus 1 15.32885 13991 0 0.9991 4541891 
Thalassemia 1 15.69047 28512 0 0.9996 6520584 
Thyrotoxicosis 0 0 . . . . 
Vitamin D 1 15.53802 2393 0 0.9948 5598582 
lithium 1 16.32624 6361 0 0.998 12313952 
thiaz 1 -0.74402 1.01038 0.5423 0.4615 0.475 
arom 1 16.04261 6352 0 0.998 9272930 
convulsants 1 -0.01631 0.86452 0.0004 0.9849 0.984 
ssri 1 0.7949 1.10136 0.5209 0.4705 2.214 
ppi 1 -0.674 0.66947 1.0136 0.314 0.51 
mtx 1 15.7304 6043 0 0.9979 6786190 
csa 1 15.79084 63906 0 0.9998 7208960 
coag 1 -0.42669 1.11556 0.1463 0.7021 0.653 
Age 1 -0.3461 0.6434 0.2894 0.5906 0.707 
Age*Age  0 0 . . . . 
Age*Age*Age 0 0 . . . . 
Age*Osteoporosis 0 0 . . . . 
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